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Thesis abstract 
Aim:  To examine the occurrence of cardiovascular disease risk factors, previously 
diagnosed atherosclerotic disease, new ischaemic events and prescriptions issued in the 
period prior to first myocardial infarction (MI) and their association with outcomes at the 
time of and after MI.     
Methods:  This thesis describes studies using linked CALIBER data from four UK sources: 
the General Practice Research Database, Hospital Episode Statistics, the Myocardial 
Ischaemic National Audit Project and Office for National Statistics mortality data.  Linkage 
of these sources created a large, rich longitudinal dataset, allowing reconstruction of the 
patient journey before and after first MI.  Quality of MI recording across the four data 
sources was first assessed and three further studies examined atherosclerotic disease, risk 
factor and drug exposures in the period preceding MI.   
Results:  Despite an increased rate of ischaemic coronary presentations in the 90 days prior 
to MI, over half of first MI patients were unheralded by atherosclerotic disease diagnoses 
(56.5% (55.6-57.4%)). However, the great majority of people with no prior diagnosed 
atherosclerotic disease had identifiable vascular disease risk factors or had recent 
presentations with chest pain.  Survival analysis showed that patients with new ischaemic 
presentations shortly before MI - possible clinical correlates of ischaemic preconditioning - 
had less severe infarcts and improved survival in the first seven days after MI (Hazard Ratio 
for coronary heart disease mortality 0.64 (0.57-0.73), P<0.001) compared to patients without 
previously recorded ischaemia. However, in the longer term ischaemic presentations shortly 
before MI were associated with poorer survival.  Prescription of aspirin for primary 
prevention in the pre-MI period was also marker for attenuated MI severity, but with no 
effect on mortality or infarct size.  There was no association between statin use for primary 
prevention and outcomes at MI. 
Conclusions:  The novel prospective data used in this thesis have provided the opportunity 
to obtain new insights into MI as the first manifestation of ischaemic heart disease.   
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Chapter 1 Background 
 
1.1 Introduction 
This chapter describes the definition and burden of myocardial infarction in the UK, 
followed by a background to the topics covered in this thesis and the justification for this 
research project.   
 
1.2 Myocardial infarction 
1.2.1 Pathophysiology 
Myocardial infarction (MI), commonly known as a heart attack, occurs when blood 
flow in the coronary arteries is severely restricted or completely blocked, leading to 
ischaemia manifesting as chest pain, and myocardial cell necrosis.  Blockage of the arteries 
is usually the result of atherosclerosis and thrombosis (local coagulation of the blood) in the 
coronary artery.  Atherosclerosis is the process by which fatty material is deposited on the 
arterial wall, reducing the lumen diameter and the flow of blood to the tissue of the heart.  In 
some patients, atherosclerotic plaque rupture or erosion leads to thrombosis and sudden 
partial or complete occlusion of the artery.  During MI, if the blockage is persistent and 
unresolved (either spontaneously or through clinical intervention), then myocardial cell 
necrosis continues, reducing the function of the heart and leading to higher risk of patient 
death. 
 
1.2.2 The definition of MI in clinical care 
In patients presenting with suspected MI, a range of clinical tools must be used that 
allow the clinician to distinguish between chest pain of non-cardiac origin, unstable angina 
and MI.  The first standard definition in 1959[1] involved a typical history of chest pain, 
electrocardiogram (ECG) changes and the appearance of biochemical markers in the blood.  
In the subsequent fifty years, while these three basic components of the MI definition have 
been unchanged, the diagnosis of MI has been refined as more sensitive cardiac markers 
have been developed.[2]  Table 1.1 describes the evolution of the MI diagnostic definition 
since the first definition in 1959. 
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In the late 1990s, troponins, were introduced as new biomarkers that were more 
specific and sensitive than any of the previous markers.[2]  Its predecessor, creatine kinase-
MB, has sensitivity of about 70% and a false positive rate of 3.4% compared to a troponin 
gold standard.[3]  The heightened sensitivity of troponins means that even the smallest of 
infarcts can be identified.   
In 2000, the advent of troponins and the need for precise definitions in both clinical 
care and research led to the redefinition of MI  by the Joint European Society of Cardiology 
and American College of Cardiology Committee (Figure 1.1,[4]).  Since troponins can be 
elevated in other disease settings and not just MI, the diagnosis of MI is based on both a rise 
and fall of troponin (or other biomarker), along with one other indicator of ischaemia.   
In the UK, the increase in MI incidence resulting from the redefinition in 2000 has 
been estimated at between 26% and 58%,[3, 5] the latter representing an additional 160,000 
MIs in the UK each year.[5]   
 
Table 1.1 The changing definition of myocardial infarction (MI) from the first 
standard definition in 1959 to the latest revision in 2012. 
Year MI definition 
1959[1] First standard definition: typical history of chest pain, ECG changes 
and the appearance of biochemical markers in the blood. 
1959-
2000[2] 
The definition remained largely unchanged, but with the addition of 
increasingly sensitive and specific biomarkers 
2000[4] Redefinition of MI: 1. Typical rise and gradual fall (troponin) or more 
rapid rise and fall (CK-MB) of biochemical markers of myocardial 
necrosis with at least one of the following: 
a. Ischemic symptoms; 
b. Development of pathologic Q waves on the ECG; 
c. ECG changes indicative of ischemia (ST segment elevation or 
depression); or 
d. Coronary artery intervention (e.g. coronary angioplasty). 
Or pathologic findings of an acute MI. 
2007[6] Revised the 2000 definition, splitting the classification into different 
types (1-5), see Table 1.2. 
2012[7] Revised the 2007 definition, accounting for more sensitive biomarker 
assays and including the diagnosis of MI by imaging. 
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1.2.2.1 Types of MI: STEMI and NSTEMI 
In a hospital setting, an ECG is used in the diagnosis of MI.  The ECG trace is 
divided into segments, which are labelled alphabetically with the letters P to U (Figure 1.2).  
Assuming the other criteria for MI have been met (chest pain and rise and fall of a cardiac 
marker), MI can be separated into two types based on the appearance of the ST segment on 
the ECG (Figure 1.2).  Elevation of the ST segment indicates ‘ST-elevation MI’ (STEMI) 
and absence of ST-elevation indicates a non ST-elevation MI (NSTEMI).  ST-elevation 
suggests severe (full myocardial wall thickness) ischaemia and the diagnosis of STEMI must 
only be offered after a rise and fall of cardiac biomarkers.   
STEMI and NSTEMI are thought to have different physiologies but since their 
classification was introduced only a decade ago, aetiological research is still ongoing.  
However, patients with STEMI tend to be younger, with fewer cardiac and non-cardiac co-
morbidities[8] and some studies have shown a better long term prognosis than 
NSTEMI.[9, 10]   
 “Either one of the following criteria satisfies the diagnosis for an acute, evolving or 
recent MI: 
1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis with at least one of the following: 
 
a. Ischemic symptoms; 
b. Development of pathologic Q waves on the ECG; 
c. ECG changes indicative of ischemia (ST segment elevation or 
depression); or 
d. Coronary artery intervention (e.g. coronary angioplasty). 
 
2. Pathologic findings of an acute MI.” 
Figure 1.1 Criteria for acute, evolving or recent myocardial infarction (The Joint European 
Society of Cardiology/ American College of Cardiology Committee definition, 2000) 
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Figure 1.2 Two electrocardiogram (ECG) traces, with segments P to U labelled.  
Normal ECG (above) and with ST-elevation (below). Adapted from 
stemcellmx.com[11] 
 
Figure 1.3 shows a scheme for the diagnosis of STEMI and NSTEMI.  Briefly, 
patients with chest pain are given an ECG to identify the presence and severity of ischaemia.  
Based on these results and on a characteristic rise and fall in troponins (or another sensitive 
and specific cardiac marker), a diagnosis of STEMI or NSTEMI can be given.  For patients 
without the rise and fall in cardiac markers, non ST-elevation acute coronary syndrome 
(ACS) (unstable angina) may be diagnosed.  
 
Chest pain 
  
ECG 
            
    
ST-elevation 
or LBBB     
no ST-
elevation    
    
Measurement 
of troponins     
Measurement 
of troponins   
          
      
Rise and fall 
of troponins   
Rise and fall 
of troponins   
No rise and 
fall of 
troponins 
      
STEMI     NSTEMI     Unstable angina 
                    
LBBB: left bundle branch block, ECG: electrocardiogram; STEMI: ST-elevation myocardial 
infarction; NSTEMI: non ST-elevation myocardial infarction. 
 
Figure 1.3 Simplified scheme of the classification of acute coronary syndromes, 
reproduced from White and Chew[12]  
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1.2.2.2 The new definition of MI in 2007 and 2012 
In 2007, a revised version of the MI definition was published.[6]  This updated the 
definition and separated MI into categories based on the circumstances leading to the infarct 
(Table 1.2).[6]  This revision also acknowledged that different conditions can lead to low 
levels of myocardial necrosis, which, given the sensitivity of troponins, need to be accounted 
for when diagnosing MI.   
In 2012, a third consensus document was published that further refined the diagnosis 
of MI based on more sensitive biomarker assays and the diagnosis of MI in specific disease 
settings.  It also defines MI through the use of advanced imaging techniques such as 
echocardiograms, radionuclide, MRI and CT scans which can show new loss of viable 
myocardium or new regional wall motion abnormality.[7]  This is of use in situations where 
the rise and fall of biomarkers cannot be observed.     
Throughout all definitions, the requirement for chest pain, ECG and cardiac 
biomarker findings has been unchanged. 
 
Table 1.2 Universal clinical classification of different types of myocardial infarction.  
Reproduced from the second consensus definition of myocardial infarction, 2007[6] 
 
Type 1 Spontaneous myocardial infarction related to ischaemia due to a primary 
coronary event such as plaque erosion and/ or rupture, fissuring, or dissection. 
Type 2 Myocardial infarction secondary to ischaemia due to either increased oxygen 
demand or decreased supply, e.g. coronary artery spasm, coronary embolism, 
anaemia, arrhythmias, hypertension, or hypotension 
Type 3 Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischaemia, accompanied by presumably 
new ST-elevation, or new LBBB, or evidence of fresh thrombus in a coronary 
artery by angiography and/ or at autopsy, but death occurring before blood 
samples could be obtained, or at a time before the appearance of cardiac 
biomarkers in the blood. 
Type 4 Myocardial infarction associated with PCI, stent thrombosis as documented by 
angiography or at autopsy. 
Type 5 Myocardial infarction associated with CABG. 
LBBB: left bundle branch block; PCI: percutaneous coronary intervention; CABG: coronary 
artery bypass graft. 
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1.2.2.3 Implications for this thesis 
The MI data analysed in this thesis are drawn from clinical care between 2003 and 
2008.  Throughout this period, the in-hospital diagnosis of MI was based on CK-MB or 
troponins and ECG results.  The high sensitivity of the troponins to detect small amounts of 
myocardial necrosis means that small infarcts that would previously have been classified as 
unstable angina (pre-2000) are now labelled as MI.  Therefore, the cohort of MIs analysed in 
this thesis may be different to historical studies of MI.  The new consensus documents in 
2007 and 2012 aimed to refine rather than alter the definition of MI, so were unlikely to 
have impacted the work in this thesis.   
 
1.2.3 Incidence and prevalence of MI in the UK 
While there has been a decline in both MI incidence and mortality over the past 
three to four decades,[13] the incidence of MI in the UK is still at 200-220 per 100,000 men 
and 80 to 90 per 100,000 women.[14]  This corresponds to roughly 124,000 MIs in the UK 
per year.  It is estimated that 23% of women and 26% of men with MI do not reach 
hospital[15] and of those who do, 11% do not survive the subsequent year.[16]  In the UK, 
approximately one in five deaths in men is due to coronary heart disease, making it the 
second leading cause of death (behind cancer).  In women, one in eight deaths are due to 
coronary heart disease, making it the third leading cause of death behind respiratory disease 
and cancer.  
Reducing the incidence of MI would be beneficial in health terms, bringing a 
reduction in preventable long-term morbidity and mortality.  It would also reduce the costs 
to the NHS, which currently spends over £4 billion on CHD care.[17]   
 
1.3 Limitations of MI research 
Traditionally, large studies of MI are retrospective in design, identifying patients at 
the time of MI and enquiring about pre-MI exposures.  Therefore, detailed data occurring 
just before MI are not collected by most studies.  Population-based cohort studies collecting 
data prospectively are often too small to capture sufficient MI patients to study subgroups, 
and often do not collect data frequently or in enough detail to study MI in detail.   
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1.4 Unprecedented opportunities for MI research offered by new 
data 
Recent linkage of routinely collected records from primary care, hospitalisation, MI 
registry and cause-specific mortality data has presented unprecedented opportunities for 
coronary heart disease research in the UK.  As well as providing enormous statistical power, 
the linkage of these different datasets greatly improves the quality of the data available and 
provides new opportunities to establish validity.  The prospectively collected primary care 
data, combined with the detail collected in the MI registry in terms of timing, infarct size, 
type and treatment, and the incident outcomes gathered from hospital and mortality 
statistics, together provide a rich data source for CHD research which allows the patient 
journey to be reconstructed from primary care registration through to death.  This is unique 
compared to the Scandinavian data linkages, which lack general practice data.[18]  Linkage 
of these routinely collected data sources provides data with huge depth and breadth at a 
relatively low cost.  
However, while the advantages of using routinely collected data for research make 
their use attractive, there are some key disadvantages that must be considered when 
undertaking research using such data.  These include the lack of relevant data for some 
research questions (for example on lifestyle and behaviours in the datasets described above), 
missingness, and the potential of confounding by indication for studies of therapies.  These 
limitations restrict the types of analyses that can be performed using routinely collected data.  
The analyses described in this thesis have therefore been      
Given the wealth of research that has been made possible by the linkage of these 
data sources, the next section describes the aspects of MI research that are addressed in this 
thesis.  The focus is on the unique data gathered prior to MI, an important period because it 
is a time when a patient may experience new symptoms or be treated with new drugs that 
might impact their subsequent MI and survival.  The next two sections describe the 
importance of this period with regard to (i) atherosclerotic disease, risk factor and chest pain 
manifestations prior to MI, and (ii) pharmacological treatment. 
 
1.5 The evolution of atherosclerotic disease prior to first MI 
Reconstructing the patient journey from general practice registration through to MI 
allows the onset and evolution of atherosclerotic disease, risk factors and chest pain prior to 
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MI to be determined.  This is important for two reasons, described in sections 1.5.1 
and 1.5.2.   
 
1.5.1 Does MI occur without warning? 
Due to the lack of prospective research in MI overall, the onset, evolution and 
timing of atherosclerotic disease prior to first MI is not well described.  Given the recent 
decrease in MI incidence and relative increase in angina incidence,[19, 20] the reduction in 
cardiovascular disease risk factors,[21] and the updated definition of MI,[22] an 
understanding of heralding of MI by disease, risk factors and chest pain would provide an 
understanding of where there may be missed opportunities for care.  Better identification of 
patients who manifest with MI without the ‘warning’ of previous disease, risk factors or 
chest pain could enable improved prevention.  
 
1.5.2 Effects on outcomes 
There has been much interest in ischaemia occurring in the period prior to MI and its 
effects on outcomes.  Patients experiencing previous atherosclerotic disease prior to MI have 
increased risk of events in other arterial beds[23] and worse atherosclerotic disease than MI 
patients unheralded by previous disease, with more diseased vessels and stenoses.[24]  
However, evidence from a large body of literature suggests that outcomes in MI patients 
unheralded by disease may be worse than for those with manifest disease. 
 
1.5.2.1  Ischaemic preconditioning 
In 1986, Murry showed that brief periods of ischaemia prior to a more prolonged 
insult could protect against cell death.[25]  This phenomenon was termed ‘ischaemic 
preconditioning’ and was shown to reduce infarct size by 75%.  This was hailed as “one of 
the most powerful and reproducible methods of delaying cell necrosis”[26] and these 
findings were successfully repeated in many in vitro studies.[27]  Since these initial 
experiments, a large body of research has demonstrated the mechanisms by which ischaemic 
preconditioning acts.  These have shown that there are two windows of protection conferred 
by an ischaemic stimulus, as described in Figure 1.4.  The first is termed the classical phase, 
which was described by Murry and occurs in the twelve hours after the ischaemic stimulus 
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with strong but transient effects on infarct size.  The second is slightly delayed, termed the 
“second window of protection” (SWOP), and occurs in the 12-96 hours after a 
preconditioning stimulus.[27]   
 
 
Figure 1.4 The two phases of ischaemic preconditioning.  Reproduced from Yellon 
2003: Preconditioning the Myocardium: From Cellular Physiology to Clinical 
Cardiology[27] 
 
Ischaemic preconditioning can occur in clinical situations in addition to 
experimental in-vitro settings.  Of particular interest here, coronary ischaemia occurring 
prior to MI has been suggested as a clinical correlate to ischaemic preconditioning.[28]  This 
includes stable angina, unstable angina and chest pain occurring in the premonitory phase, 
i.e. the period shortly before MI.  Such prodromal symptoms of MI represent partial 
occlusion of the artery and may have a preconditioning effect similar to those reported in 
experimental studies.  The effects of these exposures have been studied retrospectively in 
hospitalised MI patients, in relation to in-hospital and longer term outcomes and have been 
associated with reduced infarct size,[29, 30] better outcomes at least in the short term,[31] 
and some evidence to suggest protection in the longer term.[32, 33]   
 
1.5.2.2 Collateral circulation 
Atherosclerotic disease diagnosed prior to MI may have other beneficial effects on 
survival compared to patients for whom MI is the first manifestation of disease.  Myocardial 
ischaemia is one of the triggers of angiogenesis and arteriogenesis,[34] which allow 
collateral circulation to develop, compensating for reduced blood flow in major arteries due 
to atherosclerotic narrowing.  Preinfarction angina has been described as a determinant of 
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collateral circulation,[34, 35] which has been associated with smaller infarct sizes.[36]  
However, not all studies have found developed collateral circulation in patients with 
previous myocardial ischaemia.[37, 38] 
 
1.6 Pharmacological management of cardiovascular disease risk 
prior to MI 
1.6.1 Prescription for primary prevention 
Aspirin and statins have been shown to reduce cardiovascular morbidity and 
mortality in large randomised controlled trials, both in primary and secondary prevention, 
[39-44] although the effect of aspirin for primary prevention is currently under question.[45] 
For patients with diagnosed atherosclerotic disease, these medications have a clear 
indication and should be prescribed after initial diagnosis according to guidelines from the 
UK National Institute of Health and Clinical Excellence.[46]  Indication for aspirin and 
statins in patients without diagnosed atherosclerotic disease is less clear-cut.  Guidelines 
currently recommend statins and until 2009 recommended aspirin to patients deemed to be at 
‘high’ cardiovascular disease risk.  Therefore, for all patients without diagnosed 
atherosclerotic disease, receipt of a prescription should be dependent on an assessment of 
cardiovascular disease risk and a decision by both general practitioner (GP) and patient.  
Due to (i) the uncertainties of risk prediction, (ii) the different risk prediction tools available, 
(iii) variation between GPs in their willingness to prescribe medications, and (iv) variation in 
patients’ willingness to use them, there is likely to be variation in adherence to these 
guidelines.   
Although MI events in patients without diagnosed atherosclerotic disease are 
unpredictable, it is these patients in particular for whom the medications should have been 
targeted.  But, as described previously, the period prior to first MI has not been well-studied 
and so little is known about the initiation and duration of use of these medications in patients 
who go on to have MI.      
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1.6.2 Effects on outcomes at MI 
While aspirin and statins are effective in reducing cardiovascular events in patients 
at high risk, they do not prevent all events.  There is an emerging body of evidence 
suggesting that both aspirin and statins have effects on outcomes in patients who have MI 
despite these treatments.  However, there is little evidence available for patients who are 
using these medications for primary prevention.  Detailed data regarding risk factors and 
atherosclerotic disease diagnosis would be an important part of a study designed to explore 
outcomes at MI, due to confounding by indication, and the possibility that different effects 
of these medications might be seen for patients with different levels of cardiovascular 
disease risk.  A beneficial or harmful effect of these medications could influence the 
decision to prescribe these medications. 
   
1.7 Summary of thesis rationale 
There are two main motivations for the work described in this thesis.  First, there is 
a unique opportunity for new research into MI due to the linkage of primary care, 
hospitalisation, MI registry and mortality data.  Second, the period preceding MI in patients 
without prior disease is of interest and is poorly understood.  Many MIs occur in people with 
no previous manifestation of CHD but relatively little is known about the epidemiology of 
such MIs because, by definition, they are unexpected events.   
While the linked data provide new opportunities, a first step in the use of such data 
is an assessment of its quality.  Once the data have been shown to be of sufficient quality, 
the analyses in this thesis will be well placed to provide insight into MI as the first 
manifestation of disease at three levels; firstly to characterise the type of patients who 
experience MI as the first manifestation of atherosclerotic disease, secondly to characterize 
the effects of presentation with ischaemia prior to MI on subsequent mortality, and thirdly to 
characterize use of primary prevention medications and their effects of outcomes at MI. An 
understanding at these levels will be valuable for the future investigation of preventative 
strategies. 
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1.8 Aims and objectives 
The aim of this thesis was to take advantage of the unique opportunities presented 
by the linkage of four data sources to investigate aspects of MI as the first manifestation of 
atherosclerotic disease.  Specific objectives were as follows: 
 
1.8.1 Objectives 
 
I. To compare capture, risk factors, mortality and diagnostic validity of myocardial 
infarction in primary care, hospital discharge, disease registry and mortality 
statistics.  
 
II. To examine the evolution of atherosclerotic disease and cardiovascular disease risk 
prior to first MI, cardiovascular disease risk factors and reported chest pain 
symptoms in first MI, including the timing of onset in relation to MI.   
 
III. To examine the occurrence and timing of ischaemic presentations, including new 
atherosclerotic disease in different arterial beds and chest pain before non-fatal and 
fatal MI, and their associations with infarct size and coronary heart disease 
mortality. 
 
IV. To examine the use of aspirin and statins prescribed prior to first MI for primary 
prevention and the effects on infarct severity, size and short term mortality.   
 
1.9 Organisation of the thesis 
This thesis is organised into seven further chapters.  Chapter 2 introduces the data 
sources used in this thesis and discusses their strengths and limitations.  Chapter 3 describes 
methods used through all analyses in identifying patients with MI and applying inclusion 
criteria.  Chapters 4, 5, 6 and 7 address each of the four objectives in this thesis.  Chapter 8 
draws together and discusses the evidence gathered in this thesis and makes final 
conclusions. 
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Chapter 2 Data sources 
 
2.1 Introduction 
This chapter describes the data sources used in studies described in this thesis: the 
General Practice Research Database (GPRD), the Myocardial Ischaemia National Audit 
Project (MINAP), Hospital Episode Statistics (HES) and the Office for National Statistics 
(ONS) mortality register.  Key characteristics of the four data sources are shown in Table 
2.1. 
The GPRD has now become the larger Clinical Practice Research Datalink (CPRD), 
“the new English NHS observational and interventional research service.”[47] The CPRD 
continues to collect data in the same way as GPRD, and also holds several other NHS linked 
datasets. 
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Table 2.1 Key characteristics of the four data sources in this thesis 
 
 GPRD HES MINAP ONS mortality register 
Type of data 
source 
Longitudinal primary care 
data 
National hospitalisation 
dataset 
Acute coronary syndrome 
(ACS) register 
National death census 
Who is included? Patients registered at 
primary care practices 
Patients with 
hospitalisations for any 
cause 
Patients hospitalised with 
acute coronary syndrome in 
NHS hospitals 
People who die in England 
and Wales 
Start of data 
collection 
1987 1997 2000 Cause of death recorded 
since 1841, but since 2001 
using ICD-10 codes,  
Geographic 
regions covered 
England, Wales, Scotland England England and Wales England and Wales 
Reason for dataset 
creation 
Data are entered as part of 
routine clinical care, and the 
database was set up for 
research 
To monitor hospital 
workload and outcomes of 
care 
To compare performance of 
hospitals in meeting national 
standards for ACS 
management 
To monitor trends in death 
What is recorded? Diagnoses, prescriptions, 
symptoms, lifestyle, 
vaccinations, test results etc 
Diagnoses, procedures Details regarding ACS 
diagnosis and management 
Date and cause of death, 
including underlying and 
secondary causes. 
How are data 
coded? 
Read codes: a hierarchical 
coding system containing 
roughly 99,000 codes 
International Classification 
of Disease, version 10 and 
Office of Population, 
Censuses and Surveys 
Classification of Surgical 
operations and procedures, 
version 4 codes 
In 120 fields with multiple 
response categories as 
defined by the MINAP 
steering group. 
International Classification 
of Disease, version 10  
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2.2 General Practice Research Database (GPRD) 
2.2.1 Overview 
The GPRD is a primary care database containing anonymised patient records for 
approximately eight percent of the UK population.[48]  It was established in 1987 and is 
now one of the world's largest databases of anonymised longitudinal medical records from 
primary care.[49] 
 
2.2.2 The data 
 
2.2.2.1 Who is in the database? 
About 630 general practices provide data to the GPRD[50] and all patients 
registered within these practices are included in the database until they die or transfer to 
another practice.  Roughly half of GPRD practices consented to linkage with HES, MINAP 
and ONS at the time of this work.  The practices chosen to participate in the GPRD are a 
representative sample of the UK, and since 98% of people in Britain are registered with a 
GP, patients within the GPRD are largely representative of the UK population.[51]  At the 
time of this work (September 2012), there were 5.2 million actively registered patients in the 
GPRD.   
 
2.2.2.2 How are data entered? 
The GP records data using Vision Software.  If a GP changes the software that is 
used in the practice, then they cannot contribute data to the GPRD.  In order to enter 
computerized information, the GP types a descriptive term for the symptom or diagnosis and 
chooses the most appropriate entry from a drop-down list of possible choices, with 
corresponding Read codes (a hierarchical clinical coding system of over 80,000 terms that 
are used in general practice in the UK[52]).  GPs are encouraged to use standardised 
recording practices for entering data.  The data are uploaded to the GPRD daily, after they 
have been processed at the practice level.     
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2.2.2.3 What is measured? 
A typical dataset from the GPRD contains information on a patient’s sex, age, year 
of birth and registration details. Participating general practices are required to record (i) each 
episode of illness, or new occurrence of a symptom, and (ii) all significant morbidity events, 
for example all significant clinical contacts, all significant diagnoses and abnormal test 
results, referrals to outpatient clinics and hospital admissions.[50]  Therapeutic information 
in the GPRD includes prescriptions using codes from the Prescription Pricing Authority, 
with the corresponding date, dosage and method of administration. Additional information is 
provided on vaccinations, weight and blood pressure measurements, laboratory test results 
and on some aspects of lifestyle.  All information is entered by practice staff and is 
anonymised prior to central collection.  The GP may also make comments about the patient 
consultation in a free-text section which can be linked to the codes for the consultation.  This 
free text is not provided to researchers unless a specific request for it is made. 
 
2.2.2.4 Data structure 
The data are structured into ten file types, each containing specific information 
regarding the patient and/or practice.  These are described in Table 2.2. 
. 
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Table 2.2 General Practice Research Database file types and their contents 
 
File type What it holds Example of contents 
Patient Demographic and 
registration status of 
patients 
Patient identifier, month and year of birth, 
social deprivation†, registration status, 
death date, transfer out date 
Practice Practice administrative 
data 
Practice identifier, geographical region, 
date practice became 'Up to standard', last 
data collection date 
  
Staff Information about the staff 
members entering data 
Staff identifier, gender, role 
Consultation Administrative information 
about the consultation 
Date of clinical event, date of data entry, 
type of consultation, staff identifier and 
duration of consultation 
  
Clinical Clinical data regarding 
medical history 
Date of clinical event, date of data entry, 
GPRD medical code for the chosen Read 
code, additional details identifier*, entity 
type 
Additional 
clinical details 
(ACD) 
Specific data about a 
clinical event 
Type of information held, called an 'entity', 
specific clinical details relating to that 
entity 
Referral Clinical data with relevant 
referrals to secondary 
care etc 
The GPRD medical code for the chosen 
Read code, method of referral,  referral 
specialty, urgency of referral 
Immunisation Data associated with 
immunisations 
Reason for immunisation, type, stage, 
status and the compound used 
   
Test Test results Type of test, result, normal range of result, 
unit of measure 
   
Therapy Information about 
therapies including 
medications and 
appliances 
GPRD product code, British National 
Formulary code, quantity of product, dose, 
pack size, number of days prescribed 
† Social deprivation measured using the Index of Multiple deprivation (see later). 
*Allows a link to be made between a Read code in the 'clinical file' to additional details 
held in the 'additional clinical details' file. 
 
The GPRD stores the majority of its data using Read codes.  Some Read codes link 
to the ‘additional clinical details’ (ACD) file, which contains further details (usually) 
relating to that Read code, for example a Read code indicating smoking status may be linked 
to ACD file holding physician advice about smoking.   
An ‘entity’ code recoded next to the Read code describes the kind of information 
stored in the ACD file (e.g. an entity code of 6 linked to any Read code indicates that the 
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ACD file holds smoking data).  It is important to ensure that both Read codes and 
appropriate entity codes are searched when searching for data in the GPRD. 
 
2.2.2.5 Patient identification 
In general practice the NHS number, name, date of birth, address and postcode are 
used to identify patients.  To protect patient identities these are removed before the data are 
centrally collected.  Each patient is assigned a unique patient ID and each practice is 
assigned a practice ID to prevent identification of patients at any time.  Although date of 
birth is removed, year of birth is retained so that analyses by age can be conducted. 
 
2.2.3 Data quality 
 
2.2.3.1 Quality measures undertaken by the GPRD 
The GPRD has measures to ensure that the data it provides are research-quality.  At 
the practice level, the GPRD implements ‘up to standard’ (UTS) dates for participating 
practices.  The UTS date is deemed as the date at which the practice is considered to have 
continuous high quality data fit for use in research. This is calculated using an analysis on 
the total data in the practice, and is refreshed every time data are collected from the practice 
and processed into the database.  
Up to standard criteria include a comparison of practice death and event rates to the 
general population. It also ensures that patients who have transferred out of the practice or 
have died are recorded correctly and “is based on an assessment of the completeness, 
continuity and plausibility of data recording in key areas, in accordance with the GPRD 
Recording Guidelines.”[50]  
When a practice is UTS, then its data are recommended for use by researchers.  If a 
practice no longer meets the UTS criteria, then their records are still included in the database 
but should not be relied upon by researchers.  
At the patient level, each patient in the GPRD is labelled as ‘acceptable’ or not 
based on a number of conditions including the validity of registration status, gender, age and 
year of birth (see Appendix A, section 10.1.1).  If any of these conditions are violated, the 
patient’s record is labelled as ‘unacceptable’ and is not recommended for research. 
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2.2.3.2 Quality measures assessed by independent researchers 
In addition to the measures taken by the GPRD to ensure data quality, many 
independent, peer-reviewed publications have examined the validity of individual diagnoses.  
A systematic review of 357 validation studies of GPRD diagnoses estimated the median 
positive predictive value at 89%.[53]  This means that for 100 diagnoses coded in the 
medical records, 89 can be verified using information from either inside or outside the 
database.  A second validation study of diagnoses in the GPRD also found high positive 
predictive values for most diagnoses.[49]  Some studies have also shown that GPRD data 
also have high sensitivity, high specificity and good completeness, although few studies 
have been able to assess this.[54-60]  Most of the diagnoses and risk factors to be used in 
this project have undergone validation.  Validation studies investigating atherosclerotic 
disease and cardiovascular disease risk factors are described below. 
 
Validation of atherosclerotic disease 
• MI has been validated in the GPRD several times and using a number of methods.  
Firstly the incidence of MI in the GPRD was found to be similar to that in other general 
practice data.[61]  Secondly anonymised copies of paper medical records, hospital 
discharge summaries or death certificates were obtained to validate the MI diagnosis 
using further diagnostic criteria.[59, 61-64]  The positive predictive values from these 
studies ranged from 85% to 100%.  Thirdly, in three studies, a questionnaire 
investigating various aspects of the computerized diagnosis was sent to the GP.  The 
positive predictive values in these studies ranged from 53% to 96%.[59, 61, 65]  
Finally, two studies carried out a manual review of the complete computer records 
(including the anonymised free text) for individuals with a diagnosis of MI.  The 
records were assessed for confirmatory evidence of disease status; between 72% and 
75% of individuals were confirmed as having MI.[66, 67]  The estimates from these 
studies provide reliable evidence that the diagnosis of MI is valid within the GPRD. 
However, no studies have examined the validity of the timing of the MI code with 
respect to the true date of MI.  These results, from many different designs and study 
populations within the GPRD, indicate that the positive predictive value of MI 
diagnosis in the GPRD is likely to be high. 
Chapter 2 
48 
 
• Coronary heart disease (CHD) was validated by Moser;[68] the prevalence of treated 
CHD in the GPRD in 1996 was “broadly comparable” to that from the 1994 Health 
Survey for England.[69]  While the Health Survey for England is not necessarily an 
adequate ‘gold standard’ data source, the comparability of the two sources gives some 
indication of the accuracy of recording in both the GPRD and the Health Survey for 
England.  However, the same result could also indicate that both sources are equally 
poor at detecting coronary heart disease.   
• Two validations of stroke by GP questionnaire showed that the positive predictive value 
of a diagnosis of a cerebrovascular event was 86% and 93%.[59, 70]  These studies 
used over a thousand patients with cerebrovascular accident and validated against a 
reasonable gold standard (GP questionnaire, and a review of the full medical record).  
However, a manual review of stroke diagnoses recorded 51% as ‘probable’ and the 
remaining patients as ‘doubtful’.   
• Peripheral arterial disease has been validated once and had a positive predictive value 
of 71%[59] when compared to a GP questionnaire and medical record review.  
However, this study was performed in the 1990s and recording of peripheral arterial 
disease may have changed over time.  It was also performed in a relatively small 
number of patients (n=86), so the estimate may be imprecise.   
 
Validation of cardiovascular disease risk factors 
Hypertension and dyslipidaemia have been validated by comparing prevalence or 
incidence rates in the GPRD to those recorded in the Health Survey for England or Hospital 
Episode Statistics: rates were shown to be broadly comparable, again providing some 
indication of the accuracy of recording in these sources.[71-73]  Diabetes has been validated 
many times using different methods and has shown to have high positive predictive value 
and similar rates to other sources.[51, 59, 68, 74-78]   
Smoking was validated in patients with inflammatory bowel disease who had 
received an oral corticosteroid prescription.  The researchers compared the electronic records 
to the GP’s own records.  This showed that the sensitivity of a current smoking diagnosis on 
a particular date was 78%, with a positive predictive value of 70%.[79]  For behavioural 
factors that can change from one consultation to the next, these values are reasonable.  
However, in a group selected for a specific morbidity, the validity of a smoking record may 
be different to patients without the morbidity (for example those with inflammatory bowel 
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disease in this study may consult more frequently with the GP and have more opportunity to 
have an up-to-date smoking status recorded accurately).  There is also likely to have been an 
improvement in recording of smoking since the introduction of the Quality and Outcomes 
Framework (see section below).  Other cardiovascular disease risk factors (body mass index, 
family history) have not been validated in the GPRD. 
 
2.2.3.3 Quality measures driven by the Quality and Outcomes Framework 
For the past eight years, data quality in primary care has been driven by the Quality 
and Outcomes Framework (QOF), introduced to general practice in 2004.  Over 99% of GPs 
are signed up to this voluntary scheme, which provides financial incentives to GPs to 
maintain good practice in four clinical domains and can contribute 25% of their income.[80]  
One of these four domains is the clinical domain, encouraging quality of care and recording 
of key chronic morbidities (including secondary prevention of CHD, primary prevention of 
cardiovascular diseases, heart failure, stroke and transient ischaemic attack, hypertension, 
diabetes, chronic obstructive pulmonary disease, epilepsy, hypothyroidism, cancer, palliative 
care, smoking mental health, asthma, etc).[81]  There is some evidence to suggest that the 
scheme has led to an acceleration in the improvement of care for coronary heart disease, 
asthma and diabetes, although the improvements may now have reached a plateau,[80] and 
in fact the introduction of the QOF may actually lead to a reduction in the quality of care in 
areas not covered by the clinical indicators.[80] 
 
2.2.4 Linkage to other databases 
For this project, the GPRD will be linked with MINAP, HES and ONS mortality 
data.  Details of this linkage are described in Appendix A, section 10.1.2.  The GPRD has 
also been linked with cancer registry data and, with the recent creation of the Clinical 
Practice Research Datalink (CPRD), is set to be linked to many other datasets.   
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2.2.5 Publications 
The GPRD has been widely used for observational studies, and has more 
publications than any other primary care database, with over 890 studies published to date in 
peer-reviewed journals.[50]  Examples of important work based on GPRD include the 
findings that statins are associated with a decrease in the risk of dementia,[82] oral 
corticosteroid use is associated with an increase in risk of fractures,[83] the raised risk of MI 
in patients with psoriasis,[84] and the null association between the Measles, Mumps and 
Rubella vaccination and autism.[85] 
 
2.2.6 Strengths  
There are four key strengths of the GPRD as a research tool: 
1. Size; there are 5.2 million currently registered patients in the database, but data are 
available for a total of 11 million patients (68 million person years of data).[86]  
This provides researchers with the power to investigate rare diseases and look at risk 
in sub-groups;   
2. Representativeness of the UK population; and therefore the ability to generalise 
results from GPRD studies to the population;   
3. Data quality; data are maintained to a high standard by GPRD checks and this is 
supported by independent validation studies of diagnoses;[53] and  
4. Storage of the complete medical history of patients in the GPRD; this allows 
researchers to access detailed, prospectively collected data without recall bias. 
 
2.2.7 Weaknesses 
While the GPRD is an excellent source of data for research in primary care, 
researchers should be aware of the limitations of the data and consider ways of addressing 
these during analysis.  These limitations are discussed in the following sections: 
 
2.2.7.1 Missing data 
While recording of data on key morbidities is now improved due to the introduction 
of the QOF,[80] GPRD does not routinely record some lifestyle factors (e.g. height, weight, 
diet, alcohol consumption).  Additionally, any morbidity for which a patient does not require 
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a GP visit will not be recorded (e.g. minor respiratory infections).  In addition, some 
medications are available over the counter, making it impossible to record all therapies used 
by patients.   
Although recording of some key lifestyle factors and morbidities is poor, the 
missingness is unlikely to be at random.  It is more likely that these factors are recorded if a 
patient is more at risk, for example smoking status is more likely to be recorded if the patient 
is a current smoker,[79] and blood pressure more frequently recorded in those who have 
high blood pressure.[87]  Therefore, analysis using only non-missing data may lead to some 
bias in estimates using such lifestyle factors.  This could be negated by use of multiple 
imputation, but imputing missing values in this way can only be done with extreme care due 
to the unknown mechanism of missingness.[88] 
 
2.2.7.2 Frequency of consultation 
For some registered patients there is no or very little follow-up data after initial 
registration with the practice.  Patients who do not consult frequently are a problem for two 
reasons.  First, if they have transferred out of the practice without informing the practice, 
then their inclusion in studies will introduce error, as their outcomes could never be 
recorded.  Inclusion of these people in studies would lead to underestimation of incidence 
and outcomes.  Second, if a patient attends only infrequently, then their chances of receiving 
a diagnosis or a treatment will be less than for a patient that consults more frequently.  
However, removing patients without frequent consultations runs the risk of removing real 
healthy people and biasing the study towards an unhealthier group. 
 
2.2.7.3 Recording of existing morbidities 
When a patient joins a practice and visits the GP for a ‘new patient check-up’, their 
medical history is recorded.  This new coding of existing morbidities can be a problem for 
researchers wishing to calculate incidence.  Inclusion of this new period of registration in 
calculations of incidence can therefore result in overestimates.  To avoid any bias, the initial 
period of registration should therefore be excluded.  Evidence suggests that after the first 
year of registration, the recording of most major acute and chronic conditions has reached 
the baseline levels.[89] 
 
Chapter 2 
52 
 
2.2.8 Summary and suitability of GPRD data for this project 
The GPRD is a representative and valid source of data covering all aspects of 
primary care, from basic demographic data to diagnoses, therapies and hospital visits.  Such 
a rich data source enables this project to investigate the occurrence of atherosclerotic 
disease, cardiovascular disease risk factors and the prescription of therapies for the primary 
and secondary prevention of MI; these prospective data before MI represent a unique 
strength.  
Chapter 2 
53 
 
2.3 The Myocardial Ischaemia National Audit Project (MINAP) 
2.3.1 Overview 
The Myocardial Ischaemia National Audit Project (MINAP) is the national registry 
of patients admitted to hospitals in England and Wales with acute coronary syndromes 
(ACS).[90]  It was established by clinicians in 1998 to provide participating hospitals with a 
mechanism to audit their performance against standards defined in the National Service 
Framework (NSF) for coronary heart disease (CHD).[90, 91]  
The NSF standards aimed to improve care and access to care for patients with CHD. 
MINAP relates to the framework’s standards for treatment of ST-elevation MI (STEMI) 
patients, and those for the prescription, at discharge, of aspirin, beta blockers and statins in 
all ACS patients. However, data are also collected in MINAP on all other of forms of ACS 
(non ST-elevation infarctions (NSTEMIs) and troponin negative ACS) and their treatments 
(including primary angioplasty, prescription of clopidogrel etc).  Users of MINAP are 
therefore able to examine these aspects of coronary care in addition to those relating to the 
NSF. 
Data collection began in October 2000 and by mid-2002 all hospitals admitting 
emergency patients in England and Wales were participating in the registry.  MINAP data 
are held by the Central Cardiac Audit Database (CCAD) Group,[92] which has developed a 
highly secure electronic system to collate, hold and analyse national cardiac data 
confidentially. CCAD provides the National Institute for Clinical Outcomes Research 
(NICOR) with a dataset stripped of identifiers for audit and research purposes.  MINAP is 
currently funded by the Health Quality Improvement Partnership.[93] 
 
2.3.2 The data 
2.3.2.1 Who is in the database? 
MINAP collects a wealth of information regarding the care and outcomes of patients 
with ACS who attend one of over 225 participating National Health Service (NHS) hospitals 
in England and Wales. Each year the database accrues approximately 85,000 episodes of 
care.  Hospital staff are encouraged to enter data, using the MINAP data application 
software, for all ACS patients admitted to hospital.     
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2.3.2.2 What is measured? 
Data are collected for each patient from ambulance paramedic crews, accident and 
emergency departments and cardiac care wards. The MINAP dataset holds 123 fields[94] 
under the following categories; patient demographics, admission method, the timing of care 
given, clinical features and investigations (e.g. ECG result, cardiac biomarkers), past 
medical history (including prior cardiovascular disease risk factors, atherosclerotic disease 
and procedures, family history), drug treatment prior to admission, detail of primary 
reperfusion treatment, drug treatment in hospital, clinical complications, interventional 
treatments, hospital outcome, discharge diagnosis and discharge (secondary prevention) 
treatment (e.g. referral to specialist units).[90]  Importantly, MINAP records MI type: ST-
elevation MI and non ST-elevation MI (defined in Chapter 1).   
The dataset is revised every two years to meet the requirements of users and to 
respond to changes in management of patients.  For example, the dataset was updated to 
incorporate data items which reflect the National Institute for Health and Clinical Excellence 
guidelines for secondary prevention of MI (e.g. to record the provision of smoking cessation 
and dietary advice).  Revisions are also made in response to changes in the definition of 
acute coronary syndrome. 
 
2.3.2.3 Patient identification 
Patients are identified by their unique NHS number, which is stored in 
pseudonymised format and used to link the data to subsequent events or procedures 
undergone by the patient.  Names and addresses, including post code of residence, are 
collected by the hospitals but are not stored centrally or available to researchers.  Patient age 
is supplied to researchers rather than date of birth because this is considered too strong an 
identifier.  The NHS number and local patient case record number are encrypted before the 
data are uploaded to the secure central database.  
 
2.3.3 Data quality  
2.3.3.1 Accuracy 
MINAP provides detailed guidelines and technical advice for data entry and makes 
recommendations to staff entering the data in order to maintain data quality and ensure 
continuity of data collection.  There is also a dedicated MINAP helpdesk for problems 
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regarding data entry and clinical definitions. The MINAP data entry program is designed to 
minimise common errors that arise in entering data, with range and consistency checks to 
improve accuracy.  Staff are asked to enter data concurrently with the patient’s hospital stay 
to improve accuracy and efficiency.  
 
2.3.3.2 Validation 
An annual MINAP validation exercise requires each hospital to re-enter 20 items of 
data from the original medical records of 20 randomly selected MINAP patients, using a 
specially designed data validation tool. These 20 items are set by MINAP and include NHS 
number and variables regarding diagnosis, treatment, outcome and discharge. Agreement 
between the original and re-entered data is assessed for each of these variables. Areas in 
which agreement is inadequate (Measure of reliability Kappa value below 0.5) are identified 
and the underlying cause is resolved where possible. Reports are sent to hospitals identifying 
areas of weakness and advice is available to improve performance. Agreement varies 
between fields (high in key fields, slightly lower elsewhere) but in the 2008 validation, the 
median level of agreement between MINAP data and re-audit data (across all hospitals) was 
89.5%.[95]  This exercise has been compulsory since 2004 and allows hospitals to compare 
their performance with others and maintain the quality of their data.  
 
2.3.3.3 Completeness within the dataset  
Thirty six key fields are mandatory within the dataset including NHS number, date 
and time of arrival at hospital, discharge diagnosis, time to reperfusion therapy (if given), 
hospital mortality and secondary prevention medication prescribed at discharge. Annual 
checks for completeness are made in 20 other key variables and in 2007/8 these were 98% 
complete.[96] The completeness of variables that were not intended for audit use (e.g. 
family history of coronary heart disease, height, weight, blood pressure, previous MI or 
angina) is slightly lower but is improving with time (unpublished findings).  There are some 
data items which are incomplete because the data are not available, for example if a patient 
is sent to another hospital for intervention, and that intervention is not known, the field will 
be left blank.  
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2.3.3.4 Studies assessing validity of MINAP 
To date, there have been no peer-reviewed studies examining the validity of MINAP 
data, including its completeness.   
 
2.3.4 Linkage to other data 
The Central Cardiac Audit Database Group facilitates mortality tracking for MINAP 
records using the Office for National Statistics, which provides vital status and date of death 
for patients in the database, although cause of death cannot be determined. The MINAP 
dataset has been linked to other databases and national registries using NHS number as a 
unique identifier.  For example, MINAP has been linked with the coronary interventional 
database held by the British Cardiovascular Interventional Society (BCIS), and the surgical 
data held by the Society of Cardiothoracic Surgeons.[97, 98]  Linkage of MINAP with other 
datasets offers a unique opportunity to validate individual cases of STEMI and NSTEMI 
recorded in MINAP. 
 
2.3.5 Research published using MINAP data 
The original purpose of MINAP was to provide contemporary analyses to hospitals 
so that they were able to relate their performance to the nationally agreed targets outlined in 
the NSF CHD.[91]  For example, a NSF target for England was for 68% of “heart attack” 
patients to receive thrombolytic treatment within 60 minutes of calling for help. MINAP 
data showed that this target was exceeded in 2008/09 with an average of 72%.  The 
performance of each hospital is summarised in an annual public report “How the NHS 
manages Heart Attacks” (e.g.[96]).   
The MINAP Academic Group, based at NICOR at University College London, 
encourages use of the MINAP data for research.  This group ensures that any research 
conducted using MINAP data is of a high standard and that researchers adhere to the 
guidelines for use of the data.  
One of the first publications using MINAP showed data in relation to the original 
NSF CHD targets, focusing on access to treatment for patients with acute MI.[99] This 
showed that speed of treatment had improved with time and that the proportion of acute MI 
patients given thrombolysis had increased during the study period (1993-2002). Analyses of 
data from 2004-2005 by Birkhead[100] showed that the outcome and management of MI 
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was partly dependent on the specialty of the physician admitting the patient. Weston et 
al[101] used MINAP data to identify a reduction in mortality in non-diabetic 
hyperglycaemic patients who are treated with insulin when presenting with ACS.  
Ben-Shlomo[102] analysed data from 2002-2003 to assess ethnic differences in both 
healthcare-seeking behaviour and the in-hospital management of acute chest pain. This 
revealed that people of South Asian origin are less likely to use ambulance services and are 
managed differently to other ethnic groups in hospital. Gale et al[103] used the MINAP data 
to examine predictors of hospital outcome in patients with ST-elevation infarctions, finding 
that aspirin use and pre-hospital thrombolysis predicted survival, while increasing age, 
systolic blood pressure and heart rate predicted mortality.  Most recently, Birkhead et 
al[104] showed that angiography in NSTEMI patients has a beneficial effect on mortality, 
which was not modified by age, sex or co-morbidity. 
These publications highlight the potential of the database for answering a diverse 
range of questions about acute coronary syndromes.  The ability of MINAP to adapt over 
time and the continuous improvement in completeness will further add to its utility as a 
database fit for research. 
 
2.3.6 Strengths 
MINAP’s strengths are its size and population coverage. Data are collected from 
every acute hospital in England and Wales even though participation is not compulsory.  
Therefore, the data should be representative of all ACS patients hospitalised in England.  
Data have now been collected for over 800,000 ACS events from across England and Wales, 
giving users of the data unprecedented power to answer research questions relevant to small 
subsets. Additionally, with 123 variables describing exact timings of the events, prior 
morbidity, treatment, diagnosis and follow-up, the detail of the data represents another great 
strength.  Importantly, MINAP holds data on MI type, distinguishing between STEMI and 
NSTEMI.  Data regarding MI type are not available in HES or ONS data and are 
infrequently recorded in GPRD. 
 
2.3.7 Weaknesses 
There is uncertainty in the completeness of patient capture.  While some 
participating hospitals do record all patients admitted with suspected ACS, other hospitals 
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predominantly record only those with STEMI, which leads to under-reporting of NSTEMI.  
This may be to the lack of an agreed national standard of care for NSTEMI and other ACS, 
so hospitals with limited resources for data entry might choose to record STEMI 
preferentially, where their results can be measured against targets. In addition, where 
patients with non ST-elevation ACS are not exclusively admitted to cardiology wards, 
patient ascertainment is likely to be less complete.  Many patients (with both STEMI and 
NSTEMI) are now transferred between hospitals during the index event, which makes data 
capture more difficult. The threat to data capture of inter-hospital transfers is however, being 
addressed by linking MINAP records between hospitals.[90]  There have been no formal 
investigations to look at the capture of patients within each hospital and some hospitals are 
more rigorous with data collection than others.  
Incomplete patient capture within hospitals raises concerns about the 
representativeness of MINAP data.  This concern is amplified because a proportion of ACS 
patients die before, or soon after reaching hospital, or are admitted to private hospitals 
(although in England and Wales the number of patients admitted to private hospital will be 
negligible).  These people will be omitted from the database. 
Missingness needs to be addressed in some data fields. For example, for the 444,519 
events recorded in the years 2003-2007 inclusive, 26,032 had either age or sex missing 
(5.9%). Removing events with incomplete data (in the variables of interest) leaves a 
reasonable number of events for analysis because the database is so large.  However, 
patients with missing data may be different to patients with complete data, so removing them 
from the analysis may lead to a selection bias. Cattle et al[105] demonstrated that patients 
who have missing data in a field relating to angioplasty are more likely to have died than 
those with complete data.    
The cost of local data entry is not covered by MINAP’s funding. Each hospital must 
therefore make a financial contribution to the project to support data entry, and this 
contribution is subject to variability. As a consequence, those responsible for data entry may 
not have clinical expertise, which could lead to variability in data accuracy. 
 
2.3.8 Summary and suitability of MINAP for this project 
The MINAP database is a unique and valuable resource for researchers interested in 
the risk factors, treatments and outcomes of ACS. The detailed information recorded in the 
database creates scope for a wide range of research using MINAP data alone; linkage to 
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other sources creates an even more valuable and versatile resource. Within its first decade 
MINAP has gathered information on almost 800,000 events, which provides unprecedented 
power to investigate subgroups of risk.   
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2.4 Hospital Episode Statistics (HES) 
 
2.4.1 Overview 
Hospital Episode Statistics (HES) is a data warehouse of hospital discharge coding 
data, established in 1987 to facilitate the collection and use of hospital data in England.[106]  
Its main purposes are: 
• To monitor hospital workload and outcomes of care; 
• To compare workloads between different geographical areas and hospital 
trusts; 
• To study lengths of hospital stay and other measures of efficiency with 
which care is delivered; 
• To monitor waiting lists; and 
• To study the epidemiology of hospitalised disease.[107] 
Prior to the creation of HES (since 1950), data on a smaller sample of hospital 
admissions were collected[107] but HES now undertakes data collection from all NHS trusts 
in England by the department of Health and are held by Northgate Information Solutions on 
behalf of the NHS Information Centre for health and social care (NHS IC).   
 
2.4.2 The data 
2.4.2.1 Where do the data originate? 
HES data are input by clinical coders based on patient notes at the end of the 
admission.  These data are submitted to the Secondary Uses Service (SUS) (part of the NHS 
Information Centre), which has a dual role of providing the data to the Department of Health 
and copying it into a database.  Monthly, the SUS data are extracted and sent to HES.  Staff 
at SUS then validate and clean the data extract according to a set of rules before making it 
available to researchers.[106] 
 
2.4.2.2 Who is in the database? 
Data are collected “for each episode of admitted patient care delivered in England 
by NHS hospitals or delivered in the independent sector but commissioned by the 
NHS.”[106]  This means that data are collected for in-patients (since 1989), outpatient 
appointments (since 2003), accident and emergency (A&E) (since 2007) and adult critical 
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care (since 2008).  Data from admitted patients comprises over 16 million episodes of care 
per year and the addition of outpatient data provides a further 60 million new records per 
year.  A&E data add 12 million records per year.   
 
2.4.2.3 What is measured? 
Each HES record contains information in the following four areas:[106] 
1. Information about the patient, for example age, gender, ethnicity, socioeconomic 
status; 
2. Clinical information about diagnoses and operations (one main diagnosis and up to 
13 secondary diagnoses and twelve operation fields); 
3. Administrative information (admission and discharge dates, time waited on waiting 
list, date of admission, length of stay and the specialty of the consultant); and 
4. Geographic information (e.g. where the patient lives, where they are treated, the 
NHS trust providing care). 
 
HES collects data using three sets of codes: the World Health Organisation’s 
International Classification of Diseases Tenth Revision (ICD-10), the Office of Population, 
Censuses and Surveys Classification of Interventions and Procedures fourth revision (OPCS-
4), and A&E Clinical Codes.   
ICD-10 collects data on conditions being investigated or treated at the hospital 
admission, OPCS-4 records the procedures and interventions performed, while the A&E 
clinical codes record diagnoses, investigations and procedures that are undertaken during 
A&E attendance.   
Since the start of data collection in 1989, changes have been made to the data that 
are collected in response to updated coding systems (ICD and OPCS).  ICD-10 codes are 
now used to code the ‘primary’ diagnosis, defined by HES as “the main condition treated or 
investigated during the relevant episode of healthcare”.[106]  There is also space in the 
database for up to 13 additional secondary diagnoses to collect data on other conditions or 
co-morbidities that are relevant to patient care.  Similarly, the OPCS-4 codes are used to 
code a main procedure or intervention, with space for up to 12 secondary procedures or 
interventions. 
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2.4.2.4 Episodes, spells and patient identification 
The unit of measure in HES is the ‘Finished consultant episode’ (FCE), which is 
defined by HES as “a period of admitted patient care under a consultant or allied healthcare 
profession within an NHS trust”.  FCEs are grouped together in ‘spells’, which represent all 
FCEs in a single hospital admission.  Therefore, each ‘spell’ can have many FCEs as 
patients are often transferred between specialties and treated by more than one consultant 
during their stay.  Around 8% of hospital admissions have more than one episode of 
care.[108] 
NHS numbers are collected and individual patients are given a unique HES 
identifier during data cleaning, which allows researchers to identify multiple hospital 
admissions for the same patient.  NHS number, date of birth, address and postcode are not 
distributed by HES in order to maintain confidentiality. 
 
2.4.3 Data quality 
The nature of data recording in HES means that quality can be affected in one of 
three stages.  First, the clinician must recognise and make a correct diagnosis in the patient, 
second the clinician must document that diagnosis in the clinical notes, and third the coders 
must receive the notes and classify the diagnosis correctly using ICD-10 or OPCS-4 codes.   
While HES has procedures and checks to maintain quality, hospital data quality was 
cited as a concern by the Audit Commission in 2002,[109] and the report made several 
recommendations for improvement.  More recent assessments of data quality by the audit 
commission have shown improvements in quality,[110] but as discussed below, several 
independent studies undertaken by researchers have shown that quality is still poor in some 
areas.   
 
2.4.3.1 Data quality procedures in HES 
A HES data quality team monitors the data.  Following receipt of the data, cleaning 
takes place in a four stage process:[106] 
1. Provider mapping, which ensures that the hospital codes are correct and usable, 
mapping old codes to new ones where appropriate; 
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2. Automatic cleaning, which uses a predefined list of rule to deal with common errors 
in the dataset, for example the removal of extra characters in the codes (spaces, 
ampersands, full stops); 
3. Manual cleaning, which removes duplicated data and removes episodes outside the 
required date range; 
4. Derivation, which allows HES to add certain fields that SUS does not store (e.g. 
Primary Care Trust fields, age group, descriptions of codes, and HES identifiers). 
Throughout this process, the data quality team produces reports to ensure that the 
processes are occurring correctly and to identify any novel issues that have not been dealt 
with.  HES also publishes reports that list known issues of data quality.  The data quality 
team also feeds back information to the data providers themselves, encouraging them to take 
responsibility for the data that they provide and preventing problems arising in the next 
extract.  There are also regular audits of coding in each hospital. 
 
2.4.3.2 Independent studies of HES data quality 
Several small studies have assessed the quality of data in HES.  Some have focused 
on the reproducibility of codes: a study comparing locally entered diagnostic codes with 
codes entered by external coders showed that exact agreement was 43%- 60% for general 
diagnoses but was higher for acute diagnoses (appendicitis 51%-65%).  Approximate 
agreement was higher for general diagnoses and was yet higher (78-80%) for 
appendicitis.[111]  This indicates that although subtypes of a diagnosis may be recorded 
poorly, the overall diagnosis is likely to be correct. 
Other studies have focused on completeness: in 2002, Williams and Mann[112] 
conducted a review of validation studies looking at completeness of hospital discharge 
coding since 1990.  This showed that hospitals were failing to capture all in-patient and day-
case episodes; completeness was between 66% and 84% for diagnoses.  Accuracy of 
procedure recording was also low.  The authors attributed the inaccuracy and missingness in 
the data to the time of coding, which occurs after the spell is complete (i.e. the patient is 
discharged).  This evidence is now old and completeness is likely to have improved over 
time after the Audit Commission recommendations and the introduction of the government 
‘Payment by Results’ scheme,[113] which offers financial rewards for accurate and 
complete coding.  Evidence of an improvement with time is shown by Hodgson et al,[114] 
who compared hospital discharge coding of type 1 diabetes with a diabetes register and 
found the concordance was 91% in 2000-2006, but only 52% in 1992-1999.   
Chapter 2 
64 
 
A study of the coding of abdominal aortic aneurysm (AAA) showed good 
consistency (95%) between the presence of a repair code and a concurrent diagnostic code 
for AAA.    
While evidence from Welsh hospital-based data suggest that serious, acute 
diagnoses such as MI are only 10% under-recorded,[115] a more recent study of MI 
outcomes (2009) has shown that recording remains suboptimal in England.[116]  In a 
comparison of hospital discharge coding (on which HES is based) to the Oxford Vascular 
Study (OXVASC), the authors identified 820 incident MI cases in OXVASC.  Of these 
cases, only 53% were captured in hospital discharge data as acute MI (ICD-10 I21, I22).  A 
further 25% had less specific ischaemic heart disease codes, but 21% had no coronary codes 
at all.[116]  This suggests that improvements are still needed in recording of hospital data. 
 
2.4.4 HES data for academic purposes 
HES was designed for use in epidemiological studies and has been used as such, 
resulting in several hundred publications focusing on diverse outcomes including 
MI[117, 118] and other atherosclerotic disease,[119, 120] cancer,[121] pregnancy[122] and 
mental health.[123]   
 
2.4.5 Strengths 
HES data are collected by the hospital providers as part of routine care and as such 
form a rich dataset for researchers interested in the primary diagnosis or cause for 
hospitalization, and also in secondary or complicating conditions.  HES is nationwide in 
England and is therefore a representative source of data for patients in England.  It collects 
information on over 16 million episodes of in-patient care each year; this wealth of 
information allows researchers to assess the burden of rare conditions and allows subgroup 
analyses for more common conditions.  The Payment by Results scheme encourages coding 
of incident and relevant prevalent diagnoses of the patient, so important co-morbidities 
should be recorded.[113]  Data quality is improving with time and HES cleans and validates 
the data, thus ensuring that the data are of the best possible quality given the restraints of 
time and cost.   
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2.4.6 Weaknesses 
As a routine source of data, HES is subject to missingness, duplicated data and 
incomplete records.  Concerns have been raised about the quality of the data, and in 
particular for the completeness of recording of MI.  However, there have been no large-
scale, peer reviewed studies to examine all aspects of the data quality and highlight the 
strengths and weaknesses of the data.   
 
2.4.7 Summary and suitability of HES for this project 
The focus of this project is patient with MI.  While HES classifies diagnoses 
according to ICD-10, which does not distinguish between STEMI and NSTEMI, the types of 
MI, it has strong data on co-morbidities.  Linkage with MINAP provides additional data on 
type of MI, admission and diagnostic test characteristics.   
The lack of in-depth, large validation studies of the HES data highlight the 
importance of the new linkage of HES with GPRD, MINAP and ONS.  This linkage 
provides a new platform in which to assess the validity of acute coronary syndromes in HES.  
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2.5 Office for National Statistics (ONS) mortality records 
 
2.5.1 Overview 
The Office for National Statistics (ONS) mortality records are a complete database 
of death records for England and Wales.  Registration of death has been a legal requirement 
since 1837, after the introduction of the Births and Deaths Registration Act, and they have 
been recorded with a cause of death since 1841.  The government have collected statistics on 
cause of death from the late 19th century in order to monitor public health, allocate resources 
and evaluate public health policies.[124]   
 
2.5.2 The data 
As death registration is mandatory in the UK, any person who dies in England and 
Wales should be included in the database.  Data are entered by a local registrar.  In three 
quarters of deaths, the registrar refers directly to the Medical Certificate of Cause of Death 
(MCCD), which is completed by the doctors involved in the patient’s care and includes 
information on the underlying and other causes of death.  Learning how to fill in this form 
correctly is part of training for doctors.  One quarter of deaths are referred to a coroner (e.g. 
if patient was not seen by a doctor, cause is unclear, unnatural or suspicious) and in most 
cases the coroner confirms the information written on the MCCD.  If the cause of death 
remains unclear, data from a post-mortem or inquest are used in death registration.  
The MCCD has two parts.  Part I contains the underlying cause, which is the most 
frequently used data in routine health statistics, and is defined as either “the disease or injury 
which initiated the train of events directly leading to death”, or “the circumstances of the 
accident or violence which produced the fatal injury”.[125]  Part II records details of 
associated conditions “that contributed to the death but are not part of the causal sequence”.  
In the coding of death certificates, rules are applied to ensure that the most useful 
information regarding the cause of death is recorded in the appropriate place, and that data 
are comparable. 
Classification systems used to record mortality statistics have evolved over time to 
reflect new knowledge on the causes and types of diseases, and the World Health 
Organisation (WHO) is now responsible for maintaining the coding system: the International 
Classification of Diseases, now in its tenth revision (ICD-10) and used across much of the 
world to record both fatal and non-fatal disease.  ONS mortality data have been coded using 
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ICD-10 since 2001.[124]  Patients are identified in the ONS mortality database using their 
unique NHS number.   
 
2.5.3 Data quality 
Registrars at Local Registration Services enter data into an online system, which has 
validation checks to ensure that data are correct.  ONS performs regular diagnostic tests on 
data to identify problems: local registrars are contacted if any problems are identified.   
When the data have been uploaded to the ONS database, they are subject to a series 
of further validation processes that are designed to identify inconsistencies in the data, for 
example to ensure that all fields are complete, to check that the conditions on the death 
certificate are compatible with the gender and age of the deceased, cross-field internal 
comparisons and plausibility checks.[126] 
 
2.5.4 Summary and suitability of ONS for this project 
  ONS mortality data are a complete source of death data for England and Wales.  
They hold data on the date and underlying cause of death, which is important in this project 
to identify patients dying from MI who do not reach hospital and may not be captured in any 
of the other data sources. 
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2.6 Linkage of GPRD, MINAP, HES and ONS mortality 
 
2.6.1 Purpose of the linkage 
The Cardiovascular disease Research using Linked Bespoke studies and Electronic 
Records (CALIBER) group established the linkage of the GPRD, MINAP, HES and ONS, 
combining the rich data from each source into a single dataset.  Using such a dataset, 
researchers can address questions on the sequence and progression of  cardiovascular disease 
events and investigate their association with a range of risk factors.[127]  In creating this 
dataset, CALIBER has allowed reconstruction of the longitudinal patient journey from GP 
registration through to death (Figure 2.1).  These four data sources were linked by a trusted 
third party on behalf of the CALIBER group.  Details regarding the linkage are described in 
Appendix A, section 10.1.2.   
 
 
Figure 2.1 Linked data from CALIBER and the longitudinal patient journey 
(reproduced from Denaxas et al, 2012[127]) 
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2.7 Chapter summary 
• This chapter described the data sources to be used in this thesis: GPRD, HES, 
MINAP and ONS.   
• Each data source was created for a different purpose and each has important 
strengths and weaknesses. 
• Linkage of the national audit of MI with general practice records, hospital 
admissions data and mortality data from the Office for National Statistics provides 
major advances in terms of data quality and validity, and offers new opportunities 
for research with unprecedented power, ability to distinguish types of MI, and 
ability to follow patients prospectively through their medical record to death.    
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Chapter 3 General methods 
 
 
3.1 Introduction 
This chapter describes how the linked GPRD, MINAP, HES and ONS data were 
used to identify patients with first MI and identify morbidities, risk factors and prescriptions 
of cardiovascular medications. 
 
3.2 CALIBER data 
 
3.2.1 Converting raw data to research-ready data  
Following linkage of the four data sources by the Trusted Third Party, six billion 
records of raw data were available for research.[127]  However, these data were not in a 
usable form and required extensive processing to make them ready for researchers.   
I played a key role in developing a transparent, reusable approach to convert the data 
from their raw form to a research-ready dataset.  For each data source, this involved 
identifying where usable data may be held within the dataset and developing a strategy to 
extract and code it in a useful way that could be modified to suit researcher needs.  As 
discussed in the following sections, this involved developing a good working knowledge of 
the structure of each data source, an understanding of how each of the risk factors and 
morbidities in this thesis could be diagnosed, monitored and treated, and generating lists of 
codes for use in GPRD, HES and ONS.  Following identification of appropriate codes in 
each source, the data had to be brought together to create variables for use in the analyses for 
this PhD, for example as in Figure 3.1, which describes the way in which data are used from 
GPRD and HES to define patients with hypertension. 
This work culminated in the creation of a CALIBER data manual, see Appendix B.  
This work was a vital step in ascertaining good quality data for this thesis and the data 
manual is now being used by other researchers using CALIBER data. 
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*Secondary hypertension indicates hypertension induced by an underlying secondary cause, such as 
renal or endocrine disorders.  This category was only used when Read or ICD codes stating 
‘secondary hypertension’ were used and was not inferred from any other morbidity. Primary 
hypertension did not have specific Read codes and therefore was not defined here. 
Figure 3.1 CALIBER hypertension variable creation from multiple electronic health 
records sources, a combination of a) repeat continuous blood pressure measurements 
b) categorical data on measured blood pressure c) hypertension diagnosis in primary 
care d) hypertension diagnosis during hospitalisations and e) prescription of blood-
pressure lowering medications.  Reproduced from Denaxas et al, 2012[127] 
  
*
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3.3 Using GPRD data 
 
3.3.1 Creating variables using GPRD data 
As discussed in Chapter 2, the GPRD stores the majority of its data using a set of 
100,000 Read codes that represent terms for diagnoses, symptoms, tests, procedures, 
behavioural and demographic information, in addition to the GP’s management of 
conditions.  There are usually several Read codes that indicate a single diagnosis or 
procedure (e.g. to describe subtypes, synonyms or complications of a diagnosis).  To capture 
all patients with a particular condition, researchers can choose to do one or more of the 
following: 
• Develop a list of Read codes to indicate the diagnosis, specific symptoms, 
management, treatments and procedures used for the condition;  
• Develop a list of Read codes that indicate clinical tests, the results of which 
(available in the additional clinical details (ADR) file) can define disease 
(e.g. HbA1c and diabetes);   
• Develop a list of relevant Entity codes, which indicate further specific 
information held in the additional clinical details file, (e.g. there are specific 
Entity codes for various disease registers, to indicate the results of height 
and weight measurements, to indicate smoking status etc); and     
• Develop a list of medications specific to the diagnosis so that the diagnosis 
can be inferred from prescriptions (e.g. insulin prescription indicates 
diabetes). 
Variables for conditions in this thesis were therefore created based on a combination 
of some or all of the above information in the GPRD. 
 
3.3.2 Generating Read code lists in the GPRD 
The GPRD does not provide a standard protocol for creating lists of Read codes to 
represent a certain condition.  There are also few widely available code lists for commonly 
studied conditions.  Therefore, the CALIBER group created a standard operating procedure 
(SOP) for code list development and implemented the SOP to generate the lists of codes for 
the diagnoses, procedures, symptoms and tests used in this thesis.  I was part of a four 
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person team that developed the SOP.  The list of code lists used in this thesis to identify 
patients with cardiovascular disease and cardiovascular disease risk factors in the GPRD are 
shown in Table 3.1 and Table 3.2.  The steps in the SOP are shown in Figure 3.2.  The SOP 
was designed to maximize both the sensitivity of the initial search of Read codes, and the 
specificity of the final list by removing incorrect codes at the rating stage.   
 
3.3.2.1 Rating Read codes according to variable definitions 
For all diagnoses, procedures, symptoms and tests, Read codes were rated against 
agreed definitions (see CALIBER manual) by two independent raters, both of whom were 
clinicians (including one general practitioner).  Codes were categorized as follows: 
• Not indicative of the diagnosis (presence of the code did not indicate that 
the patient had the diagnosis); 
• Reliant on test result to indicate presence or absence of diagnosis (e.g. a 
code indicating a glucose tolerance test would be linked to a result in the 
additional clinical details file, the results of which might confirm a diabetes 
diagnosis); 
• ‘Possible’; 
• ‘Definite’; or 
• ‘History of’ the diagnosis (where the code indicated that a diagnosis had 
been made in the past and did not indicate incident morbidity). 
For some variables, categories were more specific.  See the CALIBER data manual 
for the classification of each variable.  Discrepancies between raters for all codes were 
resolved by discussion. 
For test results to confirm or refute diagnoses, raters assigned a cut-off, based on 
national standards or clinical guidelines.  Abnormal test results (defined by either categories 
in the data or by cut-offs) were considered as ‘definite’ indicators of the diagnosis; 
potentially abnormal test results (or borderline results) were considered as ‘possible’ 
indicators of disease.   
The Read code lists produced using this method were compared to the code lists of 
other researchers (where available) to check the validity of raters’ coding.  If any terms were 
missing, the search terms were updated and new codes were rated. 
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3.3.2.2 GPRD conflicting codes 
Where more than one code was recorded to indicate the presence or absence of a 
diagnosis, in the event of a conflict arising, the ‘worst case scenario’ was assumed, 
increasing the sensitivity of the code search.    
 
 
 
Figure 3.2 Standard operating procedure: method of Read code list creation in the 
GPRD 
  
 
*Conditions included diagnoses, procedures, symptoms, and tests. 
Two clinicians, including at least one general 
practitioner, generate list of keywords for the 
condition*, including all synonyms and 
abbreviations.
Keywords converted to search terms, including 
wildcards and all combinations of terms. An 
automated algorithm in Stata searches for 
these terms in the GPRD dictionary 
(SEARCH 1).
The search is re-run with updated search terms 
and exclusion terms, generating a preliminary 
code list (SEARCH 2).
Two clinicians, including at least one general 
practitioner, rate the list against condition 
definition.
Read terms that are identified in SEARCH 1 
are retained.  Based on these terms, terms that 
should be excluded or any missing synonyms 
or abbreviations are identified.
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Table 3.1  GPRD cardiovascular disease Read codes lists and the number of codes 
included 
 
GPRD cardiovascular disease Read code lists 
N Read codes in 
list 
Coronary disease and its tests 
Acute coronary syndrome 1 
Stable angina 26 
Unstable angina 14 
Coronary artery bypass graft 66 
Percutaneous coronary intervention 30 
Cardiac arrest 37 
Cardiac markers NOS 7 
CK-MB 3 
Troponins 6 
Resting ECG 123 
Exercise ECG 12 
Coronary angiogram, modality NOS 12 
Coronary angiogram results 3 
Coronary CT angiogram 1 
Coronary invasive angiogram 14 
Coronary MRI angiogram 1 
Stress echocardiogram 1 
Radioisotope scan 15 
CHD NOS 10 
Heart failure 93 
Echocardiogram 19 
Myocardial infarction, type NOS 62 
ST-elevation MI 1 
Non ST-elevation MI 1 
Thrombolysis 21 
Angiography, anatomy NOS 5 
Cerebrovascular disease and its tests 
Cerebral haemorrhage 50 
Ischaemic stroke 11 
Stroke NOS 43 
Transient ischaemic attack 9 
Carotid angiogram 6 
Carotid ultrasound 4 
Cerebral CT 3 
Cerebrovascular disease procedures 30 
Ischaemic cerebrovascular disease NEC 87 
Peripheral arterial disease and its tests 
Peripheral arterial disease 73 
Peripheral arterial angiogram 16 
Peripheral arterial ultrasound 6 
Abdominal aortic aneurysm 14 
Abdominal aortic angiogram 6 
Abdominal aortic ultrasound 2 
Peripheral arterial disease procedures 152 
Abdominal aortic aneurysm procedures 82 
Atherosclerotic disease NEC 31 
Sudden cardiac death 1 
Chest pain 38 
NOS: not otherwise specified; NEC: not elsewhere classified; CHD: coronary heart disease; MI: 
myocardial infarction; ECG: electrocardiogram.  
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Table 3.2  GPRD Read code lists for cardiovascular disease risk factors and the 
number of codes included 
 
GPRD cardiovascular disease risk factors Read code 
lists 
N Read codes in 
list 
Diabetes and its tests 
Diabetes diagnosis 513 
120 minute glucose tolerance test 2 
Fasting plasma glucose 1 
Fasting serum glucose 3 
Glucose tolerance test 19 
HbA1c 17 
Hyperglycaemia 9 
Hypoglycaemia 28 
Plasma glucose 4 
Post-prandial glucose 4 
Serum glucose 36 
Glucose problems 16 
Dyslipidaemia 51 
Obesity and surgery 
Obesity 78 
Bariatric surgery 30 
Hypertension and its tests 
Blood pressure categories 69 
Hypertension 114 
Smoking 
Smoking 124 
Family history 
Family history of cardiovascular disease 43 
Family history of coronary disease 29 
Ethnicity 167 
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3.4 Using HES data 
 
3.4.1 Creating variables using HES data 
As described in Chapter 2, HES stores morbidity and mortality information using a 
set of 15,000 ICD-10 codes.  These are separated into a primary diagnosis for each episode 
within a hospitalisation, and thirteen additional secondary diagnoses.  In HES, the primary 
diagnosis for the first episode within the admission is usually the reason for admission, so is 
often used in research.  ICD-10 codes were hand-searched based on relevant search terms as 
defined in the Read code list search.  This produced a sensitive list of ICD-10 codes, which 
was rated by two clinicians and categorised according to the variable definitions, as 
described in section 3.3.2.  The list of code lists created for use with ICD-10 data in this 
thesis is shown in Table 3.3.  The code lists themselves are in Appendix B. 
 
3.4.2 OPCS-4 procedure codes in HES 
HES data regarding the procedures, operations and interventions performed during a 
hospitalisation are coded using the OPCS Classification of Interventions and Procedures, 
version 4 (OPCS-4).  For each condition, the complete list of 11,000 OPCS-4 codes was 
hand-searched using the search terms defined in the Read code list search.  Codes were rated 
according to variable definitions as described above in section 3.3.2.  The list of code lists 
for use with OPCS code are shown in Table 3.4 and the code lists are in Appendix B. 
 
3.5 Using MINAP and ONS data 
MINAP data contains morbidity data that were recorded in hospital.  No data 
manipulation was required to use these variables in defining atherosclerotic disease, risk 
factors or medication use. 
Use of ONS data was to define a date and cause of death only.  Any contributing 
causes of death that were listed alongside the underlying cause were not used to define 
previous comorbidity, as the timing of these morbidities is unknown.  
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Table 3.3  ICD-10 code lists created and the number of codes included 
 
ICD-10 code lists for HES and ONS data 
N ICD-10 codes in 
list 
Coronary disease 
Acute ischaemic heart disease 4 
Angina 4 
Unstable angina 1 
Cardiac arrest 5 
CABG 1 
CHD NOS 9 
Heart failure 8 
Myocardial infarction 23 
Cerebrovascular disease 
Cerebral stroke 26 
Ischaemic stroke 11 
Ischaemic cerebrovascular disease (non-stroke) 28 
Stroke NOS 11 
Transient ischaemic attack 2 
Peripheral arterial disease 
Peripheral arterial disease 4 
Abdominal aortic aneurysm 6 
Cardiovascular disease risk factors 
Diabetes 65 
Dyslipidaemia 10 
Family history of cardiovascular disease 2 
Hypertension 18 
Obesity 6 
Smoking 2 
Atherosclerotic disease NEC 6 
Sudden cardiac death 1 
 
 
Table 3.4  OPCS-4 code lists created and the number of codes included 
 
OPCS-4 code lists 
N ICD-10 codes in 
list 
Coronary disease 
Cardiac arrest procedures 16 
CABG 50 
PCI 20 
Other coronary procedures 2 
Thrombolysis 2 
Cerebrovascular disease 
Stroke NOS procedures 1 
Other cerebrovascular procedure 23 
Peripheral arterial disease 
Peripheral arterial disease procedures 77 
Abdominal aortic aneurysm procedures 66 
Cardiovascular disease risk factors 
  Hypertension drug prescribing 2 
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3.6 Myocardial infarction case definitions 
This section describes how MI was defined in each of GPRD, HES, MINAP and 
ONS.  Patients with MI in any of the four sources were considered to be potential cases.  
Inclusion criteria were then applied to generate the final cohort of patients. 
 
3.6.1 Myocardial infarction in GPRD 
Any patient with a code included in one of these seven lists was included as a 
potential case in the dataset (See Appendix A, section 10.2.1 for code lists):   
• Diagnosis of ST-elevation MI; 
• Diagnosis of non ST-elevation MI;  
• Diagnosis of MI of unspecified phenotype; 
• ST segment elevation or Q waves indicating MI on ECG; 
• Cardiac markers of unspecified type, shown to be potentially abnormal or 
abnormal;  
• CK-MB, shown to be potentially abnormal or abnormal; or 
• Troponins, shown to be potentially abnormal or abnormal. 
The date of MI was the date recorded by the GP.  If the event date was missing, it was 
imputed using the system date (the date that the data are entered by the practice staff), which 
is complete for all records. 
 
3.6.2 Myocardial infarction in HES 
HES MI was defined as ICD-10 codes I21 to I23 recorded as the primary diagnosis 
in the first episode of hospitalisation (see code lists in Appendix A, section 10.2.1).  The 
date of MI in HES was the date of admission.  Where this was incomplete, date of admission 
was imputed based on the date of discharge and median duration of stay in hospital for all 
MI patients.  Where both date of admission and discharge were missing, the patient’s record 
was excluded. 
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3.6.3 Myocardial infarction in MINAP 
MINAP MI was defined by an algorithm (as shown in Figure 3.3) based on the 
international definition of MI[6] using three MINAP variables: (i) discharge diagnosis, (ii) 
raised cardiac enzymes, and (iii) the ECG that determined treatment.  This algorithm was 
developed by the CALIBER group.  Patients given a discharge diagnosis of any acute 
coronary syndrome (ACS) were included in the study.  This included: 
• STEMI; 
• NSTEMI; 
• troponin positive ACS; 
• troponin negative ACS; or  
• ACS with unknown troponin.   
 
Patients with these discharge diagnoses were then re-categorised into STEMI, NSTEMI or 
unstable angina based on: 
1. The presence of absence of recorded raised cardiac markers, and  
2. ST-elevation or left bundle branch block (LBBB) on their ECG, as shown 
in Figure 3.3. 
A comparison of the discharge diagnosis and the CALIBER diagnosis is shown in Chapter 4.   
MINAP date of admission was considered to be the date of MI.  However, this 
variable was not complete (see Chapter 4).  Twelve remaining date variables, holding data 
regarding patient admission and quality of care, can provide a reasonable proxy for date of 
admission.  An algorithm was developed using these variables to impute missing date of 
admission (where incomplete) in the order shown in Figure 3.4.  This provided a near-
complete date of admission.  Patients without any information regarding the timing of MI 
were excluded from analysis.  Only the first admission for a CALIBER diagnosis STEMI or 
NSTEMI was included. 
 
3.6.4 Myocardial infarction in ONS 
ONS MI was defined based on an underlying cause of death coded as I21, I22 or 
I23.  The date of death was taken as the date of MI. 
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*In unimputed data, missing and unknown fall into this category. 
 
Figure 3.3 CALIBER algorithm to define MI phenotype in MINAP data using discharge diagnosis, cardiac enzymes and ECG data.  
Developed by McNamara, in collaboration with the CALIBER group
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Figure 3.4 MINAP variables holding date and time data  
1. Date of admission 
2. Date of arrival of emergency services 
3. Date of call for help 
4. Date of symptom onset 
5. Date of reperfusion 
6. Date of cardiac arrest 
7. Date of referral for investigation 
8. Date of daycase transfer 
9. Date of local angio 
10. Date of first local intervention 
11. Date of return referral 
12. Date of death or discharge 
13. Date of discharge* 
* Date of discharge alone is not a good proxy for date of admission as patients 
may remain in hospital for several days or weeks.  Median length of stay was 
calculated for patients with a complete date of admission and discharge (median 
6 days, IQR 3-10 days).  The median duration was then subtracted from the date 
of discharge to impute date of admission. 
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3.7 Inclusion criteria 
Patient inclusion in the study was based on the criteria described below.  A chart 
describing the flow of data losses is described in Appendix A, Section 10.2.3.   
 
3.7.1 Time period of interest 
To obtain the maximum information for each patient in the study, the time period of 
interest was constrained to the time when all four data sources were collecting data.  This 
was between 1st January 2003 and 31st March 2009, although MINAP data in 2009 were not 
complete.  Therefore, for the majority of analyses the data were cut at the end of 2008.  This 
also allowed for up to 18 months of post-MI follow-up for each patient, as GPRD and ONS 
data were available until mid-2010.  This was considered sufficient time in which to assess 
outcomes in the MI patients. 
 
3.7.2 First MI across the linked patient record 
To identify patients with their first MI, data from potential cases across all data 
sources were combined and the earliest record of MI was taken to be the patient’s first 
(Figure 3.5).  For patients whose MI was recorded in more than one database, a record in 
another data source within 30 days of the first was considered to represent the same MI 
event.  Records after 30 days were considered to be recurrent MI (Figure 3.6).  A 30 day cut-
off was used as this was considered a reasonable time in which different data sources should 
capture a record of MI, after which any recording is likely to indicate recurrent MI.  The 
validity of this assumption was tested in the analyses of Chapter 4. 
Patients with a recorded history of MI in GPRD, HES or MINAP were excluded.  In 
HES, a history of MI was defined with a more sensitive list of codes, including any patient 
previously receiving coronary thrombolysis, as recorded in the OPCS-4 dataset, with 
Dressler’s syndrome (ICD-10 code I24.1) and those with a code indicating history of MI 
(I25.2).   
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Figure 3.5 Identifying patients with first MI across the linked data sources who were 
included in this study 
 
 
Figure 3.6 Identifying MIs across more than one data source.  If a record is recorded 
within 30 days of the earliest record, it represents the same event  
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3.7.3 Patient registration with a GPRD practice at the time of first MI 
Within the GPRD practices that consented to the linkage, any patient ever registered 
was linked with MINAP, HES and ONS data.  However, the date of hospital admission in 
MINAP or HES did not necessarily overlap with the period of GPRD registration.  GPRD is 
the major source of risk factor and cardiovascular disease data in this study and therefore 
patients who registered with a GPRD practice after their MI or transferred out of the practice 
before their MI were excluded.   
 
3.7.4 At least twelve months of up to standard registration before first MI  
Patients with less than a year of up to standard follow-up before their MI were 
removed from the analysis (definition of UTS in Data Sources Chapter 2).  Evidence shows 
that one year of registration should provide sufficient time for prevalent and historical 
diagnoses to be made and risk factors to be measured.[89]   
 
3.7.5 At least one consultation in the UTS registration period before first MI 
After registering with a general practice, a change in patient circumstances (e.g. 
emigration, or moving into a nursing home) can mean that a patient never visits their GP.  
These patients, even if they were unwell, would not consult with the physician at their 
registered practice.  To avoid including such patients in the analysis, any patients without 
consultations prior to MI were excluded.   
The application of this inclusion criterion could have resulted in overestimation of 
the proportion of patients with previous atherosclerotic disease or cardiovascular disease risk 
factors through the exclusion of truly healthy patients (those who are more unwell are more 
likely to consult more frequently).  The number of patients who were excluded by this 
criterion was recorded and its impact on the final result was assessed. 
 
3.7.6 At least 18 years of age at the time of MI 
The focus of this thesis is in atherosclerotic cardiovascular disease and risk factors 
before MI occurring in adults.  Therefore, any MIs occurring in patients under 18 years old 
were excluded.   
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3.8 Identification of demographic variables 
 
3.8.1 Year of birth and sex 
Year of birth and sex in GPRD were likely to be more accurate than those recorded 
in an acute hospital setting in MINAP or HES.  Therefore, year of birth and sex were taken 
from GPRD data. 
 
3.8.2 Ethnicity 
Ethnicity data in each of the sources were not complete so data were drawn from 
GPRD, MINAP and HES, where recorded.  Ethnicity was classified as (i) white, (ii) south 
Asian, (iii) black or other, or (iv) unknown.   
In GPRD, ethnicity is recorded in the Read codes.  In MINAP there are two 
ethnicity variables, which were combined to reduce missingness.  For patients admitted to 
MINAP more than once, data from admissions before their MI were used to assess ethnicity.  
In HES, there is an ethnicity field.  Where there was discordance within or between data 
sources in the recording of these broad categories of ethnicity, the patient ethnicity was set 
to missing.   
 
3.8.3 Social deprivation 
Social deprivation data were provided by the Office for National Statistics and were 
provided as a score based on the Index of Multiple Deprivation (IMD) 2007.[128]  This 
measures deprivation in England using information from seven domains (income, 
employment, health deprivation and disability, education skills and training, barriers to 
housing and services, crime and the living environment). Measures are provided at the level 
of the lower-layer super-output area (SOA).  There are 32,482 SOAs in England with mean 
population size of 1500.  SOA data are therefore a suitably precise measure of deprivation at 
a local level.  Data from the IMD were divided into quintiles for analysis. 
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3.8.4 Duration of pre-MI registration 
The duration of registration prior to MI was calculated as the time between the date 
of MI and the current patient registration date with the GPRD practice.   
 
3.8.5 Number and rate of consultation prior to MI 
An inclusion criterion in this study was for patients to have at least one consultation 
after registration.  Additionally, the rate of consultation is an indicator of the general health 
of patients.  Every patient contact within general practice is recorded in the GPRD against a 
specific consultation type (e.g. doctor/nurse appointment, telephone consultation, acute visit, 
out of hours visit).  A list of relevant consultation types is shown in Appendix A, 
section 10.2.2.  The rate of consultation prior to MI was calculated as follows: 
 
 
 
 
3.9 Identification of atherosclerotic disease prior to MI 
Atherosclerotic disease was categorized into cardiac disease, cerebrovascular 
disease, peripheral arterial disease (including abdominal aortic aneurysm) and 
atherosclerotic disease of unspecified site.  MINAP, HES and GPRD data were used to 
identify patients with any of these subtypes.  Any morbidity recorded in the GPRD or HES 
up to the day prior to MI was considered to have occurred prior to MI.  Morbidities recorded 
in the medical history section of the MINAP hospital record were considered to have 
occurred prior to MI.  Data from MINAP were combined from the record of the case 
admission for MI in addition to previous non-MI admissions.   
All morbidities were classified as binary variables: present or not.  Only patients 
with ‘definite’ diagnoses (including abnormal test results) were defined as having 
atherosclerotic disease.  A sensitivity analysis was conducted in each analysis to examine the 
extent to which this decision affected results.   
N consultations in medical history prior to MI
N years of pre-MI registration
Rate of consultation =
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Each of the following variables, including their definitions, units, and data files 
used, plausible ranges for continuous values, and implementation instructions are described 
in the CALIBER data manual (Appendix B). 
 
3.9.1 Cardiac disease 
3.9.1.1 Stable angina 
Patients with stable angina were identified in the GPRD using a combination of 
Read codes for diagnoses and procedures, test results and prescription data.  Patients with 
Read codes for a diagnosis of stable angina (not including vasospastic angina or cardiac 
syndrome X), symptoms of ischaemic or exertional chest pain, or procedural codes for 
coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) were 
classified as having stable angina.  Also included were those with diagnosed one, two or 
three vessel coronary disease, those with an abnormal result following an ambulatory or 
exercise ECG, invasive, CT or MRI angiogram, radioisotope scan or stress echocardiogram 
and those with at least two prescriptions for an anti-anginal medication (BNF chapters 2.6.1 
(Nitrates: glyceryl trinitrate, isosorbide dinitrate and isosorbide mononitrate) and 2.6.3 
(Other anti-anginal drugs: ivabradine, nicorandil and ranolazine)).  One prescription alone 
could not define angina as patients may have been given nitrates to rule out an angina 
diagnosis; a subsequent prescription indicates that the nitrates worked and the patient is 
likely to have stable angina.  In HES, patients with angina were identified based on ICD-10 
diagnostic codes or OPCS-4 procedural codes for angina, CABG or PCI.  In MINAP, 
patients with angina were identified based on a recorded history on admission to MINAP.   
 
3.9.1.2 Unstable angina 
Patients were defined as having unstable angina if they had a previous admission for 
unstable angina in MINAP (as assessed using the CALIBER phenotype definition algorithm) 
or a diagnostic code for unstable angina, acute coronary syndrome, or acute ischaemic heart 
disease in the GPRD or HES.    
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3.9.1.3 Heart failure 
This included patients with a recorded history of heart failure on admission to 
MINAP, severe left ventricular systolic dysfunction (ejection fraction <30%), a diagnostic 
code for heart failure of any cause in the GPRD or HES (categorized as valvular, 
hypertension or unknown), or an abnormal echocardiogram in the GPRD.   Patients with a 
left ventricular ejection fraction of <55% were categorised as ‘possible’ heart failure.  
Sensitivity analyses were performed to determine whether the inclusion of patients with 
‘possible’ in addition to ‘definite’ heart failure affected the key results. 
 
3.9.1.4 Cardiac arrest 
Patients with cardiac arrest were identified based on a list of diagnostic and 
procedure codes in the GPRD and HES.  Patients were categorised as experiencing: 
• Ventricular tachycardia; 
• Ventricular fibrillation; 
• Implanted cardiac defibrillation device; or 
• Asystole, electromechanical death, cardiac arrest or resuscitation. 
 
3.9.1.5 Coronary heart disease not otherwise specified 
In the GPRD and HES, there are several unspecific codes that do not indicate a 
particular subtype of coronary disease, but are commonly used in patients with CHD.  
Therefore, these codes were assigned to a variable of their own.   
 
3.9.2 Cerebrovascular disease 
Cerebrovascular disease was identified based on a combination of diagnostic Read 
codes, abnormal test results and relevant procedures in the GPRD, a record of previous 
stroke at MINAP admission, or diagnostic and procedure codes in HES.  In the GPRD, 
relevant diagnostic Read codes included those indicating ischaemic stroke, stroke of 
unspecified subtype, transient ischaemic attack and non-stroke ischaemic cerebrovascular 
disease.  An abnormal cerebral CT, carotid angiogram or carotid ultrasound from GPRD 
data also indicated cerebrovascular disease.  
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3.9.3 Peripheral arterial disease (PAD) 
PAD, including abdominal aortic aneurysm, was identified based on a combination 
of diagnostic Read codes, abnormal test results and procedures in the GPRD, or a record of 
PAD at MINAP admission, or diagnostic and procedure codes indicating peripheral disease 
in HES.  Relevant Read and ICD-10 codes for AAA were only those deemed by the 
CALIBER group raters to be of atherosclerotic origin.  Abnormal abdominal or peripheral 
artery ultrasound scan, aortogram or peripheral artery angiography were defined as PAD.  
Finally, patients with procedures to repair AAA or the peripheral arteries identified patients 
with PAD. 
 
3.9.4 Atherosclerotic disease of unknown phenotype 
This category included Read or ICD-10 terms such as “Atherosclerosis”, which do 
not indicate a subtype or site of atherosclerotic disease.   
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3.10 Identification of cardiovascular disease risk factors prior to 
MI 
Records of cardiovascular disease risk factors were considered to be prior to MI if 
they occurred any time in a patient’s record up to one day prior to MI.  Except where noted, 
risk factors were categorised as binary variables: present or not. 
 
3.10.1 Systolic and diastolic blood pressure measurements 
Each record of blood pressure in the GPRD is entered as a systolic and/or diastolic 
measure.  After range and consistency checks of these values (implausible values were 
excluded –see CALIBER data manual for values, Appendix B), all of the systolic records in 
a patient’s pre-MI follow-up were averaged using the mean.  Systolic blood pressure 
measurements are available at admission in MINAP, but since these are occurring during 
MI, they were not used to indicate pre-MI coronary risk.  Blood pressure measurements are 
not recorded in HES.  Mean systolic blood pressure was used to calculate Framingham risk 
scores (see below). 
 
3.10.2 Hypertension 
Patients with hypertension were identified based on data from GPRD, HES and 
MINAP.  In GPRD, hypertension was defined in three ways.  Firstly by a diagnosis of 
hypertension, secondly patients with a series of three consecutive systolic or diastolic blood 
pressure measurements above the standard cut-offs for raised blood pressure (>140mmHg 
systolic, >90mmHg diastolic) within one year, and thirdly patients with three or more 
consecutive Read codes indicating ‘high/raised blood pressure’ within one year.  The cut-
offs for high blood pressure were lower in non-diabetic patients to reflect NICE guidelines.  
Patients with a definite code for diabetes had a cut-off of diastolic blood pressure of 
>80mmHG, and for systolic >130mmHg.  In MINAP, hypertension was defined based on a 
recorded medical history of hypertension.  In HES, hypertension was identified based on 
OPCS codes for anti-hypertensive drug treatment or an ICD-10 diagnostic code for 
hypertension. 
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3.10.3 Dyslipidaemia 
Patients with dyslipidaemia were identified based on Read codes in the GPRD, ICD-
10 codes in HES or a medical history of dyslipidaemia in MINAP.  Due to the common 
prescription of lipid-regulating drugs even in patients without dyslipidaemia, these drugs 
were not included in the definition.  Due to the lack of consensus in the literature with 
respect to cholesterol measures, measures of total, HDL and LDL cholesterol were not 
assigned cut-points.  Where these individual risk factors were relevant to analysis as 
confounders, they were included as continuous variables. 
 
3.10.4 Total serum cholesterol and HDL cholesterol 
All total serum and HDL cholesterol measurements recorded in a patient’s pre-MI 
follow-up were extracted from the GPRD, based on code lists.  These were averaged using 
the mean to generate a single measure each for total and HDL cholesterol.   
 
3.10.5 Overweight and obesity 
Body mass index (BMI) was calculated for all patients based on GPRD and MINAP 
data.  Range and consistency checks were in place for these values (as sometimes weight is 
recorded in stones, and height in feet); implausible values were excluded (see CALIBER 
data manual).  Patients were categorised as underweight (BMI<18.5kg/m2), normal weight 
BMI≥18.5kg/m2 and <25kg/m2) overweight or obese (BMI≥25kg/m2) according to the 
World Health Organisation definition. 
In GPRD, BMI is recorded many times during patient follow-up.  The measure 
closest to the MI date was considered to be the most accurate BMI for the patient.   
Patients who were overweight or obese were identified using a code list indicating 
obesity in the GPRD and HES, or by a BMI of ≥25 recorded in MINAP or GPRD.  Patients 
prescribed bariatric surgery or anti-obesity drugs (Orlistat or centrally acting appetite 
suppressants, from GPRD data) were also considered to be obese.  Patients without any BMI 
data or Read codes indicating weight categories were defined as unknown. 
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3.10.6 Smoking 
In GPRD data, smoking is often recorded many times during patients follow-up to 
reflect and monitor changes over time in patient behaviour.  An algorithm was applied to the 
data to deduce the most likely smoking status for the patient at the time of MI.  This is based 
on one or more measures prior to MI and (sometimes) after MI.  If this was different to the 
MINAP record, then by default the MINAP record was used as the smoking status at MI, as 
it was considered to be the most up to date record.  Smoking status is not recorded in HES.   
Smoking status was defined as current, ex, or non.  Patients without any record of smoking 
status were defined as unknown. 
 
3.10.7 Diabetes 
A definite diagnosis of diabetes was identified based on a MINAP record of diabetes 
at admission, a HES code for diabetes, or one of the following from the GPRD data:  
1. Read codes indicating diagnosis of diabetes, its complications or 
hyperglycaemia; 
2. At least two prescriptions of anti-diabetic drugs (insulin or oral anti-
diabetics);  
3. Abnormal blood glucose or HbA1c levels (≥ 48 mmol/mol or ≥ 6.5%),  
4. Abnormal glucose tolerance test (based on a GP recorded result);  
5. Abnormal plasma or serum glucose (≥11.1mmol/l) or fasting plasma glucose 
(≥7.0 mmol/l); or  
6. Abnormal post-prandial glucose (≥11.1mmol/l). 
 
Where tests or Read codes were potentially abnormal or borderline, diabetes was 
coded as possible.  Women prescribed metformin who were under 50 years of age were not 
considered to be diabetic based on this prescription alone, as metformin is used to treat 
polycystic ovary syndrome. 
 
3.10.8 Family history of CHD 
Patients with a family history of CHD were identified based on code lists in the 
GPRD and HES data, and on a recorded family history in MINAP. 
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3.10.9 Framingham risk score 
The Framingham risk score for ten year hard CHD (MI or coronary heart disease 
death) endpoints[129] was calculated using the information derived for age, sex, average 
total and HDL cholesterol, smoking, systolic blood pressure and use of blood pressure 
lowering drugs.  For total cholesterol, HDL cholesterol and systolic blood pressure, the 
mean of all values recorded prior to MI was taken for each patient, and these composite 
measures were used in calculation of the Framingham score.  The rationale for using mean 
measures, rather than the last value prior to MI (or e.g. the mean in the year prior to MI), 
was to maximise the use of the longitudinal data available.  Additionally this strategy may 
have captured raised cardiovascular disease risk more accurately in patients with historically 
raised cholesterol or blood pressure, which had subsequently been brought to normal levels 
by cardiovascular medications.  The consequences of this decision are discussed in Chapters 
6 and 7, where Framingham scores and their components are used in regression models. 
The score was categorised into patients with <10% risk, 10-20% risk and >20%.  
This score is intended for use in patients 30-79 years of age; patients older than 79 were 
considered to have the same risk as those who were 79.  Due to missingness in some of the 
components of the risk score, Framingham risk could not be calculated for all patients, and 
this is discussed further in the subsequent analysis chapters (4-7). 
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3.11 Identification of cardiovascular drug use prior to MI 
MINAP holds records of selected cardiovascular drug use at admission.  As 
discussed in Chapter 2, prescription drugs are well-recorded in the GPRD.  Cardiovascular 
drugs were categorised by BNF chapter.  Any patient with two or more prescriptions issued 
by the GPRD and from the same BNF chapter were considered as having received the drug.  
The main drugs of interest in this thesis were: 
• blood pressure lowering drugs, including:  
o diuretics,  
o beta-adrenoceptor blocking drugs,  
o calcium channel blockers,  
o vasodilators,  
o centrally acting antihypertensive drugs,  
o adrenergic neurone blocking drugs,  
o alpha-adrenoceptor blocking drugs,  
o angiotensin-converting enzyme inhibitors;  
 
• lipid lowering, including  
o statins,  
o bile acid sequestrants,  
o ezetimibe,  
o fibrates,  
o nicotinic acids; 
 
• antiplatelets, including 
o aspirin,  
o clopidogrel,  
o dipyridamole. 
For each of these three drug categories, patients were defined as ever/never users, 
and additionally as users/ non-users in the 90 days prior to MI. 
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3.12 Identification of chest pain prior to MI 
Chest pain recorded as ‘coronary’ or ‘exertional’ in nature by the GP was used to 
define stable angina.  Two other categories of chest pain were defined in the GPRD data: 
‘unattributed by the GP to any cause’ and ‘attributed to a non-coronary cause’.  These two 
chest pain types were explored in MI cases.  A record of chest pain in MINAP was defined 
as a previous admission for chest pain of unknown cause.  HES data were not used to 
identify chest pain. 
 
3.13 Consistency within and between data sources 
It was not uncommon for the sources to differ in their assessment of atherosclerotic 
disease, cardiovascular disease risk factors and use of medications.  Concordance is 
described in Chapter 4.  It was also not uncommon for patients to be recorded, for example, 
with several different smoking statuses on the same day.  The most sensitive approach was 
used where codes were discrepant: if any data source categorised a patient as having a 
condition, an elevated risk factor or using a drug, then the patient was categorised with that 
positive result. 
 
3.14 Post-MI follow-up 
ONS mortality data were used to follow-up patients after MI.  The primary outcome 
for each study is described in each of the analysis chapters (Chapters 4-7). 
 
3.15 Missing data 
In the GPRD, usual researcher practice is to take the absence of codes for morbidity in a 
patient’s record to indicate absence of that morbidity in the patient.  As discussed in Chapter 
2, many validation studies have been performed that have assessed the positive predictive 
value of diagnoses, but few have examined their sensitivity.  Researchers must assume that 
if disease is symptomatic, then it will be recorded in the data.  For this reason, there is no 
‘missing’ data for most morbidities and only misclassification of disease status.  The 
validation study undertaken in Chapter 4 gives some indication of the extent of 
misclassification in the recording of MI.   
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However, the same does not apply to measurements of smoking status, blood 
pressure, cholesterol and smoking (for example), for which the absence of data is not 
informative.  Subsequently, there is some missingness in these variables.  However, the 
reasons for missingness of cardiovascular disease risk factors are not straightforward.  They 
are usually missing due to a lack of opportunity for the GP to take the measurements; 
patients who fail to visit their GP may be anywhere on a scale from very healthy (no need to 
visit GP) to having a large number of cardiovascular disease risk factors (but which are not 
causing symptomatic disease).  In reality, missingness is likely to be due to a combination of 
reasons and may not be related to any measured variables within the dataset.   
Due to the complexity of the missingness, multiple imputation was not explored as 
an option to deal with the missingness in these analyses.  Multiple imputation requires the 
data to be missing at random (i.e. the missingness depends on the observed data), which is 
not necessarily applicable in this setting.  This requires further exploration, beyond the scope 
of this thesis.  Indeed, the missingness of these measurements is somewhat informative in 
terms of quality of care provided by GPs.  The consequences of missing data are discussed 
further in Chapter 7. 
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3.16 Chapter summary 
• This chapter described the methods used to identify patients with MI in each of the 
four sources.  In GPRD this was with Read codes, in HES and ONS using ICD-10 
codes, and in MINAP using discharge diagnosis, cardiac markers and ECG results. 
• Data on other morbidities, symptoms and drugs were extracted from GPRD, HES 
and MINAP. 
• Death was identified using ONS mortality data. 
• Inclusion criteria common to all analyses in this thesis were also discussed.
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Chapter 4 Data quality 
 
 
4.1 Summary 
This chapter describes the quality of the data used in this thesis.  The first half of 
this chapter (section 4.2) is a paper to be submitted to the British Medical Journal (with 
some minor modifications to place it in the context of this thesis), describing the capture, 
risk factors, mortality and diagnostic validity of acute MI in GPRD, HES, MINAP and ONS.  
The second half (section 4.3) contains further details relating to the quality of the linked 
data, including the representativeness and quality of each linked source.   
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4.2 Capture of acute myocardial infarction events in primary 
care, hospital admissions, registry data and national 
mortality statistics 
 
4.2.1 Introduction 
 ‘Collect once, use many times’ is fundamental to electronic health records which 
support patient decision making, healthcare policy and public health.  Electronic health 
record systems with comprehensive population coverage across whole countries are rare 
(Singapore) and the UK has opportunities because of its single health system, the National 
Health Service (NHS).  Even within the NHS a single major disease event is still separately 
recorded in diverse clinical and administrative systems.  Thus acute myocardial infarction 
(MI) is recorded in primary care (for example in the General Practice Research Database, 
GPRD), at hospital discharge (Hospital Episode Statistics (HES)), in the national registry of 
acute coronary syndromes (Myocardial Ischaemia National Audit Project, MINAP) and in 
the Office for National Statistics (ONS) mortality data.  Establishing the validity of 
recording in these data sources is important because these individual (unlinked) sources are 
widely used to inform care and policy, and in ascertainment of outcomes in trials[130-132] 
and cohorts[133-135] as a cheaper alternative to active follow-up.  
What we do not know is how these different systems overlap, and to what extent 
risk factors and mortality are similar in MI recorded in different sources.  Previous cross 
referencing studies of acute MI have (i) compared coding of hospital discharges and cause of 
death to case note review,[116, 136] compared recording in two national registers of 
MI,[137] compared hospital discharge and death records in fatal MI, and compared primary 
care coding to results from case review.[61]   
To our knowledge, there are no studies comparing the recording of MI across linked 
sources from primary care, hospital discharge, registry data and mortality data.  
Furthermore, data linkage provides the opportunity to validate the diagnosis of MI in the 
subset of patients who have MI recorded in primary care or hospital discharge coding and 
also have a MINAP record, where MINAP is the gold standard in recording hospital 
discharge diagnosis, ECG findings and cardiac markers.  Since the four data sources 
originate from different settings (hospital-based, primary care, death registration), we expect 
to observe differences in the populations that they capture.  However, the extent of the 
differences and the characteristics of patients who are captured in each source are poorly 
understood.   
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4.2.2 Aim and objectives  
To compare the capture and diagnostic validity of acute myocardial infarction in 
primary care, hospital discharge, national ACS registry and national mortality statistics.  
Specific objectives are as follows: 
1. To establish the consistency of characteristics (risk factors, all-cause 
mortality) between cohorts of patients who are recorded with MI in each of 
the data sources, i.e. are the same kinds of patients captured?; 
2. To describe and compare capture of MI between data sources;  
3. To assess the validity of MI recorded in each source (And to establish 
whether MIs recorded in each source are of adequate validity to use in this 
thesis). 
 
4.2.3 Methods 
4.2.3.1 Data sources 
The GPRD is a primary care database containing anonymised patient records for 
roughly eight percent of the UK population.  Data are collected as part of patient care, 
including demographic details, symptoms, diagnoses, treatments, hospitalizations and death. 
Diagnoses are coded by general practitioners using the Read Clinical Terminology 
system.[52]  
HES is a database of hospital discharge coding data for all inpatient and outpatient 
care in English NHS hospitals.  It contains information from admitted patients on 
demographics, symptoms, clinical diagnoses and treatments and comprises over twelve 
million episodes of care per year. Diagnoses are coded using the International Classification 
of Diseases, tenth revision (ICD-10).   
MINAP is the national registry of patients admitted to hospitals in England and 
Wales with acute coronary syndromes (ACS).  All NHS hospitals that treat ACS patients 
contribute data to MINAP. Information in MINAP includes admission characteristics, 
demographics, co-morbidities, diagnostic tests, treatment and outcomes.  
ONS collects data on date and cause of mortality for the UK, where death 
registration is a legal requirement.  Causes of death are coded using ICD-10.   
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Of the 630 participating GPRD practices in 2010, 244 from England consented for 
their data to be linked to further data sources.  In October 2010, the identifiers of patients in 
these practices were sent to a Trusted Third Party, who performed linkage with HES, 
MINAP and ONS.  This linkage was based on a deterministic match between NHS number, 
date of birth and gender; 96% of patients with a valid NHS number were successfully 
matched.  
 
4.2.3.2 Study population 
The initial cohort comprised all eligible, registered GPRD patients whose practice 
consented to the linkage.  Start of follow-up was defined as the latest of: (i) the start of 
MINAP data collection (1st January 2003), (ii) one year post registration with GPRD 
practice, (iii) one year post GPRD practice ‘up to standard’ date (a measure defined by the 
GPRD whereby the practice meets data quality criteria), or (iv) 30 days after the start of 
HES-GPRD linkage period.  The end of follow-up was defined as the earliest of (i) the end 
of MINAP data linkage period (31st March 2009), (ii) the end of the HES linkage period, (iii) 
the last collection date from the GPRD practice, (iv) the transfer out date, or (v) the date of 
the last ONS mortality update.  Using these criteria, we restricted our period of interest to 
the time when all data sources were actively collecting MI data.   
(Note: In this analysis, the three months towards the end of the linkage period was included 
(January to March 2009), but this was excluded from the remaining analyses in this thesis.) 
   
4.2.3.3 Identifying patients with myocardial infarction 
In each data source, we identified a group of patients experiencing MI within the 
follow-up period (2003-2009), according to ‘researcher usual practice’ MI definitions.  
Patients with MI in GPRD were those who had a Read code indicating MI (Appendix A, 
section 10.3.1).  (Note: the Read code list used in this study was a modified version of the 
list used in the rest of the thesis, to reflect usual researcher practice in the current study, 
while being as sensitive as possible in the rest of the thesis).  The date of MI was the event 
date recorded by the general practitioner.  In HES data, MI was defined as ICD-10 codes 
I21-I23 as a primary diagnosis in the first episode of a hospital spell.  In MINAP, ST-
elevation MI and non ST-elevation MI were identified using hospital discharge diagnosis, 
markers of myocardial necrosis and the ECG.  Hospital admission date in MINAP and HES 
was classified as the date of MI.  Patients with MI in ONS were identified using ICD-10 
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codes I21, I22 and I23 as an underlying cause of death. Patient demographic and risk factor 
characteristics, defined using GPRD data, were compared between patients with MI 
identified using any of the four data sources in isolation.   
 
4.2.3.4 Agreement between data sources 
Patient records of MI from GPRD, HES, MINAP and ONS were pooled and the 
earliest date of MI (within our time period of interest) across each patient’s record was 
identified.  MIs were categorised as ‘fatal’ or ‘non-fatal’ according to whether the patient 
died of any cause within 7 days.  This separation was required in order to assess agreement: 
fatal events would not necessarily be hospitalised and therefore would not be expected to be 
recorded in HES and MINAP, and by definition non-fatal events would not be recorded in 
ONS mortality data.  Therefore, assessing agreement of fatal and non-fatal events separately 
provided a more realistic estimate of MI capture in each source.   
Records of MI between data sources were considered to agree if the time difference 
from the earliest date and the date recorded in another data source was less than 30 days.  
MIs recorded more than 30 days after the earliest date were considered as new events and 
were not included in the analysis.  Further MI events recorded at any later date in any of the 
data sources were not included, ensuring that only each patient’s first MI in follow-up was 
included and that each patient only appeared once in the analysis.  
  
4.2.3.5 Statistical analysis 
For patients who survived seven days after MI, agreement between data sources was 
established for GPRD, HES and MINAP in a three-way Venn diagram.  Capture by ONS 
was not assessed in this non-fatal group.   
The proportion of ‘fatal MI’ patients (who died of any cause within seven days) 
captured by each source was examined, but agreement of records across all four sources was 
not compared as we would not expect hospital data to capture patients who died before 
reaching hospital. 
Where more than one database recorded an MI (based on the 30 day definition), the 
number of days between recording was described.  Differences in agreement between health 
authorities were also examined.  Agreement was then redefined based on a 90 day definition 
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to test our assumption that 30 days was an adequate time window for MI to be recorded 
across all sources.   
In patients where MI was recorded in one source but not another, we looked for 
other codes that may have been used to describe the MI.  In MINAP, we looked for unstable 
angina or admission diagnoses of any acute coronary syndrome.  In GPRD and HES we 
looked for other acute coronary syndrome, coronary disease, chest pain or cardiac codes that 
may have been used to represent the MI, and in GPRD we additionally examined codes 
indicating contact with secondary care.  Where none of these codes was recorded, we 
tabulated all recorded Read and ICD-10 codes in the 30 days before and after the date of MI 
to ascertain any evidence of MI in the patient record. 
MINAP records detailed diagnostic criteria of MI (such as ECG findings and cardiac 
markers) that are not captured by other sources; therefore we expect the classification of 
suspected ACS in MINAP (STEMI, NSTEMI, unstable angina) to be accurate.  Considering 
the MINAP definition as the ‘gold standard’, we calculated the positive predictive value of 
GPRD or HES diagnoses of MI among patients who also had a MINAP record within 30 
days (i.e. the proportion in which the MINAP diagnosis was MI rather than something else).  
We also calculated the sensitivity of GPRD and HES for detection of MINAP MI. 
We performed a logistic regression analysis to establish whether age, sex, 
deprivation, rate of GP consultation, year of MI and mortality at 30 days explained 
suboptimal recording of MI.  
This analysis was completed using pseudo-anonymised linked data.  Approval was 
obtained from the Independent Scientific Advisory Committee (ISAC), the MINAP 
Academic Group (MAG) and the CALIBER Oversight Committee.  The study is registered 
on clinicaltrials.gov (unique identifier NCT01569139).   
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4.2.4 Results 
We identified 21,302 patients with MI in any of the four data sources.  There were 
558 (2.6%) patients recorded in ONS only, while 15,291 were recorded in GPRD, 13,344 in 
HES and 10,087 in MINAP.  Overall, 20,744 were recorded in at least one of these three 
sources.   
 
4.2.4.1 Agreement in ‘fatal’ and ‘non-fatal’ MI  
Of the 21,302 patients, 17,825 (83.7%) were non-fatal (defined as alive at seven 
days).  The agreement in recording of MI in this group was assessed in GPRD, HES and 
MINAP.  Across all patients, 75% were captured by GPRD, 68% by HES and 53% by 
MINAP.   
Figure 4.1 describes the agreement in recording for non-fatal MI.  Overall, 31% of 
patients were identified with MI in all three data sources and 64% in at least two data 
sources within 30 days.  When our time period of interest was extended to 90 days, the 
proportion with complete agreement rose to 32%, indicating that most MIs are recorded 
close to the date of MI recorded in other data sources.  The GPRD accounted for the largest 
number of MIs that could not be identified in the other sources.  Examining variation by 
strategic health authority revealed no major disparities.  
For the 3,477 ‘fatal MI’ patients who died of any cause within seven days, 82.9% 
were captured in ONS with MI recorded as the underlying cause of death, and 57.8% had a 
MI code recorded in GPRD.  As expected, HES and MINAP captured fewer of the fatal 
events (35.9% and 17.9%, respectively). 
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Figure 4.1 Overlap in recording of non-fatal MI in GPRD, HES and MINAP, within 30 
days of the first record of MI across the three sources (N patients=17,825) 
 
 
4.2.4.2 Agreement in timing between data sources 
For HES and MINAP, date of admission agreed in over 80% of patients who had MI 
recorded in both sources (Figure 4.2).  When comparing GPRD with HES, or GPRD with 
MINAP, 51.2% and 52.4% of patients’ MIs were recorded in GPRD on the date of hospital 
admission, respectively.  There was a smaller peak in GPRD recording between five and 
seven days after admission, probably reflecting GPRD recording of discharge date rather 
than admission date, followed by a ‘tail’ with smaller numbers of diagnoses in GPRD 
recorded up to 20 days after admission. 
  
 GPRD MI 
 HES MI
 MINAP MI
 3466
 19 %
 1765
 10 %
 3130
 18 %
 5583
 31 %
 1496
 8 %
 1103
 6 %
 1282
 7 %
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Figure 4.2 Histograms showing the number of days’ interval between nearest matched 
MI records in each pair of data sources: (A) MINAP and HES (N=7,288), (B) GPRD 
and HES (N=9,531), (C) GPRD and MINAP (N=6,919) 
  
 
A 
B 
C 
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4.2.4.3 Agreement in diagnosis between data sources 
Non-fatal MI 
GPRD captured over two thirds of non-fatal hospitalised MIs (identified in either 
HES or MINAP) with a Read code of MI.  A further 10 to 15% of patients were recorded 
with ACS or other cardiac diagnoses, including stable angina and revascularization, a further 
3% had a record of chest pain, but roughly 10% of hospitalized MIs were not recorded in the 
Read coded data with any cardiac diagnosis (Appendix A, Table 10.8). The most commonly 
used Read codes in these patients indicated contact with secondary care, for example codes 
for discharge letters, hospital accident and emergency attendance, or consultations with a 
cardiologist.   
HES captured 68% of MI events identified in GPRD and 73% of those identified in 
MINAP with a primary diagnosis of MI in the first episode of hospital admission.  A further 
5% were captured as primary diagnoses after the first episode, indicating that the patient was 
admitted for another reason (or initially given a different diagnosis) and experienced MI 
while in hospital.  For 14% of GPRD MIs and 6% of MINAP MI patients, HES recorded no 
cardiovascular disease codes.  Common ICD-10 codes in these patients within 30 days of the 
GPRD MI date included those for renal failure. 
MINAP captured roughly half of GPRD and HES MIs as STEMI or NSTEMI, but 
there were no records for most of the remaining patients (45% of GPRD MIs and 40% of 
HES MI patients had no MINAP record). 
 
Fatal MI 
MI patients identified by ONS mortality data (with underlying cause of death I21, 
I22 and I23 only, N=2,882) were unlikely to be captured in hospital sources; 37% were 
captured as MI by HES and 17% by MINAP.  Just over half (56%) were captured by the 
GPRD within 30 days of the death date; in the majority of patients without a GPRD MI 
code, contact with secondary care or transfer out of practice were recorded.  Of the 2,009 
patients who were identified with MI in the GPRD and died within seven days, 24% were 
recorded in HES with MI, 12% in MINAP and 81% in ONS with MI as the underlying cause 
of death.  Of the 1,248 HES MI patients and 623 MINAP MI patients who died within seven 
days, MI was recorded as the ONS underlying cause of death in roughly 80% of patients.   
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95% of patients with MI identified in GPRD, HES or MINAP and dead within seven 
days were captured with an underlying or secondary cause of death as coronary by ONS 
mortality register.  When the time window was extended to 90 days, there was very little 
change in the proportions described here.   
 
4.2.4.4 Comparison to MINAP gold standard MI definition 
For GPRD and HES MI patients with an associated MINAP record, the positive 
predictive value of the MI diagnosis (probability that the diagnosis recorded in MINAP was 
MI rather than unstable angina or a non-cardiac diagnosis) was over 90%. The sensitivity of 
GPRD or HES in detecting MINAP MI was 70.6% and 72.6%, respectively (Table 4.1).   
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Table 4.1 Comparison with MINAP cardiologist gold standard in the subset of patients recorded in primary care (GPRD) or hospital admission 
(HES) with a record in the acute coronary syndrome register (MINAP), N=7146 and 7402, respectively 
 
    MINAP cardiologist gold standard MI           
  Yes No* Total  Sensitivity (95% CI) 
Positive predictive 
value (95% CI) 
Primary care MI 
(GPRD) 
Yes 6,612 534 7,146  70.6 (69.7-71.5) 92.5 (92.0-93.0) 
No 2,750         
Total 9,362        
                    
Hospital admission 
MI (HES) 
Yes 6,797 605 7,402  72.6 (71.7-73.5) 91.8 (91.3-92.4) 
No 114         
Total 6,911               
*MINAP recorded event as unstable angina or ‘other’ diagnosis.  The number of patients who did not have GPRD MI and did not have HES MI 
were not quantified in this analysis. 
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4.2.4.5 Logistic regression analysis 
In a multiple logistic regression analysis, compared to patients who were only 
recorded in one data source, those who were recorded in multiple sources were younger, 
more likely to be male, with a lower rate of GP consultation prior to MI, alive at 30 days 
after MI, and more likely to have experienced MI in one of the later years of the time period 
of interest (Table 4.2).   
 
4.2.4.6 Comparison of characteristics and outcomes for MI patients recorded 
in different data sources 
To give some measure of the validity of events across each of the data sources, the 
demographic, risk factor characteristics and mortality experience of cohorts of MI identified 
in each sources were compared.   
 
Cardiovascular disease risk factors 
Demographic and pre-MI cardiovascular disease risk factor prevalences were 
consistent across MI patients captured by primary care (GPRD), ACS registry (MINAP) and 
hospital admissions (HES) (Table 4.3); MI patients captured by national mortality records 
(ONS) were older than patients recorded in the other sources and had a higher risk factor 
burden reflecting their age.  
 
One year mortality 
Figure 4.3 describes the all-cause one year post-MI mortality of patients captured by 
each source; primary care (GPRD) records capture patients who die before reaching hospital, 
indicated by the high initial mortality in this group compared to the two hospital sources.  At 
one year all-cause mortality was similar across GPRD, HES and MINAP (20.9%, 24.3% and 
19.3% respectively). 
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Table 4.2 Results of logistic regression analysis to examine the predictors of capture in more than one source 
 
    
Primary care (GPRD) only 
versus any combination‡, 
odds ratio (95% CI) 
Hospital admission (HES) 
only versus any 
combination‡, 
odds ratio (95% CI) 
ACS register (MINAP) only 
versus any combination‡, 
odds ratio (95% CI) 
N patients        13,071           11,927            9,400    
Age group    
 <65 1 - 1 - 1 - 
 65-74 0.71 (0.63-0.79) *** 0.73 (0.63-0.85) *** 0.50 (0.42-0.59) *** 
 75+ 0.71 (0.64-0.79) *** 0.56 (0.49-0.65) *** 0.40 (0.34-0.46) *** 
Sex    
 Male 1 - 1 - 1 - 
 Female 0.86 (0.79-0.94) *** 0.83 (0.74-0.93) *** 0.83 (0.73-0.93) **  
Social deprivation quintile    
 1 (least deprived) 1 - 1 - 1 - 
 2 1.10 (0.96-1.25)     1.03 (0.87-1.22)     1.07 (0.90-1.28)     
 3 1.05 (0.93-1.20)     1.01 (0.85-1.19)     1.06 (0.89-1.26)     
 4 1.06 (0.93-1.21)     0.88 (0.75-1.04)     0.90 (0.75-1.07)     
 5 (most deprived) 0.96 (0.85-1.09)     1.03 (0.87-1.22)     1.17 (0.97-1.41)     
Primary care consultation rate per yearα 0.85 (0.82-0.88) *** 0.87 (0.83-0.91) *** 0.85 (0.80-0.89) *** 
Mortality at 30 daysβ 2.20 (1.61-3.00) *** 0.31 (0.26-0.38) *** 0.41 (0.33-0.50) *** 
Calendar year, per one year increase 1.17 (1.14-1.19) *** 1.12 (1.08-1.15) *** 1.01 (0.98-1.04)     
*P<0.05, **p<0.01, ***p<0.001; α for an increase of 10 consultations per year; β based on ONS mortality data;  
‡ Outcome; an odds ratio above 1 indicates that the risk factor increases the odds of the MI being captured in more than one data source; 
an odds ratio below 1 indicates that the risk factor decreases the odds of the MI being captured in more than one data source. 
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Table 4.3  Prior risk factors among patients with MI recorded in primary care, 
hospital admission, ACS registry and death registry sources from 1st January 2003 to 
31st March 2009 
 
    
Primary care: 
GPRD 
Hospital 
admissions: 
HES 
ACS registry: 
MINAP 
Cause specific 
mortality: 
ONS† 
Nature of coding Read codes 
ICD-10 codes I21, 
I22, I23 as 
primary diagnosis 
Clinical diagnosis 
STEMI and 
NSTEMI 
ICD codes I21, 
I22, I23 
underlying 
cause of death 
N patients 16,668  14,319  15,479  5,698  
Age, median (IQR) 73 (61-81) 73 (61-82) 71 (59-81) 81 (73-87) 
Sex, n female (%) 6,123 (36.7) 5,261 (36.7) 5,391 (34.8) 2,491 (43.7) 
Social deprivation, 
most deprived IMD 
quintile, n (%) 
3,320 (19.9) 2,883 (20.1) 2,911 (18.8) 1,010 (17.7) 
Ethnicity, n (%)*          
 White 12,805 (76.8) 11,721 (81.9) 12,119 (78.3) 3,755 (65.9) 
 South Asian 205 (1.2) 207 (1.4) 205 (1.3) 42 (0.7) 
 Black or other 202 (1.2) 191 (1.3) 204 (1.3) 53 (0.9) 
 Unknown 3,456 (20.7) 2,200 (15.4) 2,951 (19.1) 1,848 (32.4) 
Smoking, n (%)         
 Current 4,382 (26.3) 3,745 (26.2) 4,320 (27.9) 982 (17.2) 
 Ex 9,863 (59.2) 8,352 (58.3) 8,252 (53.3) 3,483 (61.1) 
 Non 2,045 (12.3) 1,887 (13.2) 2,085 (13.5) 735 (12.9) 
 Unknown 378 (2.3) 335 (2.3) 822 (5.3) 498 (8.7) 
Systolic blood 
pressure mmHg, 
mean (SD) 
145 (15.5) 145 (15.7) 144 (15.4) 146 (16.9) 
Use of blood 
pressure lowering 
drugs, n (%) 
9,545 (57.3) 8,127 (56.8) 6,574 (42.5) 3,413 (59.9) 
Total serum 
cholesterol mmol/L, 
mean (SD) 
5.4 (0.9) 5.4 (0.9) 5.4 (0.9) 5.3 (0.9) 
HDL cholesterol 
mmol/L, mean (SD) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 
Use of lipid lowering 
medications, n (%) 5,793 (34.8) 4,809 (33.6) 4,064 (26.3) 2,011 (35.3) 
Framingham risk 
score* n (%)         
 <10% 2,893 (17.4) 2,438 (17) 3,160 (20.4) 615 (10.8) 
 10-20% 9,171 (55) 7,909 (55.2) 8,901 (57.5) 3,280 (57.6) 
 >20% 4,604 (27.6) 3,972 (27.7) 3,418 (22.1) 1,803 (31.6) 
Diabetes, n (%) 3,002 (18) 2,552 (17.8) 2,504 (16.2) 1,221 (21.4) 
Charlson index, 
mean (SD) 2.5 (1.7) 2.4 (1.6) 2.4 (1.6) 3.2 (1.9) 
Primary care 
consultation rate 
per year, median 
(IQR) 
3.7 (1.6-7.9) 3.7 
(1.6-
8.2) 2.5 
(0.7-
6.7) 4.5 
(1.8-
9.9) 
Note: all demographic and risk factor data, except where noted, are based on GPRD data. 
Note: individual patients may be captured in more than one source and therefore be represented in more 
than one column.  *Data from HES.  †Patients in the cause specific mortality column (ONS) are those 
who were recorded with myocardial infarction (ICD-10 codes I21, I22 or I23) as the underlying cause of 
death on their death certificate. 
*Where components of the score, these were imputed using the population median. 
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GPRD: General Practice Research Database; HES: Hospital Episode Statistics; MINAP: Myocardial 
Ischaemia National Audit Project; ONS: Office for National Statistics mortality data. 
Figure 4.3 Kaplan Meier curve showing crude all-cause mortality, stratified by data 
source (GPRD N=16,668, HES N=14,319, MINAP N=15,479). ONS data not shown as 
they are fatal on the date of MI, by definition  
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4.2.5 Discussion 
4.2.5.1 Principal findings 
Just one third of non-fatal MIs were captured in all three of GPRD, HES and 
MINAP, and two thirds were captured by at least two.  None of the four sources used in this 
study captured all MI events and therefore complete ascertainment of MI requires use of 
multiple sources.    
The groups of MI patients captured by each data source had similar demographic 
and cardiovascular disease risk factor profiles and, with the exception of the cohort 
identified by national mortality statistics, had similar mortality in the year after MI.  The 
positive predictive value of MI records in primary care and hospital admission were over 
90% compared to the MINAP gold standard based on the international definition of MI.[4]  
While many patients did not have a MINAP record, these figures offer some evidence for 
the validity of MI records across the sources.   
 
4.2.5.2 Strengths  
The UK government has created the Clinical Practice Research Datalink (CPRD, 
www.cprd.com) which aims to maximize use of linked electronic healthcare data.  
Evaluating the quality of the data available in these linked data sources is therefore a priority 
but there has been only one four-source comparison of primary care, hospital, registry and 
cause-specific mortality data for cancer,[138] and none for MI.   
Our study is the first to examine four major data sources for MI recording in 
England, with coverage from over six years of data collection and over 20,000 MI patients, 
more than any previous validation study of the GPRD or HES.  Our period of interest was 
restricted to a time when all data sources were collecting information on patients, so in the 
absence of error, hospitalized MI should have been recorded in hospital admission data, 
ACS registry and primary care.  All patients in our study were registered with a GPRD 
practice, providing several years of prospectively collected pre-MI data regarding 
demographics, cardiovascular disease risk factors and morbidity, allowing detailed 
comparisons to be made between patients captured by each data source.   
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4.2.5.3 Weaknesses 
Some patients in this study may have been included based on MI codes that were 
non-acute or incorrect.  These would not be associated with records in the other sources.  For 
example, overestimation of MI in the GPRD can result from repeated entry of MI codes by 
the general practitioner (GP) to indicate a history of MI.  We excluded the first year after 
practice registration to avoid inclusion of these old MIs but we cannot rule out some 
miscoding.  Additionally, in the GPRD, MI may be captured in the non-coded free text 
section of the data.  Studies are currently underway to encode this text to make is more 
easily accessible to researchers, but these data were not used in the current study.   
In the HES MI data, we excluded patients whose diagnosis at first hospital 
admission was not MI (e.g. to exclude patients with post-operative MI) and we did not apply 
this criterion to cases identified in the GPRD, MINAP or ONS.  This contributed to some of 
the discordance in the main analysis, but non-first episode MI accounted for only 5% of 
GPRD, MINAP and ONS MIs. 
 
4.2.5.4 Reasons for non-capture of MI 
There are several possible explanations for non-coding of MI in each source:   
• In the GPRD, GPs may receive limited information about a patient’s hospital 
admission, administrative problems may mean that a GP does not receive a letter, or 
diagnoses may be recorded only in the free text or paper notes rather than as Read 
codes;   
• In HES and MINAP, the diagnosis of MI may be unclear in the patient notes and be 
misinterpreted by a non-clinician coder or data entry clerk.  Alternatively, the patient 
may attend a private hospital where HES and MINAP data are not collected; 
• In MINAP, patients not admitted to cardiology wards tend not to be recorded; and 
• For patients who die within seven days of MI, the underlying cause of death may not 
be MI and therefore our study would have classified this as discordant. 
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4.2.5.5 Comparison with other literature  
Non fatal MI 
Our analysis showed that positive predictive values of MI diagnoses in GPRD and 
HES were high when compared to a gold standard based on the international definition of 
MI.  To our knowledge, there have been no previous studies examining the positive 
predictive value of a HES MI diagnosis, but our results are consistent with the results from 
several smaller validation studies of GPRD MI data, which set out to confirm the diagnosis 
of MI in the electronic record using further diagnostic criteria from within the GPRD such as 
anonymised copies of paper medical records, hospital discharge summaries, death 
certificates, [59, 61-64]  or questionnaires to the general practitioner.[59, 61, 65-67]  We 
also showed that - where recorded - the timing of a GPRD code compared to hospital 
admission date was accurate.   
Due to time, cost and logistical difficulties, the sensitivity of MI records in any of 
these data sources (i.e. the proportion of those with a true MI who are captured by the 
source) has not previously been assessed.  Here we estimated sensitivity compared to a gold 
standard MINAP MI and have shown that GPRD fails to record approximately 30% of 
hospitalized cases of non-fatal MI.  Additionally we have shown that the GPRD does not 
capture one quarter, HES one third and MINAP nearly half of non-fatal MI cases.  
Therefore, MI recording in each of the sources is incomplete. 
This is consistent with a recent study showing that recording of acute MI was 
suboptimal in hospital data.[116]  In a comparison of hospital discharge coding (on which 
HES is based) to the Oxford Vascular Study (OXVASC), the authors identified 820 incident 
MI cases in OXVASC.  Of these cases, only 53% were captured in hospital discharge data as 
acute MI (ICD-10 I21, I22).[116]  We found slightly better results; 62% of GPRD MIs and 
72% of MINAP MIs were captured by HES.   
Incomplete records in each of these data sources suggest that the incidence of MI, 
calculated based on any of these sources, is underestimated.  A two-source study of MI in 
the UK compared the incidence based on primary care records with the incidence based on 
hospital data and showed that in combination they provide the highest estimates of 
incidence.[139]  Further two source comparisons of MI in Australia,[140] Denmark[137] 
and the Netherlands[141] have shown that hospital records alone underestimate true MI 
incidence.  With the three sources used in the current study to identify non-fatal MI, we have 
shown that even using two sources will result in underestimates of incidence. 
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The relatively low completeness of MINAP is unsurprising; MINAP data are not 
collected as part of patient care and often only for patients in coronary care units.  The 
strengths of MINAP lie in its detailed treatment data and diagnostic accuracy, which other 
data sources are unable to provide.   
 
Fatal MI 
We estimate that for the hospitalized ‘fatal’ patients who died within seven days, 
85.4% and 79.6% in HES and MINAP, respectively, had MI recorded as their underlying 
cause of death.  These figures are concordant with results from the Oxford Record Linkage 
Study, where the mortality records of 5,686 patients with hospitalized MI who died within 
30 days were examined and 85.2% were recorded with MI as the underlying cause of 
death.[138]   
 
4.2.5.6 Implications for clinicians and policymakers 
Whether captured in GPRD, HES or MINAP, patients with MI have the same risk 
factor distribution and post-MI survival experience.  This indicates that each data source is 
likely to provide a source of ‘true’ MI patients which researchers can be confident is not 
heavily biased in terms of patient selection.   
Our study shows that there is no single gold standard source of MI that captures all 
events and diagnoses.  The ‘collect once, use many times’ ideal is a strategic goal and not 
likely to be realizable in the medium term given the financial and resource constraints placed 
upon the NHS.  Therefore, as an alternative to such a gold standard data source, we suggest 
use of linked data in healthcare commissioning and estimating disease burden.  Here we 
have shown that by combining data from primary care, hospital admissions, ACS registry 
and mortality data, there is a vastly improved picture of MI morbidity and mortality in 
England. 
Other researchers should choose their data source carefully, bearing in mind the 
strengths and weaknesses of each source, to meet the needs of their individual research 
questions. For example, the detailed recording in MINAP on timing, diagnostic accuracy and 
treatment make it useful for examining treatment effects at the time of MI. GPRD contains 
longitudinal primary care information over many years of follow-up, making it useful for 
pharmacoepidemiological research requiring detailed drug exposures. HES documents 
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morbidity for patients in NHS hospitals in England and is therefore useful for health services 
research, but as with MINAP it does not record hospitalizations abroad or in the private 
sector. ONS mortality records contain information on all death registrations in England and 
Wales, which is an almost complete source for fatal events. The linkages between MINAP, 
GPRD, HES and ONS require the patient to be registered with a GP have a valid NHS 
number, so linkage may fail for people such as refugees, prisoners, members of the armed 
forces and those without a permanent address.  
 
4.2.5.7 Future research 
Our descriptive and post-MI survival data show that cohorts of MI in each data 
source are similar and are all likely to represent true MI patients. However, for 
epidemiological studies with MI as an exposure or outcome, it would be worthwhile to 
compare the results based on different sources for MI recording. Further case record review 
can also take place for patients included in the UK Biobank cohort, based on multiple 
sources of patient health records, including self-reported data.[135] 
Based on the results from the current study, it may be possible to refine MI 
definitions in each source to improve sensitivity or specificity depending on individual study 
requirements. Other established data linkages will provide opportunity to compare recording 
of other diseases, which may have different levels of agreement between data sources.  
Further data linkages are also being established by CPRD, with some already complete and 
validated,[142] and the number of primary care practices involved is also set to increase.   
 
4.2.6 Conclusion  
Complete ascertainment of MI requires multiple sources.  Previous estimates of 
incidence based on single data sources are underestimates.  However, where recorded, the 
quality of MI diagnosis in each of the sources compared to a gold standard is high.  Policy 
makers and researchers can be assured that the data are valid. 
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4.2.7 Implications for this thesis 
Each of the databases has been shown to be a valid source of MI patients in terms of 
patient characteristics and mortality experience.  Timing of MI in the GPRD, HES and 
MINAP was also comparable for non-fatal events.  Therefore, in this thesis any source can 
be used to identify MI patients with confidence that the MIs are real events and recorded in a 
timely way.   
While capture of MI is suboptimal in each of the sources, none of the objectives in 
this thesis estimate incidence and so the implications of the low sensitivity of each source 
are minimal. 
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4.3 Further analyses of data quality 
In addition to the assessment of MI validity in section 4.2, further analyses were 
performed to give an indication of the quality of data used in this thesis.  The objectives of 
these analyses were:  
1. To assess the representativeness of the linked portion of each data source to 
its source (a comparison of linked to non-linked GPRD, HES, MINAP and 
ONS data): this will highlight any bias in patient selection introduced by the 
linkage; 
2. To consider overall data quality in GPRD, HES and ONS, and briefly 
describe data quality in MINAP. 
 
In addition, Appendix A, section 10.3.2 describes a comparison of the concordance of 
GPRD, HES and MINAP with respect to their recording of atherosclerotic disease diagnoses 
prior to MI. 
 
4.3.1 Previous analysis to compare linked with non-linked GPRD data 
The GPRD have performed analyses to assess the representativeness of patients 
included in the linked data compared to those that were not linked.[143]  At a randomly 
selected index date, the mean age of patients was the same in linked and non-linked 
practices.  The proportion of females, the mean BMI and duration of follow-up was also the 
same in linked and non-linked patients.   
The proportion of current smokers was slightly more in the linked practices than the 
non-linked and the linked practices tended to be from more deprived areas.  The analysis 
also showed slight variation in the geographical areas of practices in the linkage: practices in 
London were less likely and those in the South West of England were more likely to 
participate.  The authors concluded that “patients in linked practices were representative of 
the whole GPRD population.”[143] 
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4.3.2 New analysis to compare linked with non-linked HES data 
In this analysis, data from the whole of HES were compared to those in the linked 
HES data.  Data from the whole of HES were freely available online data for primary 
diagnoses for finished consultant episodes. 
 
4.3.2.1 Number of linked finished consultant episodes 
The number of records in HES increased by roughly 30% between 1998/99 and 
2007/08, from 11.9 million to 15.4 million.  The proportion of linked episodes increased by 
roughly 80% during this time, from 0.5 million to 0.9 million (Figure 4.4).  The proportion 
of HES episodes that were linked rose from 4.5% to 5.9%. 
 
Figure 4.4 Frequency of primary diagnoses in finished consultant episodes, by financial 
year in linked HES and for all of HES data, for the period 1998-2008 
 
 
4.3.2.2 Age and sex  
The mean age in the linked records was similar to the mean age for all records (47 
and 48, respectively).  The proportion of male patients was slightly lower in the linked data 
compared to the whole dataset (41% and 44%, respectively). 
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4.3.2.3 Top ten diagnoses 
The frequency of primary diagnoses within finished consultant episodes in the 
whole of HES was compared to the linked data.  Table 4.4 shows the top ten primary 
diagnoses in over 7 million finished consultant episodes in the linked data, and in over 132 
million episodes in the whole of HES.  Concordance between the linked HES and the whole 
of HES was high.  There was roughly the same distribution of codes.   
 
4.3.2.4 Conclusion 
Aside from the small differences in the distribution of men and women between the 
linked dataset and the whole of HES, the data used in this thesis are largely representative of 
the whole of HES.  This provides further evidence of the representativeness of the patients in 
this study compared to the population of England. 
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Table 4.4 Top ten diagnoses over the period 1997/98 to 2007/08 in the linked HES data, and in all of HES 
 
  Linked HES  Whole HES 
  
ICD 
code Term Frequency
In top 
20 
whole 
HES?  
ICD 
code Term Frequency
In top 
20 
linked 
HES? 
1 R10 Abdominal and pelvic pain  158,471 Yes  Z38 
Liveborn infants according to 
place of birth 4,072,251 Yes 
2 Z38 Liveborn infants according to place of birth 148,502 Yes  R10 Abdominal and pelvic pain  2,629,827 Yes 
3 R69 Unknown and unspecified causes of morbidity  137,179 Yes  R69 
Unknown and unspecified 
causes of morbidity  2,601,403 Yes 
4 R07 Pain in throat and chest 128,693 Yes R07 Pain in throat and chest 2,362,904 Yes 
5 O70 Perineal laceration during delivery  93,429 Yes  H26 Other cataract 1,768,687 Yes 
6 O26 
Maternal care for other 
conditions predominantly 
related to pregnancy 
88,862 Yes  J44 
Other chronic obstructive 
pulmonary disease  1,497,346 Yes 
7 H26 Other cataract 87,267 Yes  N39 
Other disorders of urinary 
system  1,410,763 Yes 
8 N39 Other disorders of urinary system  81,113 Yes  I25 Chronic ischaemic heart disease 1,393,717 Yes 
9 I20 Angina pectoris  69,905 Yes I20 Angina pectoris  1,371,772 Yes 
10 I25 Chronic ischaemic heart disease  68,963 Yes  J18 
Pneumonia, organism 
unspecified  1,340,080 Yes 
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4.3.3 Analysis to compare linked with non-linked MINAP data 
At the time of this work, the complete MINAP datasets contained 740,454 records 
and 26,885 (3.63%) of these were linked to other data sources.  The sections below describe 
the distribution of admission dates, age, sex, mortality and discharge diagnosis of patients 
who were linked compared to those that did not link. 
 
4.3.3.1 Number of linked MINAP admissions 
The MINAP data used for this thesis are for the period 1st January 2003 until 8th 
August 2011. The total number of MINAP admissions and the number that are linked are 
shown in Figure 4.5 by calendar year up to the last complete year (2010); the number of 
linked patients drops in 2009 as the linkage period ends. The few patients who are in the 
linked dataset after the end of the linkage period in 2009 are likely to be those whose NHS 
number was linked via a previous admission during the linkage period.  In 2003, 4.0% of 
MINAP admissions were linked and in 2008 this had risen to 4.9%. 
 
 
Figure 4.5 Frequency of all and linked MINAP admissions by year 
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4.3.3.2 Age and sex distributions 
The age and sex distributions were comparable in the linked and unlinked 
patients.  Figure 4.6 describes the age distribution.  The median age in the non-linked group 
was 71 (IQR 59-80), and in the linked group it was 70 (IQR 58-80).  Table 4.5 describes the 
sex distribution.  There was more missingness in the unlinked group.  This is likely to be 
because a valid NHS number was required for the linkage; age in those without valid NHS 
numbers may not be recorded as well as in those with NHS numbers.  After removing 
patients with missing sex, there was no difference in the distribution of sex between linked 
and unlinked patients (Chi squared P=0.77). 
 
Figure 4.6 Histograms describing the age at admission to hospital in linked (N=26,885) 
and unlinked (N=713,569) MINAP patients 
 
Table 4.5 Sex distribution in linked and unlinked patients 
 
  Not linked Linked Total 
  n (%) n (%) n (%) 
Male 459,409 (64.4) 17,402 (64.7) 476,811 (64.4) 
Female 250,626 (35.1) 9,457 (35.2) 260,083 (35.1) 
Missing 3,534 (0.5) 26 (0.1) 3,560 (0.5) 
Total 713,569 (100.0) 26,885 (100.0) 740,454 (100.0) 
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4.3.3.3 Discharge diagnosis 
The distribution of discharge diagnoses in the linked and unlinked groups were very 
similar (Table 4.6).  
Table 4.6 Discharge diagnoses in linked and unlinked admissions 
 
Final diagnosis Not linked Linked Total 
  n (%) n (%) n (%) 
Myocardial infarction (ST-
elevation) 227,096 (31.8) 8,533 (31.7) 235,629 (31.8) 
Threatened MI 2,102 (0.3) 98 (0.4) 2,200 (0.3) 
ACS troponin positive 355,417 (49.8) 12,951 (48.2) 368,368 (49.8) 
ACS troponin negative 40,862 (5.7) 1,657 (6.2) 42,519 (5.7) 
Chest pain of uncertain 
cause 20,818 (2.9) 769 (2.9) 21,587 (2.9) 
Myocardial infarction 
unconfirmed 4,181 (0.6) 152 (0.6) 4,333 (0.6) 
Other diagnosis 38,918 (5.5) 1,549 (5.8) 40,467 (5.5) 
ACS troponin unspecified 5,672 (0.8) 297 (1.1) 5,969 (0.8) 
Missing 18,503 (2.6) 879 (3.3) 19,382 (2.6) 
Total 713,569 (100) 26,885 (100) 740,454 (100) 
ACS: acute coronary syndrome. 
 
4.3.3.4 Mortality 
Thirty day mortality was the same in linked and unlinked patients at 30 days (8.6% 
in linked and 8.7% in unlinked, chi squared P=0.55).  Subsequent mortality cannot be 
compared due to high amounts of missingness in the unlinked group (6.8% missing in 
unlinked, 0.5% in linked).   
 
4.3.3.5 Conclusion 
The patients from the MINAP dataset who were linked to other sources are 
representative of those from the whole of MINAP.  Those who were linked have a low level 
of missingness in age, sex, and vital status, which indicates that patients who were linked 
may have been recorded better in the dataset overall. 
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4.3.4 Analysis to compare linked with non-linked ONS data 
In this analysis, freely available ONS cause-specific mortality data for the whole of 
England and Wales in 2004 (N=510,332) were compared to the linked dataset in 2004 
(N=25,725).  The frequency of mortality by ICD-10 chapter was similar in the linked and the 
whole datasets (Table 4.7), so there is no evidence to suggest that the patients in the linked 
ONS dataset were not representative of those in all of England and Wales.   
 
4.3.4.1 Conclusion 
Although the data were only assessed for one of the years in which the study took 
place, we assume that the data in the remaining years were not of a similar quality.  The 
results indicate that the patients in this study are representative of all individuals who died 
during the study period.
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Table 4.7 Comparison of the underlying cause of death of 510,332 patients in all of England and Wales in 2004 to 3,474 patients with recorded death 
in the linked data in 2004 
 
ICD 
chapter Underlying cause 
N in whole 
dataset 
% in chapter: 
whole dataset 
N in linked 
dataset 
% in chapter: 
linked dataset 
A00-B99 Certain infectious and parasitic diseases 5,009 1.0 218 0.9 
C00-D48 Neoplasms 138,062 27.1 6,647 25.8 
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism 1,014 0.2 60 0.2 
E00-E90 Endocrine, nutritional and metabolic diseases 7,519 1.5 407 1.6 
F00-F99 Mental and behavioural disorders 14,299 2.8 1,074 4.2 
G00-G99 Diseases of the nervous system 14,606 2.9 891 3.5 
H00-H59 Diseases of the ear and mastoid process 39 0.01 2 <0.1 
I00-I99 Diseases of the circulatory system 190,603 37.4 9,231 35.9 
J00-J99 Diseases of the respiratory system 69,213 13.6 3,399 13.2 
K00-K93 Diseases of the digestive system 24,912 4.9 1,224 4.8 
L00-L99 Diseases of the skin and subcutaneous tissue 1,670 0.3 79 0.3 
M00-M99 Diseases of the musculoskeletal system and connective tissue 4,393 0.9 199 0.8 
N00-N99 Diseases of the genitourinary system 9,397 1.8 509 2.0 
O00-O99 Pregnancy, childbirth and the puerperium 46 <0.1 2 <0.1 
P00-P96 Certain conditions arising in the perinatal period 213 <0.1 5 <0.1 
Q00-Q99 Congenital malformations, deformations and chromosomal abnormalities 1,274 0.3 59 0.2 
R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 11,566 2.3 771 3.0 
V01-Y89 External causes of morbidity and mortality 16,497 3.2 948 3.7 
Total N   510,332 100.00 25,725 100.00 
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4.3.5 Quality of GPRD, HES and ONS data 
The quality of GPRD and HES data has been assessed in a number of validation 
studies, as described in Chapter 2 (Data sources).  While these validation studies are for non-
linked data, the previous analysis showed that the linked subsets were representative of the 
whole data sources.  Additionally, GPRD data are monitored continually to identify 
inconsistencies, and HES and ONS data are cleaned before release.  Therefore, it was 
decided not to make any further assessment of data quality in GPRD, HES and ONS within 
this thesis. 
 
4.3.6 Quality of MINAP data 
There have been no formal validation studies of MINAP data and the data are not 
fully cleaned before release (as individual researchers should choose their strategy to deal 
with missingness and data inconsistencies).  Therefore, some brief analyses were conducted 
to examine the quality of the data and to assess the validity of our methods. 
 
4.3.6.1 Diagnosis of STEMI and NSTEMI: applying the CALIBER algorithm 
Our case definition of MI in MINAP was based on re-categorisation of discharge 
diagnosis using cardiac markers and ECG results, based on the international definition of 
MI,[6] as shown Figure 4.7.  Comparison between the original MINAP discharge diagnoses 
and the CALIBER-assigned diagnosis is shown in Table 4.8.  Roughly 10% of patients with 
a discharge diagnosis of STEMI and NSTEMI were recategorised, but 90% of all ACS 
discharge diagnoses were concordant with results of cardiac markers and ECG results.  
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MINAP COHORT:
N records=23,872
MI (ST segment
elevation) 
N=7,409
MI (non ST segment
elevation) and ACS  troponin 
positive N=11,544
ACS 
(Troponin
Unspecified)  N=269
ACS (Troponin
Negative)
N=1,520
Other
Diagnosis
N=1,372
Chest Pain 
of Uncertain 
Causes
N=662
Unstable
Angina
N=303
Discharge
Diagnosis
Threatened
MI n=93
MI
(Unconfirmed)
N=138
ECG
Determining 
Treatment
STEMI
N=6,683
NSTEMI
N=423
ST elevation
LBBB*
Unstable
Angina
N=625
Unstable
Angina
N=200
Unstable
Angina
N=1,400
Other
Cardiac
Enzymes
Raised
No Yes* No* YesNo* YesNo Yes*
STEMI
N=540
NSTEMI
N=10,379
ST elevation Other*
STEMI
N=10
NSTEMI
N=110
ST elevation Other*
STEMI
N=8
NSTEMI
N=61
ST elevation Other*
Missing/
Unknown
N=865
Figure 4.7 CALIBER MI phenotype algorithm, from McNamara
*In unimputed data, missing and unknown fall into this category.  
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Table 4.8 Comparison of MINAP discharge diagnosis and the CALIBER assigned diagnosis based on discharge diagnosis, raised cardiac markers 
and ECG results, based on 20,742 patients with acute coronary syndrome 
 
    CALIBER diagnosis 
STEMI NSTEMI Unstable angina Total 
    n (%) n (%) n (%) n (%) 
Original 
discharge 
diagnosis
STEMI 6,683 (90.2) 423 (5.7) 303 (4.1) 7,409 (100) 
NSTEMI/ troponin positive ACS 540 (4.7) 10,379 (89.9) 625 (5.4) 11,544 (100) 
ACS troponin unspecified 10 (0.7) 110 (7.2) 1,400 (92.1) 1,520 (100) 
Troponin negative ACS 8 (3) 61 (22.7) 200 (74.3) 269 (100) 
All ACS 7,241 (34.9) 10,973 (52.9) 2,528 (12.2) 20,742 (100) 
STEMI: ST-elevation myocardial infarction; NSTEMI: non ST-elevation myocardial infarction; ACS: acute coronary syndrome.
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4.3.6.2 Missingness in key MINAP variables 
Missingness in MINAP is low in the key variables that are used for audit, and in 
those required for the linkage (NHS number, age, sex).  Missingness in the variables used in 
this thesis is shown in Table 4.9.  Missingness is high for variables recording cardiovascular 
disease history, cardiovascular disease risk factors and drug use at admission.  While the 
MINAP data are weaker in this area, this is compensated by linkage to GPRD, where these 
data are recorded more completely.  Range checks were performed for continuous variables: 
values outside the plausible range (as defined by the CALIBER data manual) were re-coded 
to missing (<1%). 
 
4.3.6.3 Conclusion 
MINAP discharge diagnosis data were shown to be internally consistent in 90% of 
patients with ACS.  While there was high missingness (>50%) in some variables, the 
demographic variables used in the linkage and the variables used to validate MI type were 
well-completed.  Missingness in risk factor and co-morbidity data will be compensated with 
data from other sources. 
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Table 4.9 Missingness in variables used in this thesis, for 8,059 cases recorded in the 
Myocardial Ischaemic National Audit Project (MINAP) 
 
    n missing (%)  
NHS number 0 (0) 
Age 0 (0) 
Gender 4 (<0.1) 
Ethnicity 741 (9.2) 
Date of admission (before imputation) 199 (2.5) 
Date of discharge 644 (8.0) 
Previous morbidity 
Myocardial infarction 5,479 (68) 
Angina 6,169 (76.5) 
Peripheral arterial disease 6,001 (74.5) 
Cerebrovascular disease 6,250 (77.6) 
Heart failure 6,446 (80) 
PCI 6,476 (80.4) 
CABG 5,901 (73.2) 
Cardiovascular disease risk factors 
Diabetes 3,677 (45.6) 
Hypertension 4,774 (59.2) 
Hypercholesterolaemia 2,545 (31.6) 
Smoking 940 (11.7) 
Family history 13,796 (53.5) 
Height 6,304 (78.2) 
Weight 5,619 (69.7) 
Cardiovascular medications before admission 
Antiplatelet 716 (8.9) 
Beta blocker 3,727 (46.2) 
ACEI 3,759 (46.6) 
Statin 3,683 (45.7) 
Thienopyridin 3,677 (45.6) 
Admission characteristics 
Peak troponin 1,810 (22.5) 
Heart rate at admission 1,796 (22.3) 
Systolic blood pressure at admission 1,173 (14.6) 
ECG record 795 (9.9) 
Cardiac markers 831 (10.3) 
  Left ventricular ejection fraction 5,357 (66.5) 
NHS: National Health Service; PCI: percutaneous coronary intervention; CABG: 
coronary artery bypass graft; ECG: electrocardiogram; ACEI: angiotensin 
converting enzyme inhibitor. 
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4.3.7 Implications for this thesis 
These analyses of data quality have shown that the linked data are representative of 
their respective sources, and therefore it is unlikely that selection bias has been introduced 
by using the linked data. 
 
4.4 Chapter summary 
• Each of the data sources used in this thesis (GPRD, MINAP, HES and ONS) record MI 
events that are similar in terms of their demographic and risk factor characteristics, and 
with similar one year survival.  This indicates that each source is capturing similar 
cohorts of MI patients and gives some indication about the validity of each source.  The 
timing of MI was also consistent for MIs recorded in multiple sources.  
• A record of MI was captured by GPRD, MINAP and HES in about a third of patients 
and captured by at least two sources in two thirds of patients.  Therefore, using multiple 
sources to capture MI patients is ideal, and combining MI events from GPRD, MINAP, 
HES and ONS would provide a more complete picture of MI incidence in the UK. 
• The subsets of each data source used in the linkage were representative of the source 
data in terms of median age, sex and diagnoses, so it is unlikely that selection bias has 
arisen by using linked data. 
• Data quality in each of the four sources is adequate for the analyses in this thesis. 
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Chapter 5 Heralding of 
myocardial infarction 
 
 
 
5.1 Summary 
This chapter describes an analysis to assess the type and timing of atherosclerotic 
disease diagnoses, cardiovascular disease risk factors and chest pain prior to first myocardial 
infarction. 
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5.2 Literature review 
5.2.1 Introduction 
The extent to which first acute myocardial infarction (MI) is heralded by previous 
symptomatic atherosclerotic disease, major risk factors or symptoms has important 
implications for understanding MI aetiology, as well as the provision of optimal services.  
Therefore, a literature review was undertaken to assess heralding of myocardial infarction.   
This literature review focused on studies estimating (i) the proportion of patients 
with first MI with previously diagnosed atherosclerotic disease (coronary, cerebrovascular or 
peripheral arterial disease), or previously elevated cardiovascular disease risk factors, and 
(ii) the timing and onset of atherosclerotic disease in relation to MI. 
 
5.2.2 Methods 
5.2.2.1 Search strategy 
A search was conducted in the MEDLINE and EMBASE databases to find relevant 
literature.  Search terms are described in Appendix A, Table 10.16.  The searches were 
restricted to titles only to increase the specificity of the search, given the broad nature of the 
terms.   
 
5.2.2.2 Inclusion criteria 
Studies were included only if they fulfilled the following criteria: 
1. Included patients with first MI; 
2. Examined a specific objective regarding the prevalence of atherosclerotic 
disease and risk factors prior to MI; 
3. Study in humans; 
4. Manuscript written in English language. 
Titles and abstracts were reviewed to identify potentially relevant studies.  For those 
that indicated that they had focused on identifying the proportion of patients with 
atherosclerotic disease or cardiovascular disease risk factors, or examining the timing of 
atherosclerotic disease diagnosis in relation to MI, full text was sought to assess whether the 
study met the inclusion criteria. 
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5.2.3 Results 
5.2.3.1 Studies reporting heralding by atherosclerotic disease and risk 
factors 
The initial search generated 2,658 studies.  The titles and abstracts were reviewed to 
identify studies whose main aim was reporting the prevalence of patients heralded by 
atherosclerotic disease and risk factors prior to MI.  No studies were identified that estimated 
both the proportion of patients heralded by atherosclerotic disease and the proportion 
heralded by cardiovascular disease risk factors.  However, some studies provided estimates 
of the proportion heralded by disease and others estimated the proportion heralded by 
cardiovascular disease risk factors and the duration of symptoms prior to MI.  These are 
briefly summarised below.   
 
5.2.3.2 Studies reporting heralding by atherosclerotic disease 
Just one study was identified that examined the proportion of patients with different 
pre-MI manifestations of atherosclerotic disease in patients with first MI.  This was in the 
Framingham study, which began in 1948, with follow-up through to 1984 and during this 
time identified 532 men and 296 women with MI.  In this study 68.6% of men and 60.5% of 
women with MI were unheralded by prior angina, intermittent claudication, stroke/TIA or 
congestive heart failure.[144]  The prevalence of disease of each subtype was as follows: 
• Angina: 20.9% in men, 24.7% in women; 
• intermittent claudication: 9.4% in men, 10.5% in women;  
• Stroke or TIA: 5.3% in men, 8.1% in women; 
• Congestive heart failure: 3.4% in men, 9.8% in women. 
 
However, the data collected in this study is now old due to changes in the incidence 
of angina[13] and the redefinition of MI in 2000.[4]  
A more recent study (in 2009) based on patients with non ST-elevation acute 
coronary syndromes examined the presence of peripheral arterial disease, cerebrovascular 
disease and coronary artery disease prior to the event, and the occurrence of polyvascular 
disease.[145]  The CRUSADE study enrolled over 95,000 patients with NSTEACS from 
484 sites in the US; 48.9% had no prior atherosclerotic disease, 38.3% had disease in one 
territory, 11.2% in two and 1.6% in three.  Of those without prior atherosclerotic disease, 
91.8% were NSTEMI and the remaining 8.2% were ACS.  The prevalences of each major 
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cardiovascular disease risk factor were described for patients without prior atherosclerotic 
disease, but an estimate of the number of patients without either disease or risk factors was 
not reported.  While this study was large and in recently collected data, it focused on 
NSTEACS, so an estimate of heralding by atherosclerotic disease in MI overall is not 
available. 
Yawn reported both the proportion of patients with prior coronary disease and the 
proportion with previously elevated risk factors, but did not combine the two estimates.[146]  
In 298 patients, 52% of men and 30% of women had CHD diagnoses prior to their first MI.  
This study also measured the duration of coronary disease prior to first MI, showing that the 
average duration was 5 years prior to MI.  No studies were identified that aimed to assess the 
duration of diagnosed atherosclerotic disease prior to MI. However, this was a relatively 
small study and did not estimate the occurrence of peripheral or cerebrovascular disease 
prior to MI.  
 
5.2.3.3 Studies reporting angina prior to MI and ischaemic preconditioning 
There were many studies reporting the proportion of patients with angina prior to 
MI.  The majority of these focused on the prevalence and effects of prodromal angina prior 
to MI, i.e. angina of very short duration, and none reported the proportion of patients with 
and without longstanding atherosclerotic disease.  This is the subject of Chapter 6.  
However, six studies were identified that reported the prevalence of angina prior to first MI 
(Table 5.1).  These studies show that the proportion of first MI patients with previous angina 
(or chest pain likely to be angina) is likely to lie between 21% (in men only)[144] to 
63%.[147]  These studies varied widely in their timing, study designs, setting and definition 
of angina.  Four of these were retrospective and therefore relied on patient recall for 
exposure identification.  One was based on the prospective Framingham study,[144] but this 
followed patients up biennially and detailed data on the onset and evolution of disease were 
unavailable.  The other prospective study was based on just 150 women with MI, but was 
able to assess the timing of onset.[148] 
Importantly, the most recent of these studies is over a decade old and given (i) the 
recent decrease in MI incidence and relative increase in angina incidence,[19, 20] (ii) the 
reduction in cardiovascular disease risk factors,[21] and (iii) the updated definition of 
MI,[22] there is scope for an updated estimate of previous angina.  
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Table 5.1 Studies examining the proportion of patients with angina prior to first myocardial infarction 
 
Author, 
year Country 
Years of data 
collection 
Number of MI 
patients Study design Angina definition % with preinfarction angina 
Anzai, 
1995[149] 
Japan 1994-1995 291 Retrospective, 
hospital-based 
New onset <1 month duration, 
Chronic & worsening pattern <1 
month duration,  
Chronic stable angina >1 month 
duration 
Anterior Infarction: 39% new onset 
angina, 15% chronic & unstable, 
10% chronic & stable. 
      Inferior infarction: 26% new onset 
angina, 12% chronic & unstable, 
17% chronic & stable. 
Behar, 
1992[150] 
Israel 1981-1983 4,166 Retrospective, 
hospital based 
Chronic angina >1 month 43% 
      
Cupples, 
1993[144] 
USA 1948-1982 828 Prospective, 
Framingham 
study 
Physician diagnosed angina 20.9% in men, 
     24.7% in women 
Kobayashi, 
1998[147] 
Japan 1980-1995 1,637 Retrospective, 
hospital-based 
Typical chest pain at any time 
before MI.   
63% 
Pierard, 
1988[151] 
Belgium 1977-1980 732 Retrospective, 
hospital-based 
Chronic angina > 1 month.   27% chronic angina,  
   New onset angina <1 month 34% new onset 
Yawn, 
2004[148] 
USA 1996-2001 150 Prospective, 
based on medical 
records 
Any CHD diagnosis 52% in women 
           
CHD: coronary heart disease
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5.2.3.4 The prevalence of atherosclerotic disease in key MI registries 
While MI registers usually include patients with recurrent MI in addition to first 
events, they do give an indication of the frequency of disease in MI patients (Table 5.2).  
The proportion of MI patients in these studies, including over 500,000 MI patients, who had 
previous angina was between 10.1% in STEMI patients in the National Register of MI and 
74.8% in patients with non ST-elevation acute coronary syndromes in the EuroHeart Survey.  
The prevalence of cerebrovascular disease was between 5 and 13% and the prevalence of 
peripheral arterial disease between 7 and 13%.    
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Table 5.2 The prevalence of prior atherosclerotic disease in patients recorded in key myocardial infarction registries 
 
 GRACE  
[152] 
NRMI  
[153] 
MONICA 
Scotland[15] 
Euro Heart Survey 
[154]  
SWEDEHEART 
2004-2006 [155] 
REGICOR 
[156] 
  
STEMI 
(n=3,419) 
NSTEMI 
(n=2,893) 
STEMI 
(n=153,486) 
NSTEMI 
(n=337,192) 
Men 
(n=3,991) 
Women 
(n=1,551) 
STEMI 
(n=4,431) 
NSTEMI/UA 
(n=5,367) 
Men 
(n=9,386) 
Women 
(n=4,994) 
All MI 
(n=3,849) 
MI, % 19 33 21.5 28.3 32 25.6 22.3 35.6 11.3 10.6 0 
Angina, % 49 67 10.1 14.2 41.6 41.5 56.4 74.8 n/s n/s 43.9 
Stroke/TIA, 
% 6 10 9.1 12.9 5.9 5.7 5.9 8.1 n/s n/s n/s 
Peripheral 
disease, % 8 13 n/s n/s n/s n/s 7 10.6 n/s n/s n/s 
Heart failure, 
% 7 14 13.8 24 n/s n/s 8.2 11.9 4.3 9.1 n/s 
PCI, % 6 13 10.1 11.3 n/s n/s 7.3 15.2 4 2.2 n/s 
CABG, % 5 13 9.8 16.8 n/s n/s 3.4 11 3.3 1.7 n/s 
Abbreviations: STEMI: ST-elevation MI; NSTEMI: non ST-elevation MI; UA: unstable angina; n/s: not stated; GRACE: Global Registry of Acute 
Coronary Events; NRMI: National Register of Myocardial Infarction; MONICA: Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease; SWEDEHEART: the Swedish cardiac registry; REGICOR: the coronary heart disease register in Spain.
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5.2.3.5 Studies reporting heralding by elevated cardiovascular disease risk 
factors 
Several studies have reported the prevalence of ‘optimal’ risk factor profiles in 
patients with MI with respect to the four ‘major’ cardiovascular disease risk factors: 
smoking, diabetes, hypertension and total cholesterol.[157]  These studies, using a range of 
designs, have shown that most patients with MI have at least one cardiovascular disease risk 
factor.  However, no estimates have been published in patients with their first MI and 
without prior atherosclerotic disease. 
In the UK, 2% (5/202) of patients with ischaemic heart disease in the British 
Regional Heart Study were normotensive, with normal cholesterol and were non-
smokers.[158]  However, for the same set of risk factors, 13% of MI cases recorded in the 
MONICA Augsberg dataset (including fatal and non-fatal) had optimal levels.  This higher 
figure is in line with other studies; a cross sectional study of 122,000 clinical trial patients 
with MI showed that 15% of women and 19% of men had no major risk factors at the time 
of MI,[159] although if family history of CHD and obesity were considered as risk factors, 
then this fell to 8.5% of women and 10.7% of men.  In a large US study of patients with 
NSTEMI (>74,000 patients),[160] 10.5% had no recorded  major risk factors.  Yawn 
reported that 98% of women with MI had at least one CHD risk factor identified before MI, 
and 84% had at least two identified.[146] 
Greenland assessed the prevalence of risk factors in fatal and non-fatal CHD events 
in three large observational studies; for non-fatal MI in the Framingham Study, over 85% of 
young men and over 90% of older men had at least one recorded risk factor;[161] 70% of 
younger women with MI and 87% of older women also had at least one elevated risk factor.  
In fatal coronary heart disease, the number of patients with at least one elevated risk factor in 
the MRFIT cohort, the Chicago Heart Association project and the Framingham study were 
over 90%.  When borderline results were also included, nearly 100% of MI patients had 
unfavourable risk factor profiles.  Risk factors included in these analyses were smoking, 
diabetes, hypertension and high cholesterol.[161] 
 
5.2.4 Strengths of previous research 
There were two studies that reported the proportion of patients with and without 
prior atherosclerotic disease, and several that reported the proportion with and without 
elevated traditional cardiovascular disease risk factors.  They have done so in varied 
geographical populations, in large samples and at different time points.  They provide good 
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estimates of the proportion of patients with and without prior atherosclerotic disease or with 
and without cardiovascular disease risk factors.   
 
5.2.5 Limitations of previous research 
No studies were identified that reported the proportion of first MI patients who have 
no prior atherosclerotic disease and cardiovascular disease risk factors, which was the focus 
of this review.  
 
5.2.6 Limitations of this review 
The search strategy used in this review limited the search to the titles only.  
Inclusion of terms to indicate heralding of MI in the abstract produced over 30,000 articles.  
Inclusion of specific atherosclerotic disease diagnoses such as ‘angina’, ‘coronary disease’, 
‘cerebrovascular disease’ or ‘peripheral arterial disease’ (and their synonyms) would also 
have generated an unmanageable number of results.  Therefore, this search was required to 
be more specific.  Despite the high specificity and low sensitivity of the search, any relevant 
studies would have been identified as reference lists were scanned and cited reference 
searches of any papers described in the review were also performed. 
 
5.2.7 Conclusion 
This literature review indicates that there are no current studies investigating 
heralding of MI by atherosclerotic disease in all arterial beds, cardiovascular disease risk 
factors, cardiovascular medications and chest pain. 
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5.3 Objectives 
Using prospectively collected primary care data linked to detailed hospital data on 
acute coronary syndromes: 
1. To describe the initial manifestation, distribution and timing of different 
atherosclerotic presentations prior to MI; 
2. To describe the cardiovascular disease risk in patients without diagnosed 
atherosclerotic disease prior to MI;  
3. To describe the proportion of MIs that occur without any previously diagnosed 
atherosclerotic disease, cardiovascular disease risk factors or chest pain.   
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5.4 Methods 
5.4.1 Identification of patients with MI 
Analysis of the current objective was performed before the recording of MI in the 
linked data was validated (results in Chapter 4). Therefore, a pragmatic and conservative 
approach was used to identify MI in this analysis, using the assumption that recording of 
acute MI in HES and MINAP was more accurate than recording in GPRD or ONS (due to 
prevalent coding of MI and failure to record MI in the primary care record, and concern 
about the validity of a record of fatal MI in ONS). Therefore, the analyses in this objective 
were based on hospitalized cases of first MI identified in MINAP and HES, as described in 
Chapter 3.  Patients with any evidence of previous MI in HES, MINAP or the GPRD were 
excluded from the analysis. 
 
Table 5.3 Definition of acute myocardial infarction in Hospital Episode Statistics (HES) 
and the Myocardial Ischaemia National Audit Project (MINAP) 
 
Data source MI definition 
HES ICD-10 code I21, I22 or I23 as the primary diagnosis in the first 
hospital episode. 
MINAP ST-elevation MI or non ST-elevation MI following the joint American 
Heart Association / European Society of Cardiology definition.[6] 
 
5.4.2 Exclusion criteria 
Exclusion criteria are described in Chapter 3.  Briefly, patients were excluded if they 
had a recorded history of MI (n=7,163), were under the age of 18 at MI (n=1), had not been 
registered with the primary care practice for at least one year before MI (n=769), whose MIs 
occurred outside the period where all databases were collecting data (outside 1st January 
2003 to 31st December 2008, n=4,446), and patients without any primary care consultations 
in their record prior to MI (n=3).   
 
5.4.3 Heralding by atherosclerotic disease 
Atherosclerotic disease diagnoses in GPRD, MINAP and HES were identified using 
the methods described in Chapter 3.  Disease diagnosed in GPRD and HES up to one day 
before the date of admission for MI was considered to ‘herald’ MI.  Those recorded on the 
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date of MI in MINAP were also considered to herald MI.  Codes recorded in the GPRD or 
HES on or after the date of admission were considered to be new diagnoses made at the time 
of MI or post-MI, and were not included in the analysis.  Atherosclerotic disease was 
categorised into the following phenotypes: 
• Coronary heart disease (CHD), including: 
o stable angina, including patients with percutaneous coronary intervention 
(PCI) or coronary artery bypass graft (CABG), 
o unstable angina, 
o cardiac arrest*, 
o heart failure*, 
o CHD of unspecified type; 
• Peripheral arterial disease (PAD), including abdominal aortic aneurysm (AAA); 
• Cerebrovascular disease, including: 
o stroke,  
o transient ischaemic attack (TIA),  
o other non-stroke ischaemic cerebrovascular disease; 
• Atherosclerotic disease of unspecified type. 
 
*although these were not necessarily coronary in nature, these were categorized as coronary 
diagnoses for this analysis. 
 
5.4.4 Duration of atherosclerotic disease before first MI 
The duration of each diagnosed disease phenotype was calculated based on the time 
between the earliest recorded code in the GPRD or HES and the date of MI.  MINAP does 
not record dates of previous atherosclerotic disease and therefore if MINAP data alone 
indicated heralding, the date of onset was recorded as unknown.  In addition, the date of 
onset was recorded as unknown if the earliest GPRD Read code indicating disease in the 
GPRD indicated a ‘history of’ the disease rather than an incident diagnosis.   
 
5.4.5 Initial manifestation of atherosclerotic disease before first MI 
The initial manifestation of disease was determined based on the phenotype of 
longest duration.  If two phenotypes were recorded on the same day (i.e. with the same 
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duration) then the following hierarchy (created by CALIBER collaborators, unpublished), 
was used to determine which phenotype should be classed as the initial manifestation: 
1. Heart failure (most severe) 
2. Unstable angina 
3. PCI or CABG 
4. Stable angina 
5. CHD of unknown subtype 
6. Atherosclerotic disease of unknown type 
7. PAD 
8. Cerebrovascular disease 
9. Cardiac arrest 
10. TIA (least severe) 
 
5.4.6 Polyvascular atherosclerotic disease  
The presence of polyvascular atherosclerotic disease (i.e. disease in more than one 
arterial bed) was based on the number of arterial beds affected (coronary, peripheral, 
cerebrovascular) at the time of MI.   
 
5.4.7 Cardiovascular disease risk factors before first MI 
Smoking status (categorised as current, ex, non and unknown), diabetes, 
dyslipidaemia, hypertension (each categorised as binary variables, present or absent), BMI 
(classified as underweight, normal, overweight, obese or unknown) and family history of 
CHD were recorded in the GPRD and HES up to one day before MI.  Identification of these 
risk factors is described in Chapter 3.   
 
5.4.8 Cardiovascular drugs before first MI 
Prescriptions of lipid lowering, blood pressure lowering and antiplatelets 
medications (as described in Chapter 3) were assessed based on GPRD prescription dates 
and MINAP recording of use at admission.  A binary variable was created for each 
medication to describe use in the six months before MI. 
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5.4.9 Chest pain before first MI 
Experience of chest pain in patients without diagnosed atherosclerotic disease was 
explored.  As discussed in Chapter 3, two types of chest pain were of interest:  
• Chest pain attributed to a non-coronary cause; and  
• Chest pain unattributed to any cause.   
 
Consultations for either of these types of chest pain up to the day before MI were 
extracted from GPRD records, as described in Chapter 3.  Admissions to MINAP hospitals, 
with discharge diagnoses of ‘other’ were also recorded as chest pain.   
 
5.4.10 ‘Unheralded’ MI 
This chapter describes heralding of MI by atherosclerotic disease diagnoses, 
cardiovascular disease risk factors and chest pain.  However, patients without these factors 
recorded in their medical record are not termed ‘unheralded’.  This is for two reasons: firstly, 
the term ‘unheralded’ is misleading when used out of context because it implies that disease, 
risk factors and chest pain are the only signs that may precede MI (which is not the case), 
and secondly, such symptoms may have been experienced by the patient but not been 
reported or recorded in the medical record.  However, the term unheralded may be used in 
conjunction with a qualifying factor (e.g. “unheralded by atherosclerotic disease”, or 
“unheralded by disease or cardiovascular disease risk factors”). 
 
5.4.11 Statistical analysis 
In the main analysis, the proportions of patients with each type of atherosclerotic 
disease were reported.  The initial manifestation was also reported, and the onset and median 
duration of disease prior to MI were described for coronary, cerebrovascular and peripheral 
arterial disease.  The proportion of patients with diagnosed disease in one, two or three 
arterial beds was calculated.  The prevalence of each risk factor was then compared in 
patients with and without atherosclerotic disease diagnosed prior to MI.  The frequency and 
rate of consultations were assessed monthly in the five years leading to MI, and daily in the 
year prior to MI.  Finally, the occurrence of MI without previous disease, risk factors, 
cardiovascular medications and chest pain was examined and described by age and sex.   
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5.4.12 Sensitivity analyses 
Various analyses were undertaken to assess the sensitivity of the results to analytic 
decisions and assumptions.  First, the sensitivity of the rating of Read and ICD-10 codes was 
assessed.  The analysis was repeated including codes rated as ‘possible’ indicators of 
atherosclerotic disease in addition to the ‘definite’ codes used in the main analysis.  Due to 
the uncertainty of its effects, a minimum consultation rate was not applied to this analysis.  
To assess how this would have affected the results, the patients were stratified by 
consultation rate and the proportion of patients with atherosclerotic disease in each stratum 
was examined.  The third sensitivity analysis addressed the assumption that one year of pre-
MI follow-up was sufficient for prevalent atherosclerotic disease to be identified by the GP.  
This was increased to three years and the proportion of patients with diagnosed disease was 
compared to the results of the main analysis.  The final sensitivity analysis assessed the 
effect of including patients with atherosclerotic disease diagnosed prior to the UTS date.  It 
is possible that the date of diagnosis prior to UTS was inaccurate.  Therefore, the prevalence 
and pattern of onset of each subtype diagnosed only inside the UTS period was compared to 
the results in the main analysis.    
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5.5 Results 
 
5.5.1 Description of cases 
There were 11,255 patients with MI who met all eligibility criteria.  They had a 
median age of 72 and 38.2% were female (Table 5.4).  Detailed clinical data were 
unavailable in HES but of the 8,059 patients recorded in MINAP, 48.1% were STEMI and 
51.9% were NSTEMI.   
 
Table 5.4 Demographic characteristics of patients with myocardial infarction 
(N=11,255) 
 
    N=11,255 
Age in years, median (IQR) 72 (60-81) 
Female, n (%) 4,294 (38.2) 
Ethnicity, n (%)  
White 9,129 (81.1) 
South Asian 82 (0.7) 
Other 207 (1.8) 
Unknown 1,837 (16.3) 
IMD quintile, n (%) 
1 (Least deprived) 2,229 (25.5) 
2 1,911 (21.9) 
3 1,812 (20.8) 
4 1,644 (18.8) 
5 (Most deprived) 1,135 (13) 
Consultations per year, median (IQR) 6.4 (3.4-10.8) 
Years of pre-MI GPRD registration, 
median (IQR) 8.6 (5.5-13.4) 
MI type*, n (%) 
STEMI 3,304 (48.1) 
NSTEMI 3,567 (51.9) 
*In 6,871 MINAP patients only.  MI: myocardial infarction; GPRD: 
General Practice Research Database; IQR: inter-quartile range; 
STEMI: ST-elevation myocardial infarction; NSTEMI: non ST-
elevation myocardial infarction 
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5.5.2 Atherosclerotic disease before MI 
Of the 11,255 first MI patients, 4,897 (43.5%, (95% CI: 42.6-44.4%)) were heralded 
by previously diagnosed atherosclerotic disease.  Table 5.5 shows the atherosclerotic disease 
manifestations of these patients.  The most common manifestation was stable angina and the 
coronary arteries were most frequently diseased.  The annual proportion of heralded patients 
varied between 41.5 and 46.1% during the study period but with no evidence of a time trend 
(p=0.1) (Appendix A, Figure 10.3).  Appendix A, Table 10.17 describes the initial 
manifestations in these patients; 16.1% of patients first manifested with cerebrovascular or 
peripheral disease, and while many of these patients subsequently developed symptomatic 
coronary disease before MI, a fifth (1,053 patients) of patients heralded by disease had 
peripheral or cerebrovascular disease only. 
When the prevalence of previous disease was examined by MI types (restricting the 
analysis to MINAP patients, in whom MI type was known, N=6,871), there were striking 
differences.  The proportion of patients with any prior disease in NSTEMI patients was 
50.4% compared to 29.4% in STEMI patients.  The differences in heralding between STEMI 
and NSTEMI patients are explored in paper 1 (Appendix A, section 0). 
 
5.5.2.1 Polyvascular disease before MI 
Of the 44% of patients with diagnosed atherosclerotic disease prior to MI, the 
majority had just one arterial bed with manifest disease; 31.1% of patients had disease in one 
arterial bed, 10.4% in two and 2.0% of patients had disease diagnosed in all the coronary, 
cerebrovascular and peripheral arteries.  Polyvascular disease was strongly related to older 
age (P<0.001). Figure 5.1 shows that the majority of single and double vascular disease was 
in the coronary circulation. 
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Table 5.5 Manifestations of atherosclerotic disease before first myocardial infarction 
(MI), and the duration between manifestation and MI (N=11,255) 
 
    Median duration before MI, 
years (IQR) n (%) 
Any atherosclerotic disease 4,897 (43.5) 6.7 (2.5-11.9) 
Coronary disease 3,836 (34.1) 3.4 (0.7-7.7) 
Stable angina 2,902 (25.8) 6.1 (1.8-11.6) 
Unstable angina 562 (5.0) 2.1 (0.1-5.6) 
PCI or CABG 519 (4.6) 5.7 (1.3-11.1) 
Heart failure 1,122 (10.0) 3.3 (1.0-6.5) 
Cardiac arrest 108 (1.0) 2.4 (0.2-5.3) 
CHD not otherwise specified 2,265 (20.1) 6.8 (2.5-12.1) 
Other atherosclerotic disease 2,356 (20.9) 4.9 (1.9-8.9) 
Cerebrovascular disease 1,256 (11.2) 5.7 (2.3-10.6) 
Peripheral arterial disease 1,204 (10.7) 5.1 (2.1-9.0) 
Atherosclerotic disease of 
unknown subtype 117 (1.0) 3.0 (1.3-6.0) 
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CHD: 
coronary heart disease; IQR: inter-quartile range.  *Patients with atherosclerotic disease of 
unknown subtype were those with unspecific Read codes recorded in the GPRD (see 
methods).  Patients appear more than once if they are diagnosed with more than one type of 
atherosclerotic disease before MI. 
 
 
 
Figure 5.1 Proportion of all patients with coronary heart disease (CHD), 
cerebrovascular disease (CVD) and peripheral arterial disease (PAD) and 
combinations of each of these in 11,255 patients with first myocardial infarction   
(56% of patients had no previously diagnosed atherosclerotic disease, 31% had disease at 
one site, 10% had two and 2% at three sites.) 
  
Chapter 5 
154 
 
5.5.3 Onset and duration of atherosclerotic disease before MI 
Of the 4,897 patients who had previously diagnosed disease, 4,540 (92.7%) had a 
reliable date of onset (i.e. were first recorded with atherosclerosis in the GPRD or HES with 
a code which indicating incident disease).  Table 5.5 shows the median duration between 
first ever diagnosis of atherosclerotic disease and MI, and the median duration between first 
diagnosis of specific phenotypes of atherosclerotic disease and MI.  The median duration 
between first diagnosis and MI was 6.7 years.  The median duration of cerebrovascular and 
peripheral disease was 4.9 years, slightly more than for coronary disease (median 3.4 years).  
Of patients heralded by disease, 6.6% were diagnosed twenty years or more before MI, 
33.0% ten years or more, 59.7% five years or more and 84.9% one year or more (Table 5.6).  
There was a long duration of heralding in most patients with previously diagnosed disease.    
The rate of atherosclerotic disease onset in the ten years prior to MI was relatively 
stable (shown in Figure 5.2) until the year prior to MI when there was a large increase in the 
rate.  To examine this pattern further, the rate of disease onset was described by arterial site 
(Figure 5.3).  This showed that the rapid increase in disease diagnosis before MI was 
restricted to coronary heart disease presentations.  The rate of coronary disease in the year 
before MI was 4.6 times higher than in the remaining nine years before MI (95% CI 4.16-
5.01) P< 0.001.  No such rise was seen in cerebrovascular of peripheral disease 
presentations.  The rate of coronary diagnoses in the last year of pre-MI follow-up is 
displayed in more detail in Figure 5.4, showing that the rapid rise in the onset of coronary 
disease was restricted to the 90 days before MI.   
 
Table 5.6 Cumulative onset of atherosclerotic disease before MI, in patients with a 
complete date of onset (N=4,540) 
 
Duration of 
atherosclerotic disease 
Cumulative n (%) with atherosclerotic 
disease before MI 
≥20 years 301 (6.6) 
≥15 years 643 (14.2) 
≥10 years 1,497 (33) 
≥5 years 2,711 (59.7) 
≥2 years 3,566 (78.5) 
≥1 years 3,853 (84.9) 
≥0.5 years 4,053 (89.3) 
≥1 day 4,540 (100) 
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Figure 5.2 Rate of atherosclerotic disease onset in the ten years prior to first myocardial 
infarction (MI), per 1,000 person years (95% confidence intervals) in 11,255 patients 
 
Figure 5.3 Rate of coronary heart disease (CHD), peripheral arterial disease (PAD) and 
cerebrovascular disease (CVD) onset in the ten years prior to first myocardial infarction 
(MI), per 1,000 person years (95% confidence intervals) in 11,255 patients 
 
Figure 5.4 Monthly rate of coronary diagnosis in the three years prior to first myocardial 
infarction (MI), per 100,000 person days (95% confidence intervals) in 11,255 patients. 
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5.5.3.1 The premonitory period 
The weeks or months preceding MI is often called the ‘premonitory’ or ‘prodromal’ 
period, where patients experience chest pain or other symptoms that, retrospectively, can be 
described as associated with the patient’s subsequent MI.  Based on the data from this 
analysis, the premonitory period was defined as the 90 days prior to MI.   
Diagnoses of coronary disease in the 90 days before MI were stable angina (n=272), 
unstable angina (n=96), CABG or PCI (n=34), CHD not otherwise specified (n=107).  In 
total, 344 (3.1%) patients were first diagnosed in these three months; for comparison, only 
83 patients were diagnosed with the same disease outcomes in the three to six months before 
MI, and 61 from six to nine months before MI.    
In addition to the patients with diagnosed coronary disease in the 90 days before MI, 
a further 403 (6.3%) patients without diagnosed atherosclerotic disease consulted their GP 
with chest pain that was recorded as non-coronary (n=15) or that was not attributed to any 
cause (n=396).  One patient was admitted to hospital and had a MINAP discharge diagnosis 
of ‘other’ (i.e. not acute coronary syndrome) in the 90 days before MI.  The monthly 
frequency of consultation for chest pain in patients without atherosclerotic disease diagnosis 
was stable until the month before MI, when a large increase in consultations was seen 
(Figure 5.5).  Examining the daily consultation rate for chest pain in only the year prior to 
MI, the increase in consultations begins in the 30 to 50 days before MI and the largest rise is 
in the week before MI. 
The monthly and daily rate of consultation for all causes were also calculated for all 
patients (N=11,255) (Figure 5.6 and Figure 5.7).  The rate of consultation increased steadily 
over the three years prior to MI, but then exponentially in the five months prior to MI.  A 
closer examination of this pattern describes the largest increase in the thirty days prior to MI.  
In the 11,255 patients included in this analysis, the number of all-cause consultations 
doubles from approximately 400 per day (roughly 4% of future MI patients per day) in the 
ninety to thirty days before MI, to nearly 1400 (roughly 12%) the day before MI.  
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Figure 5.5 Frequency of chest pain consultations in patients without diagnosed 
atherosclerotic disease, in (A) five years before myocardial infarction (MI), (B) 
one year before MI and (C) 100 days before MI (N=7,325) 
A 
B 
C 
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Figure 5.6 Monthly rate of consultation for any cause in primary care for 11,255 
patients with MI, in the three years leading up to MI 
 
 
 
Figure 5.7 Daily rate of consultation for any cause in primary care for 11,255 patients 
with MI, in the 90 days leading up to MI 
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5.5.4 Demographic characteristics of patients with and without previously 
diagnosed atherosclerotic disease 
Overall, patients with prior atherosclerotic disease tended to be older, were more 
likely to be female and with more social deprivation than patients unheralded by disease 
(Table 5.7).  The peak in MI without previous disease was younger for men than women 
(age group 50-59 age group for men, but 70-79 group for women) (Figure 5.8).  Patients 
with prior atherosclerotic disease had a higher rate of consultation before MI, reflecting their 
increased disease burden and need for services, but were registered with the GPRD practice 
for a similar duration before MI. 
 
Table 5.7 Demographic variables in 11,255 myocardial infarction patients with and 
without previously diagnosed atherosclerotic disease 
 
    
No previous 
diagnosed 
atherosclerotic 
disease  
N=7,325 
Previously 
diagnosed 
atherosclerotic 
disease  
N=5,950 
Total  
 
 
 
N=11,255 
Median age, years (IQR) 66 (56-77) 78 (69-84) 72 (60-81) 
Female, n (%) 2,166 (34.1) 2,128 (43.5) 4,294 (38.2) 
Ethnicity, n (%)  
White 5,087 (80) 4,042 (82.5) 9,129 (81.1) 
South Asian 49 (0.8) 33 (0.7) 82 (0.7) 
Other 124 (2.0) 83 (1.7) 207 (1.8) 
Unknown 1,098 (17.3) 739 (15.1) 1,837 (16.3) 
IMD quintile, n (%) 
1 (Least deprived) 1,322 (26.8) 907 (23.8) 2,229 (25.5) 
2 1,092 (22.2) 819 (21.5) 1,911 (21.9) 
3 1,029 (20.9) 783 (20.6) 1,812 (20.8) 
4 875 (17.8) 769 (20.2) 1,644 (18.8) 
5 (Most deprived) 607 (12.3) 528 (13.9) 1,135 (13.0) 
Primary care 
consultations per year, 
median (IQR) 4.7 (2.4-8.3) 8.8 (5.4-13.6) 6.4 (3.4-10.8) 
Years of pre-MI GPRD 
registration, median (IQR) 8.4 (5.3-13.2) 8.8 (5.6-13.7) 8.6 (5.5-13.4) 
IMD: index of multiple deprivation; GPRD: General Practice Research Database; IQR: inter-
quartile range. 
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Figure 5.8 Demographic distribution of patients with myocardial infarction, with and 
without previously diagnosed atherosclerotic disease, with 95% confidence intervals, in 
men (N=6,961) and women (N=4,294) 
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5.5.5 Cardiovascular disease risk factors and medication prescriptions in 
patients with and without previously diagnosed atherosclerotic disease 
The prevalences of hypertension, diabetes and dyslipidaemia were higher in patients 
heralded by atherosclerotic disease diagnoses.  However, current smoking and family history 
of coronary disease were more prevalent in those unheralded by disease.  Levels of 
overweight and obesity were similar between the groups.  The pre-MI prevalence of 
cardiovascular disease risk factors is shown in Table 5.8.   
The risk factor burden in patients without diagnosed atherosclerotic disease (Figure 
5.9) was on average slightly lower than in patients with diagnosed atherosclerotic disease; 
the median number of traditional cardiovascular disease risk factors in patients with previous 
disease diagnoses was 2 (IQR 1-3) compared to 1 (IQR 1-2) in those without.  In patients 
heralded by diagnosed atherosclerotic disease, 459 patients (9.4%) had no recorded elevated 
risk factors and in unheralded patients 979 (15.4%) had no recorded elevated risk factors. 
Prescribing of blood pressure lowering, lipid lowering and antiplatelet medications 
in the six months before MI is also shown in Table 5.8.  Prescribing was higher in those with 
diagnosed atherosclerotic disease, but even in those without established disease, 15.9% of 
patients were prescribed antiplatelets, 35.4% were prescribed blood pressure lowering and 
15.0% were prescribed lipid lowering medications, indicating known raised risk among this 
group.  Prescription of one, two or three of lipid lowering, blood pressure lowering and 
antiplatelets drugs is shown in Figure 5.10.  In patients with diagnosed atherosclerotic 
disease, it was most common to be receiving all three drug classes.  In patients without 
diagnosed disease, it was most common to be receiving none, although 5.9% of such patients 
were prescribed all three medications in the six months before MI. 
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Table 5.8 Cardiovascular disease risk factors and prescription of cardiovascular 
medications in patients with and without previously diagnosed atherosclerotic disease 
 
    
No previously 
diagnosed 
atherosclerotic 
disease  
N=6,358 
Previously 
diagnosed 
atherosclerotic 
disease  
N=4,897 
TOTAL  
 
 
 
N=11,255 
    n (%) n (%) n (%) 
Hypertension 2,857 (44.9) 3,566 (72.8) 6,423 (57.1) 
Diabetes 758 (11.9) 1,188 (24.3) 1,946 (17.3) 
Dyslipidaemia 1,161 (18.3) 1,675 (34.2) 2,836 (25.2) 
Family history CHD 2,421 (38.1) 1,655 (33.8) 4,076 (36.2) 
Weight 
Underweight 18 (0.3) 27 (0.6) 45 (0.4) 
Normal weight 356 (5.6) 259 (5.3) 615 (5.5) 
Overweight or 
obese 1,360 (21.4) 980 (20.0) 2,340 (20.8) 
Weight unknown 4,624 (72.7) 3,631 (74.1) 8,255 (73.3) 
Smoking status 
Non-smoker 906 (14.2) 641 (13.1) 1,547 (13.7) 
Ex-smoker 3,116 (49) 3,213 (65.6) 6,329 (56.2) 
Current smoker 2,274 (35.8) 1,007 (20.6) 3,281 (29.2) 
  Unknown 62 (1.0) 36 (0.7) 98 (0.9) 
Blood pressure 
lowering 2,250 (35.4) 3,592 (73.4) 5,842 (51.9) 
Lipid lowering 954 (15) 2,272 (46.4) 3,226 (28.7) 
Antiplatelets 1,013 (15.9) 2,976 (60.8) 3,989 (35.4) 
CHD: coronary heart disease.  
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Figure 5.9 Number of traditional cardiovascular disease risk factors in 11,255 
myocardial infarction (MI) patients with and without previously diagnosed 
atherosclerotic disease (hypertension, dyslipidaemia, overweight or obese, family 
history coronary heart disease, diabetes, current smoking), with 95% confidence 
intervals 
 
 
 
 
Figure 5.10 Number of different drugs prescribed in the six months prior to 
myocardial infarction (MI), in 11,255 patients with and without previously diagnosed 
atherosclerotic disease (lipid lowering, blood pressure lowering, antiplatelets), with 
95% confidence intervals 
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5.5.6 MI without warning 
810 of 11,255 (7.2% 95% CI (6.7-7.7%)) first MI patients experienced no previous 
atherosclerotic disease diagnoses before their MI, had no elevated cardiovascular disease 
risk factors and had not been prescribed any of the three key cardiovascular drugs in the six 
months before MI.  In the eyes of the general practitioner, these are healthy patients whose 
MIs are without warning.  If cardiovascular drug use was extended to ever-use rather than 
use in the six months prior to MI, then 736 patients (6.5%) occur without warning.  If 
consultation for chest pain is also included, 703 (6.2%) occur without warning. 
The distribution of this subset of patients by age and sex is shown in Figure 5.12.  
Men were most likely to experience MI without warning (N=540 versus 270 in women) and 
most frequently in age groups 60 to 80.  Women who had MI without warning tended to be 
older (peak in age group 80-89).  In both men and women, patients who had their MI 
without warning tended to older than patients with known elevated cardiovascular disease 
risk (Figure 5.13).   
The consultation rate preceding MI was lower in patients who had MI without 
warning compared to those with elevated cardiovascular disease risk (median 3.5 
consultations per year (IQR 1.7-6.6) and 5.0 (IQR 2.6-8.5), respectively, Kruskal Wallis 
P=0.0001 for a comparison of medians).  When the total number of consultations in the year 
prior to MI was assessed, the median number of consultations for patients with elevated 
cardiovascular disease risk (but without known atherosclerotic disease diagnoses) was 7 
(IQR 3-13), and was lower in patients who had MI without warning (median 5 (IQR 2-9)).   
 
Figure 5.11 Distribution of 11,255 myocardial infarction patients 
by previous atherosclerotic disease and cardiovascular disease 
risk factors 
Without warning
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Figure 5.12 Number of men and women who had myocardial infarction without 
warning (total N=810) 
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Figure 5.13 Demographic distribution of patients (5,159 men, 2,166 women) with 
myocardial infarction, with no previously diagnosed atherosclerotic disease, with and 
without elevated risk factors or cardiovascular medication prescriptions, with 95% 
confidence intervals 
 
5.5.7 Sensitivity analyses 
5.5.7.1 ‘Possible’ diagnostic codes to define atherosclerotic disease 
The codes used to define atherosclerotic disease in this thesis were rated as ‘definite’ 
indicators of atherosclerotic disease by two independent raters, including one general 
practitioner.  However, many Read codes were rated as ‘possible’ indicators of disease.  In 
the main analysis, only definite codes were used.  In this sensitivity analysis, the possible 
codes were included.  This made very little difference to the overall estimate of the 
proportion of patients with prior atherosclerotic disease (46.4% compared to 43.5% in the 
original analysis) or to the prevalences of specific atherosclerotic disease phenotypes (Table 
5.9).  This indicates that the list of ‘definite’ rated codes was sensitive. 
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5.5.7.2 Variation in the proportion heralded with atherosclerotic disease, by 
consultation rate 
The proportion of patients with atherosclerotic disease varied between percentiles of 
consultation rate (Appendix A, Figure 10.4).  Patients with the lowest consultation rates had 
the lowest prevalence of atherosclerotic disease diagnosis at MI and those with the highest 
consultation rate had the highest prevalence.  However, a low rate of consultation may be 
due either to good health or to a reluctance to visit the GP despite symptomatic disease.  
When the analysis was restricted to patients with a high consultation rate (top 25th 
percentile), the prevalence of atherosclerotic disease rose from 43.5% in the original analysis 
to 66.1%.  When the analysis was restricted to patients with low consultation rate, just 
19.3% of patients were heralded (see Table 5.9).  This suggests that introducing a minimum 
consultation rate would have changed the results of the study.  
 
5.5.7.3 Excluding patients with less than three years of pre-MI UTS follow-up 
In the main analysis, all MI patients were required to have at least one year of up to 
standard (UTS) follow-up prior to MI (where the UTS date is defined by the GPRD as the 
date when the practice starts to provide continuous good quality data).  This was to allow 
adequate time for GPs to record prevalent conditions after patient registration with the 
practice and was shown by Lewis et al to be a sufficient time period.[89]  However, some 
authors using GPRD data exclude patients who do not have at least three years of 
registration.  When patients with less than three years of registration were excluded, the 
proportion heralded by atherosclerotic disease overall was increased by less than half a 
percent.  The proportion of patients with prevalent atherosclerotic disease, stratified by 
disease subtype, showed very similar results (Table 5.9).  This indicates that the criterion to 
include only patients with at least one year of pre-MI follow-up was adequate to identify 
prevalent atherosclerotic disease. 
 
5.5.7.4 Patients diagnosed with atherosclerotic disease within the UTS 
period only 
In this analysis, only MI events that occurred within the UTS period were included, 
when GPRD data are marked as being of good quality.  However, atherosclerotic disease 
diagnoses were allowed to occur beforehand.  Of the 4,897 patients with diagnosed 
atherosclerotic disease, 1,346 (27.5%) were first diagnosed with atherosclerotic disease 
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before the practice UTS period began.  Excluding these patients in a sensitivity analysis 
gives us a similar (albeit lower) pattern of prevalence of the different types of atherosclerotic 
disease, and a similar pattern of onset.  (Appendix A, Figure 10.5). 
 
 
 
 
  
  
 
169
Table 5.9 Prevalence of atherosclerotic disease in sensitivity analyses 
 
  
Original analysis 
N=11,255 
Possible Read 
codes in 
addition to 
definite 
N=11,255 
Top 25% of 
consultation 
rates N=2,814 
Bottom 25% of 
consultation 
rates N=2,814 
Excluding 
patients without 
at least three 
years of pre-MI 
UTS follow-up 
N=10,302 
Atherosclerotic 
disease 
diagnosed 
within UTS only 
N=9,909 
n (%) n (%) n (%) n (%) n (%) n (%) 
Any atherosclerotic disease 4,897 (43.5) 5,224 (46.4) 1,859 (66.1) 544 (19.3) 4509 (43.8) 3,551 (35.8) 
Coronary disease 3,836 (34.1) 4,242 (37.7) 1,501 (53.3) 411 (14.6) 3540 (34.4) 2,680 (27) 
Stable angina 2,902 (25.8) 2,908 (25.8) 1,175 (41.8) 274 (9.7) 2673 (25.9) 1,912 (19.3) 
Unstable angina 562 (5) 586 (5.2) 253 (9) 54 (1.9) 511 (5) 360 (3.6) 
PCI or CABG 519 (4.6) 519 (4.6) 229 (8.1) 45 (1.6) 464 (4.5) 291 (2.9) 
Heart failure 1,122 (10) 1,194 (10.6) 576 (20.5) 71 (2.5) 1031 (10) 771 (7.8) 
Cardiac arrest 108 (1) 109 (1) 56 (2) 8 (0.3) 100 (1) 81 (0.8) 
CHD not otherwise specified 2,265 (20.1) 2,921 (26) 936 (33.3) 201 (7.1) 2101 (20.4) 1,361 (13.7) 
Other atherosclerotic 
disease 2,356 (20.9) 2,407 (21.4) 999 (35.5) 194 (6.9) 2172 (21.1) 1,638 (16.5) 
Cerebrovascular disease 1,256 (11.2) 1,315 (11.7) 571 (20.3) 85 (3) 1160 (11.3) 834 (8.4) 
Peripheral arterial disease 1,204 (10.7) 1,235 (11) 515 (18.3) 107 (3.8) 1116 (10.8) 823 (8.3) 
Unknown atherosclerotic 
disease 117 (1) 155 (1.4) 58 (2.1) 9 (0.3) 106 (1) 78 (0.8) 
 MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CHD: coronary heart disease; UTS: up to 
standard.   
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5.6 Discussion 
5.6.1 Main findings 
Over half of first MIs represent the first clinical manifestation of atherosclerotic 
disease.  The majority had at least one elevated cardiovascular disease risk factor or were 
being treated with a cardiovascular medication in the six months before MI; 7% of all MI 
patients had no previously diagnosed atherosclerotic disease or elevated risk factors in their 
medical record.  Ours is the first study to quantify this proportion of MIs, which are 
completely without warning or unheralded by disease or cardiovascular disease risk factors.   
There was also identified a clear premonitory period before MI, during which there 
was a rapid increase in the rate of coronary disease diagnosis and GP consultations for chest 
pain (in the group without diagnosed atherosclerotic disease).  There were no increases in 
the rate of cerebrovascular or peripheral arterial disease during this time.   
 
5.6.2 Comparison with other literature 
5.6.2.1 Previous atherosclerotic disease 
Previous estimates of the proportion of MI patients with previous angina or coronary 
disease were between 21% and 63%.  The estimates of heralding by stable angina and 
coronary disease prevalence generated in the current study are comparable with these 
estimates (25.8% and 34.1%, respectively).  The wide range of estimates in the literature 
reflects differences in timing of studies, their setting, the local prevalence of angina and risk 
factors, inclusion criteria and study design.  The most comparable study to ours in terms of 
design was Yawn et al,[148] where the prevalence of physician-diagnosed pre-MI coronary 
disease was estimated in women.  This was based on prospectively collected medical records 
in the US (1996-2001) and generated an estimate of 52% heralding by coronary disease.  
The estimate of heralding by coronary disease in women in the current study was 42%, but 
was based on several thousand more patients than Yawn’s study, which included only 150 
cases. 
A comparison with studies reporting the baseline results of MI registry data showed 
equally wide-ranging estimates.  For example, the Global Registry of Acute Coronary 
Events (GRACE) found 49% of STEMI patients and 67% of NSTEMI patients had previous 
angina,[152] compared to this study’s estimates of 16% and 33%, respectively.  Even the 
estimates of heralding by any coronary disease in this study are still far below the 
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prevalences described in GRACE patients.  The difference may have been due to the 
retrospective nature of the data from GRACE and the definition of previous angina.  
However, a Scottish register of 2,887 MI patients[162] showed more similar results to the 
current study; 21.4% with angina compared to 26.4%. 
The estimates generated for PAD and cerebrovascular disease are also comparable 
to those of GRACE (GRACE PAD prevalence: 8% in STEMI, 13% in NSTEMI, our 
estimates: 7% and 13%, respectively. GRACE cerebrovascular disease prevalence: 6% in 
STEMI, 10% in NSTEMI, our estimates: 7% and 13%, respectively).[152]  Our overall 
results for all MI are also comparable to the Scottish study,[162] which found 7.6% with 
PAD and 10.4% stroke in their MI patients, which compares well to our prevalences of 
11.1% and 11.7%, respectively. 
This study extends these findings and is the first to estimate the proportion of 
patients with any form of pre-MI atherosclerotic disease and examine the onset and duration 
of specific disease subtypes before MI.  Our estimate of 45% with previous atherosclerotic 
disease is comparable with the 51% of hospitalised patients with non ST-elevation acute 
coronary syndromes (unstable angina and MI) without any evidence of atherosclerotic 
disease in the CRUSADE registry.[145]   
The results from this study regarding polyvascular disease are also in line with other 
published findings.  In over 95,000 patients with unstable angina and NSTEMI in the 
CRUSADE registry, Bhatt and colleagues estimated the prevalence of disease in one 
vascular territory to be 38.3%.[163]  Our estimate was slightly lower, at 31.1%.  They found 
11.2% of patients with disease at two sites and 1.6% at three sites; our estimates were 10.4% 
and 2.0%, respectively.  Since the analyses in this thesis have shown that patients with 
STEMI have a lower atherosclerotic burden, and our estimates were for STEMI and 
NSTEMI combined, this could explain our lower estimates than those from CRUSADE, 
which was in NSTEMI alone. 
Quantifying the burden of atherosclerotic disease before MI represents a step 
forward in our understanding of unheralded MI and in elucidating whether MIs truly occur 
in some patients without warning.  It also highlights the importance of secondary prevention 
of cardiovascular disease.  This study showed that a large proportion of patients with MI had 
previously diagnosed atherosclerotic disease and should have been receiving lipid lowering 
drugs and antiplatelets to reduce their risk of further vascular events, but only a third were in 
receipt of all three.  The MIs included in these studies can be seen as ‘failures’ of secondary 
prevention. 
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5.6.2.2 Prodromal symptoms of MI 
Prodromal chest pain symptoms before MI were described in the 1970s by 
Harper[164] and Stowers & Short,[165] who both showed a steep increase in ischaemic 
symptoms in the four weeks before MI.  These studies were based on retrospective data from 
MI survivors and therefore ours is the first study to quantify, in detail and without recall 
bias, the increase in coronary disease diagnosis and chest pain before MI.  We also showed 
the increase in all-cause consultations in the prodromal period, and that this was equivalent 
to 4% of patients consulting per day in the years prior to MI, with an increase only to 12% in 
the day before MI.   
As this was a case-only analysis, the results cannot show whether such patients are 
identifiable from the large numbers of patients who consult with chest pain (or for any 
cause) or are newly diagnosed with coronary disease in general practice every day, and there 
are few public health implications of this analysis.  However, Ruigomez[166] examined the 
incidence of ischaemic heart disease (IHD) in the year following a first chest pain 
consultation in the GPRD and found that patients with unspecific chest pain were eighteen 
times more likely to develop IHD than control patients without chest pain.  Patients with 
chest pain who developed IHD were older, more likely to be male and had a worse 
cardiovascular disease risk profile.  These findings suggest that further investigation is 
warranted in MI patients who have previously presented with chest pain or recent angina to 
characterise the short term risk of coronary events in such patients.  Further research could 
also identify patients for whom this is a remediable premonitory period. 
Many studies have examined whether coronary symptoms occurring shortly before 
MI confer a survival advantage.[29, 31, 33, 167]  The ischaemic preconditioning theory 
suggests that pre-MI coronary symptoms may condition the myocardial tissue to ischaemia, 
so that during MI the myocardial tissue is preserved leading to smaller infarcts and better 
outcomes.[30, 168]  This was the subject of investigation in Chapter 6. 
 
5.6.2.3 Risk factor burden 
Our estimate of the risk factor burden in MI patients is consistent with other studies, 
showing that MI patients overall tend to have one or more elevated traditional cardiovascular 
disease risk factors.[159, 169, 170]  In this study the recorded burden of risk factors in 
patients unheralded by diagnosed atherosclerotic disease was lower than for those heralded.  
However, those without diagnosed atherosclerotic disease tended to be younger than those 
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without disease, providing less time for increased cardiovascular disease risk and while the 
prevalence cardiovascular disease risk factors was lower in this group, over a third were 
current smokers, nearly half were hypertensive and many also had diagnosed diabetes or 
dyslipidaemia.  These are key cardiovascular disease risk factors, which indicate raised risk 
and show that there are targets for prevention in most patients, not least for smoking.   
There could be some bias in the recording of cardiovascular disease risk factors in 
patients with and without prior atherosclerotic disease. Patients with diagnosed disease 
consult more frequently in general practice and have known atherosclerotic disease, and so 
the opportunity and motivation exist for close monitoring of risk factors.  Conversely, those 
without disease have fewer opportunities for risk factor measurement.  In this analysis, the 
frequency with which individual risk factors were measured in patients with and without 
disease was not examined.  Further still, the levels of management and treatment of 
cardiovascular disease risk between both groups were not compared.  Therefore, patients 
without prior atherosclerotic disease could represent a group in which there are many missed 
opportunities for care either due to:  
(i) Fewer GP consultations and less opportunity for identification of raised risk; 
(ii) Differences in frequency of vascular disease risk factor measurement; or 
(iii) Differences in intensity of treatment. 
 
A comparison with healthy controls is required to understand if and why risk factors 
are not measured and to find ways of identifying patients at high risk of unheralded MI.  
Given the large proportion of patients in this study whose first atherosclerotic disease 
manifestation was MI, this highlights the need for assessment and good quality management 
of vascular disease risk in primary care.  However, such patients must be identified by the 
GP from all of the patients without atherosclerotic disease, which represents a challenge.  
Therefore, further work to identify patients at high risk, based on other characteristics or 
levels of cardiovascular disease risk, is essential in reducing the burden of MI. 
 
5.6.2.4 Out of the blue MI 
7.2% of first MI patients had no previously recorded diagnosed atherosclerotic 
disease or raised cardiovascular disease risk.  To our knowledge, no studies have previously 
estimated this proportion.  Patients who had MI without warning were more likely to be men 
between 50 and 70 years of age.  Fewer women had MI without warning and those who did 
tended to be older.   
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It is widely thought that patients experiencing MI without warning are men who fail 
to visit their GP despite having truly elevated risk or symptomatic disease.  To some extent 
this may be true: the rate of consultation in patients with MI without warning was lower than 
in those with diagnosed disease or known elevated cardiovascular disease risk, and was 
lower in men than women.  Although there were fewer opportunities for measurement of risk 
prior to MI without warning, the median number of consultations in the year prior to MI was 
just 2 fewer than in patients with elevated cardiovascular disease risk (5 in MI without 
warning versus 7 in those with known raised risk).  This shows that in the majority of 
patients, there were likely to be opportunities for cardiovascular disease risk to be measured.  
However, in this study the measurement of cardiovascular disease risk in primary care and 
the reasons that these patients consulted in the year prior to MI were not examined.  This is 
an important area of further research: to identify patients who are at risk of MI without 
warning could add aid risk prediction.    
 
5.6.2.5 Non-atherosclerotic causes of MI  
While it is thought that few MIs occur in patients with normal coronary 
arteries,[171] various non-atherosclerotic causes of MI have been suggested,[172-174] 
including clotting abnormalities, coronary vasospasm, dissection, emboli, infections and 
inflammatory disorders.  These cannot be explored in the current data, but may be 
responsible for a proportion of MIs occurring without warning.  
 
5.6.3 Strengths 
Our study was large and based on over 11,000 cases of MI.  The confidence interval 
for our estimate was small and indicated that the true proportion of hospitalised MI patients 
with previously diagnosed atherosclerotic disease lay between 43.9 and 45.6%.  Most large 
studies of MI recruit patients at the time of MI and enquire retrospectively about previous 
atherosclerotic disease and risk factors.  A major strength of this study is that the data were 
collected prospectively for many years prior to MI.  This provided the detail to examine the 
onset and type of atherosclerotic disease and its treatment before MI.  It also had the benefit 
of avoiding errors in recall. 
The three databases used in this analysis have been validated and shown to be of 
high quality (Chapter 2, Chapter 4).  MINAP data are subject to annual checks in data 
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quality; the most recent assessments showed that completeness and validity were high in key 
fields.[175]  HES also undergoes extensive validation of codes and checks for 
completeness.[176]  The GPRD has been used extensively in research and a wide range of 
diagnoses, including MI and other atherosclerotic disease outcomes, have undergone 
validation.[53, 59, 62, 64, 65, 68, 177-182]  As discussed in Chapter 2 (Data sources), the 
GPRD has stringent data quality controls at the patient and practice level, and provides 
researchers with UTS dates within which the data are of suitable quality for research.  
Additional quality improvement in the GPRD has been driven by the Quality and Outcomes 
Framework[183] (QOF) introduced in 2004, which aimed to improve the quality of care in 
general practice and has improved collection of data, particularly regarding cardiovascular 
disease.   
Aspects of the linkage quality are examined in Chapter 4 but showed that the 
patients included in these linked data are representative of the sources from which they 
came.[143]  Our cases were therefore representative of all hospitalised MIs in the UK and 
were based on the international definition of MI in MINAP[6] and on widely used ICD-10 
codes in HES.  MINAP data hold information from all NHS hospitals in England and Wales 
and HES collects data from all English hospitals.  In addition, the GPRD has been shown to 
be representative of the UK population.   
All of our MI cases had at least one year of pre-MI UTS follow-up.  Some studies 
have indicated that one year is insufficient for the GP to record prevalent diagnoses in new 
patients.  A sensitivity analysis extending this criterion to three years had no effect on the 
overall atherosclerotic disease prevalence before MI.  Therefore, one year was sufficient 
time in which to record prevalent diagnoses in the majority of patients.  Indeed, the median 
duration of follow-up was 8.7 years (IQR 5.5-13.5), which far exceeds even this more 
stringent three year requirement.  Additionally the duration of primary care registration was 
very similar in patients heralded and unheralded by diagnosed disease, indicating that the 
absence of atherosclerotic diagnoses in unheralded patients was not due to inadequate time 
in follow-up.   
Over a quarter of the patients with atherosclerotic disease were first diagnosed 
before the GPRD UTS period began.  To examine the possibility that this introduced error 
into our description of the onset of disease, a sensitivity analysis was performed excluding 
these patients.  The patterns in the onset of different types of atherosclerotic disease were 
unchanged in this analysis. 
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Our estimates of heralding were based on GPRD Read codes rated as ‘definite’ 
indicators of atherosclerotic disease.  A sensitivity analysis was performed to examine 
whether the addition of codes rated as ‘possible’ would affect our estimates.  The proportion 
heralded increased only by a few percent, indicating that the codes rated as ‘definite’ had 
high sensitivity.  Use of ICD-10 codes in defining HES MI was also examined: nearly all 
were recorded with I21 (“Acute MI”), and of those recorded with I22 (“Subsequent MI”) or 
I23 (“Certain current complications following acute MI”), most were also recorded as acute 
MI in MINAP.  Therefore, the rating and choice of MI codes were adequate. 
 
5.6.4 Weaknesses 
This study only included cases that reached hospital.  Approximately one third of 
MI cases die before reaching hospital[184] and our study was therefore biased towards 
patients who survived.  Our results are therefore not generalisable to patients who die before 
reaching hospital.  The four source comparison of the capture of MI across GPRD, HES, 
MINAP and ONS has subsequently shown that each of the four data sources contributed 
valid MI events.  However, this study was performed before those data were analysed, when 
it was considered that including cases recorded only in ONS or GPRD would bring concerns 
about the acute nature of the MIs and of their exact timing.  This would have affected our 
interpretation of the duration and onset of heralding diagnoses and chest pain consultations 
prior to MI. 
Patients in this study were followed up through the electronic health records from 
primary care.  Therefore, diagnoses could only be made if patients attended the practice or a 
hospital and disclosed symptoms or underwent tests.  Despite a similar time in follow-up, 
patients with and without atherosclerotic disease had widely different average annual 
consultation rates (heralded by atherosclerotic disease 8.8 consultations per year, unheralded 
4.8 consultations per year).  Some researchers choose to implement a minimum consultation 
rate to reduce the chances of misclassification in patients who consult less frequently (as 
infrequent consulters are less likely to receive diagnoses).  In our study, this would have a 
large effect on the results.  A sensitivity analysis showed that the proportion heralded was 
19.3% in the low consultation rate group and 66.1% in the higher consultation group.  These 
results can be interpreted in two ways: either some symptomatic atherosclerotic disease was 
missed in those who consulted less frequently, or they were a truly healthier group of 
patients with no cause to consult.  Due to the seriousness of atherosclerotic disease, patients 
are likely to consult if they are symptomatic, and therefore a minimum consultation rate was 
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not introduced in this analysis.  The exclusion of patients without any consultations prior to 
MI would have made little impact on the results (n=14). 
The GPRD does not routinely collect data on behavioural factors including diet, 
alcohol intake and exercise which, if measured, may have indicated increased cardiovascular 
disease risk and reduced the proportion of patients who had MI ‘without warning’.  This is a 
limitation of the data but these factors are not routinely incorporated into cardiovascular 
disease risk scores and so are likely to contribute less to a patient’s overall cardiovascular 
disease risk than the risk factors included.  Additionally, identifying patients with only poor 
diet or exercise alone is of limited use as GPs are unlikely to intervene unless a more 
traditional cardiovascular disease risk factor was raised (e.g. patient became overweight, 
hyperlipidaemic or hypertensive).  The absence of lifestyle data is a drawback to using 
routinely collected records rather than data from researcher-led studies, but the opportunities 
for research on a large scale and the relevance of these results to routine clinical care 
outweigh this disadvantage.  
 
5.6.5 Implications 
The British Heart Foundation estimates that there are 124,000 MIs in the UK per 
year.[14]  If 70% of these are first MIs,[15] and 56% of these are unheralded by previous 
atherosclerotic disease, then there may be up to 50,000 unheralded MIs per year. This 
represents a significant burden, both financially and in terms of morbidity, and strengthens 
the need for primary prevention in primary care.  The results in this study also emphasise the 
need for secondary prevention after diagnoses in the coronary, cerebrovascular or peripheral 
arteries. 
 
5.6.6 Further research 
A research priority is a comparison of patients who experience MI without prior 
atherosclerotic disease (or without warning) to the general population.  This may elucidate 
novel risk factors for MI.  Over half of first MIs occur without previous disease and these 
contribute significant morbidity and financial burden to the healthcare system.  
Understanding why some patents with or without elevated risk factors have MI and others 
do not is of importance in reducing this burden.  Further research into the prodromal period 
before MI and the possibility of reducing the risk of MI in patients who consult for new 
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coronary disease or chest pain could also be of value.  A second priority is determining 
whether the premonitory symptoms experienced shortly before MI represents a period 
potentially of remediable risk. 
 
5.6.7 Conclusion 
This aim of this thesis was to gain an improved understanding of MI that occurs as 
the first manifestation of disease; the first step was therefore to examine the evolution, 
prevalence and timing of different atherosclerotic disease subtypes and risk factors before 
MI.  This was the first study to prospectively evaluate the onset of coronary, cerebrovascular 
and peripheral arterial atherosclerotic disease, risk factors and chest pain symptoms before 
first MI.   
Nearly half of first MIs were preceded by diagnosed atherosclerotic disease and for 
most patients this has been recognised for many years.  This implies that there is often a long 
period during which the GP can intervene with effective secondary prevention measures.   
For the other half of first MI patients, the MI was the first manifestation of 
atherosclerotic disease.  Nearly all of these patients had recognised elevated cardiovascular 
disease risk, but very few reported symptoms to the GP prior to MI.  The challenge now 
remains to characterize differences between these MI patients and the general population 
who do not have MI, and to identify any missed opportunities in the management of patients 
with recorded raised risk. 
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5.7 Chapter summary 
• No large study has previously evaluated the occurrence of atherosclerotic disease, 
cardiovascular disease risk factors and cardiovascular medication prescription prior 
to first MI using prospectively collected data. 
• Patients with first MI were identified in MINAP and HES.  The prevalence and 
timing of previous atherosclerotic disease, major cardiovascular disease risk factors 
and cardiovascular drug prescriptions were assessed.   
• Half of MI patients had a previous diagnosis of atherosclerotic disease and there was 
a prodromal period prior to MI in which the rate of coronary diagnoses and chest 
pain consultation was increased. 
• MI occurring without prior coronary, cerebrovascular or peripheral arterial disease, 
risk factors or symptoms was uncommon, in just 7% of patients. 
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Chapter 6 Effect of ischaemic 
manifestations prior to 
myocardial infarction 
 
 
 
6.1 Summary 
This chapter describes an investigation into new and existing ischaemic 
atherosclerotic disease presentations and chest pain prior to first MI and their effects on MI 
type and mortality.    
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6.2 Literature review 
 
6.2.1 Introduction 
Ischaemic preconditioning describes the phenomenon by which brief episodes of 
ischaemia prior to a prolonged ischaemic insult can lead to smaller infarct size, first 
described in 1986 by Murry[25] under experimental conditions.  Since this groundbreaking 
study, ischaemic preconditioning has been hailed as the “most powerful experimental 
method of delaying the onset of myocardial necrosis known so far”[33]  and has been shown 
beyond doubt to occur in humans.[185]  There is a substantial body of published research 
investigating the occurrence, mechanisms and outcomes of ischaemic preconditioning and 
the topic has been extensively reviewed.  As discussed in Chapter 1, many studies have 
investigated naturally occurring angina prior to MI as a clinical correlate to ischaemic 
preconditioning.[27, 186]   
The following sections review the evidence to date regarding the effects of 
atherosclerotic disease and chest pain prior to MI on infarct size, presentation and clinical 
outcomes.  Since the focus of this thesis is MI as the first manifestation of atherosclerotic 
disease, the review focused on studies assessing the effects of angina prior to first infarction. 
 
6.2.2 The evidence to date 
6.2.2.1 Search strategy 
There have been several published reviews of the occurrence and effects of 
preinfarction angina.  A brief search was conducted in the MEDLINE database to identify 
review articles examining the natural ischaemic preconditioning effect of preinfarction 
angina.  Search terms for this were “Ischemic preconditioning” (as an exploded Medical 
Subject Heading), but restricting to review articles in humans and written in the English 
language.  This search, performed in September 2010, generated 783 results.  Titles were 
reviewed and full text of potentially relevant papers was sought.   
None of these reviews were systematic and none focused on patients with first MI.  
Therefore, a systematic literature search was performed to identify studies examining 
outcomes of patients with first MI.   
A literature search was completed in the English language medical literature 
(MEDLINE and EMBASE) for studies examining ischaemic preconditioning and 
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preinfarction angina.  Search terms are described in Appendix A, Table 10.20. The search 
was initially conducted in January 2011 and repeated in September 2012 to identify any 
recently published studies.  Studies were included if they fulfilled the following criteria: 
1. Naturally occurring ischaemia exposure (experimentally-induced ischaemia 
as an exposure was excluded) prior to first MI; 
2. Study in humans; 
3. Manuscript written in English language; 
4. Outcomes investigated included: infarct size, severity, post-MI cardiac or 
all-cause mortality. 
 
Titles and abstracts of the 1017 studies identified in the initial search were screened 
for relevance.  Any studies deemed to be relevant were obtained as full text and were 
assessed with respect to the inclusion criteria.  To ensure that no relevant studies were 
missed, the reference lists of all included studies were examined.   
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6.2.3 Results 
Twenty eight studies were identified that examined the effects of previous angina on 
MI size, severity or subsequent mortality.  These were published between 1998 and 2011, 
with between 22 and 4,166 first MI patients and a total of 11,703 patients.  The prevalence 
of ‘preinfarction angina’ ranged from 21%[187] to 67%,[188] (median 49%).  The studies 
came from a large range of geographical regions, including Europe, North America, South 
America, the Middle East and Asia.  
 
6.2.3.1 The effect of preinfarction angina on infarct size 
There is good overall evidence for a protective effect of preinfarction angina on 
infarct size, as measured by peak creatine kinase (CK) and other techniques. This was the 
conclusion of several review papers of preinfarction angina and ischaemic 
preconditioning[186, 189] and has been reported in eighteen studies of patients with first MI 
(Table 6.1).  Key studies reporting these effects are described below, by the type of angina 
exposure that was examined (chronic angina versus new onset angina).     
 
Chronic angina 
Three studies reported effects of chronic angina and all described a protective effect 
of angina on infarct size.[147, 149, 187]  Romero-Farina identified 131 patients with a 
history of MI and reported a smaller necrotic zone in patients with chronic angina (of more 
than a month’s duration) prior to their MI (% necrosis 4.5 ± 8.8% in those with angina, 11.4 
± 11.9% in those without angina, P=0.002).[187]  However, this analysis was performed in 
patients who had survived for one to ten years after their MI and who had reduced systolic 
function.  It therefore represents a highly selected group of patients who are unlikely to be 
representative of MI patients overall.    
Anzai reported the effects of chronic or prodromal angina on infarct size, and found 
a beneficial effect of this combined exposure on peak creatine kinase levels in patients with 
anterior and inferior MI (peak CK level lower in angina, P<0.03).[149]  This was a slightly 
larger study (N=291) and the only inclusion criteria were (i) reaching hospital with a MI 
diagnosis and (ii) the ability to provide a detailed clinical history.  While this study 
population is much less selected than the smaller study described above, these criteria would 
have excluded patients who died before reaching hospital or in the emergency room and 
therefore are unlikely to be representative of the general population experiencing their first 
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MI.  Kobayashi also reported lower peak CK levels in patients with previous chronic or 
prodromal angina prior to MI compared to patients with no previous angina, in a much 
larger study of 1,637 patients.[147]   
In all of these studies, baseline characteristics of patients with and without previous 
angina were tabulated.  In the studies of Anzai and Romero-Farina, there were no differences 
in baseline characteristics, indicating that the differences shown in infarct size were unlikely 
to be driven by differences in cardiovascular disease risk factors or use of beta blockers, 
angiotensin converting enzyme inhibitors (ACEI) or calcium channel blockers prior to 
MI.[149, 187]  However, these two studies may have been too small to show differences in 
baseline characteristics - in Kobayashi’s larger study, there were differences in sex, 
hypertension, and hypercholesterolaemia between those with and without previous angina.  
Since infarct size was not an outcome of interest, an adjusted analysis was not performed 
and the observed differences in infarct size may have been due to differences in vascular 
disease risk.  Additionally, each of these studies was based on retrospective angina data and 
therefore subject to error in recall. 
 
New onset prodromal angina 
Fifteen studies investigated the effects of new onset or prodromal angina shortly 
before MI, with exposure definitions ranging from angina in the 24, 48 or 72 hours before 
MI, to new onset angina in the one month before MI.  Thirteen of these studies described a 
beneficial effect of prodromal angina on infarct size; two showed no effect.  The studies 
described below are those in which the main focus of the analysis was to report the effects of 
previous angina on infarct size.   
Ottani (1995) reported infarct size as a primary outcome, and showed that of 25 
hospitalised first MI patients, the 12 with prodromal angina, defined as angina within 24 
hours or infarct, had lower CK-MB release indicating smaller infarcts (86.3 ± 66 IU/L in 
those with angina, 192.3 ± 108 IU/L in those without angina, P<0.01).[37]  The investigators 
estimated that angina afforded a protection of 33% on infarct size (95% CI 7.1-58.9%).  
However, this study was performed in a small and highly selected group of patients, who 
had undergone thrombolysis, were reperfused within 90 minutes and had a patent infarct-
related artery.  These inclusion criteria were chosen to mimic experimental conditions, so the 
effect of angina on MI shown here is unlikely to be representative of that in a general 
population.   
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In a second study published a decade later, Ottani (2005) reported a beneficial effect 
of prodromal angina in 22 hospitalised first MI patients undergoing primary percutaneous 
coronary intervention (PPCI).[190]  The twelve patients who experienced angina in the 24 
hours before infarct had a lower QRS score (measure of infarct size) at 7 days  than those 
without angina (score=4.5 ± 2.5 in those with angina, 6.5 ± 2.4 in those without angina, 
P=0.07).  This was a small study restricting to patients undergoing PPCI and investigated 
whether the beneficial effect observed in thrombolysed patients (in the 1995 study) was due 
to ischaemic preconditioning rather than faster thrombolysis in patients with previous 
angina.  Nevertheless, this study lends support to the body of evidence that angina prior to 
MI has a protective effect on infarct size. 
Yamagishi (2000) analysed the effect of preinfarction angina occurring in the 72 
hours before MI on subsequent myocardial injury, as measured by resting 123I-BMIPP and 
201TI myocardial SPECT up to one month after MI.  Peak CK levels were lower in patients 
with angina (P=0.02), and previous angina was associated with a decreased necrotic 
area.[38]  Baseline characteristics of patients with and without prior angina were compared 
and shown to be similar between the groups, so were unlikely to confound the associations 
observed.  This was one of the larger studies assessing infarct size (n=136) but was 
conducted in hospitalised patients who had survived the acute phase of MI.   
In a study of hospitalised MI patients in Japan, there was no effect of prodromal 
angina occurring in the 2 to 48 hours prior to infarct, as measured by peak CK (22.1 ± 9.2 
UI/L in patients with angina, 40.0 ± 33.3UI/L in patients without angina, P=0.1).  However, 
there was a trend towards smaller infarct size in the group with angina, but the study may 
have been underpowered: despite data collection from 26 sites in Japan, just 25 patients were 
included in this study because the inclusion criteria were so extensive, leading to a small and 
highly selected group of patients.[191] 
Finally, Iglesias-Garriz reported the effect of angina in the 24 hours before MI on 
infarct size in 116 hospitalised patients without diabetes who had undergone 
angioplasty.[192]  This study showed a beneficial effect of angina on the necrotic region, but 
no effect on peak CK-MB concentrations.  Baseline cardiovascular disease risk factors in the 
groups with and without angina were tabulated and shown to be similar.  Therefore, 
differences in infarct size are unlikely to be confounded by cardiovascular disease risk 
factors.  However, no assessment was made of prior cardiovascular drug use, which may 
have been different in patients with and without previous angina, and could have affected 
infarct size. 
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All of these studies used retrospectively collected exposure data and therefore may 
be subject to error and recall bias.  None of these studies were designed to show the effect of 
prodromal or chronic angina on outcomes in a general population setting, but to prove the 
concept of ischaemic preconditioning and identify possible mechanisms through which 
preinfarction angina might act.  Nearly all of the studies had strict inclusion criteria and 
therefore what the effect would be in an unselected cohort is unclear.  Additionally, none of 
these studies compared the effects of angina at different times prior to MI.     
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Table 6.1 Effects of previous angina on infarct size, as measured by peak creatine kinase, size of necrotic area or QRS score at risk in patients with first MI 
Author, year Country MI patients included Angina definition 
N MI 
patients 
N (%) 
exposed 
Peak CK (IU/l) in patients +/- 
angina* 
Effect of angina on 
infarct size 
Anzai, 1995[149] Japan Hospitalised first Q wave anterior wall MI Chronic and prodromal; new onset <1 month, chronic 
& worsening pattern <1 month, chronic stable angina 
>1 month 
291 117 (61%) Anterior infarct + 1824 ± 1458 
- 2819 ± 2515 
Interior infarct: + 1315 ± 1230 
- 1934 ± 1303 
Smaller infarct, 
P<0.016 for anterior, 
P=0.028 for inferior 
Ottani, 1995[37] Italy Hospitalised MI patients with thrombolysis Prodromal; typical angina occurring at rest within 24 
hours of infarct, or complete absence of symptoms 
25 12 (48%) + 86.3 ± 66 
- 192.3 ± 108 
Smaller infarct, P<0.01 
Kobayashi, 
1998[147] 
Japan Hospitalised first MI  Chronic and prodromal; stable or unstable angina 1637 1032 
(63%) 
+ 2790 ± 2842 
- 3288 ± 3037 
Smaller infarct, P<0.01 
Napoli, 
1998[193] 
Italy Hospitalised first Q wave MI with thrombolysis 
<65 years 
Prodromal; new onset angina in the 48 hours 
preceding MI 
90 48 (53%) + 976 ± 168 
- 1612 ± 328 
Smaller infarct, P<0.05 
Noda, 1999[191] Japan Hospitalised first MI in left anterior descending 
artery with PTCA 
Prodromal; new onset angina 2-48 hours before 
onset 
25 11 (44%) + 22.1 ± 9.2 
- 40.0 ± 33.3 
NS, P=0.10 
Inoue, 1999[194] Japan Hospitalised inferior MI, total occlusion of right 
branch and successful angioplasty within 
24hrs 
Prodromal; angina pectoris in 24 hours prior to MI 75 18 (24%) + 1294 ± 188 
- 1836 ± 136 
Smaller infarct, P=0.04 
Yamagishi, 
2000[38] 
Japan Hospitalised MI undergoing imaging Prodromal; chest pain in 72 hours before onset of MI 136 48 (35%) + 2504 ± 1745 
- 3518 ± 2550 
Smaller infarct, P=0.02 
De Felice, 
2001[195] 
Italy Hospitalised first Q wave MI with thrombolysis Prodromal; chest pain in 7 days prior to MI 90 Not stated + 1865 ± 1562 
- 2630 ± 1360 
Smaller infarct, 
P=0.002 
Abe, 2002[188] Japan Hospitalised first anterior wall MI Prodromal; angina within 48 hours 36 24 (67%) + 2747 ± 1939 
- 4891 ± 2639 
Smaller infarct, P<0.05 
Colonna, 
2002[196] 
Italy Hospitalised first MI Prodromal; angina in the 7 days preceding MI 51 25 (49%) + 5994 ± 2820 
- 9831 ± 5859 
Smaller infarct, 
P=0.005 
Papado-poulos, 
2003[197] 
Greece Hospitalised NSTEMI patients without known 
history of CHD, < 75 years 
Prodromal; angina in the last 48 hours before MI - 
separated into those occurring <12 hours 
40 22 (55%) + 48 ± 28 
- 116 ± 81 
Smaller infarct, 
P<0.003 
Tomoda, 
2004[198] 
Japan Hospitalised STEMI Chronic and prodromal; ≥1 occurrence of chest pain 
in 24 hours before MI, or angina >24 hours before MI 
613 166 (27%) + 3500 ± 2625 
- 3937 ± 2727 
NS, P=0.30 
Iglesias-Garriz, 
2005[199] 
Spain Hospitalised first STEMI patients treated with 
primary coronary angioplasty, no valvular 
disease, post infarct angina,VF/VT, diabetes 
Prodromal; angina in the 24 hours prior to infarct 78 32 (41%) + 343 ± 256 
- 353 ± 256 
P=0.859 
Smaller infarct as 
measured by % 
necrotic area, P=0.033 
Ottani, 2005[190] Italy Hospitalised first anterior MI, treated with PCI Prodromal; new onset angina in the 24 hours prior to 
infarct 
22 12 (55%) QRS score at 7 days*: 
+ 4.5 ± 2.5 
- 6.5 ± 2.4 
Smaller infarct, P=0.07 
Tamura, 
2006[200] 
Japan Hospitalised first anterior wall ST-elevation MI Prodromal; typical chest pain within 48 hours of onset 
of MI 
142 70 (49%) + 3652 ± 2440 
- 5507 ± 3058 
Smaller infarct, 
P=0.0002 
Mladenovic, 
2008[201] 
Serbia Hospitalised first uncomplicated single vessel 
MI 
Prodromal; History of angina within 2 months, except 
for within 24 hours 
46 27 (59%) + 193.6 ± 108.8 
- 281.8 ± 171.4 
Smaller infarct, 
P=0.039 
Romero-Farina, 
2008[187] 
Spain Patients with a history of MI Chronic; chronic angina prior to MI 131 27 (21%) % necrosis* 
+ 4.5 ± 8.8 
- 11.4 ± 11.9 
Smaller infarct, 
P=0.002 
Takeuchi, 
2011[202] 
Japan Hospitalised first anterior STEMI undergone 
successful reperfusion therapy, imaging within 
a week, total or subtotal occlusion of left 
anterior descending artery 
Prodromal; typical chest pain episodes within 48 
hours 
125 60 (48%) Normotensives: + 2904 ± 1693 
- 4979 ± 2471 
Hypertensives: + 2885 ± 2215 
- 5278 ± 2801 
Smaller in 
normotensives, P<0.05,  
not smaller in 
hypertensives, P>0.05 
*Peak CK was used to measure infarct size, except where noted.  MI: myocardial infarction; CHD: coronary heart disease; PTCA: percutaneous transluminal coronary angioplasty; VF: ventricular fibrillation; VT: ventricular tachycardia; STEMI: 
ST-elevation MI: NSTEMI: non ST-elevation MI; PCI: percutaneous coronary intervention.
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6.2.3.2 The effect of preinfarction angina on infarct severity 
The effect of preinfarction angina on infarct severity as measured by ST-elevation 
and the appearance of Q waves at ECG have been reported in six studies of first MI (Table 
6.2), although no studies focused their analysis on these outcomes and none performed 
multivariate analyses. 
One study examined the effect of chronic angina alone on the appearance of Q 
waves at MI.[150]  Over 4,000 patients who survived to seven days and were eligible for 
recruitment into the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) 
were included in the study.  A history of chronic angina was associated with more Q waves 
at MI (P<0.001).  However, this was in a crude analysis and the study reported important 
differences between patients with and without previous angina in terms of age, sex, diabetes 
and hypertension prevalence, so the association may be confounded by background vascular 
disease risk.   
Two further studies examined the effect of chronic angina and new onset angina on 
the appearance of Q waves.  In a Belgian study of 732 hospitalised, unthrombolysed first MI 
patients, there were no differences in the proportion of patients with non-Q wave MI in those 
with and without angina.[151]  In a subsequent study a decade later in 1,637 first MI 
patients, findings were similar, although important differences were reported between the 
angina groups with respect to cardiovascular disease risk.[147]  Based on the different 
associations described here and the absence of multivariate analysis, the effects of previous 
chronic angina on MI severity are unclear.  These studies suggest that the new onset angina 
may be driving benefits in infarct severity and that chronic angina alone is associated with 
poorer outcomes.  However, in studies of only new onset angina in the 7 days or 24 hours 
before infarct, the reported effects are also inconsistent, with effects in different directions.   
In a small study of 25 highly selected MI patients (described in section 6.2.3.1), 
Ottani (1995) showed a trend towards fewer Q waves in patients with prodromal angina in 
the 24 hours prior to MI, but no effect on ST-elevation.  This study may have been too small 
to show a real effect of prodromal angina because as in a slightly larger study of 75 MI 
patients, there was good evidence for a beneficial effect of prodromal angina in the same 
time period on ST-elevation.[194]  Similarly, in a study of 90 patients, chest pain in the 
seven days prior to MI was associated with fewer Q waves (P=0.002).[195]  This evidence, 
along with evidence from review articles suggest that preinfarction angina is associated with 
fewer Q waves and less ST-elevation in patients with MI.[168]  
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Table 6.2 Studies reporting the effect of previous angina on infarct severity, as measured by ST-elevation or appearance of Q waves at 
electrocardiogram (ECG) 
 
Author, 
year 
Country MI patients included Angina definition N MI 
patients 
N (%) 
exposed 
Effect of exposure
Pierard, 
1988[151] 
Belgium Hospitalised first MI, no thrombolysis Chronic and prodromal; chronic >1 
month or new onset <1 month 
732 447 
(61%) 
No effect 
Behar, 
1992[150] 
Israel Trial population of hospitalised first MI who 
survived 7 days 
Chronic; angina >1 month 4,166 1,801 
(43%) 
More Q wave MI, P<0.0001 
Ottani, 
1995[37] 
Italy Hospitalised first MI patients with 
thrombolysis 
Prodromal; angina ≤ 24 hours prior 
to MI 
25 12  
(48%) 
No effect on ST-elevation, trend 
towards fewer Q waves P=0.1 
Kobayashi, 
1998[147] 
Japan Hospitalised first MI  Chronic and prodromal ; stable or 
unstable angina 
1,637 1,032 
(63%) 
More non-Q wave MI in angina 
group, P<0.01 
Inoue, 
1999[194] 
Japan Hospitalised first inferior MI with total 
occlusion of right branch and successful 
angioplasty within 24 hours 
Prodromal; angina ≤ 24 hours prior 
to Mi 
75 18  
(24%) 
Less ST segment elevation, 
P<0.01 
De Felice, 
2001[195] 
Italy Hospitalised first Q wave MI with 
thrombolysis 
Prodromal; chest pain ≤7 days prior 
to MI 
90 Not 
stated 
Fewer Q waves, P=0.002 
 
Table 6.3 In-hospital cardiac mortality in patients with first myocardial infarction (MI) 
 
Author, 
year 
Country MI patients 
included 
Timing of 
angina 
exposure 
before MI 
Exposure 
assessment 
N MI 
patients 
N (%) 
exposed 
Outcomes 
assessed 
Was multivariate 
analysis 
performed? 
Effect of exposure 
Anzai, 
1995[149] 
Japan First Q wave 
MI only 
Chronic or 
prodromal 
Retrospective 291 189 
(61%) 
In-hospital cardiac 
death 
Yes - beta 
adrenergic and 
calcium antagonists 
Protective on in-hospital 
cardiac mortality RR=1.56 
p=0.049 
Kobayashi, 
1998[147] 
Japan Hospitalised 
MI 
Chronic or 
prodromal 
Retrospective 1,637 1,032 
(63%) 
In-hospital death 
due to:  
• cardiogenic 
shock/CHF 
• arrhythmias,  
• cardiac rupture 
No No crude effect seen for 
cardiogenic shock/CHF or 
arrhythmias. 
 
Angina was protective on 
death due to cardiac rupture, 
P<0.01 
RR: rate ratio; CHF: congestive heart failure. 
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6.2.3.3 The effect of preinfarction angina on in-hospital mortality 
Studies examining in-hospital mortality were separated into those reporting effects 
on cardiac death and those reporting effects on all-cause mortality.  If preinfarction angina 
were to have any effect on mortality through ischaemic preconditioning or collateral 
channels, it would most likely be restricted to (or stronger in) cardiac mortality.   
 
In-hospital cardiac mortality 
In patients hospitalised with first MI, two studies examined the effects of 
preinfarction angina on in-hospital cardiac death (Table 6.3).  In a study of 291 patients with 
Q wave MI, the 189 who had ever experienced previous angina were protected against 
cardiac mortality at multivariate analysis: those without angina were at increased risk 
(RR=1.56, P=0.049).[149]  This analysis was adjusted for cardiovascular disease risk factors 
and the use of beta blockers, ACEI and calcium channel blockers prior to MI.  
Cardiovascular medications given in response to chest pain symptoms or high cardiovascular 
disease risk may negate the effect of ischaemic preconditioning and the effects of these have 
not been addressed in most other studies. 
In a larger study of 1,637 patients, no effect of previous angina was seen for in-
hospital death due to cardiogenic shock, congestive heart failure or arrhythmias, although 
there was some crude effect of previous angina on death due to cardiac rupture 
(P<0.01),[147] which alone drove an association with overall in-hospital mortality.  No 
adjusted analysis was performed to examine independent predictors of cardiac mortality in 
this study. 
Both of these studies were based on hospitalised MI patients who were not highly 
selected for inclusion, and therefore are more representative of all hospitalised MI patients in 
their respective countries.  However, as above, angina data were collected retrospectively 
and therefore may be subject to error.   
 
In-hospital all-cause mortality 
Six studies examined all-cause in-hospital mortality (Table 6.4).  Behar examined 
the effects of chronic angina alone compared to no angina in a large group of hospitalised 
MI patients (n=4,166), and showed an adverse effect on mortality in a crude analysis 
(OR=1.30 (95% CI 1.10-1.53)); no multivariate analysis was performed and this effect may 
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have been attenuated if it had been adjusted for the substantial differences observed between 
patients in terms of cardiovascular disease risk.  This study was in a highly selected 
population of patients who survived for seven days and were recruited into a trial.  
Therefore, the effects of chronic angina in general populations are unclear. 
Two studies assessed the joint effects of chronic and prodromal angina.  Pierard 
reported no differences in in-hospital mortality compared to patients with no angina in a 
crude analysis of 732 patients.  A larger and more recent study in 1637 patients, which 
performed a well-adjusted analysis (including demographic variables, cardiovascular disease 
risk factors and previous atherosclerotic disease), reported lower mortality in the group with 
angina (OR=0.665, P=0.014).  The differences observed for chronic angina compared to 
chronic &/or prodromal angina may be the result of the different exposure definitions, but 
could also be related to use of thrombolysis in the studies.  It has been suggested that the 
beneficial effects of ischaemic preconditioning only occur in reperfused myocardium; Behar 
and Pierard both performed studies in the pre-thrombolytic era, which could explain the lack 
of beneficial effects. 
Of the three studies examining the effect of prodromal angina on mortality, only one 
performed a multivariate analysis[203] and found some evidence for lower mortality in the 
group with angina, although this failed to reach significance (OR=0.44 (95% CI 0.16-1.17) 
p=0.09).  The two other studies showed no effect but the low numbers of fatalities in these 
studies meant that they were likely to be underpowered to demonstrate an effect. 
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Table 6.4 In-hospital all-cause mortality in patients with first myocardial infarction (MI) 
 
Author, 
year 
Country MI patients 
included 
Timing of pre-MI 
angina exposure 
Exposure 
assessment 
N MI 
patients 
N (%) 
exposed 
Outcome 
assessed 
Was multivariate 
analysis performed? 
Effect of exposure 
Pierard, 
1988[151] 
Belgium Hospitalised first 
MI, unthrombolysed 
Chronic and new 
onset; chronic >1 
month, new onset 
<1 month 
Retrospective 732 200 
chronic, 
247 new 
onset 
(61%) 
In-hospital 
all-cause 
No No effect of chronic and new onset 
angina. 
Behar, 
1992[150] 
Israel Hospitalised first MI 
surviving to seven 
days, included in 
the SPRINT trial 
Chronic; angina 
for >1 month 
Retrospective 4,166 1791 
(43%) 
In-hospital 
all-cause 
No Worse mortality in angina group 
OR=1.30 (95% CI 1.10-1.53)  
Kobayashi, 
1998[147] 
Japan Hospitalised MI Chronic and new 
onset 
Retrospective 1,637 1032 
(63%) 
In-hospital 
all-cause 
Yes - age, sex, risk 
factors, previous 
atherosclerotic 
disease 
Lower mortality in the angina group: 
adjusted OR=0.665, P=0.014.   
Papadop-
oulos, 2003 
275[204] 
Greece Hospitalised first 
NSTEMI aged ≤75, 
without prior CAD, 
CHF, collateral 
circulation 
Prodromal; ‘Late’ 
angina ≤12 hrs, 
‘early’ angina 
within 12-48 hours 
of admission 
Retrospective 66 12 ‘early’ 
(18%) 
16 ’late’ 
(24%) 
In-hospital 
all-cause 
No No effect of 12 hour or 48 hour angina. 
Tomoda, 
2004[198] 
Japan Hospitalised first 
STEMI undergoing 
primary PCI  <6hrs 
after onset 
Prodromal; angina 
in 24 hours of 
infarct 
Retrospective 202 59 
(29%) 
In-hospital 
all-cause 
No No effect of previous angina, mortality 
in patients with angina: 8.5% and 
without angina: 8.4%, P=0.85 
Ishihara, 
2005 
150[203] 
Japan Hospitalised first 
anterior MI 
undergoing 
angiography within 
12 hours 
Prodromal; angina 
within 24 hours of 
infarct 
Retrospective 598 206 
(34%) 
30 day all-
cause 
Yes - demographics, 
risk factors, collateral 
circulation, 
reperfusion, 
multivessel disease 
Some evidence for lower mortality in 
angina group : 
Adjusted OR=0.44 (95% CI 0.16-1.17) 
p=0.09   
NSTEMI: non ST-elevation MI; STEMI: ST-elevation MI; PCI: percutaneous coronary intervention; OR: odds ratio; CAD: coronary artery disease; CHF: congestive heart failure
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6.2.3.4 The effect of preinfarction on post-hospital outcomes 
 
Post-hospital cardiac mortality 
Two studies compared long term cardiac mortality after first MI in patients with and 
without previous angina (Table 6.5).[144, 149]  Patients with and without previous angina in 
the Framingham study were followed up for up to 34 years after MI.  Men with angina had 
significantly higher mortality than those without angina after adjusting for cardiovascular 
disease risk factors (RR=1.49 (95% CI 1.12-2.00)) although no evidence for an effect was 
seen in women (RR=1.12 (95% CI 0.76-1.65)).[144]  This study also examined the effect of 
non-coronary exposures (stroke and peripheral arterial disease) on post-MI mortality.  In 
both men and women at multivariate analysis, there were higher rates of mortality (coronary 
and all-cause) in patients with either cerebrovascular or peripheral ischaemia, although these 
did not reach significance.[144]  The prospectively collected exposure data and 
representativeness to the general population are strengths of this study, but due to the 
biennial follow-up, misclassification of angina was possible.  Additionally, the study began 
in 1948, and the data are now somewhat outdated due to changes in the MI definition, MI 
incidence and angina incidence in the last fifty years. 
The second study examining cardiac mortality did so in patients with chronic or new 
onset angina compared to patients without angina.  This study showed that patients without 
angina had higher one year cardiac mortality than those with angina, after adjusting for 
demographic, risk factor and cardiovascular drug use (RR=1.85 p=0.003).[149]  The reason 
for the discrepancy compared to the Framingham study are likely to be due to the substantial 
difference in follow-up duration (34 years versus 1 year) but may also be due to the 
differences in the definitions of angina or proportion of patients who had previous angina 
(22% in Framingham, 65% in the Japanese study).    
 
Post-hospital all-cause mortality 
Due to the logistical difficulties of doing so, the majority of studies did not assess 
long-term follow-up, and even fewer were able to examine cause-specific mortality after 
hospitalisation.  Three studies described all-cause mortality during long term follow-up 
(Table 6.6).  Pierard, who reported no effect on in-hospital mortality, showed that long term 
survival was adversely affected by previous chronic and prodromal angina.[151]  Similarly, 
Behar, who initially showed poorer mortality in those with chronic angina, showed that this 
was maintained at one and five years.[150]  Both studies adjusted for demographics, 
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cardiovascular disease risk factors and some cardiovascular drugs.  These studies imply that 
chronic angina is associated with worse mortality in long term follow-up after MI.  Studies 
including recurrent MI have also examined coronary heart disease mortality and have tended 
to show worse mortality in patients with chronic angina than in those without.[205, 206]   
In 202 hospitalised STEMI patients in Japan, Tomoda assessed various outcomes 
with respect to prodromal angina in the 24 hours prior to infarct.[198]  The 59 patients with 
prodromal angina had worse all-cause mortality than the group without, but this did not 
reach significance (P=0.39).  In this analysis, only ten patients died during longer term 
follow-up, so there was insufficient power to find any effects or to perform multivariate 
analysis.  Therefore, the effects of prodromal angina on longer term mortality are unclear.   
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Table 6.5 Longer term cardiac mortality in first myocardial infarction (MI) patients with and without previous angina 
 
Author, 
year 
Country MI patients 
included 
Timing of 
angina 
exposure 
before MI 
Exposure 
assessment 
N MI 
patients 
N (%) 
exposed 
Outcomes 
assessed 
Was multivariate 
analysis performed? 
Effect of exposure 
Cupples, 
1993[144] 
United 
States 
First MI Chronic Prospective 828 184 (22%) 34 years 
coronary 
heart 
disease 
mortality 
Cardiovascular disease 
risk factors 
In men: previous angina  RR1.49 (95% 
CI 1.12-2.00).   
In women: 1.12 (95% CI 0.76-1.65) 
Anzai, 
1995[149] 
Japan First Q wave 
MI 
Chronic 
and 
prodromal 
Retrospective 291 189 (65%) One year 
cardiac 
mortality 
Yes – demographics, 
risk factors, beta 
adrenergic and calcium 
antagonists 
At multivariate, absence of angina 
predicted mortality RR=1.85 p=0.003 
RR: rate ratio 
 
Table 6.6 Longer term all-cause mortality in myocardial infarction (MI) patients with and without previous angina 
 
Author, 
year 
Country MI patients 
included 
Timing of 
angina 
exposure 
before MI 
Exposure 
assessment 
N MI 
patients 
N (%) 
exposed 
Outcomes 
assessed 
Was multivariate 
analysis performed? 
Effect of exposure 
Pierard, 
1988[151] 
Belgium Hospitalised 
first MI, un-
thrombolysed 
Chronic and 
prodromal; 
chronic >1 
month, new 
onset <1 
month 
Retrospective 732 200 
chronic, 
247 new 
onset 
(61%) 
3 year all-
cause 
Yes - beta blockers, 
admission delay, age, 
sex, smoking, diuretics 
Angina related to higher mortality 
p=0.008.   
Behar, 
1992[150] 
Israel Hospitalised 
first MI 
survivors to 7 
days, included 
in SPRINT trial 
Chronic >1 
month 
Retrospective 4,166 1,791 
(43%) 
One year, 
five years 
all-cause 
Yes – demographics, 
previous disease, 
cardiovascular disease 
risk factors 
Adjusted OR=1.29 (95% CI 1.16-1.44) 
higher mortality in angina group 
Tomoda, 
2004[198] 
Japan Hospitalised 
first STEMI 
with PCI  <6 
hours after 
onset 
Prodromal; 
angina in 24 
hours before 
infarct 
Retrospective 202 59 
(29%) 
Follow-up 
all-cause, 
duration not 
stated. 
No No effect, P=0.39 
OR: odds ratio; PCI: percutaneous coronary intervention. 
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6.2.3.5 Age, diabetes, reperfusion and BMI 
There is debate in the literature regarding the effects of ischaemic preconditioning 
and preinfarction angina in the elderly.  Experimental studies of ischaemic preconditioning 
showed that it was ineffective in elderly animal hearts, and early clinical studies showed 
similar results.  However, more recent studies have shown effects in elderly patients and 
there is a suggestion that this might be affected by physical activity.[207-209] 
In addition to the possibility of differing effects by age, there have also been studies 
examining effect modification by hypertension,[202] type of reperfusion,[210, 211] 
gender,[212] and diabetes.[213]  Few studies have examined these effects and the results 
have been inconsistent.  Even in some of the larger studies, the ability to detect effects in 
subgroups is likely to have been low.  Therefore, the effects in patients with and without 
diabetes, hypertension, BMI and by gender have not been well-characterised.   
 
6.2.3.6 Mechanisms for improved survival in patients with preinfarction 
angina 
The mechanisms for the observed beneficial effects of preinfarction angina on 
infarct size and (possibly) in-hospital mortality are not fully understood.  Three mechanisms 
have been suggested.  First, patients with chronic angina may have developed collateral 
channels, so that when flow is occluded in the main artery, it is compensated by flow in 
collateral channels.  However, Kloner (2001) postulated that for patients with new onset 
angina in the week or days before MI, there is no opportunity for the development of these 
vessels.[214]  Additionally, some studies have shown that collateral vessels do not occur 
more frequently in patients with preinfarction angina.  Second, Andreotti suggested that 
preinfarction angina was associated with faster reperfusion times, therefore preventing 
myocardial necrosis.[215]  This was also shown by Evrengul (2005) but no evidence of 
faster reperfusion was shown by Ottani (1995).[216, 217]  Finally, ischaemic 
preconditioning may be delaying necrosis in this subgroup of patients.  Brief episodes of 
ischaemia prior to the final insult may have triggered the cascade of chemical reactions that 
prevent subsequent cell necrosis (as described in Chapter 1). 
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6.2.4 Strengths of previous research 
The effects of preinfarction angina, defined in a number of different ways, have 
been extensively evaluated in a number of geographical regions and in different patient 
populations.   
 
6.2.5 Limitations of previous research 
There are a number of limitations to the current body of literature investigating 
preinfarction angina and the possible effects of ischaemic preconditioning.  These were 
discussed in the previous sections and include: 
• widely differing exposure definitions, from 24 hours in many 
studies,[37, 194, 198, 201, 203] to 48 hours,[188, 191, 193, 202] 72 hours,[38] 7 
days,[195, 196] 30 days[147, 149] or chronic angina of more than 30 days.[144, 147]  
This heterogeneity is likely to have contributed to some of the discrepancies observed, 
although no systematic differences in outcomes were noted between the shorter 
‘prodromal’ exposure times and the longer term exposures;   
• lack of prospectively collected data on symptoms and events.  Retrospective data on the 
main exposure and potential confounders or explanatory variables are potentially 
problematic, particularly for the onset and duration of angina, medication use and 
diagnosed morbidities prior to MI.  Any misclassification of the main exposure or 
confounding variables may result in residual confounding, bias and incorrect effect 
measures; 
• most studies were in hospitalised or trial patients, highly selected for specific research 
questions.  The results of these studies are therefore not generalisable to all hospitalised 
patients due to strict inclusion criteria such as restriction to specific types of MI (Q 
wave, STEMI, NSTEMI, anterior or interior MI), requirement to survive for several 
days, undergo PCI or angiography shortly after MI, or have certain morbidities.  The 
results are also not generalisable to the general population because a substantial 
proportion of people with MI do not reach hospital.  This means that the extent of 
ischaemic presentations prior to MI in general populations is unclear;  
• poor adjustment, or no adjustment, for baseline characteristics in assessing the in-
hospital and post-hospital effects of previous angina on mortality.  Some of the 
beneficial effects seen may be due to poor adjustment for risk lowering medications; 
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• low power to detect effects in many of the smaller studies and low numbers of fatalities 
in assessing mortality effects.  Iglesias-Garriz published a meta-analysis of six studies 
examining the effect of angina in the 24 hours before MI on post-MI in-hospital 
mortality.[192]  Pooling these studies provided the power to demonstrate an effect, 
which the individual studies were unable to achieve.  This showed a reduced risk in the 
1217 of 3497 patients with prodromal angina (OR=0.61 (95% CI 0.48-0.78));   
• changes in the definition of MI[6] and in treatment practices over the past sixty years 
over which these studies spanned. While there is some evidence to suggest that the 
likelihood of ST-elevation is decreased in patients with preinfarction angina, this effect 
has not been well-characterised.  No studies have assessed infarct severity as the main 
focus of the study and none have adjusted for differences in baseline covariates in 
multivariate analysis; 
• all but one[144] of the included studies restricted their exposure definitions to either 
chest pain or angina.  Given recent interest in the ischaemic preconditioning effects of 
ischaemia in other arterial beds based on experimental studies and randomised 
trials,[218, 219] naturally occurring ischaemia in the peripheral or cerebrovascular 
arteries may have some effect in observational clinical studies, but these have not been 
assessed.    
 
One final limitation was also identified, which was not discussed in the review 
above.  This relates to the timing of exposure.  The timing of ischaemic symptoms with 
respect to MI is important due to the cellular mechanisms involved in ischaemic 
preconditioning and the possible development of collateral channels.  Most studies of 
preinfarction angina have focused on the 24 to 72 hours before MI.  These time periods fit 
with theories of ischaemic preconditioning and the second window of protection in the 12-72 
hours after the ischaemic stimulus, as discussed in Chapter 1.[27]   
Two studies (not included in this review as they included recurrent MI) have 
compared angina occurrence in different time periods on MI outcomes.  Kloner compared 
angina occurring in the 24 hours prior to MI with angina at other times (48h, 72h, 1 week, 1 
month >1 month).  There was no effect of angina beyond 24 hours on in-hospital re-
infarction, severe congestive heart failure or death.[220]  Similarly, Hirai[221] found a 
protective effect of angina in the 7 days before MI on left ventricular ejection fraction, but 
no effect of angina occurring more than 7 days prior to MI.   
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These studies imply that the preconditioning effect is short-lived.  However, this 
review has identified studies showing beneficial effects of chronic angina on in-hospital 
outcomes.  Additionally, Herlitz (1993) reported that patients with chronic angina had 
smaller infarcts than those with new onset angina in the three months prior to MI.[222]  
Therefore, the effects of timing of angina are uncertain. 
 
6.2.6 Limitations of this review 
There are two main limitations of this review.  The first is the possibility that not all 
studies were identified by the literature search.  However, the search strategy was broad and 
the reference lists of all included studies were searched.  Therefore, I am confident that I 
have identified the key studies in the field.   
The second limitation is the possibility of publication bias.  Although several studies 
were identified showing no effect of preinfarction angina on outcomes, there is a possibility 
that further studies showing no effects were not published.   
 
6.2.7 Conclusion 
There appears to be a real effect of preinfarction angina on some clinical outcomes 
at the time of MI.  While the mechanisms for this are not fully understood, there is a strong 
possibility that ischaemic preconditioning has some effect at MI.  This includes an 
association with reduced infarct size, attenuated severity in presentation, and a possible 
association with lower in-hospital mortality.  However, various aspects of the effect of 
preinfarction angina are unclear: first, the effects on clinical presentation with ST-elevation 
or non ST-elevation MI; second, the effects of ischaemic exposures at different times prior 
to MI and third the effects of ischaemia in non-coronary arterial beds.  Additionally, 
characterising the preinfarction experience of patients who do not reach hospital may 
provide further insight into the effects of this exposure. 
To address these limitations a large, prospective study was performed examining the 
occurrence, timing and effect of different types of symptoms and disease manifestations in 
different arterial beds before MI.  The population-based data will allow the effects in the 
general population to be characterised.  The size of the study and the detail of the 
prospective data will allow adjustment for well-measured risk factors and cardiovascular 
prescriptions provided to these patients.  Additionally, it will allow subgroup analysis, 
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assessment of effect modification by age, reperfusion or hypertension, as suggested above, 
and examination of the effects by MI type.    
 
6.3 Objectives 
1. To describe the ischaemic coronary, cerebrovascular and peripheral arterial clinical 
presentations and chest pain consultations recorded in primary care in the 90 days 
before admission with first acute MI.   
2. To compare the characteristics of patients admitted with acute MI with and without 
new presentations of ischaemia before MI, including peak troponin, MI type 
(STEMI, NSTEMI), heart rate, in-hospital treatment, time to presentation and 
reperfusion (MINAP cases only). 
3. To examine the association between pre-MI ischaemic presentations and post-MI 
coronary heart disease mortality, and whether associations are modified by 
previously diagnosed atherosclerotic disease, age, sex, diabetes, hypertension, 
reperfusion strategy or use of cardiovascular medications before MI.   
4. To examine the association between timing of the ischaemic presentation and 
coronary heart disease mortality (split time into days before infarction: 1-2, 3-7, 8-
30, 31-90 days). 
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6.4 Methods 
The prospectively collected medical records of a cohort of MI patients were 
reviewed to assess the occurrence of chest pain and new onset ischaemic atherosclerotic 
disease in any arterial bed in the 90 days prior to MI.  Those with and without these 
presentations were compared in terms of their MI characteristics and subsequent coronary 
heart disease mortality. 
   
6.4.1 Definition of acute myocardial infarction 
Patients with MI were identified based on a record in any one of the four data 
sources.  MI definitions are described in detail in Chapter 3 (Methods) and briefly in Table 
6.7.   
 
Table 6.7 Definition of acute myocardial infarction in each of the four data sources: 
GPRD, HES, MINAP and ONS 
 
Data source MI definition 
GPRD Read code for MI, raised markers of myocardial necrosis, or ECG 
result indicative of MI. 
HES ICD-10 code I21, I22 or I23 as the primary diagnosis in the first 
hospital episode. 
MINAP ST-elevation MI or non ST-elevation MI following the joint American 
Heart Association / European Society of Cardiology definition.[6] 
ONS ICD-10 code I21, I22 or I23 as the underlying cause of death. 
 
 
6.4.2 Categorisation of ischaemia before MI 
Patients were initially categorized into three groups based on their pre-MI 
experience of ischaemic atherosclerotic disease and chest pain, according to the scheme 
in Figure 6.1.  Atherosclerotic disease diagnoses were split into coronary, cerebrovascular 
and peripheral arterial and were based on codes in the GPRD, MINAP and HES patient 
records (as described in Chapter 3 Methods).  Coronary disease included stable and unstable 
angina, coronary heart disease (CHD) not otherwise specified, receipt of percutaneous 
coronary intervention or coronary artery bypass graft;  cerebrovascular disease included 
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ischaemic stroke and transient ischaemic attack; peripheral arterial disease included 
symptoms of intermittent claudication and new diagnoses of peripheral arterial disease. 
• Patients with ‘no prior ischaemic presentations’ had no atherosclerotic disease 
diagnoses in their electronic health record prior to MI and no consultations for chest 
pain in the 90 days before MI. 
• Patients with ‘new ischaemic presentations’ had either a new atherosclerotic disease 
diagnosis in the 90 days before MI (either first ever diagnosis or diagnosis in a new 
arterial bed, for example new coronary disease diagnosis in the presence of longer 
term cerebrovascular disease) or a chest pain consultation in the 90 days before MI.  
• Patients with ‘existing ischaemic diseases’ had no new atherosclerotic disease 
diagnoses or chest pain consultations in the 90 days before MI but had long-standing 
atherosclerotic disease (>90 days’ duration).   
Atherosclerotic disease diagnoses in different arterial beds and chest pain 
consultations were based on codes in the GPRD, MINAP and HES patient records as set out 
in Chapter 3 and the CALIBER manual (see Appendix B). The codes used to define 
diagnosis of atherosclerotic disease were those rated by two clinicians as definitely 
indicative of disease (a sensitivity analysis was conducted to assess whether inclusion of 
‘possible’ codes in addition to ‘definite’ codes affected the results).  The assumption that 
presentation with chest pain had the same effect as presentation for ischaemic atherosclerotic 
disease was tested in a sensitivity analysis.   
In the second part of analysis, the timing of the closest ischaemic presentation prior 
to MI was split into categories (1-2 days, 3-7 days, 8-30 days and 31-90 days before MI).  
This categorisation is based on definitions of pre-infarction angina used in the body of 
literature that examines natural ischaemic preconditioning.   
The timing of onset of atherosclerotic disease was taken as the date of the first code 
indicating disease in the patient’s GPRD record (except where the code indicated prevalent 
disease, where the timing of onset was set to missing).   
 
6.4.3 Exclusion criteria 
Patients were excluded if they had a recorded history of MI (n=6,337), were under 
the age of 18 at MI (n=2), had not been registered with the primary care practice for at least 
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one year before MI (n=8,516), whose MIs occurred outside the period where all databases 
were collecting data (outside 1st January 2003 to 31st December 2008, n=23,804), and 
patients without any primary care consultations in their record prior to MI (n=12).   
Patients were also excluded if they had diagnosed abdominal aortic aneurysm, heart 
failure or cardiac arrest (i.e. non-ischaemic cardiovascular disease) at any time before MI but 
with no ischaemic diagnoses in their medical records (n=676).  A sensitivity analysis was 
performed including these patients to assess the effect of this exclusion on the results of the 
main analysis.   
 
6.4.4 Cardiovascular disease risk factors and risk lowering medication prior 
to MI 
Age, sex, deprivation, duration of registration and primary care consultation rate 
were taken from primary care (GPRD) records.  Ethnicity was taken from GPRD, HES and 
MINAP.  Cardiovascular disease risk factor data were derived from GPRD and HES 
(recorded at any time up to the day before MI) and MINAP.  Risk factors included in this 
analysis were smoking (categorized as non, ex, current or unknown at the time of MI), 
hypertension (either diagnosed hypertension or three consecutive raised (>140/90mm Hg) 
measurements), total serum cholesterol (mean of all total serum cholesterol measurements 
prior to MI), HDL cholesterol (mean of all total serum HDL measurements prior to MI) and 
diabetes (diagnosed diabetes or insulin prescription) (all described in Chapter 3).    
Risk lowering medication use in the six months prior to MI was based on 
prescriptions issued in primary care up to the day before MI and reported use of these drugs 
at hospital admission (available in MINAP data).  Specific drug categories of interest were 
blood pressure lowering, lipid lowering and antiplatelets, 
The Framingham risk score for ten year ‘hard’ CHD (MI or coronary heart disease 
death) endpoints[129] was also calculated as described in Chapter 3.  
 
6.4.5 Follow up after MI and primary outcome 
Patients with MI were followed for up to 7.6 years after MI (median 2.6 years).  The 
primary outcome was death with an underlying cause of coronary heart disease (ICD-10 
codes I20-I25), as recorded in ONS mortality data.  As recording of cause of death may be 
inexact, a sensitivity analysis was conducted using all-cause mortality as an outcome. 
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6.4.6 Statistical analysis 
The type and timing of new and existing ischaemic presentations in the 90 days 
before MI were described.  Characteristics of MINAP patients with no prior ischaemic 
presentations, new ischaemic presentations and existing ischaemic diseases, for whom there 
were data on MI type and severity, were compared in terms of admission heart rate, systolic 
blood pressure, ECG, raised markers of myocardial necrosis, time to hospital admission and 
time to reperfusion.  Groups were compared using chi squared tests for categorical variables, 
Kruskal Wallis tests for comparing medians, and t tests for comparing means.   
Cox regression analysis was used to compare the post-MI coronary heart disease 
mortality of patients with new and existing ischaemic presentations to patients with no prior 
ischaemic presentations.  Tests for proportional hazards, based on Schoenfeld residuals, 
were performed on all models and interactions with time were fitted where there was non-
proportionality.  In the first instance, interactions with time were fitted based on follow-up 
time categories of 0-7 days, 8-30 days, 31-90 days, 91 days to one year and one to two years, 
which were considered to be the time points at which the mortality effects may change.  
Time periods were combined where the effects of previous ischaemic presentations were 
similar based on similar effect measures and assessed using likelihood ratio tests comparing 
models with combined versus separate time periods.  Regression analyses were adjusted for 
age, sex, hypertension, total serum cholesterol, diabetes, smoking, blood pressure lowering, 
lipid lowering and antiplatelet medication prescription in the six months before MI.  A 
directed acyclic graph (DAG) describes the associations between ischaemic presentations, 
coronary heart disease mortality and these variables in Appendix A, Section 10.5.2.  
Likelihood ratio tests were used to assess interactions between any of these explanatory 
variables and the main exposure. 
Cox regression analysis was also used to compare the coronary heart disease 
mortality of patients with presentations at different times before MI to patients without any 
prior ischaemic presentations.   
 
6.4.7 Further analyses and sensitivity analyses 
MI type was available in the subset of patients recorded in MINAP.  The main 
analysis (examining the effect of new ischaemic presentations on coronary heart disease 
mortality) was repeated in this subset only, and was adjusted for MI type to examine its 
confounding effect. 
Chapter 6 
205 
 
In another analysis the effects on MI outcomes of previously consulting with a GP 
for reasons other than ischaemia were examined.   
The new ischaemic presentations exposure was split into its constituent components 
(chest pain, new and established CHD, cerebrovascular disease, peripheral arterial disease) 
to assess differences between these presentations. 
To align our results with the literature examining 30 day mortality, the analysis was 
repeated using a pre-specified cut point at 30 days post-MI. 
All analyses were performed in Stata version 11.  The study details are registered 
online at clinicaltrials.gov (NCT01604486, May 2012) and a time-stamped detailed analytic 
protocol is shown in Appendix B.   
  
 
206
 
Figure 6.1 Categorisation of patients with acute myocardial infarction, according to prior atherosclerotic disease and chest pain consultations 
Atherosclerotic disease, defined as myocardial ischaemia (stable or unstable angina, percutaneous coronary ischaemia, coronary artery bypass 
graft), cerebral ischaemia (ischaemic stroke, transient ischaemic attack) and new peripheral arterial disease diagnoses including intermittent 
claudication.  
*Patients with diagnoses in a different arterial territory include those with new coronary, peripheral arterial or cerebrovascular disease against a background of existing 
disease in a different territory.  Note: new atherosclerotic disease included a single first prescription of nitrates before MI.
Established atherosclerotic disease
(>90 days since 1st diagnosis?)
No Yes
New diagnosis of atherosclerotic 
disease ≤90 days before MI?
Diagnosis of atherosclerotic disease 
in a different arterial territory* ≤90 
days before MI?
Yes
New 
atherosclerotic 
disease 
diagnosis in 90 
days
(N=812)
NoYes
No
Chest pain consultation?
YesNo
Chest pain consultation?
Established 
atherosclerotic 
disease: 
new diagnosis 
in 90 days
(N=229)
Yes
No
No chest pain or 
atherosclerotic 
disease in 90 
days
(N=8,364)
Chest pain in 90 
days
(N=516)
Established 
atherosclerotic 
disease: no new 
chest pain or 
diagnoses in 90 
days
(N=5,956)
Established 
atherosclerotic 
disease: chest 
pain in 90 days
(N=562)
New ischaemic presentations (N=2,119)No prior ischaemic 
presentations
(N=8,364)
Existing ischaemic 
diseases:
(N=5,956)
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6.5 Results: new ischaemic presentations prior to MI 
 
6.5.1 Atherosclerotic disease diagnoses in the 90 days before MI 
There were 16,439 patients with first MI between 1st January 2003 and 31st 
December 2008 and who met all inclusion criteria.  Table 6.8 describes the different 
subtypes of ischaemic atherosclerotic diseases and chest pain that patients presented with in 
the 90 days before MI.  Overall 2,119 (12.9%) patients presented to their family physician 
with new ischaemic presentations in the 90 days before MI, 8364 (50.9%) had no prior 
ischaemic presentations, and 5,956 (36.2%) had existing ischaemic diseases with no new 
presentations in the 90 days before MI.  As shown in Chapter 5, coronary disease was the 
most common atherosclerotic disease presentation in the 90 days before MI.  Figure 6.2 
shows the proportion of MI patients presenting with chest pain and new ischaemic 
atherosclerotic disease in the 90 days prior to MI, broken down by timing of presentation 
   
6.5.2 Demographic and cardiovascular disease risk factor distribution 
Table 6.9 describes the demographic distribution of patients, according to new or 
existing ischaemic presentation before MI.  Those with new ischaemic presentations in the 
90 days prior to MI were older than those with no prior presentations (P<0.001).  They had a 
similar proportion of women and distribution of social deprivation.  They were more likely 
to have a higher Framingham risk score, and higher prevalence of diabetes and hypertension 
(P<0.001 for each comparison).  They had been registered in the primary care practice for a 
similar duration but had a higher rate of primary care consultation compared to patients 
without new ischaemic presentations (median 7.4 consultations per year, IQR (4.2-12.4), 
compared to (4.7 (2.4-8.3), P<0.001). 
Those with existing ischaemic diseases (>90 days’ duration) were older, more likely 
to be female and had a higher prevalence of high Framingham risk (risk greater than 20%), 
(P<0.001 for each comparison).  They had the highest primary care consultation rate prior to 
MI (median 9.0 consultations per year, IQR (5.6-14.0)) and had been registered with their 
primary care practice for longer than those without prior ischaemic presentations (P<0.001). 
 Differences in ethnicity between the groups were driven by differences in the 
‘unknown’ group and due to the high proportion of patients with unknown ethnicity, 
ethnicity was not included in the main analysis. 
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6.5.3 Prescription of cardiovascular medications 
The number and proportion of patients with a first or repeat prescription of blood 
pressure lowering, lipid lowering, and antiplatelet medications in the 90 days before MI are 
shown in Table 6.9 and Figure 6.3.  Patients with new ischaemic presentations were more 
likely to be initiated on blood pressure lowering, lipid lowering or antiplatelet medications 
compared to those with no prior ischaemic presentations (P<0.001 for each). They were also 
more likely to obtain a repeat prescription in the 90 days prior to MI (P<0.001).  However, 
in those with no prior ischaemic presentations, 34.3% were already prescribed blood 
pressure lowering medications, 11.0% lipid lowering and 9.9% antiplatelets, suggesting that 
increased cardiovascular disease risk was acknowledged by the primary care physician.   
For patients with existing ischaemic diseases, fewer patients were newly initiated on 
these medications in the 90 days prior to MI than those with new ischaemic presentations, 
but a larger proportion had repeat prescriptions written in the 90 days prior to MI. 
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Table 6.8 New atherosclerotic disease diagnoses and chest pain consultations in 16,439 patients with and without 'established' disease (>90 days' 
duration) 
 
    
No established 
disease N=9,692 
Established disease 
>90 days' duration 
N=6,747 Total N=16,439 
n (%) n (%) n (%) 
Any atherosclerotic disease 796 (8.2) 225 (3.3) 1,021 (6.2) 
Coronary disease 671 (6.9) 126 (1.9) 797 (4.8) 
Stable angina 525 (5.4) 92 (1.4) 617 (3.8) 
Unstable angina 209 (2.2) 34 (0.5) 243 (1.5) 
CHD not otherwise specified 234 (2.4) 49 (0.7) 283 (0.6) 
PCI or CABG 77 (0.8) 14 (0.2) 91 (1.7) 
Cerebrovascular disease 107 (1.1) 65 (1) 172 (1) 
Peripheral arterial disease 42 (0.4) 35 (0.5) 77 (0.5) 
Presentation of unknown type† 2 (0) 22 (0.3) 24 (0.1) 
Single nitrate prescription 16 (0.2) 4 (0.1) 20 (0.1) 
Chest pain 516 (5.3) 562 (8.3) 1,078 (6.7) 
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CHD: coronary heart disease 
† where the only code indicating atherosclerotic disease in a patient's record was of unknown type 
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Figure 6.2 Proportion of all myocardial infarction (MI) patients (N=16,439) with new ischaemic presentations in the 90 days period prior to MI, 
stratified by those consulting for chest pain and those with new ischaemic atherosclerotic disease, with 95% confidence intervals 
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Table 6.9 Demographic and cardiovascular disease risk factor distribution in patients 
in each exposure group 
 
    
No new ischaemic 
presentations 
New ischaemic 
presentations 
Existing 
ischaemic 
diseases 
N patients 8,364 2,119 5,956
Age, median (IQR) 68 (57-79) 72 (61-81)*** 79 (70-85)*** 
Sex, n female (%) 3,030 (36.2) 803 (37.9) 2,652 (44.5)*** 
IMD quintile, n (%) 
1 (least deprived) 1,773 (21.3) 485 (23) 1,045 (17.6)*** 
2 1,680 (20.1) 418 (19.8) 1,168 (19.6) 
3 1,688 (20.2) 422 (20) 1,171 (19.7) 
4 1,596 (19.1) 389 (18.4) 1,282 (21.6) 
5 (Most deprived) 1,603 (19.2) 399 (18.9) 1,281 (21.5) 
Ethnicity, n (%) 
White 5,799 (69.3) 1,562 (73.7)*** 4,552 (76.4)*** 
South Asian 66 (0.8) 20 (0.9) 34 (0.6) 
Black or other 184 (2.2) 51 (2.4) 122 (2) 
Unknown 2,315 (27.7) 486 (22.9) 1,248 (21) 
Smoking, n (%) 
Non-smoker 1,225 (14.6) 282 (13.3)*** 792 (13.3)*** 
Ex-smoker 4,055 (48.5) 1,262 (59.6) 3,876 (65.1) 
Current smoker 2,830 (33.8) 554 (26.1) 1,186 (19.9) 
Unknown 254 (3) 21 (1) 102 (1.7) 
Hypertension, n (%) 3,725 (44.5) 1,264 (59.7)*** 4,320 (72.5)*** 
Total serum cholesterol in 
mmol/L, mean (SD) 5.6 (0.8) 5.6 (0.9) 5.3 (1)*** 
HDL cholesterol in mmol/L, 
mean (SD) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3)*** 
Diabetes, n (%) 1,026 (12.3) 377 (17.8)*** 1,505 (25.3)*** 
Framingham risk, n (%) 
<10% 1,940 (22.9) 390 (17.7)*** 639 (11.1)*** 
10-20% 4,776 (56.3) 1,181 (53.6) 2,973 (51.7) 
>20% 1,763 (20.8) 633 (28.8) 2,134 (37.1) 
Blood pressure lowering, n 
(%) 
First prescription in 90d 82 (1) 130 (6.1)*** 51 (0.9) 
Any prescription in 90d 2,867 (34.3) 1,220 (57.6)*** 4,261 (71.5)*** 
Lipid lowering, n (%) 
First prescription in 90d 103 (1.2) 158 (7.5)*** 132 (2.2)*** 
Any prescription in 90d 918 (11) 668 (31.5)*** 2,601 (43.7)*** 
Antiplatelets, n (%) 
First prescription in 90d 79 (0.9) 253 (11.9)*** 72 (1.2) 
Any prescription in 90d 825 (9.9) 883 (41.7)*** 3,283 (55.1)*** 
Nitrates, n (%) 
First prescription in 90d 0 (0) 419 (19.8)*** 45 (0.8)*** 
Any prescription in 90d 0 (0) 680 (32.1)*** 1,654 (27.8)*** 
Consultation rate per year, 
median (IQR) 4.7 (2.4-8.3) 7.4
(4.2-
12.4)*** 9.0 (5.6-14)*** 
Years of pre-MI GPRD 
registration, median (IQR) 8.2 (5.2-12.9) 8.3 (5.1-13.4) 8.7
(5.4-
13.5)*** 
IQR: inter-quartile range; SD: standard deviation; IMD: index of multiple deprivation; HDL: high density 
lipoprotein.  *P<0.05, **p<0.01, ***p<0.001, compared to the group with no ischaemic presentations, 
from Chi squared test for categorical variables, Kruskal Wallis test for comparing medians, T test for 
comparing means  
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Figure 6.3 Proportion of patients (N=16,439) with first and repeat prescriptions for blood pressure (BP) lowering, lipid lowering and anti-platelet 
medications in the 90 days before first myocardial infarction, in patients with and without ischaemic presentations, with 95% confidence intervals 
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6.5.4 MINAP hospital characteristics 
In the subset of patients whose MIs were recorded in the MINAP dataset (N=6,693), 
the clinical characteristics of MI differed across exposure groups (Table 6.10).  Those with 
new ischaemic presentations in the 90 days before MI or with existing ischaemic diseases 
were more likely to experience a non ST-elevation MI type compared to those without any 
prior ischaemic presentations (62.3% and 64.6% versus 42.3%, respectively, P<0.001), and 
as a result, they were less likely to be reperfused.   
MI size, measured by peak troponin values, was lower (P<0.001) in those with 
ischaemic presentations (median 1.3, IQR 0.3-6.9), and in patients with existing ischaemic 
diseases (1.4, IQR 0.3-7.5) compared to (2.6, IQR 0.6-13.0) those without prior ischaemic 
presentations.  Patients with existing ischaemic diseases had a higher heart rate at admission 
than those without prior ischaemic presentations (P<0.001), but systolic blood pressure was 
similar in the three groups.   
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Table 6.10 Clinical characteristics of 6,693 MINAP patients with and without 
ischaemic presentations in the 90 days before MI 
 
    
No prior ischaemic 
presentations 
New ischaemic 
presentations 
Existing ischaemic 
diseases 
N MI 3,857   696   2,140 
MI type, n (%) 
STEMI 2,192 (57.7) 257 (37.7)*** 786 (35.4)*** 
NSTEMI 1,604 (42.3) 424 (62.3) 1432 (64.6) 
ECG record, n (%) 
ST segment 
elevation 2,094 (55.2) 237 (34.8)*** 719 (32.4)*** 
Left bundle branch 
block 91 (2.4) 23 (3.4) 134 (6) 
ST segment 
depression 385 (10.1) 110 (16.2) 414 (18.7) 
T wave changes 
only 437 (11.5) 97 (14.2) 283 (12.8) 
other abnormality 288 (7.6) 79 (11.6) 283 (12.8) 
Normal ECG 209 (5.5) 45 (6.6) 139 (6.3) 
Unknown 292 (7.7) 90 (13.2) 246 (11.1) 
Peak troponin in µg/L, 
median (IQR) 2.6 (0.6-13) 1.3 (0.3-6.9)*** 1.4 (0.3-7.5)*** 
Unknown, n (%) 655 (17.3) 85 (12.5) 261 (11.8) 
Raised markers, n (%) 3,408 (89.8) 610 (89.6) 2,006 (90.4) 
Unknown, n (%) 388 (10.2) 71 (10.4) 212 (9.6) 
Heart rate at 
admission (bpm), 
median (IQR) 77 (77.4-525) 77 (65-90) 80 (68-98)*** 
Unknown, n (%) 857 (22.6) 156 (22.9) 487 (22) 
Systolic BP at 
admission (mmHg), 
median (IQR) 140 (122-160) 138 (122-157) 140 (120-159) 
Unknown, n(%) 861 (22.7) 158 (23.2) 481 (21.7) 
Reperfusion, n (%) 
Thrombolysis 1,662 (43.8) 180 (26.4)*** 526 (23.7)*** 
PCI or angioplasty 274 (7.2) 23 (3.4)*** 88 (4)*** 
Reperfusion NOS 10 (0.5) 1 (0.2) 5 (0.3) 
Time to admission in 
minutes, median (IQR) 144.2 (80.8-360.4) 175.9 (89.6-500.3)** 159.5 (85.2-356.1) 
Unknown, n(%) 905 (23.8) 235 (34.5) 681 (30.7) 
Admission to 
reperfusion in 
minutes, median (IQR) 24 (13.1-50.2) 28.4 (17.5-61.2)** 28.4 (15.3-61.2)*** 
Unknown, n(%) 1,936 (51) 482 (70.8) 1,634 (73.7) 
Symptom onset to 
reperfusion in 
minutes, median (IQR) 146.4 (96.1-281.8) 172.6 (104.9-345.2)* 170.4 (111.4-290.5)** 
Unknown, n(%) 2,166 (57.1) 511 (75) 1704 (76.8) 
MI: myocardial infarction; STEMI: ST-elevation MI; NSTEMI; non ST-elevation MI; BP: blood pressure; IQR: 
inter-quartile range; bpm: beats per minute; ECG: electrocardiogram; PCI: percutaneous coronary 
intervention; NOS: not otherwise specified. 
*P<0.05, **p<0.01, ***p<0.001, compared to patients with no prior ischaemic presentations, from Chi 
squared test for categorical variables, Kruskal Wallis test for comparing medians, T test for comparing 
means 
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6.5.5 Coronary heart disease mortality after MI 
Figure 6.4 shows the crude coronary heart disease mortality experience of patients in 
each of the three main exposure groups.  Due to non-proportional hazards (test for 
proportional hazards in the crude model P<0.001, suggesting strong evidence against the 
null hypothesis of proportional hazards (Appendix A, Figure 10.7)), follow-up time after MI 
was split at 7, 30 and 90 days and one and two years.  The hazard ratio for the effect of new 
ischaemic presentations on coronary heart disease death was calculated for each time period 
(Figure 6.5).   
Patients with new ischaemic presentations preceding MI had lower coronary heart 
disease mortality in the first seven days after MI compared to patients with no prior  
ischaemic presentations, even after adjustment for age, sex, cardiovascular disease risk 
factors and cardiovascular medication prescriptions in the six months before MI (HR=0.64 
(95% CI 0.57-0.73), P<0.001).  In this first week after MI there was weak evidence for an 
effect of existing ischaemic diseases on coronary heart disease mortality (HR=0.92 (95% CI 
0.85-1.00) P=0.051).  There was no evidence that the main effect in the first week after MI 
was modified by age, sex, diabetes, previous hypertension or reperfusion (P>0.05 in each 
case). 
The effects observed in the 7-30 and 30-90 days after MI looked similar and there 
was no evidence that their effects differed (based on likelihood ratio tests (LRT) comparing 
nested models P=0.8506), so these periods were combined.  During the 7-90 days after MI, 
the protective effect seen in the first week was lost (HR for new ischaemic presentations 
0.88 (0.65-1.20), P=0.421).  For patients with existing ischaemic diseases, this period saw an 
increase in the rate of mortality compared to patients without ischaemic presentations 
(HR=1.24 (1.01-1.51), P=0.038).   
The effects after 90 days until the end of follow-up were also combined based on 
evidence from LRTs.  After 90 days, there was evidence for higher mortality risk in those 
with new ischaemic presentations prior to MI (HR=1.42 (95% CI 1.13-1.77) P=0.002).  
There was also a stronger effect of existing ischaemic diseases during this period (HR=2.24 
(95% CI 1.91-2.64) P<0.001). 
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Figure 6.4 Crude Kaplan Meier estimates for coronary heart disease mortality 
following acute myocardial infarction in patients (N=16,439) with no prior ischaemic 
presentations, those with new ischaemic presentations and those with existing 
ischaemic diseases 
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Notes: MI: myocardial infarction; HR: hazard ratio.   The model is adjusted for age, sex, diabetes, total cholesterol, 
HDL cholesterol, smoking status, hypertension, and use of lipid lowering, blood pressure lowering, antiplatelets and 
nitrates. 
 
Figure 6.5 Adjusted hazard ratios for the effect of new ischaemic presentations and 
existing ischaemic diseases on coronary heart disease mortality, split by time after 
myocardial infarction (N patients=16,439) 
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        HR (95% CI)  N patients     N  dead 
 
Notes: CVD: cardiovascular; HR: hazard ratio.  *Fully adjusted model includes age, sex, diabetes, total cholesterol, 
HDL cholesterol, smoking status, hypertension, and use of lipid lowering, blood pressure lowering, antiplatelets and 
nitrates. 
Figure 6.6 Forest plot describing the hazard ratios for the effect of new ischaemic 
presentations in the 90 days before myocardial infarction on coronary heart disease 
mortality, in crude and adjusted models (N=10,483)  
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6.6 Results: timing of clinical presentation 
6.6.1 Number of patients presenting at different times 
The time of presentation before MI was split into four groups (1-2 days, 3-7 days, 8-
30 days, and 31-90 days).  The distribution of disease diagnoses occurring in these time 
periods is shown in Table 6.11.  Patients with existing ischaemic diseases were excluded 
from this analysis. 
 
6.6.2 Demographic and cardiovascular disease risk factor distribution 
The demographic distribution of patients in each group is described in Table 6.12 
and the distribution of key cardiovascular disease risk factors is described in Figure 6.7.  
Median patient age was lowest in the group with no prior ischaemic presentations and 
increased in patients with presentations.  The patients presenting at more distal times to MI 
tended to be older. 
There was some evidence for a trend in the proportion of women in each group.  
Patients without prior ischaemic presentations had a lower proportion of women and those 
with presentations in the 31-90 days prior to MI with the highest proportion (P for trend 
0.013). 
The proportions of patients who were smoking or hypertensive at the time of MI 
were highest in patients without prior presentations and lowest in those with presentations in 
the 31-90 days prior to MI (P for trend<0.001 for both) (Figure 6.7).  The proportion with 
diabetes or prescribed cardiovascular drugs in the 90 days prior to MI showed the opposite 
trend, with the lowest prevalences in patients without prior ischaemic presentations and the 
highest in those who presented in the 31-90 days prior to MI (P for trend <0.001 for each 
variable), (Figure 6.7, Figure 6.8).  
Patients with no prior ischaemic presentations had the lowest consultation rate in 
their pre-MI registration, and those who presented in the 31-90 days prior to MI had the 
highest consultation rate (P for trend<0.001).  All patients had a similar duration of 
registration with their GPRD practice prior to MI (test for trend p=0.380).    
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Table 6.11 Numbers of patients with each ischaemic presentation including coronary heart disease, peripheral arterial disease, cerebrovascular 
disease and chest pain, and the timing of these presentations with respect to myocardial infarction (MI)(total N=2,119) 
 
Timing of ischaemic presentation prior to MI Total 
    1-2 days 3-7 days 8-30 days 31-90 days 
Any atherosclerotic disease 146 186 366 323 1021 
Coronary disease 129 160 292 216 797 
Stable angina 93 114 232 171 617 
Unstable angina 32 53 98 44 243 
PCI or CABG 14 17 22 13 91 
CHD not otherwise specified 31 58 86 73 283 
Cerebrovascular disease 17 18 62 75 172 
Peripheral arterial disease 1 11 21 44 77 
Atherosclerosis recorded but arterial territory not specified  2 3 7 12 24 
Chest pain & no atherosclerotic disease 187 109 128 92 516 
Chest pain in established atherosclerotic disease 114 106 178 164 562 
New nitrate prescription 6 6 5 3 20 
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CHD: coronary heart disease   
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Table 6.12 Demographic distribution of patients with and without clinical presentations in the 90 day period before myocardial infarction (MI), by 
timing of presentation (N=10,483) 
 
No prior ischaemic 
presentations 
Timing of ischaemic presentation before MI 
    1-2 days 3-7 days 8-30 days 31-90 days 
N patients 8,364   452   405   676   586   
Age, median (IQR) 68 (57-79) 69 (60-79) 71 (60-80) 72 (62-80) 75 (63-82) 
Sex, n female (%)  3,030 (36.2) 152 (33.6) 137 (33.8) 270 (39.9) 244 (41.6) 
IMD quintile, n (%) 
1 (least deprived) 1,773 (21.3) 108 (23.9) 120 (29.6) 138 (20.5) 119 (20.4) 
2 1,680 (20.1) 79 (17.5) 70 (17.3) 141 (20.9) 128 (22) 
3 1,688 (20.2) 90 (20) 78 (19.3) 141 (20.9) 113 (19.4) 
4 1,596 (19.1) 98 (21.7) 60 (14.8) 131 (19.4) 100 (17.2) 
5 (most deprived 1,603 (19.2) 76 (16.9) 77 (19) 123 (18.2) 123 (21.1) 
Ethnicity, n (%) 
White 5,799 (69.3) 326 (72.1) 288 (71.1) 497 (73.5) 451 (77) 
South Asian 66 (0.8) 6 (1.3) 3 (0.7) 7 (1) 4 (0.7) 
Black or other 184 (2.2) 13 (2.9) 12 (3) 17 (2.5) 9 (1.5) 
Unknown 2,315 (27.7) 107 (23.7) 102 (25.2) 155 (22.9) 122 (20.8) 
Smoking, n (%) 
Non-smoker 1,225 (14.6) 56 (12.4) 45 (11.1) 100 (14.8) 81 (13.8) 
Ex-smoker 4,055 (48.5) 259 (57.3) 243 (60) 392 (58) 368 (62.8) 
Current smoker 2,830 (33.8) 133 (29.4) 113 (27.9) 177 (26.2) 131 (22.4) 
Unknown 254 (3) 4 (0.9) 4 (1) 7 (1) 6 (1) 
Hypertension, n (%) 3,725 (55.5) 240 (46.9) 235 (42) 403 (40.4) 386 (34.1) 
Total serum cholesterol in mmol/L, mean (SD) 5.6 (0.8) 5.6 (1) 5.6 (0.9) 5.6 (0.9) 5.5 (1) 
HDL cholesterol in mmol/L, mean (SD) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3) 1.4 (0.3) 
Diabetes, n (%) 1,026 (12.3) 52 (11.5) 67 (16.5) 117 (17.3) 141 (24.1) 
Consultations per year, n (IQR) 4.7 (2.4-8.3) 6.4 (3.5-10.7) 6.6 (3.7-11.2) 7.5 (4.1-12.7) 9.1 (5.2-14.5) 
Years of pre-MI GPRD registration, n (IQR) 8.2 (5.2-12.9) 8.2 (5-14) 8.3 (5.1-12.8) 8.2 (5.1-13.1) 8.5 (5.2-13.5) 
IMD: index of multiple deprivation; GPRD: General Practice Research Database; HDL: high density lipoprotein, IQR: inter-quartile range; MI: myocardial infarction 
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Figure 6.7 Sex and key cardiovascular disease risk factor prevalence, by timing of ischaemic presentation before first myocardial infarction, with 
95% confidence intervals (N=10,483) 
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Table 6.13 Prescription of key cardiovascular medications in the six months and 90 days before myocardial infarction (MI) (N=10,483) 
 
No prior ischaemic 
presentations, 
N=8,364 
Timing of ischaemic presentation prior to MI 
    
1-2 days, 
N=452 
3-7 days,  
N=405 
8-30 days,  
N=676 
31-90 days, 
N=586 
Blood pressure lowering, n (%)                     
First prescription in 90 days 82 (1) 13 (2.9) 15 (3.7) 39 (5.8) 63 (10.8) 
Prescription in 90 days 2,867 (34.3) 221 (48.9) 218 (53.8) 389 (57.5) 392 (66.9) 
Prescription in 6 months 3,019 (36.1) 231 (51.1) 222 (54.8) 404 (59.8) 416 (71) 
Lipid lowering, n (%) 
First prescription in 90 days 103 (1.2) 11 (2.4) 13 (3.2) 41 (6.1) 93 (15.9) 
Prescription in 90 days 918 (11) 81 (17.9) 111 (27.4) 214 (31.7) 262 (44.7) 
Prescription in 6 months 994 (11.9) 84 (18.6) 120 (29.6) 224 (33.1) 282 (48.1) 
Antiplatelets, n (%) 
First prescription in 90 days 79 (0.9) 40 (8.8) 29 (7.2) 77 (11.4) 107 (18.3) 
Prescription in 90 days 825 (9.9) 141 (31.2) 132 (32.6) 282 (41.7) 328 (56) 
Prescription in 6 months 914 (10.9) 149 (33) 142 (35.1) 304 (45) 359 (61.3) 
Nitrates, n (%) 
First prescription in 90 days 0 (0) 77 (17) 75 (18.5) 132 (19.5) 135 (23) 
Prescription in 90 days 0 (0) 114 (25.2) 121 (29.9) 226 (33.4) 219 (37.4) 
  Prescription in 6 months 5 (0.1) 120 (26.5) 129 (31.9) 232 (34.3) 232 (39.6) 
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Figure 6.8 Prevalence of patients prescribed cardiovascular medications in the 90 days prior to myocardial infarction, by timing of ischaemic 
presentation before first myocardial infarction (with 95% confidence intervals) (N=10,483) 
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6.6.3 Coronary heart disease mortality after MI, by timing of presentation 
There was a strong effect of the timing of clinical presentation prior to MI.  Patients 
who presented in the 1-2 days before MI had the lowest rate of coronary heart disease 
mortality (HR=0.53 (95% CI 0.40-0.714)), with a weaker effect in patients presenting 3-90 
days before MI (Figure 6.10).  The crude Kaplan Meier survival curves for the first seven 
days after MI are shown in Figure 6.9, stratified by timing of ischaemic presentation.  The 
hazard ratios are shown in Figure 6.10 (test for trend p=0.07). 
 
 
 
 
Figure 6.9 Seven day unadjusted Kaplan Meier for coronary heart disease (CHD) 
death after first acute myocardial infarction, stratified by the timing of ischaemic 
presentation with relation to the myocardial infarction (N=10,483) 
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*Multivariable adjusted model includes age, sex, cardiovascular disease risk factors, and cardiovascular 
medications. HR: hazard ratio. 
Figure 6.10 Hazard ratios and 95% confidence intervals describing the association of 
new ischaemic presentations at different times prior to first myocardial infarction (MI) 
with coronary heart disease mortality at 7 days after MI (N=10,483)  
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6.7 Results: possible explanations for the effects 
6.7.1 Causal diagram 
New ischaemic presentations in the 90 days before MI were strongly associated with 
improved survival in the first seven days after first MI.  Possible mechanisms for this effect 
are shown in Figure 6.11.  Where possible, in a post-hoc analysis, each of these possible 
pathways were assessed to determine the likelihood of a real ischaemic preconditioning 
effect.   
 
 
MI: myocardial infarction; STEMI: ST-elevation MI; NSTEMI: non ST-elevation MI. 
Figure 6.11 Causal diagram describing possible mechanisms for improved survival 
following presentation to the GP with atherosclerotic disease or chest pain before MI 
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6.7.2 Health seeking behaviour 
Patients who consult for ischaemia in the 90 days before MI may be displaying 
health seeking behaviour, which might be associated with unknown confounders associated 
with better outcomes.  A Cox regression analysis was performed to compare patients who 
consulted for any reason other than ischaemia in the 90 days before MI to those who did not 
consult.  A consultation for a reason other than ischaemia in the 90 days before MI 
(n=11,495) was associated with an increased rate of coronary heart disease mortality at 7 
days (HR=1.18 (95% CI: 1.09-1.28), P<0.001) (Figure 6.13).  This health seeking behaviour 
could also feasibly affect the time taken for a patient’s decision to go to hospital. 
 
6.7.3 Time to hospital presentation and reperfusion treatment 
There was insufficient power to adjust for admission and reperfusion treatment 
times in the subset of patients where this information was recorded.  However, a comparison 
of the times in the two groups (Table 6.10) showed that the times to presentation and 
reperfusion treatment were longer in patients who consulted their GP for new ischaemic 
presentations.  There was strong evidence for a longer time to presentation (P=0.0057) and 
longer time to reperfusion treatment (P=0.0062) in the group with clinical presentations 
before MI.  Therefore, a faster time to reperfusion treatment is unlikely to explain the 
improved short term survival of these patients. 
 
6.7.4 Faster reperfusion and collateral channels 
One of the suggested mechanisms by which ischaemia prior to MI improves in-
hospital outcomes is through faster reperfusion times.  The data to assess this pathway were 
not available in this analysis and faster reperfusion remains a possible explanation of 
improved survival.  Another mechanism is the development of collateral channels in patients 
with existing angina.  There were no angiographic data in this analysis to assess this 
mechanism, and collateral channels could be responsible for improved survival, particularly 
in patients with existing ischaemic diseases. 
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6.7.5 Use of cardiovascular medications 
As discussed in section 6.5.3, a higher proportion of patients who had a new 
ischaemic presentation within 90 days of MI were initiated on blood pressure lowering, lipid 
lowering and anti-platelet medications compared to patients without prior ischaemic 
presentations.  However, adjusting for prescription of cardiovascular drugs only changed the 
HR by a small fraction and showed that these drugs were negatively confounding the 
association (crude HR=0.68 (95% CI 0.60-0.76), cardiovascular medication adjusted 
HR=0.60 (95% CI 0.53-0.68)).      
 
6.7.6 Adjusting for MI type 
MI type was available in 7,666 patients (6,693 from MINAP, 973 from GPRD).  
Restricting to only these patients, the effect size was similar to the effect seen in the main 
analysis for the short term effect (HR=0.58 (95% CI 0.38-0.88), P=0.010 compared to 0.64 
(95% CI 0.57-0.73) in the main analysis).  After adjusting for MI type, the hazard ratio for 
the first seven days of follow-up in those with new ischaemic presentations was 0.60 (0.39-
0.92), P=0.018), suggesting that MI type was not a strong confounder of the main 
association.   
When the results were stratified by MI type, the effect in NSTEMI was similar to the 
main effect HR=0.61 (95% CI 0.30-1.23), but the effect in STEMI was weaker at 0.83 (95% 
CI 0.48-1.41), suggesting some of the short term increased survival among people with pre-
event ischaemia could be explained by a higher proportion of NSTEMI.  However, there was 
limited power in this smaller subgroup and the observed differences could be due to chance 
variation (Figure 6.12, Figure 6.13, and Figure 6.14). 
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Notes: MI: myocardial infarction; HR: hazard ratio; STEMI: ST-elevation MI; NSTEMI: non ST-elevation MI. 
Figure 6.12 Hazard ratios comparing coronary heart disease death in patients with new 
ischaemic presentations in the 90 days prior to myocardial infarction (MI) to those 
with no prior ischaemic presentations.  Hazard ratios are presented for coronary heart 
disease death in 0-7 days, 7-90 days and 90+ days post MI in patients with MI type 
recorded, stratified by MI type and adjusted for MI type (N with MI type 
recorded=7,666) 
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6.7.7 Coronary risk 
Patients with existing ischaemic diseases had the worst Framingham cardiovascular 
disease risk profile, with 37% of patients in the highest risk category (>20% ten year hard 
CHD risk), compared to 29% in patients with new ischaemic presentations and 21% in those 
with no ischaemic presentations.  Framingham risk was strongly associated with prior 
ischaemic presentations (P=0.001).  In a crude analysis, Framingham risk was also 
associated with subsequent mortality.   
However, adjusting for coronary risk score did not affect the hazard ratios for 
patients with new ischaemic presentations or existing ischaemic diseases (risk-adjusted 
HR=0.64 (95% CI 0.57-0.73) and main analysis 0.64 (95% CI 0.57-0.73) (Figure 
6.13, Figure 6.14).  This is likely to be because the confounding effect was accounted for by 
adjustment for the individual cardiovascular disease risk factors; at multivariate analysis 
Framingham risk score was not associated with mortality.   
 
6.7.8 Further sensitivity analyses 
6.7.8.1 30 day mortality 
In the 30 days post-MI, the effect on mortality seen for new ischaemic presentations 
was slightly diluted  compared to the effect observed in the first seven days in the main 
analysis (HR=0.75 (95% CI 0.68-0.83), P<0.001).  There was no effect of existing ischaemic 
diseases compared to patients with no prior presentations (HR=0.97 (95% CI 0.90-1.04), 
P=0.345).  After 30 days, the effect of new ischaemic presentations and existing ischaemic 
presentations was harmful, similar to the main analysis (Figure 6.13, Figure 6.14).   
These results suggest that new ischaemic presentations are strongly associated with 
mortality benefits very shortly after MI and that after this brief period, mortality worsens.  
Combining the brief, initial beneficial period with a period of higher subsequent mortality 
led to a dilution of the beneficial effect.  This also shows that the effect of new ischaemic 
presentations on coronary heart disease mortality changes quickly over follow-up and the 
analysis incorporating interactions with time in follow-up was appropriate. 
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6.7.8.2 All-cause mortality 
The hazard ratio for the effect of new ischaemic presentations on all-cause mortality 
was 0.75 (95% CI 0.67-0.84), P<0.001), a slightly weaker effect size than described in the 
main analysis (Figure 6.13, Figure 6.14).  This suggests that there is a reduced effect, or no 
effect at all, of new ischaemic presentations on non-coronary heart disease mortality, as the 
inclusion of non-coronary heart disease deaths leads to a diluted effect measure.    
 
6.7.8.3 Definite and possible codes 
In the main analysis, diagnostic codes rated by clinicians as ‘definite’ indicators of 
disease were used to define ischaemic presentations.  When codes rated as ‘possible’ were 
included, there was little change in the hazard ratios for the effects on post-MI mortality (7 
day HR=0.65 (95% CI 0.57-0.73), P<0.001) (see Figure 6.13, Figure 6.14).  This suggests 
that the lists of codes rated as definite were sensitive enough to capture patients with 
atherosclerotic disease. 
 
6.7.8.4 Non-ischaemic atherosclerotic disease 
In the main analysis, patients with non-ischaemic atherosclerotic disease, including 
abdominal aortic aneurysm, heart failure and cardiac arrest were excluded.  A sensitivity 
analysis including these additional patients showed a diluted effect.  The hazard ratio for 
coronary heart disease mortality seven days after MI was 0.77 (95% CI 0.69-0.87).  This was 
weaker than for the main analysis (HR=0.64 (9% CI 0.57-0.73)), (Figure 6.13, Figure 6.14).  
This suggests that the strong association of new ischaemic presentations with mortality seen 
in the main analysis were the result of ischaemia, rather than a generalised atherosclerotic 
disease status.  
  
Chapter 6 
233 
 
 
Figure 6.13 Results of sensitivity analyses part 1: hazard ratios (HR) for the 0-7 days, 
7-90 days and 90+ days post myocardial infarction (MI), comparing the rate of 
mortality in patients with new ischaemic presentations (N=2,119) prior to MI to that of 
patients with no prior ischaemic presentations (N=8,364) 
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Figure 6.14 Results of sensitivity analyses part 2: hazard ratios (HR) for the 0-7 days, 
7-90 days and 90+ days post myocardial infarction (MI), comparing the rate of 
coronary heart disease mortality in patients with existing ischaemic diseases (N=2,140) 
prior to MI to that of patients with no prior ischaemic presentations (N=8,364) 
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6.7.8.5 Chest pain and atherosclerotic disease exposures 
In another sensitivity analysis, the exposure was split into new onset ischaemic 
atherosclerotic disease and chest pain to examine the validity of the combined exposure in 
the main analysis.  The effect was the same (P=0.6445 for LRT) in each group (chest pain 7 
day CHD mortality HR=0.67 (95% CI 0.56-0.80), P<0.001, ischaemic atherosclerotic 
disease HR=0.70 (95% CI 0.58-0.83), P<0.001), so the combined exposure was justified 
(Figure 6.15). 
 
 
Figure 6.15 Sensitivity analysis describing the seven day coronary heart disease 
mortality effects in the main analysis, and in those with chest pain in the 90 days prior 
to myocardial infarction (N=1,078), and in those with new ischaemic atherosclerotic 
disease  (N=1,041), compared to patients without any prior ischaemic presentations 
(N=8,364) 
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6.7.8.6 Effects of ischaemia in different arterial beds 
The main exposure in this analysis was any new ischaemic presentation.  This 
included chest pain, new nitrate prescription, and atherosclerotic disease diagnosis in any 
arterial bed.  To examine this exposure further, the exposure was split into its constituent 
parts to examine which arterial beds were most strongly associated with mortality.  This 
showed that the effects were restricted to myocardial ischaemia and chest pain.  New onset 
coronary disease, with or without revascularisation, was strongly protective on mortality 
after MI.  Chest pain in established disease and in patients without established disease has a 
strong protective effect on mortality after MI, compared to patients with no prior ischaemic 
presentations.  Peripheral and cerebrovascular ischaemia were not associated with improved 
early coronary heart disease mortality.  The number of patients with each subtype of 
exposure is shown in Table 6.14 and results of the Cox regression analyses for the first seven 
days after MI are shown in Figure 6.16. 
 
Table 6.14 Numbers of patients with each subtype of exposure  
 
     N (%) 
No established 
atherosclerotic 
disease >90 days 
before MI 
No prior ischaemic presentations 8,364 (50.9) 
Chest pain 516 (3.1) 
New coronary disease, with CABG or PCI 608 (3.7) 
New coronary disease, no CABG or PCI* 79 (0.5) 
New CVD 92 (0.6) 
New PAD 33 (0.2) 
Established 
atherosclerotic 
disease >90 days 
before MI 
Chest pain 562 (3.4) 
New CHD, with CABG or PCI 116 (0.7) 
New CHD, no CABG or PCI* 14 (0.1) 
New CVD 64 (0.4) 
New PAD 35 (0.2) 
Existing ischaemic diseases 5,956 (36.2) 
*Includes patients with new nitrate prescriptions in the 90 days prior to myocardial infarction (MI).  
CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; CVD: cerebrovascular 
disease; PAD: peripheral arterial disease.
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CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; CVD: cerebrovascular disease; PAD: peripheral arterial disease. 
Figure 6.16 Hazard ratios for coronary heart disease mortality in the first seven days after myocardial infarction (MI) for patients with 
new ischaemic presentations (N=2,119) compared to those with no ischaemic presentations (N=8,364), stratified by type of ischaemic 
presentation prior to MI 
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6.8 Discussion 
 
6.8.1 Summary 
In this prospective analysis of fatal and non-fatal MI patients, those with new 
ischaemic presentations in the 90 days preceding MI had a lower rate of coronary heart 
disease mortality in the week following MI compared to those with no prior ischaemic 
presentations.  This effect was largest in patients who consulted shortly before their infarct.  
Over the following months, the effect transitioned and for patients surviving past 90 days, 
previous ischaemia was associated with an increased rate of coronary heart disease 
mortality. 
To our knowledge, no other studies have prospectively examined the onset of 
atherosclerotic disease or chest pain consultations in the period leading to MI.  However, 
several studies have examined the effect of new-onset or chronic ‘pre-infarction angina’, 
measured retrospectively after MI.  These studies have shown that pre-infarction angina is 
associated with improved in-hospital outcomes including smaller infarcts and in-hospital 
coronary heart disease mortality.[28, 30, 32, 147, 195, 206, 209, 216, 223]  Our result 
showing improved mortality at seven days is consistent with this in-hospital effect of 
previous ischaemia.  The effects on longer term coronary heart disease mortality have been 
less well-studied and have shown contradictory results, perhaps due to variation in the 
definition and timing of their exposures,[32, 147, 224] or their methods to examine changes 
in the effect over time.  The current analysis showed that after 90 days of follow-up, the rate 
of coronary heart disease mortality was higher in the group with ischaemic presentations 
compared to those without any presentations.  The effects described in this analysis were not 
explained by pre-MI coronary risk, MI type or by cardiovascular medications prescribed in 
response to ischaemic presentations. 
Only one study has investigated the timing of angina prior to MI: Kloner showed 
that patients who reported angina in the 24 hours before infarct had a lower event rate and 
smaller infarcts, but found no effect of angina occurring more than 24 hours before 
infarct.[220]  The detail of exposure definition, follow-up data and size of the current study 
provide sufficient power to clarify the effect of exposures at different time points on both 
short and longer term coronary heart disease mortality.   
In this study, ischaemic presentations closest in time to the MI had the strongest 
effect on mortality, but that there was also an effect of patients with consultations for 
ischaemic presentations up to 90 days prior to MI.   
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The overall exposure of ischaemia in any arterial bed prior to MI was associated 
with improved short term coronary heart disease mortality.  However, further analysis 
showed that the effect was restricted to patients with myocardial ischaemia (chest pain or a 
new coronary diagnosis).  The number of patients with non-myocardial ischaemia in the 90 
days prior to MI was low and these effects require further consideration given studies 
showing evidence for a remote preconditioning effect on post-MI survival.[218, 225, 226] 
 
6.8.2 Possible explanations 
Although this study was not designed to investigate mechanisms for differences in 
survival, various factors were examined to explain the effects that were seen in the main 
analysis.   
 
6.8.2.1 Time to hospital admission and reperfusion 
The differences in rates of coronary heart disease mortality between groups did not 
appear to be explained by faster time to hospital admission or reperfusion.  The times were 
longer in those who consulted with their primary care physician, perhaps because symptoms 
built up gradually in these patients.  These results are similar to a study of hospitalized MI 
patients, where patients without angina had the shortest delay time from symptom onset to 
admission and those with angina (stable or unstable) had longer delays.[222] 
 
6.8.2.2 Prescription of cardiovascular medications 
It was hypothesised that patients who presented to their physician with new 
ischaemia would be prescribed drugs in response to these symptoms to reduce their 
cardiovascular disease risk (anti-anginal, blood pressure lowering, lipid lowering, or 
antiplatelets), which could have affected subsequent mortality.  The cardiovascular 
medication prescription data in this study were of high quality: these drugs are mainly 
prescribed in primary care and cannot be prescribed without being recorded in the database.  
In this study, patients with new ischaemia were more likely to be prescribed these drugs but 
adjusting for this did not change the association with coronary heart disease mortality.  
While other analyses have, to differing degrees, controlled for drug use (ascertained 
retrospectively),[227, 228] ours is the first to adjust for drugs with data collected 
prospectively, in all four of these drug classes. 
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6.8.2.3 The effect of MI type: STEMI and NSTEMI 
The majority of studies in natural ischaemic preconditioning were conducted before 
the relatively new classification of MI into STEMI and NSTEMI, and therefore none have 
compared the effects between MI types.  This study showed that previous ischaemic 
presentations were associated with increased NSTEMI.  This is consistent with our previous 
study describing a higher atherosclerotic burden in NSTEMI patients overall,[229] and 
experimental evidence showing reduced ST-elevation on repeated arterial occlusion during 
CABG.[214]  In the Global Registry of Acute Coronary Events, previous nitrate therapy in 
over 50,000 patients with acute coronary syndrome (ACS) was shown to be associated with 
increased non ST-elevation ACS.  However, in a natural setting, whether ischaemic 
symptoms are causally related to subsequent MI type, or whether patients with NSTEMI are 
simply more likely to experience an intermittent, stuttering onset of MI cannot be 
determined from these data.   
In the current study there was a suggestion of differing effects of pre-MI ischaemic 
presentations on survival among STEMI and NSTEMI patients, though there was 
insufficient power among those with known MI type to exclude the possibility that the 
observed differences simply reflected chance variation.  The majority of previous research in 
this field has been in STEMI patients only and has shown evidence for effects on short term 
outcomes; the results from this study suggest that there may also be an effect in NSTEMI.  
It is has been widely shown that in-hospital survival is poorer for STEMI patients 
than NSTEMI patients, but that NSTEMI patients have a poorer longer term prognosis.  
Given the finding that patients with first AMI and prior atherosclerotic disease diagnoses are 
more likely to have NSTEMI,[229] some of the effect seen in the main analysis may have 
been driven by differences in MI type.   
Our subgroup analysis showed that although adjusting for MI type slightly 
attenuated the hazard ratio for MI overall, some evidence for an effect persisted.  This 
suggests that MI type is not responsible for much of the protective effect of prior ischaemic 
presentations. 
 
6.8.2.4 Health-seeking behaviours 
Patients visiting their physician in the weeks or months before MI may be displaying 
health seeking behaviour, which is associated with improved outcomes in some studies (e.g. 
the ‘worried well’).  However, in a sensitivity analysis there was no protective effect 
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associated with consultation for reasons other than ischaemia, suggesting that the observed 
effect is specific to ischaemic presentations prior to MI and not simply a result of increased 
health-seeking behaviour.   
 
6.8.2.5 Coronary risk  
The initial tabulation of patients showed that patients with existing ischaemic 
diseases and those with new ischaemic presentations in the 90 days prior to MI had the 
highest Framingham risk.  When the prevalence of each risk factor and medication were 
examined by timing of ischaemic presentation, the prevalence of risk factors and 
prescription of cardiovascular medications in those who presented very shortly before MI 
were at a similar level to the prevalence in patients with no ischaemic presentations.  Due to 
these associations between presentation and risk factors, the multivariate models were 
adjusted for each risk factor and medication.  However, even after taking account of these, 
an association between presentation and mortality remained.     
The main results were also adjusted for pre-MI coronary risk scores (based on 
Framingham 10 year ‘hard’ CHD outcomes).  This had no effect on the results seen in the 
main analysis, including for longer term follow-up.  This might be for two reasons.  First, 
the analysis was already adjusted for all components of the risk score, so additional 
adjustment for the composite added little further data to the analysis.  Second, the lack of 
effect may have been due to the unsuitability of Framingham risk scores in this population 
(some of whom already had diagnosed atherosclerotic disease and diabetes, for whom the 
score was not designed).  It is possible that a risk score designed for UK primary care data, 
or for patients with and without diagnosed disease, may have had more effect.  However, 
another measure of coronary risk is unlikely to explain away the associations found here.    
 
6.8.2.6 Ischaemic preconditioning 
As the effects seen in our analysis were not explained by any of the factors 
discussed here and are unlikely to be entirely explained by residual confounding, the results 
may represent a natural ischaemic preconditioning effect in a clinical setting.  Classic 
preconditioning occurs in the few hours prior to MI and is unlikely to explain these 
observations.  However, ‘delayed’ preconditioning, whereby ischaemia in the 12 hours prior 
to MI has a beneficial effect on survival,[230] could explain some of the effect that was 
observed, particularly in the group presenting in the 1-2 days prior to MI.  The effects seen 
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at times further removed from MI are more difficult to explain using classic or delayed 
preconditioning theory, but it is possible that symptoms of ischaemia persisted after their 
physician consultation and occurred closer to MI than recorded in these data.  An alternative 
explanation is the possibility of collateral channel formation in patients with ischaemia.[223]  
 
6.8.3 Strengths 
This study was in a population based sample, drawn from primary care practices in 
England.  Patients with AMI in this study were drawn from four data sources and inclusion 
of fatal AMI patients who did not reach hospital is unique, as most other studies drew their 
samples from hospitals or trial populations. 
The quality of the linked data was a major strength of this study.  The prospective 
data from primary care allowed detailed measurement of chest pain and atherosclerotic 
disease exposures prior to MI without errors in recall.  Only codes rated by two clinicians as 
‘definite’ indicators of a diagnosis were used in to define exposure, and a sensitivity analysis 
confirmed that inclusion of ‘possible’ codes had no effect on our result, so our exposure 
definitions were likely to have been adequate.  GPRD diagnoses have undergone extensive 
validation and shown to be of high quality.[53]  MINAP hospital data provided detailed 
information regarding diagnosis of MI, type, size and timing; MINAP data undergo regular 
checks of validity and completeness to ensure data quality.  ONS mortality data are near 
complete due to mandatory death registration in the UK, and these data allowed us to 
characterize the exposure effect in fatal MI cases who did not reach hospital, and examine 
longer term follow-up for all patients in the study. 
 
6.8.4 Weaknesses 
Presentations to the GP were referred to as ‘ischaemic presentations’ but this is an 
assumption based on patient consultation with their primary care physician and the recording 
of certain codes for new atherosclerotic disease and chest pain.  The ischaemic nature of 
their symptoms is inferred and not based on ST segment monitoring or myocardial perfusion 
imaging.  This is a weakness of using routinely collected, observational data, which has not 
been collected for the purpose of research.  However, chest pain prior to MI is likely, in 
retrospect, to have been ischaemic in nature, and a new diagnosis of coronary disease is also 
likely to be associated with ischaemia.  Any misclassification of symptoms is unlikely to 
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have been differential with respect to coronary heart disease mortality and therefore should 
not affect the hazard ratios generated in the analysis. 
Not all patients with ischaemic symptoms will report these to a primary care 
physician but any underestimation of exposure is unlikely to account for the observed 
association.  While there is likely to be some residual confounding that our observational 
analysis could not take account of, this is unlikely to account entirely for the observations in 
this study.  Misclassification in the true timing of symptoms, which may have preceded the 
date of consultation in general practice, may indicate that our results include a time lag, 
whereby the effect seen at 1-2 days might actually reflect true symptoms shortly beforehand.  
Cardiovascular medication data were based on prescriptions issued in primary care.  
Misclassification of drug exposures could also have arisen from failure to collect or use 
prescribed medications, from over the counter use of aspirin, or through patients saving 
medications that were prescribed earlier.     
The risk factor measures adjusted for in this analysis may not be an accurate 
reflection of true cardiovascular disease risk at the time of MI.  This is for two reasons.  
First, the measures of all risk factors may have been collected long before MI; we did not 
assess the duration between risk factor measurements and the date of MI.  Second, our 
measures of blood pressure and cholesterol were based on means of data collected 
throughout pre-MI follow-up, so may not have been an accurate reflection of those measures 
at any one time.  Other strategies to deal with such repeated measurements in routinely 
collected data could have been used (for example taking the closest measure to MI or 
averaging those taken in the year before MI), but we justify use of averaged measures in this 
study as a pragmatic attempt to capture past and current information about a patient’s 
cardiovascular disease risk.  However, adjustment for cardiovascular disease risk factors did 
not cause substantial attenuation of the associations described between ischaemic 
manifestations and coronary heart disease mortality, so any misclassification of these risk 
factor measures is unlikely to explain the results of this analysis.  A final weakness of this 
analysis was the inability to look at ischaemia occurring in the one to two hours prior to MI, 
which is suggested as ‘classical’ preconditioning and associated with large reductions in 
infarct size.  Ischaemic presentations on the date of MI were not included in this analysis as 
they were likely to represent coding of the infarct itself rather than pre-MI symptoms.  This 
is another disadvantage of using routinely collected data rather than researcher-led studies, 
but such data are likely to be the only way of ascertaining pre-MI data in a large, population-
based sample.   
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6.8.5 Implications for research 
While the overall effect of previous ischaemia was characterised with some 
certainty, our understanding of the role of MI type was limited by GPRD population 
coverage and the proportion of practices consenting to data linkage.  Future data linkage will 
involve more primary care practices and may therefore allow characterization of the 
differential effects of natural preconditioning by MI type and gain improved understanding 
of the effects in non-coronary arterial beds. 
 
6.8.6 Conclusion 
In the first prospective study of symptoms of ischaemia prior to MI, symptoms 
reported to the general practitioner prior to MI were associated with a lower rate of short 
term and a higher rate of longer-term coronary heart disease mortality following MI.  The 
strongest effects were observed in patients with exposures closest to MI, but there was still 
an effect of ischaemia occurring up to 90 days prior to MI.  These observations are 
consistent with a natural ischaemic preconditioning effect, observed for the first time in a 
clinical setting. 
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6.9 Chapter summary 
• Chest pain, angina and ischaemia occurring shortly before MI have been suggested 
as clinical correlates to ischaemic preconditioning.   
• This study compared patients with and without new or existing ischaemic 
presentations prior to MI in terms of subsequent infarct characteristics and coronary 
heart disease mortality. 
• Patients with new ischaemic presentations in the 90 days before MI experienced 
lower CHD mortality in the first seven days after MI compared to those with no 
prior ischaemic presentations, but subsequent mortality was higher.  
• For patients in whom MI type was recorded, those with previous ischaemia were 
more likely to have non ST-elevation MI type.  
• These observations could represent a natural ischaemic preconditioning effect, 
observed in a clinical setting. 
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Chapter 7 Aspirin and statins 
prior to myocardial 
infarction 
 
 
 
7.1 Summary 
This chapter describes an investigation into the prescribing of aspirin and statins for 
primary prevention and their association with outcomes at MI, including presentation with 
ST-elevation, infarct size and short term mortality.  A review of the literature on this topic is 
followed by an analysis of aspirin and statin prescribing for patients identified with MI in 
GPRD, HES, MINAP and ONS.    
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7.2 Literature review 
 
7.2.1 Introduction 
Aspirin and statins have been shown to reduce cardiovascular morbidity and 
mortality in randomised controlled trials, both in primary and secondary prevention.[39-44]  
Risk prediction scores are often advocated for use in primary care to establish which patients 
at most risk from cardiovascular disease and to prioritise treatment with aspirin and statins.  
The first and most well-recognised risk prediction tool is the Framingham risk score, which, 
for coronary heart disease, takes information on patient age, blood pressure, cholesterol and 
smoking to generate a predicted risk of ‘hard’ CHD endpoints (MI and coronary heart 
disease death) over ten years.  UK guidelines for use of aspirin and statins in primary 
prevention are described in the next sections.   
 
7.2.1.1 Aspirin for primary prevention of cardiovascular disease 
Recommendations by British bodies for the use of aspirin in primary prevention of 
cardiovascular disease are described in Table 7.1.  Up until 2009, low dose aspirin was 
recommended for prophylactic use in patients with a cardiovascular disease risk of 20% or 
more over ten years by the Joint British Societies’ (JBS) guidelines on prevention of 
cardiovascular disease in clinical practice.[231]  It was also recommended by the National 
Institute for Health and Clinical Excellence (NICE) in nearly all patients with type 2 diabetes 
mellitus,[232] and by the Scottish Intercollegiate Guidelines Network (SIGN) 2007 
guideline on prevention of cardiovascular disease.[233]  Framingham risk equations are 
most frequently used in estimating cardiovascular disease risk, and for the British guidelines 
described here, recommendations are based on 20% risk of a first cardiovascular disease 
event (i.e. coronary, cerebrovascular, peripheral arterial) over ten years. 
However, in 2009, a meta-analysis of data from randomised trials called into 
question the use of aspirin in primary prevention, concluding that it was of uncertain value in 
the reduction of occlusive events.[45]  The Medicines and Healthcare Regulatory Agency 
subsequently issued guidance indicating that use of aspirin in primary prevention of 
thrombotic vascular disease was unlicensed[234] and more recent guidance issued by SIGN 
does not recommend aspirin.[235]  However, ongoing trials are continuing to establish its 
effect in primary prevention, and it is likely that many patients initiated on aspirin prior to 
the 2009 guidance are still using aspirin off label.   
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Table 7.1 British guidelines for the use of aspirin in primary prevention of 
cardiovascular disease 
 
 Aspirin 
JBS 2, 
2005[231] 
• Aspirin 75mg daily for: 
− Individuals with ≥20% cardiovascular disease risk over 10 years once 
hypertension, if present, is controlled to systolic <150mmHg and 
diastolic <90mmHg; 
− All people with diabetes. 
NICE, 
2008[236] 
In patients with diabetes, offer low dose aspirin, 75mg daily to: 
• A person who is 50 years old or over, if blood pressure is below 
145/90mmHg; 
• A person who is under 50 years old and has significant other 
cardiovascular disease risk factors (features of metabolic syndrome, 
strong early family history of cardiovascular disease, smoking, 
hypertension, extant cardiovascular disease, microalbuminuria). 
MHRA, 
2009[234] 
“Aspirin is not licensed for the primary prevention of vascular events.  If aspirin 
is used in primary prevention, the balance of benefits and risks should be 
considered for each individual, particularly the presence of risk factors for 
vascular disease (including conditions such as diabetes) and the risk of 
gastro-intestinal bleeding.” 
SIGN, 
2007,[233] 
2012[235] 
2007 guideline: 
• Consider aspirin daily for: 
− Patients with a calculated cardiovascular disease risk of ≥20% over 
ten years;  
− All people with type 2 diabetes who are over 50 years of age, and for 
selected younger individuals who are considered to be at increased 
cardiovascular disease risk. 
2012 guideline: 
• Aspirin is not recommended for the primary prevention of vascular disease 
when benefits are considered against the increased risk of haemorrhage. 
JBS: Joint British Societies; NICE: National Institute for Health and Clinical Excellence; MHRA: 
Medicines and Healthcare Regulatory Agency; SIGN: Scottish Intercollegiate Network. 
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7.2.1.2 Statins for primary prevention of cardiovascular disease 
Statins have been recommended by NICE, SIGN and the JBS for primary prevention 
of cardiovascular disease for several years.  The guidelines for use of statins are described 
in Table 7.2.  The most recent British guidelines from NICE recommend use of statins in 
patients who have 20% or greater cardiovascular disease risk over ten years and in people 
with diabetes.  Previous guidelines from JBS and SIGN use the same threshold for statin 
treatment.  Other lipid lowering therapies are not recommended for primary prevention of 
CHD (including fibrates, nicotinic acid and anion exchange resins, ezetimibe). 
 
Table 7.2 British guidelines for the use of statins in primary prevention of 
cardiovascular disease 
 
 Statins 
JBS, 
1998[237] 
Prescribe statins preferentially to patients with a 30% ten year risk of CHD.  
When resources allow, treat patients with ≥15% ten year risk of CHD. 
JBS 2, 
2005[231] 
Prescribe statins in the following groups: 
• Asymptomatic people at high CVD risk (≥20% over 10 years): in all people 
to achieve the total and LDL cholesterol targets. (Audit standards: Total 
cholesterol <5.0mmol/l, LDL cholesterol <3.0mmol/l.  Optimal treatment 
standards: total cholesterol <4.0mmol/l, LDL cholesterol <2.0mmol/l). 
• All people aged 40 years or more with diabetes. 
• All people with diabetes aged 18-39 and at least one of the following: 
retinopathy, nephropathy, poor glycaemic control, elevated blood pressure 
requiring drug therapy, total cholesterol >6mmol/l, features of metabolic 
syndrome, family history of premature CVD. 
SIGN, 
2007[233] 
• Adults >40 years of age, with 10 year risk of CVD event ≥20% should be 
considered for daily treatment 
NICE, 
2008[232] 
• ≥20% risk of cardiovascular disease over 10 years based on an appropriate 
risk calculator or by clinical assessment in older people, people with 
diabetes or high risk ethnic groups.  Treatment with simvastatin 40mg is 
recommended. 
JBS: Joint British Societies; NICE: National Institute for Health and Clinical Excellence; SIGN: Scottish 
Intercollegiate Network; CHD: coronary heart disease; CVD: cardiovascular disease. 
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7.2.1.3 Adherence to guidelines in primary care 
There is some evidence to suggest that guidelines regarding use of primary 
preventative medications are not being met.  An analysis of the Health Survey for England in 
1998 found that just 3% of people with the highest ten year Framingham CHD risk of over 
30% (reflecting the 1998 JBS guidelines[237]) were taking lipid lowering medication.[238]  
More recently the same authors found that use had increased over time but was still far 
below the prevalence expected if the guidelines were followed.[239]  However, introduction 
of more guidelines and the Quality Outcomes Framework[183] will also have led to an 
increase in the prevalence in statin prescribing, particularly to those at high risk.   
Lack of guideline adherence is due to multiple factors including concerns of the GP 
regarding: cost to the patient and health service, increased workload to monitor treatment, 
dosage and side effects, the unnecessary medicalisation of asymptomatic patients, other 
treatment priorities, low patient life expectancy, and concerns about lack of change in patient 
lifestyle and health behaviour.[240]  Barriers to guideline adherence on the patient side 
include refusal to take medication and concerns about side effects.[241]   
  
7.2.1.4 Literature review aim: MI outcomes in users of aspirin and statins 
While cardiovascular events are reduced by statin and aspirin use, some patients do 
have MI while using these drugs.  Compared to MI patients who do not use these drugs, 
these patients may be at higher risk for adverse outcomes at the time of MI for two reasons:  
first, the GP believed them to be at a high enough vascular disease risk to require 
medication, and second they have had MI despite this increased level of protection.     
Few studies have examined the effects of aspirin and statin use in patients who still 
go on to have MI.  Therefore, the aim of this review was to collate the evidence to date 
regarding the effect of aspirin and statin prescribed prior to MI on presentation (STEMI and 
NSTEMI or the appearance of Q waves), infarct size and short term mortality. 
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7.2.2 Literature review methods 
7.2.2.1 Search strategy 
Databases and sources 
A literature search was completed in May 2012 in the English language medical 
literature for studies examining the effects of previous antiplatelet or lipid lowering agent 
use on outcomes at MI.     
 
Search keywords and terms 
Searches were conducted in Medline and Embase.  Search terms are described in 
Appendix A, Table 10.21.  Three searches were combined: the first to identify studies 
examining MI, the second to identify studies examining cardiovascular therapies, and the 
third to restrict the search to studies indicating use prior to infarction.   
 
Inclusion criteria 
Studies were included only if they fulfilled the following criteria: 
1. Included patients with first MI; 
2. Examined a specific objective regarding the effect of prior use of a 
cardiovascular medication; 
3. Examined clinical outcomes at the time of MI including infarct size, or 
clinical presentation, or post-MI outcomes; 
4. Study in humans; 
5. Manuscript written in English language. 
 
 
Procedure 
Titles and abstracts of the studies identified in the initial search were screened for 
relevance.  Any studies deemed to be relevant were obtained as full text and were assessed 
according to the inclusion criteria.  To ensure that no relevant studies were missed, the 
reference lists of all included studies were examined.  Cited reference searches were also 
performed for key studies.  
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In the first instance, only studies meeting all inclusion criteria were included.  
However, this was shown to be too restrictive in the evaluation of effects for most drugs.  
Therefore, the inclusion criteria were relaxed twice: first to include studies in recurrent MI, 
and second to include studies in all acute coronary syndromes rather than MI only. 
 
 
7.2.3 Results: aspirin 
Three studies met all inclusion criteria and examined the effects of aspirin use prior 
to first MI.[242-244]  These studies investigated effects on infarct size[242] and 
severity.[242-244]  The size of the studies varied from 342 patients in the setting of a 
randomised trial, to over 100,000 patients in a coronary heart disease register.  Aspirin was 
the most widely studied medication in relation to outcomes at MI and a further eight studies 
were identified that examined the effects of aspirin use prior to MI as a main research 
question but did not restrict their study to first MI.  The findings from these studies are 
summarised below and in Table 7.3. 
 
7.2.3.1 Effects on infarct size 
Of the three studies that met all inclusion criteria, only one (Ridker, 1991) examined 
the effects on infarct size.[242]  An additional four studies that included recurrent MI also 
examined infarct size.  These are described below. 
The US Physicians’ Health Study, a randomised, double blind placebo-controlled 
trial of low-dose aspirin, assessed infarct size in first non-fatal MI.[242]  There was no effect 
of aspirin on infarct size as measured by peak CK-MB levels (145.0 IU/l in aspirin group, 
142.8 in placebo group, P=0.93).  This result was stratified by age group (40-59, 60-89) and 
there was no effect modification.  No multivariate analysis was performed and although 
there is no confounding by indication due to randomisation of patients to aspirin or placebo, 
there may have been important differences in the groups of patients who had MI and these 
were not accounted for.  Additionally this study was restricted to non-fatal MI and the 
authors acknowledged that there may be a real effect of aspirin on infarct size, but that this 
may have been unobservable in an analysis restricted to non-fatal MI.  Power to detect an 
effect of aspirin may also have been a limitation of this study.  Despite a large study 
population of over 22,000 physicians, only 342 cases arose over the five year study period. 
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Abdelnoor (1999),[245] Col (1995)[246] and Mukamal (1999)[247] showed a 
beneficial effect of aspirin use,[245-247] while one small Israeli study found no effect.  The 
studies showing beneficial effects performed multivariate analyses taking into account 
demographic variables, previous coronary disease diagnoses, cardiovascular disease risk 
factor and medication use and still showed an effect of previous aspirin use.  After 
adjustment, there was a smaller infarct size in patients with previous aspirin (P<0.001 
Abdelnoor,[245] P=0.03 Mukamal[247]).  Col (1995) dichotomised infarct size into ‘large’ 
versus ‘small’, where large infarcts were defined as those with peak CK levels more than 
five times normal, and small infarcts were peak CK less than two times normal.[246]  Using 
this categorisation, patients using aspirin prior to MI had 1.40 times the odds (95% CI 1.06-
1.84) of having a ‘small’ infarct after adjusting for demographic variables, risk factors and 
other cardiovascular medication use prior to MI. 
While these studies performed multivariate analyses, there might be some residual 
confounding by indication if the adjustments were inadequate or confounders were poorly 
measured.   
The randomised trial held information about dose and duration of use.  However, 
this was the same across all exposed patients in the study and therefore no information about 
potential dose-response effects of aspirin could be examined.  Duration of use was not 
included in the analysis.  In each of the other studies described, no information on dose or 
duration of use was available as exposure information was ascertained retrospectively.  
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Table 7.3 Studies examining the effect of previous aspirin use on infarct size 
 
Author, 
year 
Country Patients included Years of 
data 
collection 
N 
patients 
N (%) 
taking 
aspirin 
Exposure 
measurement 
Peak CK or CK-MB 
(IU/l) in patients +/- 
aspirin  
Was multivariate 
analysis 
performed? 
Effect measure/ P value, 
where reported 
Ridker, 
1991[242] 
United 
States 
Hospitalised first MI 
patients in the 
Physicians’ Health 
Study  
1982-1987 342 129 (38%) Patients 
prospectively 
randomised to 
aspirin vs. placebo 
+ 145.0 
 -142.8 
No No effect, P=0.93 
Col, 
1995[246] 
United 
States 
Hospitalised MI 
patients in the 
Worcester Heart 
Attack Study 
1975-1990 2,114 332 (16%) Retrospective: 
categorised as 
users or non-users 
Not stated Yes, adjusted for 
age, sex, previous 
CHD, smoking, beta 
blocker and calcium 
channel blocker use, 
thrombolysis. 
Smaller infarct ; adjusted 
OR=1.40 (95% CI 1.06-
1.84) 
Abdelnoor, 
1999[245] 
Norway Hospitalised MI 
patients 
1993-1995 753 158 (21%) Retrospective, by 
patient interview: 
categorised as 
users or non-users 
In thrombolysed: 
+ 1272 (683-3350) 
- 2183 (1050-3340) 
In non-thrombolysed: 
+ 557 (372-928) 
- 923 (594-1625) 
Yes, adjusted for 
age, previous CHD, 
smoking, beta 
blocker and nitrate 
use. 
In thrombolysed: smaller 
infarct P<0.001 
In non-thrombolysed: no 
effect, P=0.73 
Mukamal, 
1999[247] 
United 
States 
Hospitalised MI 
patients in the 
Onset Study 
1989-1996 1,043 317 (30%) Retrospective, by 
patient interview: 
categorised as 
users or non-users 
+ 649.8 ± 342.7 
- 735.3 ± 41.2* 
Yes, adjusted for 
demographics, risk 
factors and other 
cardiovascular 
medications 
Smaller infarct: 12% 
difference, P=0.03 
Beigel, 
2011[248] 
Israel Hospitalised MI 
patients 
Not stated 174 56 
(32%) 
Retrospective, by 
patient interview: 
categorised as 
users or non-users 
+ 1428 ± 215 
- 1808 ± 339 
No No effect , P=0.35 
MI: myocardial infarction; OR: odds ratio; CK: creatine kinase; CHD: coronary heart disease. 
*Adjusted for demographics, previous risk factors, previous medication use 
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7.2.3.2 Effects on clinical presentation 
The three studies of first MI investigated the effect of use on clinical presentation.  
Ridker and Kennon examined the effect on Q wave appearance at ECG and Bjorck 
examined the effect on ST-elevation at MI (comparing the frequency of STEMI and 
NSTEMI).[242-244]   
In the Physicians’ Health Study trial data, Ridker showed no effect of previous 
aspirin use on clinical presentation with Q waves (aspirin group 56.3% Q wave MI, placebo 
group 59.0%, P=0.54), but as above with respect to infarct size, may have been 
underpowered to detect an effect given its relatively small size (n=342).   
The more recent studies in first MI showed a beneficial effect, with prior aspirin 
users experiencing 50% decreased odds of Q wave MI (OR=0.53 (95% CI 0.34-0.84) 
P=0.007) and 30%-40% decreased odds of ST-elevation (Kennon adjusted OR=0.57 (95% 
CI 0.35-0.94) p=0.03, Bjorck adjusted OR=0.72 (95% CI 0.69-0.76)), even after taking 
account of age, gender, previous coronary disease, cardiovascular disease risk factors and 
use of other cardiovascular medications.  Three further studies including recurrent MI also 
showed decreased odds of Q wave MI in aspirin users.  As discussed previously, there is still 
the possibility of residual confounding in these studies due to poorly measured confounders 
(ascertained retrospectively in all studies) or insufficient adjustment.  However, all of these 
studies appear to be well-adjusted for cardiovascular disease risk, cardiovascular disease and 
use of other drugs, so the effect seen in these studies may be real.  Additionally these studies 
were large (there were over 100,000 patients included in the study based on the Swedish 
registry and in all of the others were over 500 patients) and so their findings were unlikely to 
be due to chance.  Finally the patients included were not highly selected and therefore 
representative of hospitalised MIs from their respective source populations. 
A further four studies were identified that examined the effect of aspirin on clinical 
presentation in acute coronary syndromes overall.  These largely showed the same results 
regarding the effects on clinical presentation with non-Q wave MI and less ST-elevation in 
prior aspirin users.[249-252]  These studies also showed a tendency for prior aspirin users to 
manifest with unstable angina rather than MI.[249, 250] 
Limitations of all of these studies are that they did not examine the effect of aspirin 
dose or duration on presentation, and that they are restricted to hospitalised patients who 
survived for long enough to provide information on previous drug use.  The effect in general 
populations, including patients who die before reaching hospital, is therefore unknown.  
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Table 7.4 Effect of prior aspirin therapy on clinical presentation at MI 
 
Author, 
year 
Country Patients included Years of 
data 
collection 
N 
patients 
N (%) 
taking 
aspirin 
Exposure 
measurement 
Effect of aspirin 
on presentation 
Was multivariate 
analysis 
performed? 
Effect measure/ P value, 
where reported 
Ridker, 
1991[242] 
United 
States 
Hospitalised first MI 
patients in the 
Physicians’ Health Study 
1982-1987 342 129 
(38%) 
Patients 
prospectively 
randomised to 
aspirin vs. placebo 
Aspirin group: 
56.3% Q wave MI 
placebo group: 
59.0% Q wave MI 
No No effect on Q waves, P=0.54 
Kennon, 
2000[243] 
United 
Kingdom 
Hospitalised first MI 
patients 
1988-1998 1,395 
 
121 
(9%) 
Retrospective: 
categorised as 
users or non-users 
Aspirin group: 
81.8% STEMI 
70.0% Q wave MI 
Non-aspirin group: 
89.7% STEMI 
80.0% Q wave MI 
Yes, adjusted for 
age sex, ethnicity, 
cardiovascular 
disease risk factors 
and beta blockers 
use. 
Fewer Q wave MI, fewer 
STEMI;  
adjusted OR for Q wave 
development: 0.53 (95% CI 
0.34-0.84) P=0.007;  
adjusted OR for ST-elevation: 
0.57 (95% CI 0.35-0.94) 
P=0.03 
Bjorck, 
2010[244] 
Sweden Hospitalised first MI 
patients in the RIKS-HIA 
Register 
1996-2006 103,459 28,583 
(28%) 
 
Retrospective: 
categorised as 
users or non-users 
Aspirin group: 
20.2% STEMI 
Non-aspirin group: 
48.0% STEMI 
Yes, adjusted for 
age, sex, previous 
atherosclerotic 
disease, 
cardiovascular 
disease risk factors 
and other drugs 
Fewer STEMI; adjusted OR for 
ST-elevation: 0.72 (95% CI 
0.69-0.76) 
Col, 
1995[246] 
United 
States 
Hospitalised MI patients 
in the Worcester Heart 
Attack Study 
1975-1990 2,114 332 
(16%) 
Retrospective: 
categorised as 
users or non-users 
Aspirin group: 
65% Q wave MI 
Non-aspirin group: 
48% Q wave MI 
Yes, adjusted for 
age, sex, previous 
CHD, smoking, beta 
blocker and calcium 
channel blocker 
use, thrombolysis. 
More non Q wave MI ; 
adjusted OR for non Q wave 
MI: 1.38 (95% CI 1.06-1.79) 
Abdelnoor, 
1999[245] 
Norway Hospitalised MI patients 1993-1995 753 158 
(21%) 
Retrospective, by 
patient interview: 
categorised as 
users or non-users 
Aspirin group: 
45% non Q wave 
Non-aspirin group: 
24% non Q wave 
Yes, adjusted for 
age, previous CHD, 
smoking, beta 
blocker and nitrate 
use. 
More non Q wave MI; adjusted 
OR for non Q wave MI: 1.67 
(95% CI 1.10-2.54) P=0.018 
Mukamal, 
1999[247] 
United 
States 
Hospitalised MI patients 
in the Onset Study 
1989-1996 1,043 317 
(30%) 
Retrospective, by 
patient interview: 
categorised as 
users or non-users 
Aspirin group: 
38.9% Q wave MI 
Non-aspirin group: 
48.7% Q wave MI 
Yes, adjusted for 
demographics, risk 
factors and other 
cardiovascular 
medications 
Fewer Q wave MI; adjusted 
OR for Q wave MI: 0.77 (95% 
CI 0.61-0.97) P=0.03 
MI: myocardial infarction; OR: odds ratio; STEMI: ST-elevation MI 
Note: the dashed line separates studies including only first MI and those including recurrent MI 
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7.2.3.3 Effects on short term mortality 
None of the three studies examining the effects of aspirin in first MI described the 
effects on mortality.  However, two studies including recurrent MI and seven studies of ACS 
investigated the effects of prior aspirin use on short term mortality, with conflicting results 
(Table 7.5).   
Portnay (2005) showed a protective effect of prior aspirin use on 30 day mortality in 
118,992 MI patients and 39,531 aspirin users aged over 65 in the US Medicare dataset 
(RR=0.93 (95% CI 0.90-0.96) P<0.001).[253]  The beneficial effect of prior aspirin persisted 
to six months.  The strengths of this study were its large size, the use of prospective data on 
medications from the medical record, the exclusion of patients who had contraindications to 
aspirin (bleeding, aspirin allergy) and a well-adjusted multivariate analysis. 
This was supported by data from the Global Registry of Coronary Events (GRACE) 
and from the Myocardial Ischaemia National Audit Project (MINAP).  Spencer (2002) 
showed a beneficial effect of aspirin at 30 days in 4,794 ACS patients with previously 
diagnosed coronary artery disease (Multivariable adjusted OR=0.69 (95% CI 0.50-
0.95)).[254] This was found after multivariate analysis, adjusting for previous disease, risk 
factors and in-hospital treatment –in  an unselected cohort of patients from centres across the 
world.  Based on these and other data from GRACE, prior aspirin use was included in 
calculation of the GRACE risk score for hospital mortality (aspirin independent association 
with mortality OR=0.73 (95% CI 0.58-0.91)).[255]  A study based on MINAP data also 
found aspirin to be one of the factors that was independently associated with lower in-
hospital mortality in 34,722 STEMI patients.[103] 
Conversely, two studies based on patients enrolled in trials showed higher mortality 
in aspirin users at 30 days based on multivariate analysis.[249, 256]  These were large 
studies of over 14,000 patients in total, and since the randomised treatment was aspirin use 
at the time of MI, the study excluded patients with aspirin contraindications.  Multivariate 
adjusted analyses were also performed here and patients previously using aspirin had 16% 
increased odds of mortality in one study (OR=1.16 (95% CI 1.00-1.33)) and 42% increased 
in the other (OR=1.42, no 95% CI reported).  Indeed, the TIMI risk score includes aspirin as 
a predictor of mortality.[257]  
In a smaller German study (N=8,224 and 2,022 aspirin users) of STEMI patients, 
Bauer showed no effect of prior aspirin use on in-hospital mortality at multivariate analysis 
(OR=0.98 (95% CI 0.80-1.21)), although there was a higher crude mortality in aspirin users 
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(12.8% in prior aspirin users and 8% in the untreated group).[258]  In this analysis, patients 
with contraindications to aspirin were not excluded.   
Four additional large studies found no effect of previous aspirin on mortality. [259-
261]  Spencer showed that in ACS patients without previous coronary artery disease[254] 
(N=6,414), there was no effect of previous aspirin on mortality.  Among this group, 19% 
were aspirin users.  The aspirin users had lower odds of in-hospital death after adjustment 
for clinical factors, but this was lost after further adjustment for in-hospital medications and 
cardiac procedures.  A study examining predictors of 30 day death and non-fatal re-
infarction showed that aspirin was not an independent predictor of these outcomes in 9,461 
STEMI patients in the PURSUIT trial.[262] 
The overall evidence for short term mortality in previous aspirin users is therefore 
unclear.  Reasons for differences between studies may lie in the differing guidelines for 
aspirin use across study settings, the types of patients included (all MI or just STEMI), and 
the quality of adjustment for confounders.
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Table 7.5 Effect of prior aspirin therapy on 30 day mortality 
 
Author, 
year Country Patients included 
Years of 
data 
collection 
N 
patients 
N (%) taking 
aspirin 
Exposure 
measurement 
Effect of 
aspirin on in-
hosp/30 day 
death 
Was multivariate analysis 
performed? Effect measure/ P value 
Portnay, 
2005[253] 
United States Hospitalised MI patients in 
Medicare, the Cooperative 
Cardiovascular Project (aged 
≥65 years) without 
contraindications to aspirin 
1994-1996 118,992 39,531 (33%) Prospective, in 
the medical 
record 
Lower mortality 
in aspirin 
group. 
Yes, adjusted for demographics, 
cardiovascular disease history, 
other drugs. 
Adjusted RR=0.93 (95% 
CI 0.90-0.96) P<0.001 
Bauer, 
2009[258] 
Germany Hospitalised STEMI patients in 
ACOS registry 
2000-2002 8,224 2,022 (25%) Retrospective, 
by patient 
interview: yes/no 
Crude higher 
mortality in 
aspirin group. 
Yes, adjusted for demo-
graphics, prior MI and stroke, 
diabetes. 
Adjusted OR=0.98 (95% 
CI 0.80-1.21) 
Borzak, 
1998[259] 
Multi-centre Hospitalised unstable angina 
patients in TIMI 7 
Not stated 410 263 (64%) Retrospective: 
yes/no 
No effect Yes, adjusted for demographics, 
cardiovascular disease history, 
CHD risk factors. 
Not given 
Alexander, 
1999[249] 
Multi-centre: 
N.America, Latin 
America, Europe 
Hospitalised NSTEACS in the 
Multicentre (PURSUIT trial) 
1995-1997 9,461 6,039 (64%) Retrospective, 
by case report 
form: yes/no 
Higher mortality Yes, adjusted for demographics, 
cardiovascular disease history, 
CHD risk factors, other drugs. 
Adjusted OR=1.16 (95% 
CI 1.00-1.33) 
Lancaster, 
2001[256] 
Multi-centre: 
N.America, Latin 
America, Europe 
Hospitalised UA or non-Q 
wave MI in the ESSENCE or 
PRISM-PLUS trials 
1994-1998 4,690 2,780 (59%) Retrospective Higher mortality Yes, adjusted for demographics, 
prior coronary disease, CHD risk 
factors. 
Adjusted OR=1.42 (no 
95% CI given) 
Spencer, 
2002[263] 
Multi-centre: 
worldwide 
Hospitalised ACS in the 
Global Registry of Coronary 
Events 
1999-2001 11,388 4,872 (43%) Retrospective: 
yes/no 
Lower mortality 
in CAD+.   
No effect CAD- 
Yes, adjusted for demographics, 
CHD risk factors, history of CHD, 
PCI and CABG, treatment in-
hospital. 
Adjusted OR in patients 
with a history of CAD: 
0.69 (0.50-0.95), and 
without history of CAD: 
0.77 (0.55-1.07) 
Collet, 
2004[264] 
France Hospitalised ACS in a French 
registry 
1999-2002 1,358 355 prior 
users (26%), 
73 recent 
withdrawers 
(5%) 
Retrospective: 
non-use, prior 
use, recent 
withdrawal 
Recent 
withdrawal 
predicted 
death, no effect 
of prior use 
Yes, adjusted for demographics, 
smoking, diabetes, history of MI, 
hypercholesterolaemia. 
Adjusted OR for 
withdrawal: 2.05 (95% CI 
1.08-3.89), P=0.03 
Rich, 
2010[260] 
Multicentre 
worldwide 
Hospitalised ACS patients 
enrolled in the TIMI trials 
1989-2005 66,443 17,839 (27%) Retrospective No effect Yes, adjusted for demographics, 
prior coronary disease, CHD risk 
factors, CABG, PCI. 
Adjusted OR=1.01 (95% 
CI 0.90-1.13) 
El-Menyar, 
2012[261] 
Middle East Hospitalised ACS in Gulf 
Registry of Acute Coronary 
Events 
2008-2009 7,827 3,209 aspirin 
users (41%) 
(70% aspirin, 
1% clopidogrel 
29% dual) 
Retrospective: 
yes/no 
No effect Yes, adjusted for demographics, 
cardiovascular disease history, 
CHD risk factors, other drugs. 
Not given 
MI: myocardial infarction; UA: unstable angina; ACS: acute coronary syndrome; NSTEACS: non ST-elevation ACS; STEMI: ST-elevation MI; CAD: coronary artery disease; OR: odds ratio 
Note: the dashed line separates studies including recurrent MI and those including all ACS patients. 
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7.2.4 Results: statins 
Three studies were identified that examined the effects of prior statin use at first MI 
on infarct size, presentation and mortality.[244, 265, 266]  One of these was a large study of 
over 100,000 patients and performed multivariate analysis to examine the presentation of MI 
(STEMI versus NSTEMI).  The two other studies were smaller, in roughly 300 patients and 
assessed the effects of statins on infarct size, presentation and mortality.  One of these 
smaller studies was restricted to patients without previously diagnosed atherosclerotic 
disease.[265]  Five further studies were identified which examined the effects of statins in 
patients with recurrent MI.  All of these studies were restricted to hospitalised patients, and 
all but one of these studies measured statin use retrospectively.    
 
7.2.4.1 Effects on infarct size 
Two studies in first MI patients measured infarct size,[265, 266] both in STEMI 
patients (Table 7.6).  In a US study of 281 patients drawn from hospitals between 2004 and 
2006, prospectively collected electronic health records were used to assess previous statin 
use.  Fifty patients (18%) were statin users and their infarct size was smaller, on average, 
than non-users (P=0.006).  This study reported the type of statin and the mean dose, but did 
not examine the effects of each statin or dose on the outcome, and did not perform 
multivariate analysis to assess the independent effects of statin on infarct size, despite large 
differences between the groups in terms of cardiovascular disease risk. 
The second study, including 310 hospitalised patients in Japan, was restricted to 
those receiving fibrinolytic therapy.  Thirty-nine patients were statin users (13%) and at 
multivariate analysis there was a smaller infarct size in the statin-treated group.  The odds of 
‘large’ infarct size (defined as the upper tertile of the Area Under Curve of creatine kinase) 
in the treated group were a quarter of those in the untreated group (Adjusted OR=0.25 (95% 
CI 0.07-0.91) P=0.035)[266] after adjusting for demographics, key cardiovascular disease 
risk factors, Killip class on admission, TIMI flow grade and multivessel disease. 
Despite the relatively small size of both of these studies, they both found important 
differences between statin users and non-users in infarct size.  Infarct size was also smaller 
in statin users in two additional studies that included recurrent MI (Table 7.6), including a 
large multicentre study of over 10,000 patients with MI.[267, 268] 
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Table 7.6 Effect of previous statin treatment on infarct size 
 
Author, 
year 
Country Patients included Years of 
data 
collection 
N 
patients
N (%) 
taking 
statin
Exposure 
measurement 
Effect of 
statin on 
infarct size 
Was multivariate 
analysis performed?
Effect measure/ P 
value, where reported 
Moran, 
2008[265] 
United 
States 
Hospitalised STEMI 
without previous 
atherosclerotic 
disease 
2004-2006 281 50 
(18%)
Used 
electronic 
health records 
+ statin  
87.8ng/ml 
-statin 
134.5ng/ml 
No Smaller infarct  in statin 
users; P=0.006 
Kiyokuni, 
2009[266] 
Japan Hospitalised first 
STEMI receiving 
fibrinolytic therapy 
Not stated 310 39 
(13%)
Retrospective 
from patient 
interview: 
yes/no 
+statin:  
2187± 1967 
-statin: 
3334± 3320 
IU/l 
Yes, demographics, 
CHD risk factors, 
TIMI flow grade, 
multivessel disease, 
PCI, MI type 
Smaller infarct in statin 
users; Adjusted OR for 
large size OR=0.25 
(95% CI 0.07-0.91) 
P=0.035 
Ishii, 
2006[267] 
Japan Hospitalised first MI 
with PCI within 24 
hours 
1998-2003 386 40 
(10%)
Retrospective 
from patient 
interview: 
yes/no 
Smaller infarct No P=0.015 
Aronow, 
2008[268] 
Multi-
centre, 13 
countries 
Hospitalised MI in 
GUSTO or PURSUIT
1994-1997 10,548 1,028 
(10%)
Retrospective : 
yes/no 
Smaller infarct Yes, adjusted for 
demographic, clinical 
and treatment 
characteristics. 
Adjusted OR for large 
size (>3 times upper 
limits of normal) 
OR=0.94 (95% CI 0.88-
0.99) P=0.04 
MI: myocardial infarction; STEMI: ST-elevation MI; PCI: percutaneous coronary intervention; OR: odds ratio. 
Note: the dashed line separates studies including only first MI and those including recurrent MI 
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7.2.4.2 Effects on clinical presentation 
Two studies in first MI patients examined differences in clinical presentation 
between statin users and non-users.[244, 266]  One was a large study of over 100,000 in the 
Swedish RIKS-HIA register; in an adjusted analysis taking account of differences in 
demographics, cardiovascular disease risk factors (including smoking, hypertension and 
diabetes), and other cardiovascular drug use, there was an independent protective effect of 
statin use on ST-elevation (OR=0.79 (95% CI 0.74-0.84)).  This included over 12,000 statin 
users and so was well-powered to detect a difference between groups.  A smaller Japanese 
study in STEMI patients receiving fibrinolytic therapy found that the sum of ST-elevation 
was smaller in the statin treated group compared to the untreated group (P=0.004) (Table 
7.7).   
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Table 7.7 Effect of previous statin treatment on presentation at myocardial infarction with ST-elevation 
 
Author, 
year 
Country Patients 
included 
Years of 
data 
collection 
N 
patients
N (%) 
taking 
statin 
Exposure 
measurement 
Effect of 
statin on 
presentation 
Was multivariate 
analysis 
performed? 
Effect measure/  
P value, where 
reported 
Bjorck, 
2010[244] 
Sweden Hospitalised first 
MI patients in the 
RIKS-HIA 
Register 
1996-2006 103,459 12,267 
(12%) 
Retrospective: 
yes/no 
Fewer STEMI Yes, adjusted for 
demographics, CHD 
risk factors, other 
drugs, CABG, PCI 
Adjusted OR for ST-
elevation: 0.79 (95% CI 
0.74-0.84) 
Kiyokuni, 
2009[266] 
Japan Hospitalised first 
STEMI receiving 
fibrinolytic therapy
Not stated 310 39  
(13%) 
Retrospective 
from patient 
interview: yes/no 
Less ST-
elevation 
No P=0.012 for smaller 
sum of ST-elevation in 
the statin group on 
admission, P=0.004 for 
one hour after 
admission 
MI: myocardial infarction; STEMI: ST-elevation MI; OR: odds ratio 
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7.2.4.3 Effects on in-hospital mortality 
There is disagreement regarding the short term mortality effects of statins prior to 
MI (Table 7.8).  Only one study in first MI patients assessed short term mortality, and this 
did not perform an adjusted analysis to assess the independent effect of statins, finding no 
effect of statins on 30 day mortality (P=0.305).[265]  Importantly, this was the only study 
restricting to patients whose first manifestation of atherosclerotic disease was the MI.   
However, of the four studies including recurrent MI that examined mortality, three 
showed a beneficial effect of prior statin use.  The largest of these was a US study of 78,224 
NSTEMI patients investigating use and recent withdrawal of statins.  Patients using statins 
before and during MI had the lowest mortality, and patients previously using statins who had 
these withdrawn at MI had higher mortality than never users.  This study adjusted for 
demographics, medical history, cardiovascular disease risk factors and other preadmission 
medications and suggested that statin use must be continued to the day of MI in order to 
have a beneficial effect.[254] 
Another large study in over 10,000 trial patients showed no effect of previous statin 
use on mortality (P=0.22), although no multivariate analysis was performed.  Two further 
smaller studies (<1000 patients) in hospitalised STEMI patients undergoing PCI found lower 
mortality in statin users at multivariate analysis.  Additionally, in a study developing the 
GRACE risk score, prior statin use was independently associated with lower in-hospital 
mortality (Adjusted OR=0.50 (95% CI 0.34-0.97).[255] 
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Table 7.8 Effect of previous statin treatment on in-hospital and 30 day mortality 
 
Author, 
year 
Country Patients 
included 
Years of 
data 
collection 
N patients N (%) taking 
statin 
Exposure 
measurement 
Effect of statin 
on short term 
mortality 
Was multivariate 
analysis performed?
Effect measure/ P value, 
where reported 
Moran, 
2008[265] 
United 
States 
Hospitalised 
STEMI without 
previous 
atherosclerotic 
disease 
2004-2006 281 50 (18%) Used electronic 
health records 
No effect No P=0.305 
Spencer, 
2004[254] 
United 
States 
Hospitalised 
NSTEMI patients 
in the NRMI* 
2000-2002 78,224 13,781 before 
admission 
(18%), 4870 
of whom 
withdrawn at 
MI (35%) 
Retrospective : Prior 
to hospital and in 
hospital, prior to 
hospital and 
continued at hospital, 
no prior use 
Lower mortality 
in continuing 
users, no effect 
in withdrawing 
compared to 
never users 
Yes, adjusted for 
demographics, 
medical history, CHD 
risk factors and 
preadmission 
medications 
Withdrawn vs. continuers: 
HR=1.83 (95% CI 1.58-
2.13), Withdrawn vs. never 
HR=1.03 (95% CI 0.93-
1.15) 
Aronow, 
2008[268] 
Multi-
centre, 13 
countries 
Hospitalised MI in 
GUSTO or 
PURSUIT 
1994-1997 10,548 1,028 (10%) Retrospective : 
yes/no 
No effect No P=0.22 
Lev, 
2009[269] 
Israel Hospitalised 
STEMI 
undergoing PCI 
2001-2007 950 327(34%) Retrospective Lower mortality Yes, adjusted for 
demographics, 
medical history, CHD 
risk factors, renal 
insufficiency, CABG. 
Adjusted OR=0.4 (95% CI 
0.13-0.96), P=0.045 
Garot, 
2010[270] 
France Hospitalised 
STEMI 
undergoing PCI 
complicated by 
cardiogenic shock 
Not stated 111 30 (27%) Retrospective Lower mortality Yes Adjusted OR=0.35 (95% 
CI 0.15-0.88) P=0.026 
MI: myocardial infarction; UA: unstable angina; ACS: acute coronary syndrome; NSTEACS: non ST-elevation ACS; STEMI: ST-elevation MI; NRMI: National Registry of 
Myocardial Infarction; HR: hazard ratio. 
Note: the dashed line separates studies including only first MI and those including recurrent MI 
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7.2.5 Strengths of previous research 
There is some strong evidence for the effects of aspirin and statins prior to MI 
overall, in terms of their effects on clinical presentation and infarct size.  The studies 
included were often from large samples, from diverse populations in registries and trials, and 
across different geographic regions.  Most of the studies reported large differences in patient 
baseline characteristics between those treated and not treated with medications.  The 
statistical analyses performed in many of the studies fully adjusted for these differences by 
adjusting for demographic variables, cardiovascular disease risk factors, other cardiovascular 
medication use and sometimes hospital treatments.   
All of the studies were in hospitalised MI patients and nearly all used a combination 
of clinical history, raised cardiac markers (troponins, creatine kinase, lactate dehydrogenase) 
and ECG findings to diagnose MI.  While some of the studies into the effects of aspirin were 
conducted before the redefinition of MI in 2000, many were also conducted after this and 
effects on ST-elevation and non ST-elevation MI were reported.   
 
7.2.6 Limitations of previous research 
While the evidence for use of aspirin and statins in MI overall was often strong, 
there are several limitations to their findings.  These limitations are described in the 
following sections.  
 
7.2.6.1 First and subsequent atherosclerotic disease presentations 
A study of ACS patients in GRACE compared the effect of aspirin on 28 day 
mortality in patients with and without prior known coronary artery disease (CAD).[263]  
This suggested that aspirin was protective in patients with prior CAD but not in patients 
without.  No other studies examined differences between those with and without disease, but 
one study restricting to patients without prior atherosclerotic disease found no effect on 
mortality.  These findings are particularly relevant to the focus of this thesis: MI as the first 
manifestation of atherosclerotic disease, and the provision of aspirin and statins for primary 
prevention.   
  Since the pattern of prescribing of aspirin and statins in patients with and without 
prior disease is likely to be different, and there is a suggestion that their effects on outcomes 
may be different, further research differentiating between patients with and without disease 
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would be of interest.  If aspirin and statins can improve outcomes of patients who have MI, 
in addition to their effects in preventing MI altogether, then the evidence for use of these 
medications in primary prevention will be strengthened. 
 
7.2.6.2 Differing levels of cardiovascular disease risk 
The effect modification by previous disease shown in the GRACE study may also 
suggest that there are differing effects by level of cardiovascular disease risk.  The majority 
of studies included in this review performed multivariate adjusted analyses taking account of 
cardiovascular disease risk factors and previous disease but none stratified results according 
to level of risk. Patients at more risk may be afforded more protection in the same way that 
patients with previously diagnosed atherosclerotic disease were more protected in the 
aforementioned study.[254]  Given that prescribing guidelines recommend use of statins in 
the high risk group only, and that patients at high risk have previously been recommended 
aspirin, then examining their effects by level of risk would be pertinent.  
 
7.2.6.3 Generalisability of patients 
Many studies included in this review reported outcomes for patients in trial 
populations: TIMI,[260] PURSUIT,[268] ESSENCE/PRISM-PLUS.[271]  These patients 
are often specially selected and are unrepresentative of all patients with MI, although no 
systematic differences were noted between results from trial populations and results from 
registries. 
In studies recruiting hospital patients (i.e. non-trial settings), strict inclusion criteria 
were often applied to reach the final study population such as inclusion of specific MI 
types,[254, 258] age ranges,[253] patients surviving to discharge,[268] undergoing specific 
procedures such as angiography or PCI,[267, 269] or not undergoing thrombolysis.[247] 
Few studies used an unselected patient population.  Therefore, the representativeness of 
these studies is questionable.  Additionally, a third of MI patients do not reach hospital, so 
there may be considerable error in the estimates of these studies if patterns of drug use in 
patients who reach hospital are different to those who do not.      
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7.2.6.4 Study design 
With a few exceptions, all of the studies included in this review identified patients at 
the time of MI and enquired retrospectively about history of cardiovascular medication use.  
(exceptions: Ridker, where aspirin use was randomised, Moran, where electronic health 
records were used, and Portnay, where Medicare records regarding prescriptions were 
extracted).  These studies will also have used retrospective data on cardiovascular disease 
risk and previous cardiovascular disease.  All of this information is subject to error in recall, 
which could have led to residual confounding and incorrect effect estimates. 
Additionally, since these drugs are usually prescribed for increased global 
cardiovascular disease risk, there may be important confounding by indication.  It is 
therefore important to adjust carefully for cardiovascular disease risk and previous 
cardiovascular disease to avoid this bias. 
A final issue in study design was the failure of most studies to exclude patients with 
contraindications for aspirin and statins (aspirin allergy, gastrointestinal bleeding, pregnancy 
or breast-feeding, and liver injury (acute or chronic)).   
 
7.2.6.5 Differing exposure definitions: dose, duration and withdrawal 
In most studies, previous drug use was defined simply as use or not prior to MI.  
Other studies used more complex definitions such as use within four days of admission, use 
for more than a week before admission, use ‘on a regular basis’ before admission, use for 
one month or more before admission, or use at the time of hospital admission.  These 
different exposure definitions are likely to affect the study outcome, making the studies less 
comparable.  The timing of exposure is potentially of importance if the drug itself triggers 
responses at the time of MI, or if the effects are cumulative.   
Due to the retrospective nature of the majority of exposure data, detailed 
information on dose and duration had not been collected.  One early study of aspirin use did 
investigate the effect of dose and duration on clinical presentation of ACS, based on 
retrospective data.[250]  This showed that there was no effect of low doses aspirin (<500mg 
per week) on clinical presentation, but that there was a dose-response effect with higher 
doses.  The effects on subsequent mortality were not described.  The effects of dose and 
duration of statins have not yet been investigated.  
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There has also been some interest in the effect of withdrawing from aspirin and 
statins shortly before ACS and the effect that this has on outcomes.  Collet (2004) showed 
that recent withdrawal of aspirin, within three weeks of ACS, was a predictor of 
mortality.[264]  Similarly, withdrawing statin treatment shortly before MI was associated 
with similar mortality to patients who never used statins, while patients who continued use 
had the best mortality experience.  This suggests that statin use must be continued to the day 
of MI in order to have an effect.[254] 
 
7.2.7 Limitations of this literature review 
There is a possibility that some published studies will have been missed as the grey 
literature was not searched and the search terms may not have been sensitive enough to 
capture all relevant studies.  However, the search strategy was relatively broad and the 
reference lists of all studies were searched.  In addition, cited reference searches were 
performed for the largest studies.  Therefore, the key studies of cardiovascular medication 
use prior to MI were likely to have been identified.  Finally, there may have been publication 
bias where studies failing to show an association have not been published.   
 
7.2.8 Conclusion 
A summary of the findings of this review are described in Table 7.9.  There is good 
evidence that prior aspirin and statin therapy benefit both clinical presentation and infarct 
size in MI overall, but their effects on subsequent short term mortality are unclear.  
However, the effects of prescribing for primary prevention in patients without prior 
diagnosed atherosclerotic disease and at different levels of cardiovascular disease risk have 
not been well studied.  Given guidelines to prescribe these medications in those at high risk, 
an understanding of their effects on MI outcomes is important.  Additionally, more complex 
facets of exposure have not been well studied, including the effects of withdrawal prior to 
MI, and the effects of dose and duration of use.  Finally, all studies to date have been in 
hospitalised patients and therefore effects in general populations are unclear.  The following 
study aims to address these limitations. 
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Table 7.9 Summary of the associations described in the literature review between 
aspirin use, statin use and infarct size, clinical presentation and mortality 
 
 Aspirin Statins 
Infarct size ↓ ↓ 
Clinical presentation severity 
(% ST-elevation) 
↓ ↓ 
Mortality ? ? 
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7.3 Objectives 
Among people who have first MI without previously diagnosed atherosclerotic disease:  
1. To describe initiation and duration of use of aspirin and statins prior to MI. 
2. To compare receipt of aspirin or statin prescriptions by level of cardiovascular 
disease risk. 
3. To compare infarct type and size in users and non-users of aspirin or statins, and 
examine effect modification by cardiovascular disease risk.  
4. To compare 30 day mortality in users and non-users of aspirin or statins, and 
examine effect modification by cardiovascular disease risk. 
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7.4 Methods 
The prospectively collected medical records of a cohort of MI patients without 
previously diagnosed atherosclerotic disease were reviewed to assess prescriptions of 
cardiovascular medications prior to MI, and outcomes at the time of MI and post-MI.   
   
7.4.1 Definition of acute myocardial infarction 
Patients with MI were identified based on a record in any one of the four data 
sources.  MI definitions are described in detail in Chapter 3 (Methods) and briefly in Table 
7.10.   
Table 7.10 Definition of acute myocardial infarction in each of the four data sources: 
GPRD, HES, MINAP and ONS 
 
Data source MI definition 
GPRD Read code for MI, raised markers of myocardial necrosis, or ECG result 
indicative of MI. 
HES ICD-10 code I21, I22 or I23 as the primary diagnosis in the first hospital 
episode. 
MINAP ST-elevation MI or non ST-elevation MI following the joint American Heart 
Association / European Society of Cardiology definition.[6] 
ONS ICD-10 code I21, I22 or I23 as the underlying cause of death. 
 
7.4.2 Diagnosed atherosclerotic disease prior to MI 
Patients with previous atherosclerotic disease, identified as described in Chapter 3 
(General Methods) were excluded from this analysis.  Only patients with Read codes rated 
as ‘definite’ indicators of atherosclerotic disease were included in this analysis; a sensitivity 
analysis including patients with ‘possible’ codes was performed to assess how this may have 
affected the results.  
 
7.4.3 Measuring cardiovascular disease risk scores prior to MI 
Using only data collected prior to MI, age, sex, smoking, blood pressure, 
antihypertensive use, total cholesterol and HDL cholesterol were used to calculate the 
Framingham risk score for ‘hard’ CHD endpoints (MI and coronary heart disease 
Chapter 7 
273 
 
death),[129, 272] which assigns points to different levels of cardiovascular disease risk 
factors and sums them to generate an overall ten year risk of hard CHD endpoints.  These 
risk factors were identified as described in Chapter 3 (General Methods).  The Framingham 
risk point scores (ranging from -4 to 26 in this cohort), based on combinations of these risk 
factors, are usually categorised to give an estimate of the percentage risk for hard CHD 
endpoints over the subsequent ten years, where a higher point total indicates higher CHD 
risk.  In this analysis, the scores were categorised as high risk (>20% risk of CHD over ten 
years), intermediate risk (10-20% risk) and low risk (<10% risk over ten years).  In men, 
high  (>20%) risk is defined as a point score of 16 and above, intermediate risk (10-20%) as 
12-15 points and low risk (<10%) as 11 points or lower.  In women, high risk is defined as a 
score of 23 or above, intermediate risk as 20-22 points and low risk as 19 points or fewer.  
However, the point scores were also used in their raw form to give a more refined picture of 
coronary risk and to examine the comparability of current aspirin users compared to non-
users.  The Framingham scores were also used to assess prescribing in accordance with 
guidelines.  A 15% CHD risk is equivalent to a 20% cardiovascular disease risk,[231] which 
is the guideline recommended point at which statins (and previously aspirin) should be 
considered for intervention.  Therefore, prescribing above and below this cut-off was 
examined. 
 
7.4.4 Other cardiovascular disease risk factors prior to MI 
Other cardiovascular disease risk factors included in this analysis were hypertension 
and diabetes.  Only patients with definite diagnoses of type 1 or type 2 diabetes and 
hypertension were included in this analysis. 
 
7.4.5 Aspirin and statin prescriptions prior to MI 
Information regarding aspirin and statin use was extracted from the GPRD records.  
For aspirin, drugs of interest were defined as any aspirin-containing product.  Statins 
included were atorvastatin, fluvastatin, lovastatin, pravastatin rosuvastatin, simvastatin, and 
cerivastatin (withdrawn from the market in 2001 due to safety concerns, but historical 
records of cerivastatin were available). 
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7.4.5.1 Use of aspirin and statins at MI 
To calculate use at the time of MI, the date of the last prescriptions issued prior to 
MI was recorded.  Patients were allocated to one of the following categories: 
• Current use, defined as use at the time of MI.  This was based on the 
number of days before MI that the prescription was issued and the duration 
that the prescription was intended to last.  A buffer of 14 days was added to 
account for time lags in the patient filling the prescription and beginning to 
use the tablets (sensitivity analyses were conducted to assess whether the 
results were altered by shorter and longer buffers or by different definitions 
of ‘current’ use); 
• Previous use, defined as patients who had one or more prescriptions in their 
medical record, but the final prescription issued prior to MI was not 
indicated to last until the date of MI;  
• Never use, defined as no record of prescription in the database. 
 
7.4.5.2 Duration of use and dose prior to MI 
Duration of use was calculated for patients who were current users at the time of MI.  
It was calculated as the duration in years between the date of first prescription and the date 
of MI.  For the last prescription, the dose was recorded in order to assess the effects of the 
dose taken at the time of MI.  As the relative effects of each statin are different, dosages 
were standardised to the equivalent dose of simvastatin as presented in the Statin Drug Class 
Review (Table 7.11).[273]  
Table 7.11 Equivalent doses of statins (Source[273]) 
 
Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin 
- 40 20 20 - 10 
10 80 40 or 80 40 5 20 
20 - 80 - 10 40 
40 - - - - 80 
80 - - - - - 
 
  
Chapter 7 
275 
 
7.4.6 Exclusion criteria 
Patients were excluded if they had a recorded history of MI (n=6,337), were under 
the age of 18 at MI (n=2), had not been registered with the primary care practice for at least 
one year before MI (n=8,516), whose MIs occurred outside the period where all databases 
were collecting data (outside 1st January 2003 to 31st December 2008, n=23,804), and 
patients without any primary care consultations in their record prior to MI (n=12).  Patients 
who had a clear contraindication to aspirin or statins were also excluded.  Exclusions were: 
history of stomach ulcer or gastrointestinal bleeding (n=1,454), aspirin intolerance (n=481), 
pregnancy or breastfeeding within a year of MI (n=9) and acute or chronic liver disease 
(n=634). 
 
7.4.7 Infarct size, presentation and subsequent mortality 
Infarct size was determined using peak troponin values recorded in the MINAP data 
source.  Only patients with a MINAP record had this information recorded (N=2,964).  MI 
presentation with ST-elevation or non ST-elevation was recorded in all patients included in 
the MINAP dataset and in a subset of those in the GPRD (N=4,010).  HES and ONS data do 
not record MI type.  All-cause mortality was recorded in ONS mortality data within 30 days 
of MI with a date of death. 
   
7.4.8 Statistical analysis 
The demographic characteristics and missingness of key cardiovascular disease risk 
factors were tabulated.  The initiation and duration of prescribing of aspirin and statins prior 
to MI were described.  For men and women separately, age and other components of 
Framingham risk were then compared for current, previous and never users of aspirin and 
statins. 
The numbers of patients who were never, current or previous users of aspirin and 
statins were then compared at each Framingham risk point score.  This comparison was 
performed to assess whether patients taking these medications were comparable to those 
who did not.  Substantial overlap in the distribution of Framingham risk would suggest some 
degree of haphazardness in the prescription of aspirin and statins to people with similar 
cardiovascular disease risk, suggesting that valid comparisons could be made in terms of MI 
type, size and mortality outcome. 
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A DAG in Appendix A, Section 10.6.2 describes the relationships between the 
variables included in the following analyses. 
 
7.4.8.1 Presentation with STEMI or NSTEMI 
In the subset of patients for whom MI type (STEMI or NSTEMI) was recorded, this 
was compared in never, current and previous users of each medication using logistic 
regression.  Complete case analyses were performed.  Three models were fitted: (i) a crude 
model to examine the unadjusted association between aspirin or statin and presentation, (ii) a 
model adjusted for age at MI, sex, diabetes (based on a diagnosis or abnormal test results), 
smoking status (categorised as non, current, ex at the time of MI), hypertension (based on a 
diagnosis or measured blood pressure over 140/90mm Hg) and use of antihypertensive drugs 
including ACEI, ARBs and beta blockers, and (iii) a final model adjusting for the same 
parameters as model (ii) but with the inclusion of total cholesterol.  Total cholesterol was not 
included in the second model because this was a complete case analysis; the high 
missingness in total cholesterol (roughly 50%, see section 7.5.2.1) would resulted in loss of 
power in the final, multivariable adjusted model.  Therefore, results from both models (ii) 
and (iii) were examined to interpret the association between medication use and the 
outcome. 
 
7.4.8.2 Infarct size 
In patients with a record of infarct size, this was compared in never, current and 
previous users of aspirin and statins using multiple linear regression.  After examining the 
distribution of peak troponin values, there was a substantial skew and therefore the outcome 
was log transformed (Appendix A, section 10.6.1).  Results presented are the exponentiated 
coefficients from the log-linear regression model, which can be interpreted as the estimated 
relative effects of the exposure on infarct size.  Three models were fitted to the data as above 
((i) crude, (ii) adjusted, (iii) adjusted including total cholesterol).  For the final adjusted 
models, the assumptions of multiple linear regression were checked by plotting the residuals 
on a histogram to assess their normality: these are shown in Appendix A, section 10.6.6. 
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7.4.8.3 30 day mortality 
Cox regression analysis was used to compare 30 day mortality after MI in never, 
current and previous aspirin and statin users.  Crude and adjusted models were fitted, as 
above.  Tests for proportional hazards were performed on all models and interactions with 
time were fitted where there was non-proportionality.  Interactions with time were fitted 
based on follow-up time categories of 0-7 days and 8-30 days, which were considered to be 
the time points at which the mortality effects may change (i.e. reflecting in-hospital 
mortality and a short post-hospital period).   
 
7.4.8.4 Model specification 
For each of the three outcomes, effect modification by Framingham risk category 
(low, intermediate, high, missing) was examined using likelihood ratio tests comparing the 
final adjusted model with and without interaction terms.  Age and total cholesterol were 
initially fitted in all models as linear variables; the assumption of linearity was tested with 
likelihood ratios tests comparing these models to models where these variables were fitted as 
quadratic and cubic terms.  If there was evidence that these terms contributed to a better 
model, the quadratic or cubic terms were used in the main analysis.  
 
7.4.8.5 Dose and duration of use 
The effect of aspirin duration and statin dose and duration were separately assessed 
in each of the models described above.  These effects were assessed only in patients who 
were defined as current users, as the effects in previous users were expected to be more 
complex and potentially associated with the reasons for drug withdrawal rather than use of 
the drug itself. 
 
7.4.8.6 Sensitivity analyses 
Several sensitivity analyses were performed.  The main cardiovascular disease risk 
factors were accounted for in the main analysis.  In additional analyses, the final models 
were also adjusted for BMI, family history of CHD and social deprivation (IMD quintile).   
Exclusion of patients with atherosclerotic disease, and recording of patients with 
diabetes and hypertension were based on definite diagnoses recorded in the GPRD data.  
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Therefore, an analysis was performed excluding patients with ‘possible’ atherosclerotic 
disease diagnoses, and using possible hypertension and diabetes diagnoses in addition to 
definite diagnoses.   
The prescription data in this analysis were based solely on GPRD prescribing data.  
In the subset of patients with MINAP data, there were also data available regarding use of 
antiplatelets and statins at admission.  The MINAP data were not used in the main analysis 
as the time of administration of these drugs (i.e. for chronic, daily use, or whether 
administered at admission) was unclear.  However, the prevalence of use in the GPRD and 
MINAP data were compared. 
Presentation with ST-elevation or not at MI is related to comorbidity; patients with 
more comorbidity tend to have NSTEMI rather than STEMI.[10]  To assess whether the 
associations between the medications and ST-elevation were driven by greater morbidity in 
users of these medications, the results were adjusted for GPRD consultation rate, which is a 
marker of general morbidity.   
Sensitivity analyses were performed to assess the robustness of the definition of 
‘current’ aspirin and statin use.  In addition to changing the buffer of time allowed for a 
prescription to be collected and used (14 days in the main analysis, zero and 28 days in the 
sensitivity analyses), the definition of current use was changed to ‘two or more prescriptions 
in the six months prior to MI.’ 
Due to concerns regarding the use of peak troponin to accurately measure infarct 
size, and problems with its recording in MINAP, a sensitivity analysis was conducted using 
peak creatine kinase as the measure of infarct size, rather than peak troponin. 
All analyses were performed in Stata version 11.  The study details are registered 
online at clinicaltrials.gov (NCT01692795, September 2012) and a time-stamped detailed 
analytic protocol is shown in Appendix B.    
Chapter 7 
279 
 
7.5 Results 
 
7.5.1 Study population 
Of the 14,807 patients identified with first MI who did not have contraindications to 
aspirin or statins, 6,703 had previously diagnosed atherosclerotic disease.  There were 8,104 
patients remaining who experienced first MI across the four data sources and met all 
inclusion criteria.  The median age was 68 (IQR 57-79) and 2,951 (36.4%) were women 
(Table 7.12).  Of these patients 1,324 (16.3%) had been prescribed aspirin prior to their MI, 
and 1,160 (14.3%) had been prescribed statins.   
Table 7.12 Demographic and risk factors characteristics of 8,104 patients with first MI 
 
Age, median (IQR) 68 (57-79) 
Women, n (%) 2,951 (36.4) 
Smoking, n (%)   
 Non-smoker 1,201 (14.8) 
 Ex-smoker 3,924 (48.4) 
 Current smoker 2,724 (33.6) 
 Unknown 255 (3.1) 
Diabetes, n (%) 938 (11.6) 
Systolic blood pressure in mmHg, mean (SD) 145 (16.4) 
Missing blood pressure, n (%) 444 (5.5) 
Blood pressure lowering, n (%) 3,461 (42.7) 
Total serum cholesterol in mmol/L, mean (SD) 5.8 (1.1) 
Missing total cholesterol, n (%) 3,989 (49.2) 
HDL cholesterol in mmol/L, mean (SD) 1.4 (0.4) 
Missing HDL cholesterol, n (%) 5,053 (62.4) 
Framingham risk, n (%)   
 <10% 572 (7.1) 
 10-20% 1,604 (19.8) 
 >20% 857 (10.6) 
 Missing 5,071 (62.6) 
IQR: inter-quartile range; SD: standard deviation; HDL: high density lipoprotein 
 
7.5.2 Framingham risk scores 
Framingham risk scores were calculated only using data collected prior to MI in 
patients without previously diagnosed atherosclerotic disease.  For the patients whose risk 
scores could be calculated, 572 patients (7.1%) were in the lowest risk group (<10%), 1,604 
(19.8%) were in the intermediate risk group (10-20%) and 857 (10.6%) were in the highest 
risk group (>20%).   
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7.5.2.1 Missingness in Framingham risk 
For 5,071 (62.6%) patients, a Framingham risk could not be calculated due to 
missingness in total cholesterol, HDL cholesterol, smoking or blood pressure values (49.2% 
of MI patients in this study had missing total cholesterol, 62.4% had missing HDL values, 
3.2% missing smoking and 5.5% missing blood pressure values).  The main analysis was 
based on patients with non-missing data only, reducing the power (particularly when 
adjusting for total cholesterol).  To assess the potential for any bias in the complete case 
analysis, patients with missing Framingham risk were compared to those with complete 
values in terms of risk factors that were recorded (Table 7.13).  Logistic regression analyses 
were also performed to assess predictors of missingness.     
The primary care consultation rate in patients with missing Framingham risk was 
lower than that of patients with complete scores.  Patients with missing risk scores were 
comparable to the overall group of patients with complete risk scores in terms of age and 
sex; their levels of current smoking were between the prevalence for intermediate and high 
risk groups.  Their mean systolic blood pressure was between the low and intermediate risk 
groups but fewer patients were in receipt of blood pressure lowering medications than in any 
of the groups with calculable risk.   
In a logistic regression analysis, missingness in smoking was strongly associated 
with older ages (P<0.001), being a woman (P=0.001), consulting less frequently (P=0.02) 
and being normotensive (P<0.001).  Missingness in blood pressure was strongly associated 
with lower age (P=0.006), lower consultation rate (P<0.001) and being an ex-smoker 
(P=0.003).  Missingness in total cholesterol and HDL cholesterol were associated with older 
age (P<0.001), being a woman and having a lower consultation rate.  It was also associated 
with being normotensive, non-diabetic and being categorised as an ex-smoker (P<0.001 for 
all).   
Overall, patients who consulted less frequently were more likely to have missing 
values.  The true Framingham risk of these patients is likely to be a mixture of those at high 
and lower risk, based on the recorded risk factors in these patients.  The implications of this 
missingness are considered in the Discussion.    
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Table 7.13 Risk factor distribution in patients at each level of Framingham risk compared to those whose Framingham risk could not be calculated 
due to missingness in one or more variables (N=8,104) 
 
<10% 10-20% >20% Missing 
N patients 572   1,604   857   5,071   
Age, median (IQR) 59 (49-66) 67 (59-75) 75 (63-81) 69 (56-80) 
Women, n (%) 384 (67.1) 452 (28.2) 234 (27.3) 1,881 (37.1) 
Smoking, n (%) 
Non-smoker 117 (20.5) 228 (14.2) 83 (9.7) 773 (15.2) 
Ex-smoker 332 (58) 963 (60) 405 (47.3) 2,224 (43.9) 
Current smoker 122 (21.3) 409 (25.5) 365 (42.6) 1,828 (36) 
Unknown 0 (0) 0 (0) 0 (0) 246 (4.9) 
Systolic blood pressure in mm Hg, mean (SD) 139 (13.6) 146 (13.5) 154 (13.4) 144 (17.4) 
Missing blood pressure, n (%) 0 (0) 0 (0) 0 (0) 444 (8.8) 
Blood pressure lowering, n (%) 227 (39.7) 959 (59.8) 704 (82.1) 1,571 (31) 
Total serum cholesterol in mmol/L, mean (SD) 6 (1.2) 6 (1) 6 (1.2) 6 (1.1) 
Missing total cholesterol, n (%) 0 (0) 0 (0) 0 (0) 3,989 (78.7) 
HDL cholesterol in mmol/L, mean (SD) 2 (0.5) 1 (0.4) 1 (0.3) 1 (0.3) 
Missing HDL cholesterol, n (%) 0 (0) 0 (0) 0 (0) 5,053 (99.6) 
Rate of primary care consultation, median (IQR) 6.4 (3.8-10.9) 5.6 (3.4-9.2) 5.9 (3.8-9.7) 3.7 (1.7-7.0) 
IQR: inter-quartile range; SD: standard deviation; HDL: high density lipoprotein 
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The rest of the results section is separated into two parts, first describing aspirin use 
and its associations with each outcome, and then statins.   
 
7.6 Results: aspirin 
 
7.6.1 Description of aspirin use prior to MI 
Of the 1,324 patients who had ever been prescribed aspirin, 761 were defined as 
current users at the time of MI, and 563 were previous users. 
 
7.6.1.1 Initiation on aspirin therapy 
The rate of initiation on aspirin therapy in the ten years prior to MI is 
described Figure 7.1, increasing from six per thousand patients ten years before MI to 35 per 
1000 patients in the year prior to MI. 
 
Figure 7.1 Rate of initiation on aspirin in the ten years prior to first myocardial 
infarction (MI), for 8,104 patients 
 
7.6.1.2 Duration of aspirin use 
In 761 current users, the duration of use ranged from just one day to seventeen years 
(median 3.0 years (IQR 1.14-5.56 years)).  In the 563 previous users, the duration of use also 
ranged from two weeks to seventeen years but the distribution was more highly skewed, 
with half of patients using aspirin for a year or less (median 0.91 years (IQR 0.19-3.12 
years)) (see Appendix A, section 10.6.4 for more detail).  In previous users, the median time 
between last aspirin use and MI was 1.7 years (IQR 0.3-4.7 years).    
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7.6.2 Aspirin use and Framingham risk 
 
7.6.2.1 Risk factor distribution in never, current and previous aspirin users 
The cardiovascular disease risk factors included in the Framingham risk score were 
tabulated for never, current and previous aspirin users (Table 7.14).  These were all recorded 
prior to MI.  Current and previous users of aspirin were older than never users, they were 
less likely to be current smokers and had lower levels of total cholesterol, but had higher 
blood pressure and a greater prevalence of blood pressure lowering drugs.  Levels of 
missingness in total and HDL cholesterol were lower in current and previous aspirin users.  
Of the patients whose overall Framingham risk could be calculated, current and previous 
aspirin users were more likely to fall in the highest risk category than never users.  However, 
in never users, missingness in blood pressure and cholesterol (HDL or total) meant that 
calculation of a Framingham score was possible in fewer patients.    
   
  
Chapter 7 
284 
 
Table 7.14 Demographic distribution and components of the Framingham risk score in 
never aspirin users and current users (N=8,104) 
 
    No aspirin Current aspirin Previous aspirin 
N patients 6,780   761   563   
Age, median (IQR) 66 (56-77) 77 (69-84) 76 (66-84) 
Women, n (%) 2,336 (34.5) 354 (46.5) 261 (46.4) 
Smoking, n (%) 
Non-smoker 984 (14.5) 137 (18) 80 (14.2) 
Ex-smoker 3,142 (46.3) 459 (60.3) 323 (57.4) 
Current smoker 2,437 (35.9) 142 (18.7) 145 (25.8) 
Unknown 217 (3.2) 23 (3) 15 (2.7) 
Systolic blood pressure in 
mm Hg, mean (SD) 144 (16.6) 150 (13.5) 149 (15.3) 
Missing blood pressure, n 
(%) 433 (6.4) 8 (1.1) 3 (0.5) 
Blood pressure lowering, n 
(%) 2,463 (36.3) 603 (79.2) 395 (70.2) 
Total serum cholesterol in 
mmol/L, mean (SD) 5.9 (1.1) 5.4 (1) 5.6 (1) 
Missing total cholesterol, n 
(%) 3,562 (52.5) 225 (29.6) 202 (35.9) 
HDL cholesterol in mmol/L, 
mean (SD) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 
Missing HDL cholesterol, n 
(%) 4,432 (65.4) 352 (46.3) 269 (47.8) 
Framingham risk, n (%) 
<10% 481 (7.1) 49 (6.4) 42 (7.5) 
10-20% 1,246 (18.4) 207 (27.2) 151 (26.8) 
>20% 606 (8.9) 153 (20.1) 98 (17.4) 
  Missing 4,447 (65.6) 352 (46.3) 272 (48.3) 
IQR: inter-quartile range; SD: standard deviation; HDL: high density lipoprotein 
 
7.6.2.2 Use of aspirin at different levels of Framingham risk 
Framingham risk scores are calculated differently in men and women.  Therefore, in 
a comparison of use of aspirin at different risk scores, the results were stratified by sex.  
There were 1,963 men and 1,070 women with a calculable Framingham risk score based on 
information recorded in their GPRD record prior to MI. 
 
Men 
For each Framingham risk score, the numbers of patients never, previously and 
currently prescribed aspirin is shown in Figure 7.2, Figure 7.2 and Table 7.15.  Of the 623 
men categorised with CHD risk of >20%, 103 (16.5%) were current aspirin users.  
Prescribing of aspirin was proportionally higher in those at highest risk, but there was 
considerable prescribing in those categorised as medium risk (10-20% CHD risk), 123 of 
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1152 patients, (10.7%)), and some prescribing in those categorised at low (<10%) risk (14 of 
188 patients, 7.5%).  Large numbers of patients at high cardiovascular disease risk did not 
receive aspirin.   
 
Women 
In women, prescribing of aspirin in the high risk group was greater than for men 
(Figure 7.3, Table 7.16).  Fifty of 234 (21.4%) women categorised as >20% CHD risk were 
currently receiving aspirin.  There was also a relatively high frequency of aspirin 
prescription in women at intermediate CHD risk, of whom 84 of 452 patients were currently 
using aspirin (18.6%).  Just 35 of 384 (9.1%) patients categorised at low risk were receiving 
aspirin.  The overlap in Framingham risk scores between current users and non-users at the 
time of MI indicates that a valid comparison can be made between these groups in both men 
and women.   
 
7.6.2.3 Use of aspirin and prescribing guidelines 
Until 2009, aspirin was recommended at ≥20% cardiovascular disease risk.  This is 
equivalent to ≥15% CHD risk using this Framingham risk score, and a point total of 14 in 
men and 22 in women.  Of the 1,393 men who were categorised as ≥20% cardiovascular 
disease risk, 202 (14.5%) were receiving aspirin at the time of MI.  Of the 400 women 
categorised with >20% cardiovascular disease risk, 81 (20.3%) were receiving aspirin.   
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Figure 7.2 Number of current and never aspirin users by Framingham risk point total, 
in 1,963 men 
 
 
 
Figure 7.3  Number of current and never aspirin users by Framingham risk point total, 
in 1,070 women 
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Table 7.15 Number and percentage of men who were current, previous or never aspirin 
users at each level of risk (N=1,963) 
 
Men  Current Previous Never Total 
Framingham 
point total 
CHD 
risk n (%) n (%) n (%) n (%)   
≤6 
Low 
<10% 
1 (0.4) 2 (1.1) 15 (1) 18 (0.9) 
 
7 1 (0.4) 0 (0) 11 (0.7) 12 (0.6) 
8 0 (0) 0 (0) 15 (1) 15 (0.8) 
9 2 (0.8) 1 (0.6) 23 (1.5) 26 (1.3) 
10 5 (2.1) 3 (1.7) 35 (2.3) 43 (2.2) 
11 5 (2.1) 3 (1.7) 66 (4.3) 74 (3.8) 
12 
Medium 
10-20% 
8 (3.3) 9 (5) 123 (8) 140 (7.1) 
13 16 (6.7) 20 (11.2) 206 (13.3) 242 (12.3) 
14 52 (21.7) 27 (15.1) 282 (18.3) 361 (18.4) 
15 47 (19.6) 41 (22.9) 321 (20.8) 409 (20.8) 
High CVD 
risk: ≥20% 
PRESCRIBE 
ASPIRIN 
16 
High 
>20% 
59 (24.6) 39 (21.8) 234 (15.2) 332 (16.9) 
17 33 (13.8) 23 (12.8) 142 (9.2) 198 (10.1) 
18 9 (3.8) 8 (4.5) 57 (3.7) 74 (3.8) 
19 2 (0.8) 3 (1.7) 13 (0.8) 18 (0.9) 
≥20 0 (0) 0 (0) 1 (0) 1 (0) 
Total  240 (100) 179 (100) 1544 (100) 1963 (100) 
Point score totals in men ≤11 indicate low risk of CHD, 12-15 indicate intermediate risk of CHD, and 
≥16 indicate high risk of CHD.  A point score of ≥15 indicates high cardiovascular disease risk (used by 
current guidelines), including the risk of coronary, cerebrovascular and peripheral events as outcomes. 
 
Table 7.16 Number and percentage of women who were current, previous or never 
aspirin users at each level of risk (N=1,070) 
 
Women 
CHD 
risk 
Current Previous Never Total 
  
Framingham 
point total n (%) n (%) n (%) n (%) 
≤6 
Low 
<10% 
1 (0.6) 0 (0) 7 (0.9) 8 (0.7) 
  
7 0 (0) 0 (0) 0 (0) 0 (0) 
8 0 (0) 0 (0) 4 (0.5) 4 (0.4) 
9 0 (0) 1 (0.9) 1 (0.1) 2 (0.2) 
10 1 (0.6) 1 (0.9) 5 (0.6) 7 (0.7) 
11 0 (0) 1 (0.9) 1 (0.1) 2 (0.2) 
12 0 (0) 0 (0) 11 (1.4) 11 (1) 
13 0 (0) 0 (0) 11 (1.4) 11 (1) 
14 0 (0) 3 (2.7) 12 (1.5) 15 (1.4) 
15 2 (1.2) 2 (1.8) 25 (3.2) 29 (2.7) 
16 2 (1.2) 2 (1.8) 43 (5.4) 47 (4.4) 
17 5 (3) 5 (4.5) 57 (7.2) 67 (6.3) 
18 9 (5.3) 7 (6.3) 59 (7.5) 75 (7) 
19 15 (8.9) 11 (9.8) 80 (10.1) 106 (9.9) 
20 Medium 
10-20% 
16 (9.5) 14 (12.5) 103 (13.1) 133 (12.4) 
21 37 (21.9) 16 (14.3) 100 (12.7) 153 (14.3) 
22 31 (18.3) 24 (21.4) 111 (14.1) 166 (15.5) 
High CVD 
risk: ≥20% 
PRESCRIBE 
ASPIRIN 
23 
High 
>20% 
34 (20.1) 15 (13.4) 90 (11.4) 139 (13) 
24 8 (4.7) 8 (7.1) 50 (6.3) 66 (6.2) 
25 6 (3.6) 2 (1.8) 15 (1.9) 23 (2.1) 
26 2 (1.2) 0 (0) 4 (0.5) 6 (0.6) 
Total  169 (100) 112 (100) 789 (100) 1070 (100) 
Point score totals in women ≤19 indicate low risk of CHD, 20-22 indicate intermediate risk of CHD, and 
≥20 indicate high risk of CHD.  A point score of ≥22 indicates high cardiovascular disease risk (used by 
current guidelines), including the risk of coronary, cerebrovascular and peripheral events as outcomes.
Chapter 7 
288 
 
7.6.3 Aspirin and ST-elevation at MI presentation 
In the subset of patients whose MIs were recorded with MI type (N=4,010), 2,122 
(52.9%) were STEMI and 1,888 (47.1%) were NSTEMI.  Compared to never users, current 
aspirin users were less likely to have ST-elevation (54.6% STEMI in never users, 37.7% in 
current users).  The proportion presenting with STEMI in previous users was also lower than 
that of never users (48.4%) (Figure 7.4). 
 
 
Figure 7.4 Proportion of patients with ST-elevation at myocardial infarction in never, 
current and previous aspirin users, with 95% confidence intervals (N=4,010) 
 
At logistic regression analysis (Table 7.17), the crude odds of ST-elevation in 
current aspirin users were half of those of never users (OR=0.50 (0.40-0.64)).  There was 
also some evidence for an association between previous aspirin use and ST-elevation 
(OR=0.78 (0.60-1.01)).  The association between current use and ST-elevation was slightly 
attenuated on adjustment for age and sex, but further attenuated at a multivariable adjusted 
analysis taking account of all cardiovascular disease risk factors included in the Framingham 
risk score and diabetes.  At multivariate analysis current aspirin users had lower odds of ST-
elevation at MI (multivariable adjusted OR=0.66 (0.49-0.89), P=0.006), but there was no 
association between previous use and ST-elevation (OR=1.02 (0.74-1.42), P=0.894).  When 
stratified by Framingham risk category (Appendix A, Figure 10.13), there was no evidence 
for a difference in the proportion of patients with ST-elevation by risk group (P value for 
interaction=0.3015).    
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Table 7.17 Crude and adjusted odds ratios to describe the association between aspirin use and ST-elevation at MI (N=4,010) 
 
Aspirin use prior to 
MI n STEMI (%) 
Crude OR (95% CI) 
N=4,010 
Age and sex adjusted OR 
(95% CI) 
N=4,010 
Multivariable adjusted OR 
(95% CI)± 
N=4,001 
Multivariable adjusted 
OR (95% CI)± including 
cholesterol† 
N=2,153 
Never aspirin users 3,450 1,884 (54.6) 1 - 1 - 1 - 1 - 
Current 308 116 (37.7) 0.50 (0.40-0.64) *** 0.59 (0.46-0.76) *** 0.64 (0.50-0.83) ** 0.66 (0.49-0.89) **  
  Previous 252 122 (48.4) 0.78 (0.60-1.01)     0.88 (0.68-1.15) 0.93 (0.71-1.22)  1.02 (0.74-1.42)     
± Adjusted for statin and antihypertensive use, age (as a linear term in this model), sex, hypertension, diabetes, smoking 
† Total cholesterol fitted as a quadratic term in this model (likelihood ratio test compared to a linear term P=0.0512) 
OR: odds ratio; STEMI: ST-elevation myocardial infarction. 
*** P<0.001, ** P<0.01, * P<0.05  
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7.6.3.1 Duration of aspirin and ST-elevation at MI presentation 
In a crude logistic regression analysis, the duration of aspirin use was associated 
with presentation.  For each one year increase in duration of use, the odds of ST-elevation 
reduced by 11% (crude OR=0.89 (95% CI 0.85-0.94)).  After adjusting for age, all 
cardiovascular disease risk factors and cardiovascular drug use except total cholesterol, there 
was some attenuation of the association, but still some evidence for 6% lower odds of ST-
elevation for each additional year of aspirin use (multivariable adjusted OR=0.94 (95% CI 
0.90-0.99), P=0.024).  However, after taking account of total cholesterol, the association was 
no longer statistically significant OR=0.96 (0.91-1.02), P=0.207.  There was no evidence of 
an interaction by Framingham risk score and both age and total cholesterol were fitted as 
quadratic terms.  Categories of duration of aspirin use were also created and the association 
in each one year categories is described in Figure 7.5.  
 
 
 
OR: odds ratio; STEMI: ST-elevation myocardial infarction. 
Figure 7.5 Forest plot describing the multivariable adjusted odds ratios (OR) for ST-
elevation myocardial infarction, comparing patients with different durations of aspirin 
use to patients never using aspirin (N=4,010)   
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7.6.4 Aspirin and infarct size 
Overall the median observed peak troponin values were higher in never users 
compared to current and previous users (Figure 7.6).  In crude multiple linear regression 
analysis using log-transformed peak troponin as an outcome, current aspirin use was 
associated with a 30% reduction in infarct size (relative infarct size 0.71 (95% CI: 0.54-
0.93)).  Previous aspirin use was not associated with a crude reduction in infarct size 
(estimated relative infarct size 0.85 (95% CI 0.63-1.15)).    
When adjusted for all cardiovascular disease risk factors (age fitted as a linear term) 
except total cholesterol, the association was no longer statistically significant and was 
attenuated further still on adjustment for total cholesterol (fitted as a linear term) (adjusted 
relative infarct size in current users compared to never users 0.99 (95% CI 0.72-1.38), 
P=0.973, and in previous users 1.01 (95% CI 0.69-1.46), P=0.976).  When the final model 
was stratified by risk category, there was no evidence for different effects of aspirin in 
different categories of Framingham risk (P for interaction 0.278, Appendix A, Figure 10.15).   
 
 
Figure 7.6 Box plots describing the median and inter-quartile range of infarct size 
(based on peak troponin in µg/L) in never, current and previous aspirin users 
(N=2,964)  
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7.6.5 Aspirin and 30 day mortality 
In a crude analysis, there was strong evidence for higher 30 day mortality in current 
and previous aspirin users than never users (HR for current use=1.52 (95% CI: 1.34-1.72), 
previous use HR=1.39 (95% CI 1.20-1.61)).  These associations were attenuated and no 
longer significant on adjustment for age and sex, and there was little further attenuation on 
adjusting for statin use, hypertension, diabetes and smoking, (adjusted HR for current use 
HR=1.10 (95% CI 0.95-1.26), P=0.20, and for previous use HR=1.02 (95% CI 0.87-1.20), 
P=0.783).  The association was further attenuated on adjustment for total cholesterol (Table 
7.18).  There was no evidence for effect modification by level of Framingham risk (P=0.90), 
although stratification of the crude model showed a strong association between aspirin use 
and mortality in those with missing Framingham risk (Figure 7.8).   
 
 
Figure 7.7 Crude all-cause mortality in the 30 days after myocardial infarction in 
current, previous and never aspirin users (N=8,104) 
 
7.6.6 Aspirin dose and MI outcomes 
In the main study population, 739 (97.1%) aspirin users at the time of MI were 
prescribed 75mg.  Just 22 patients (2.9%) were prescribed a dose of 300mg, but there was 
insufficient power to examine the effect of this higher dose on MI presentation, infarct size 
or mortality. 
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Table 7.18 Crude and adjusted hazard ratios (HR) describing the association between current and previous aspirin use and 30 day 
mortality(N=8,104) 
 
Aspirin use 
prior to MI n Dead at 30 days (%) 
Crude HR (95% CI) 
N=8,104 
Age and sex adjusted HR 
(95% CI) 
N=8,104 
Multivariable adjusted HR 
(95% CI)± 
N=7,849 
Multivariable adjusted HR (95% 
CI)± and total cholesterol† 
N=4,088 
Never 6,780 1,733 (25.6) 1 - 1 - 1 - 1 - 
Current 761 286 (37.6) 1.52 (1.34-1.72) *** 1.09 (0.96-1.24)  1.10 (0.95-1.26) 1.05 (0.87-1.25)     
  Previous 563 195 (34.6) 1.39 (1.20-1.61) *** 1.02 (0.88-1.19) 1.02 (0.87-1.20) 1.00 (0.81-1.24)     
± Adjusted for statin and antihypertensive use, age (as a cubic term in this model, likelihood ratio test P=0.0032 for age as a cubic term compared to a quadratic term), sex, 
hypertension, diabetes, and smoking. 
† Adjustment for total cholesterol as a cubic term in this model (likelihood ratio test P=0.0718 for total cholesterol as a cubic term compared to a quadratic term) 
*** P<0.001, ** P<0.01, * P<0.05  
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Figure 7.8 Crude hazard ratios (HR) describing 30 day mortality in 
never, current and previous aspirin users, at different levels of 
Framingham risk (N=8,104) 
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7.7 Results: statins 
7.7.1 Description of statin use prior to MI 
Amongst the 8,104 patients in this study, 804 were currently using statins at the time 
of MI and 356 had previously used statins but their prescription record indicated that they 
were no longer taking statins at the time of MI.   
 
7.7.1.1 Initiation on statin therapy 
The rate of initiation is shown in Figure 7.9.  The rate increased from three per 
thousand patients ten years before MI to forty-seven per thousand patients in the year before 
MI.   
 
 
Figure 7.9 Rate of initiation on statins in the ten years prior to first myocardial 
infarction in 8,104 patients 
 
7.7.1.2 Duration of statin use 
In 804 current users, the duration of use ranged from just one day to nearly eighteen 
years (median 2.0 years (IQR 0.78-4.0 years)).  The distribution of durations is described in 
Appendix A, section 10.6.5.  In the 356 previous users, the duration of use ranged from forty 
days to fourteen years but the distribution was more highly skewed, with half of patients 
using statins for a year or less (median 0.87 (IQR 0.20-2.4 years)).  In previous users, the 
time between last statin use and MI was estimated at a median of 0.74 years (IQR 0.1-2.3 
years).  
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7.7.2 Statin use and Framingham risk 
 
7.7.2.1 Risk factor distribution in never, current and previous statin users 
The demographic and risk factor characteristics, stratified by statin use, are 
described in Table 7.19.  Current and previous users of statins were the same age as never-
users, were more likely to be female and more likely to have a calculable Framingham risk 
score.  The proportion of current smokers was higher in never users.   
Of the 857 patients identified by this study in the highest Framingham risk category 
(>20% CHD risk over ten years), only 298 (34.8%) of them had ever been prescribed a 
statin.  High missingness in recording of total and HDL cholesterol in never statin users 
meant that risk scores could not be calculated in 70.3% of this group.   
 
Table 7.19 Demographic and risk factor characteristics, stratified by previous statin 
use, in 8,104 first MI patients 
 
    
Never statin 
users 
Current statin 
users 
Previous statin 
users 
N patients 6,944   804   356   
Age, median (IQR) 68 (57-79) 68 (59-75) 67 (57.5-76) 
Women, n (%) 2,488 (35.8) 318 (39.6) 145 (40.7) 
Smoking, n (%) 
Non-smoker 1,032 (14.9) 117 (14.6) 52 (14.6) 
Ex-smoker 3,269 (47.1) 471 (58.6) 184 (51.7) 
Current smoker 2,396 (34.5) 214 (26.6) 114 (32) 
Unknown 247 (3.6) 2 (0.2) 6 (1.7) 
Systolic blood pressure 
in mm Hg, mean (SD) 145 (16.8) 148 (13.3) 147 (14.6) 
Missing blood pressure, 
n (%) 443 (6.4) 0 (0) 1 (0.3) 
Blood pressure 
lowering, n (%) 2,606 (37.5) 627 (78) 228 (64) 
Total serum cholesterol 
in mmol/L, mean (SD) 5.8 (1.1) 5.7 (1) 6.2 (1.1) 
Missing total 
cholesterol, n (%) 3,947 (56.8) 23 (2.9) 19 (5.3) 
HDL cholesterol in 
mmol/L, mean (SD) 1.4 (0.4) 1.3 (0.4) 1.4 (0.4) 
Missing HDL 
cholesterol, n (%) 4,862 (70) 131 (16.3) 60 (16.9) 
Framingham risk, n (%) 
<10% 396 (5.7) 126 (15.7) 50 (14) 
10-20% 1,109 (16) 342 (42.5) 153 (43) 
>20% 559 (8.1) 205 (25.5) 93 (26.1) 
  Missing 4,880 (70.3) 131 (16.3) 60 (16.9) 
IQR: inter-quartile range; SD: standard deviation; HDL: high density lipoprotein  
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7.7.2.2 Statin use at different levels of Framingham risk 
 
Men 
The numbers of patients currently, previously and never prescribed statins are 
described in Figure 7.10 and Table 7.20 by Framingham CHD risk score.  There were 623 
men defined as being at high risk of CHD (>20%), of whom 149 (23.9%) were current statin 
users.  Of the 1,152 men at intermediate risk, 228 (19.8%) were current statin users.  Of 188 
patients categorised at low risk, 32 (17.0%) were statin users.  In 3,190 patients with missing 
Framingham risk scores, the prevalence of statin prescribing was 2.4% (77 patients). 
 
Women 
Figure 7.11 and Table 7.21 describe current, previous and never statin use in the 
1,070 patients for whom Framingham risk could be calculated.  Of these, 234 women were 
categorised at high risk and 23.9% of them were current statin users.  However, of the 452 
patients categorised as at intermediate risk, 25.2% were current statin users and of those at 
low risk, 24.5% were statin users.  However, there were 1,881 women whose Framingham 
risk score could not be calculated and just 2.9% of them were statin users.  The substantial 
overlap in scores between users and non-users, for both men and women, indicates that a 
valid comparison can be made in the subsequent analyses.   
 
7.7.2.3 Use of statins and prescribing guidelines 
Statins are recommended for patients at ≥20% cardiovascular disease risk (same 
threshold as for aspirin).  This is equivalent to >15% CHD risk using this Framingham risk 
score, and a point total of 14 in men and 22 in women (Figure 7.2 and Figure 7.2).  Of the 
1,393 men who were categorised as ≥20% cardiovascular disease risk, 315 (22.6%) were 
receiving statins at the time of MI.  Of the 400 women categorised with ≥20% 
cardiovascular disease risk, 94 (23.5%) were receiving aspirin.  However, 25.4% of patients 
who did not have high cardiovascular disease risk were in receipt of statins prior to MI. 
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Figure 7.10 Number of current, previous and never statin users by Framingham risk 
point total, in 1,963 men 
 
 
 
Figure 7.11 Number of current, previous and never statin users by Framingham risk 
point total, in 1,070 women 
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Table 7.20 Number and percentage of men who were current, previous or never statin 
users at each level of risk (N=1,963) 
 
Men  Current Previous Never Total 
Framingham 
point total 
CHD 
risk n (%) n (%) n (%) n (%)   
≤6 
Low 
<10% 
1 (0.2) 2 (1.1) 15 (1.1) 18 (0.9) 
 
7 1 (0.2) 2 (1.1) 9 (0.7) 12 (0.6) 
8 3 (0.7) 0 (0) 12 (0.9) 15 (0.8) 
9 5 (1.2) 4 (2.3) 17 (1.2) 26 (1.3) 
10 11 (2.7) 4 (2.3) 28 (2) 43 (2.2) 
11 11 (2.7) 1 (0.6) 62 (4.5) 74 (3.8) 
12 
Medium 
10-20% 
26 (6.4) 7 (4) 107 (7.8) 140 (7.1) 
13 36 (8.8) 22 (12.4) 184 (13.4) 242 (12.3) 
14 85 (20.8) 29 (16.4) 247 (17.9) 361 (18.4) 
15 81 (19.8) 36 (20.3) 292 (21.2) 409 (20.8) 
High CVD 
risk: ≥20% 
PRESCRIBE 
STATIN 
16 
High 
>20% 
81 (19.8) 39 (22) 212 (15.4) 332 (16.9) 
17 47 (11.5) 23 (13) 128 (9.3) 198 (10.1) 
18 16 (3.9) 7 (4) 51 (3.7) 74 (3.8) 
19 5 (1.2) 1 (0.6) 12 (0.9) 18 (0.9) 
≥20 0 (0) 0 (0) 1 (0.1) 1 (0.1) 
Total  409 (100) 177 (100) 1377 (100) 1963 (100) 
Point score totals in men ≤11 indicate low risk of CHD, 12-15 indicate intermediate risk of CHD, and 
≥16 indicate high risk of CHD.  A point score of ≥15 indicates high cardiovascular disease risk (used by 
current guidelines), including the risk of coronary, cerebrovascular and peripheral events as outcomes. 
 
Table 7.21 Number and percentage of women who were current, previous or never 
statin users at each level of risk (N=1,070) 
 
Women 
CHD 
risk 
Current Previous Never Total 
  
Framingham 
point total n (%) n (%) n (%) n (%) 
≤6 
Low 
<10% 
1 (0.4) 2 (1.7) 5 (0.7) 8 (0.7) 
  
7 0 (0) 0 (0) 0 (0) 0 (0) 
8 2 (0.8) 1 (0.8) 1 (0.1) 4 (0.4) 
9 1 (0.4) 0 (0) 1 (0.1) 2 (0.2) 
10 2 (0.8) 0 (0) 5 (0.7) 7 (0.7) 
11 1 (0.4) 0 (0) 1 (0.1) 2 (0.2) 
12 2 (0.8) 0 (0) 9 (1.3) 11 (1) 
13 2 (0.8) 0 (0) 9 (1.3) 11 (1) 
14 3 (1.1) 1 (0.8) 11 (1.6) 15 (1.4) 
15 5 (1.9) 0 (0) 24 (3.5) 29 (2.7) 
16 13 (4.9) 3 (2.5) 31 (4.5) 47 (4.4) 
17 14 (5.3) 8 (6.7) 45 (6.6) 67 (6.3) 
18 19 (7.2) 11 (9.2) 45 (6.6) 75 (7) 
19 29 (11) 11 (9.2) 66 (9.6) 106 (9.9) 
20 Medium 
10-20% 
38 (14.4) 19 (16) 76 (11.1) 133 (12.4) 
21 38 (14.4) 17 (14.3) 98 (14.3) 153 (14.3) 
22 38 (14.4) 23 (19.3) 105 (15.3) 166 (15.5) 
High CVD 
risk: ≥20% 
PRESCRIBE 
STATINS 
23 
High 
>20% 
27 (10.2) 13 (10.9) 99 (14.4) 139 (13) 
24 24 (9.1) 5 (4.2) 37 (5.4) 66 (6.2) 
25 4 (1.5) 5 (4.2) 14 (2) 23 (2.1) 
26 1 (0.4) 0 (0) 5 (0.7) 6 (0.6) 
Total  264 (100) 119 (100) 687 (100) 1070 (100) 
Point score totals in women ≤19 indicate low risk of CHD, 20-22 indicate intermediate risk of CHD, and 
≥20 indicate high risk of CHD.  A point score of ≥22 indicates high cardiovascular disease risk (used by 
current guidelines), including the risk of coronary, cerebrovascular and peripheral events as outcomes. 
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7.7.3 Statin and ST-elevation at MI presentation 
There were some crude differences in the presentation of MI in statin users and non-
users.  As described Figure 7.12, never users were more likely to have a STEMI compared to 
current and previous users.  Current users had 24% lower odds of ST-elevation compared to 
never users (OR=0.76 (95% CI 0.62-0.94)).  There was no evidence for an association 
between previous statin use and MI type (P=0.979).  Adjusting for age and sex attenuated 
the association between current use and ST-elevation only slightly, but when the association 
between statin use and ST-elevation at MI was adjusted for all known cardiovascular disease 
risk factors,  the association of current use and ST-elevation was no longer statistically 
significant (Multivariable adjusted OR=0.95 (95% CI 0.75-1.21), P=0.697) (Table 7.22).  
There was no evidence for effect modification by level of Framingham risk (Appendix 
A, Figure 10.19). 
 
 
Figure 7.12 Proportion of patients with ST-elevation at MI in never, current and 
previous statin users (N=4,010) 
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Table 7.22 Odds ratios for ST-elevation among patients with myocardial infarction (MI), comparing never, current and previous users of statins 
(N=4,010) 
 
Statin use 
prior to MI n STEMI (%) 
Crude OR (95% CI) 
N=4,010 
Age and sex adjusted 
OR (95% CI)  
N=4,010 
 
Multivariable 
adjusted OR (95% 
CI)± 
N=4,001 
Multivariable adjusted 
OR (95% CI)± including 
total cholesterol† 
N=2,153 
Never 3,415 1,835 (53.7) 1 - 1- 1- 1 - 
Current 405 190 (46.9) 0.76 (0.62-0.94) **  0.78 (0.63-0.96) * 0.93 (0.74-1.17)  0.95 (0.75-1.21)  
  Previous 190 97 (51.1) 0.90 (0.67-1.20)     0.90 (0.67-1.21) 1.00 (0.73-1.35)     0.96 (0.70-1.33)     
± Adjusted for aspirin and antihypertensive use, age (as a linear term in this model), sex, hypertension, diabetes and smoking. 
† Total cholesterol adjusted for as a quadratic term in this model (likelihood ratio test P=0.0512 compared to cholesterol as a linear term). 
OR: odds ratio. 
*** P<0.001, ** P<0.01, * P<0.05 
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7.7.4 Statins and infarct size 
Median infarct size was smaller in current and previous statin users than never users 
(peak troponin 2.7µg/L in never users, 2.27µg/L in current users, 2.07µg/L in previous 
users, Figure 7.13), (estimated relative infarct size in current users: 0.81 (95% CI 0.63-1.03), 
previous use 0.73 (95% CI 0.51-1.03)).  Adjusting the regression model for age and sex did 
not change the effect measures, but further adjustment for, cardiovascular disease risk 
factors including hypertension, diabetes, smoking, aspirin and antihypertensive use 
attenuated the associations and showed no independent association between statin use and 
infarct size (Table 7.23).  On stratification by Framingham risk, there was no evidence of an 
interaction between statin use and Framingham risk on infarct size (P=0.546, Appendix 
A, Figure 10.20).   
 
Figure 7.13 Box plots describing the median and inter-quartile range of peak troponin 
(in µg/L) in never, current and previous statin users (N=2,964)  
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Table 7.23 Multiple linear regression analysis to describe the effect of statin use prior to MI on infarct size in 2,964 patients 
 
Statin use prior 
to MI n Median size (IQR) 
Crude regression 
coefficient  (95% 
CI) 
N=2,964 
Age and sex adjusted 
regression coefficient 
(95% CI) 
N=2,964 
Multivariable adjusted 
regression coefficient  
(95% CI)± 
N=2,912 
Multivariable adjusted 
regression coefficient  
(95% CI)± including 
total cholesterol† 
N=1,583 
Never 2,530 2.7 (0.6-13.5) 1 - 1 - 1- 1 - 
Current 298 2.2 (0.5-11.3) 0.81 (0.63-1.03)     0.82 (0.65-1.05) 0.94 (0.72-1.23) 0.98 (0.74-1.30) 
  Previous 136 2 (0.6-10.1) 0.73 (0.51-1.03)     0.73 (0.52-1.03) 0.79 (0.55-1.13) 0.82 (0.56-1.19) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the multiple linear regression model.   
± Adjusted for aspirin, antihypertensive use, age (as a linear term in this model), sex, hypertension, diabetes and smoking 
† Total cholesterol fitted as a linear term in this model. 
IQR: inter-quartile range. 
*** P<0.001, ** P<0.01, * P<0.05  
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7.7.5 Statins and 30 day all-cause mortality after MI 
There was a crude association between current statin use and 30 day mortality; 
current statin use was associated with lower mortality (HR=0.84 (95% CI 0.73-0.98)).  
There was no crude association between previous statin use and mortality.  This is also 
described in the Kaplan Meier mortality curves in Figure 7.14.  After adjusting for age and 
sex, there was no longer a significant association between current statin use and mortality 
(Table 7.24).  Further multivariable analysis did not attenuate the association any further.  
Model diagnostics are described in Appendix A, section 10.6.6.  There was no evidence for 
an interaction between statin use and Framingham risk category (P value for interaction 
0.657). 
 
 
 
Figure 7.14 Crude all-cause mortality in the 30 days after myocardial infarction (MI), 
stratified by statin use prior to MI in 8,104 patients 
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Table 7.24 Hazard ratios (HR) for death at 30 day all-cause mortality following myocardial infarction (N=8,104) 
 
Statin use 
prior to MI n Dead at 30 days (%) 
Crude HR 
(95% CI) 
N=8,104 
Age and sex adjusted 
HR (95% CI) 
N=8,104 
Multivariable adjusted 
HR (95% CI)± 
N=7,849 
Multivariable adjusted 
HR (95% CI)± including 
total cholesterol† 
N=4,088
Never 6,944 1,937 (27.9) 1 - 1 - 1- 1 - 
Current 804 191 (23.8) 0.84 (0.73-0.98) *   0.93 (0.80-1.09) 0.91 (0.77-1.08) 0.97 (0.81-1.16) 
  Previous 356 86 (24.2) 0.86 (0.69-1.06)     0.93 (0.95-1.15) 0.91 (0.73-1.15) 0.98 (0.77-1.24) 
± Adjusted for aspirin use, antihypertensive use, age (fitted as a cubic term, likelihood ratio test P=0.0032), sex, hypertension, diabetes, smoking 
† Additional adjustment for total cholesterol included as a cubic term (likelihood ratio test P=0.0718 compared to cholesterol as a quadratic term). 
*** P<0.001, ** P<0.01, * P<0.05  
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7.7.6 Statin dose  
There was variation in the dose of statins prescribed (between 5mg per day and 
80mg per day, as shown in Table 7.25).  The patients taking 5mg doses per day were 
combined with those taking 10mg for their inclusion at analysis.  In a comparison of the 
demographic and risk factor characteristics of patients prescribed these different doses, 
stronger doses were not associated with increased coronary risk, but were associated with 
higher total cholesterol (Appendix A, Table 10.22). 
The dose variation allowed an analysis of the effect of statin dose on MI 
presentation, infarct size and 30 day mortality.  There was no effect of increasing dose on 
any of the outcomes (Multivariable adjusted OR for ST-elevation at MI=1.00 (0.99-1.00)), 
multivariable adjusted estimated relative infarct size 1.00 (0.99-1.00), multivariable adjusted 
hazard ratio for 30 day mortality 1.00 (0.99-1.00) (Table 7.26).   
 
Table 7.25 Statin dose and number of patients prescribed that dose prior to MI 
 
Dose, mg* 
Current statin 
users 
Previous statin 
users Total 
5 6 11 17 
10 90 72 162 
20 353 143 496 
40 293 111 404 
80 62 15 77 
Missing dose 0 4 4 
*standardised to simvastatin equivalent dose. 
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Table 7.26 Number and proportion of patients with ST-elevation at myocardial infarction (MI), median infarct size, and number and proportion of 
patients dead at 30 days, according to various doses of statins prescribed prior to MI in 8,104 patients 
 
Statin dose prior to 
MI 
N with MI type 
recorded 
STEMI (%)
 
N with infarct 
size recorded 
Median size (IQR) N with mortality 
record 
Dead at 30 days 
(%) 
No statins 3,418 1,835 (53.7) 2,533 2.7 (0.6-13.5) 6,944 1,937 (27.9) 
10mg 79 42 (53.2) 61 2.1 (0.5-13.8) 96 24 (25) 
20mg 249 111 (44.6) 183 2.0 (0.5-13.6) 353 90 (25.5) 
40mg 231 119 (51.5) 162 2.4 (0.5-11) 293 63 (21.5) 
  80mg 33 15 (45.5) 25 2.8 (0.7-10) 62 14 (22.6) 
IQR: inter-quartile range; STEMI: ST-elevation myocardial infarction. 
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7.7.7 Sensitivity analysis  
7.7.7.1 Additional cardiovascular disease risk factors 
The models described in these analyses were repeated in an adjusted analysis taking 
account of BMI, family history of CHD and social deprivation, as measured by IMD 
quintile.  Adjusting for these additional factors made no difference to the conclusions in the 
main analysis.  The multivariable adjusted OR in the sensitivity analysis was 0.65 (95% CI 
0.48-0.88)), P=0.005, compared to 0.66 (95% CI 0.49-0.89) p=0.006 in the main analysis.  
Full results of these additional analyses are shown in Appendix A, section 10.6.7.   
 
7.7.7.2 Inclusion of possible diagnoses 
The main analysis included only patients with definite atherosclerotic disease 
diagnoses prior to MI.  In an analysis including patients with possible diagnoses of 
atherosclerotic disease, 7,666 patients without atherosclerotic disease were identified.  Of 
these patients, 668 (8.7%) were current aspirin users, 515 (6.7%) were previous aspirin 
users.  There were 722 current statin users (9.4%) and 324 (4.2%) previous statin users.  
When the main analyses of the three outcomes were repeated, there were no differences in 
the conclusions.  The results are shown in Appendix A, section 10.6.7. 
 
7.7.7.3 GPRD prescription data versus MINAP admission drug use 
Of the subset of patients included in this analysis who had a MINAP record 
(N=3576), 92% had a record of antiplatelet use, and 52% had a valid record of statin use 
prior to MI.  For patients who had a record of drug use, concordance between GPRD 
prescription data and MINAP data are described in tables Table 7.27 and Table 7.28.  For 
never users, concordance between GPRD and MINAP was high (>90% agreement).  
However, for current and previous users, agreement was poorer.  In particular, for aspirin 
use, there was only 51% agreement.  For MINAP patients, it is unclear whether the aspirin 
was taken by the patient for primary prevention (therefore representing the exposure of 
interest), or whether it was administered in the ambulance or the emergency room (and 
therefore not the exposure of interest).  Since admission drug use was only available in a 
small subset of patients, and due to the high missingness in statin use and the unclear timing 
of antiplatelet use, MINAP data were not used as part of the main exposure in this analysis. 
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7.7.7.4 Adjustment for consultation rate 
Patients experiencing NSTEMI tend to be those with more comorbidity.  Therefore, 
aspirin use may be simply a marker of poorer health rather than being independently 
associated with NSTEMI.  Therefore, the main analysis describing presentation in users and 
non-users of aspirin was adjusted for consultation rate, a marker of general morbidity in the 
GPRD.  After adjusting for consultation rate, the odds ratio comparing current and never 
users in terms of ST-elevation MI was unchanged.  (OR in main analysis=0.66 (95% CI 
0.49-0.89) p=0.006, and in an analysis adjusted for consultation rate OR=0.67 (95% CI 0.52-
0.87), P=0.004).  Results are shown in Appendix A, section 10.6.7. 
 
7.7.7.5 Differing definitions of ‘current use’ 
The buffer of 14 days between a last prescription and MI was changed in two 
sensitivity analyses to zero or 28 days.  Using either of these definitions did not affect the 
conclusions of the main analysis.  An alternative definition of current use was also tested in 
a sensitivity analysis, where current use was defined as two or more prescriptions in the six 
months prior to MI.  Using this definition, there were no changes in the conclusions of the 
main analysis.  Results of these analyses are in Appendix A, section 10.6.7. 
 
7.7.7.6 Peak creatine kinase as a measure of infarct size 
Due to limitations of the recording of peak troponin in terms of the grouping of data 
around round numbers and the lack of information on assay type in this analysis, the 
analyses describing the associations between aspirin and statin use and infarct size were 
repeated using peak creatine kinase as the measure of infarct size.  This showed the same 
result as the main analysis, with no associations between either drug and infarct size at 
multivariable adjustment (current aspirin use exponentiated multiple linear regression 
coefficient 0.83 (95% CI 0.63-1.11), P=0.207, and for current statin use 1.02 (95% CI 0.82-
1.27), P=0.865).
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Table 7.27 Comparison of GPRD prescription and MINAP aspirin use at admission in 3,437 patients 
 
Aspirin at 
admission: 
MINAP 
response 
GPRD prescription 
Never Current Previous Total 
n (%) n (%) n (%) n (%) 
No 2,841 (96.0) 130 (48.7) 181 (85.8) 3,152 (91.7) 
Yes 118 (4.0) 137 (51.3) 30 (14.2) 285 (8.3) 
Total 2,959 (100) 267 (100) 211 (100) 3,437 (100) 
GPRD: General Practice Research Database; MINAP: Myocardial Ischaemia National Audit Project 
 
Table 7.28 Comparison of GPRD prescription and MINAP statin use at admission in 1,928 patients 
 
Statin at 
admission: 
MINAP 
response 
GPRD prescription 
Never Current Previous Total 
n (%) n (%) n (%) n (%) 
No 1,464 (91.5) 49 (22.4) 73 (67) 1,586 (82.3) 
Yes 136 (8.5) 170 (77.6) 36 (33) 342 (17.7) 
Total 1,600 (100) 219 (100) 109 (100) 1,928 (100) 
GPRD: General Practice Research Database; MINAP: Myocardial Ischaemia National Audit Project 
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7.8 Discussion 
 
7.8.1 Summary 
This study was the first to our knowledge to prospectively assess the prescription of 
statins and aspirin for primary prevention and their associations with outcomes at MI, and to 
assess these associations at different levels of coronary risk.  It was also the first to assess 
the associations between these medications and mortality in general populations.  Our results 
show that prescribing of aspirin was most frequent in the groups with highest Framingham 
risk, but there was also considerable prescribing in patients with intermediate risk, and some 
prescribing in patients with low risk.  Prescribing of statins was of a similar prevalence 
across all risk groups.  The variation in Framingham risk across patients for whom this was 
measured also indicates the failure of this risk score to accurately identify patients at high 
risk. 
There was evidence to suggest that current aspirin use at the time of MI was a 
marker for attenuated infarct severity, even after adjusting for age, sex, cardiovascular 
disease risk factors, statin and antihypertensive use.  This association was robust to further 
adjustment for family history, BMI, social deprivation and for GPRD consultation rate, an 
indicator of general morbidity.  Longer duration of aspirin use was also associated with 
lower odds of ST-elevation.  However, there was no association between aspirin use and 
infarct size or mortality.  Patients defined as previous aspirin users, i.e. withdrawers, had the 
same MI outcomes as patients who had never used aspirin.  Statin use, dose and duration 
were not associated with any of the outcomes examined in this study.  Explanations for these 
associations are described below in the context of other literature. 
 
7.8.2 Possible explanations: aspirin 
7.8.2.1 Prescription of aspirin by Framingham risk category 
Reflecting previous guidelines (Table 7.29, reproduced from the literature review), 
prescribing was highest in those categorised as high risk.  Prescribing in patients at 
intermediate and low risk is likely to reflect guidance to prescribe aspirin in patients with 
type 2 diabetes, which is not included in the Framingham score.  However, 80% of women 
and 85% of men defined as at high cardiovascular disease risk were not being treated.  This 
may be an underestimate of true aspirin use due to over the counter use. It may also reflect 
both patient and GP preference in not prescribing aspirin, concerns of polypharmacy in the 
elderly,[274] or a lack of recognition of high risk by GPs, as this study did not measure GP 
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recognition of raised risk.  There is evidence that many GPs do not use risk calculators, at 
least in other parts of Europe, which may also have contributed to the under-use observed 
here.[275]  
 
Table 7.29 British guidelines for the use of aspirin in primary prevention of 
cardiovascular disease 
 
 Aspirin 
JBS 2, 
2005[231] 
• Aspirin 75mg daily for: 
− Individuals with ≥20% cardiovascular disease risk over 10 years once 
hypertension, if present, is controlled to systolic <150mmHg and 
diastolic <90mmHg; 
− All people with diabetes. 
NICE, 
2008[236] 
In patients with diabetes, offer low dose aspirin, 75mg daily to: 
• A person who is 50 years old or over, if blood pressure is below 
145/90mmHg; 
• A person who is under 50 years old and has significant other 
cardiovascular disease risk factors (features of metabolic syndrome, 
strong early family history of cardiovascular disease, smoking, 
hypertension, extant cardiovascular disease, microalbuminuria). 
MHRA, 
2009[234] 
“Aspirin is not licensed for the primary prevention of vascular events.  If aspirin 
is used in primary prevention, the balance of benefits and risks should be 
considered for each individual, particularly the presence of risk factors for 
vascular disease (including conditions such as diabetes) and the risk of 
gastro-intestinal bleeding.” 
SIGN, 
2007,[233] 
2012[235] 
2007 guideline: 
• Consider aspirin daily for: 
− Patients with a calculated cardiovascular disease risk of ≥20% over 
ten years;  
− All people with type 2 diabetes who are over 50 years of age, and for 
selected younger individuals who are considered to be at increased 
cardiovascular disease risk. 
2012 guideline: 
• Aspirin is not recommended for the primary prevention of vascular disease 
when benefits are considered against the increased risk of haemorrhage. 
JBS: Joint British Societies; NICE: National Institute for Health and Clinical Excellence; MHRA: 
Medicines and Healthcare Regulatory Agency; SIGN: Scottish Intercollegiate Network. 
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7.8.2.2 Presentation with ST-elevation 
The studies included in the literature review support the results found in this 
analysis, with less ST-elevation at MI in aspirin users.[243-246]  Attenuated severity of 
coronary presentations in aspirin users has also been reported in other contexts; Garcia-
Dorado[250] and Alexander[249] examined the association between aspirin and the severity 
of manifestation in acute coronary syndromes overall, finding that previous aspirin use was 
associated with less MI and more unstable angina.  Garcia-Dorado also showed that longer 
duration of use was also associated with severity of ACS, which is similar to our results 
describing less ST-elevation in patients who had been using aspirin for longer periods.[250]   
It is plausible that aspirin does have a true effect on presentation with ST-elevation; 
its antiplatelet properties may reduce the likelihood of sudden thrombotic events that often 
characterise STEMI patients.  The association in the current study was the same at all levels 
of cardiovascular disease risk, indicating that aspirin may reduce the occurrence of 
thrombotic events irrespective of baseline risk.  This result is further strengthened by the 
absence of an association in previous users, who had similar distribution of Framingham 
risk, indicating that the results are less likely to be due to confounding by indication.  
However, all of the studies examining the effects of aspirin, including the current study, are 
observational and therefore none can describe the causal nature of the relationship.  For 
example, even within the highest risk group, patients with a poorer risk factor profile (e.g. 
with very high blood pressure, uncontrolled diabetes, smokers) may have more severe 
atherosclerosis and may be more likely to receive aspirin than their high risk peers, therefore 
confounding the association observed between aspirin and ST-elevation.   
While the causal relationships remain unclear, this study has described and reported 
the association between aspirin use and ST-elevation for the first time in patients taking 
aspirin for primary prevention.   
 
7.8.2.3 Infarct size 
Larger infarcts, measured by increased troponin or CK release, are usually 
associated with ST-elevation, a marker of greater myocardial damage.  However, while 
aspirin use was a marker for decreased ST-elevation in this study, it did not drive an 
association between aspirin use and infarct size.   
The literature review described consistently smaller infarcts in aspirin users, even in 
studies which were adjusted for cardiovascular disease, cardiovascular disease risk factors, 
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and other drug use.  While there was a crude association with infarct size in our study, this 
was lost after adjustment for all cardiovascular disease risk factors and other drug use.  The 
studies reviewed may not have measured or adjusted sufficiently for confounding factors, 
due to their respective design.  Alternatively, the lack of association with infarct size in our 
study may be due to several limitations in its measurement in this study.   
First, peak troponin is not the optimal measure of infarct size; imaging techniques 
including MRI scanning are likely to be the gold standard in measuring damage to the 
myocardium.  While there is a correlation between peak troponin and infarct size ([276]), 
this is imperfect.  Second, recording of troponin in MINAP is grouped around round 
numbers, for example at 50 and 100 (see Appendix A, Section 10.6.2).  Peak troponin data 
in MINAP are not collected for the type of research in this study and therefore the recorded 
data may not be an accurate reflection of the true value.  Third, for patients who are 
reperfused early, there may not be a characteristic rise and fall in troponin, meaning that no 
peak troponin value is collected.  Fourth, the meaning of the peak troponin values are 
dependent on the assay used (T or I) and these data were not used in this analysis.  However, 
a sensitivity analysis using peak creatine kinase (which does not show this grouping) instead 
of peak troponin as a measure of infarct size showed the same result.  Finally, there may be 
selection bias in the patients included.  Peak troponin was recorded in 83% of patients with a 
MINAP record, but only 37% of the whole sample.  As discussed in Chapter 4 (Data 
quality), patients recorded in MINAP tend to be younger and more likely to survive than 
other hospitalised patients who do not have a MINAP record.  If there is also a bias in the 
patients who have their peak troponin values recorded, then the effect measure produced in 
this study is unlikely to reflect any true association between prior aspirin use and infarct 
size.   
 
7.8.2.4 Mortality 
There was no overall association between aspirin use and mortality.  However, in a 
crude analysis, stratification by Framingham risk showed that the association between 
aspirin and mortality was strongest in patients with missing Framingham risk.  This was 
explained entirely by the confounding effects of cardiovascular disease risk factors in this 
group and the mixture of patients in this group at very high risk (who were in receipt of 
aspirin) and very low risk patients who were not.   
The associations of aspirin use with short term mortality were inconsistent in the 
literature, with results in different directions (see Table 7.5).  Interestingly, a MINAP study 
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examining predictors of mortality in STEMI patients in the MINAP dataset showed an 
independent protective effect of aspirin use prior to hospitalisation (OR=0.55 (95% CI 0.46-
0.67), P<0.001).[103]  In a crude analysis our results for hospitalised and non-hospitalised 
MIs showed the opposite trend.  In the literature review, the largest study of over 118,000 
elderly US patients described a protective association between aspirin and mortality.[253]  It 
is possible that aspirin use in this large US study reflected a healthy user effect, or that the 
effects were different in the older population covered by the study.  Another plausible 
explanation is effect modification by previous coronary disease diagnosis, as reported by 
Spencer (2002).[263]  In patients with previous disease, aspirin was protective, while there 
was no association in those without disease.  If coronary disease prevalence was high in the 
elderly patients of the US study, this could partially explain the reported decreased risk.  In 
the current analysis, higher mortality was found in users with the highest coronary risk, 
reflecting UK guidelines which previously indicated use of aspirin in patients at the highest 
coronary risk.   
Other large studies of ACS patients have also shown higher mortality in aspirin 
users, or no association at all.[249, 260, 271]  Given the effect measures produced by the 
studies in Table 7.5, it is plausible that there is no true association between mortality and 
aspirin use for primary prevention, and studies showing higher mortality in aspirin users are 
confounded due to poorly measured confounders or insufficient adjustment.   
 
7.8.3 Possible explanations: statins 
7.8.3.1 Prescription of statins by Framingham risk category 
Despite guidance to prescribe statins to patients at high cardiovascular disease risk, 
only 23% of MI patients with cardiovascular disease risk above the 20% threshold (i.e. 
above 15% CHD risk) were in receipt of statins and the level of statin prescribing was the 
same across levels of Framingham risk.  This is likely to reflect prescribing in patients with 
high total cholesterol, irrespective of other cardiovascular disease risk factors.  In patients 
whose Framingham scores could not be calculated (mostly due to lack of cholesterol 
measurement), levels of statin prescribing were below 3%.  These results indicate that for 
the majority of patients, statin prescribing is dependent on a measurement of cholesterol 
rather than a raised global cardiovascular disease risk score.  This also means that there the 
results described regarding statin use and outcomes are less likely to be confounded by high 
cardiovascular disease risk. 
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7.8.3.2 Presentation with ST-elevation 
Of the two studies reporting associations with MI presentation, both described lower 
ST-elevation in users of statins.  Further evidence for the association of statins with reduced 
severity of coronary disease presentation is from the ADVANCE study in the United 
States,[277]  which reported a favourable influence of statins on initial presentation with 
CHD, being associated with stable angina rather than MI.  A study of GRACE registry 
patients with ACS also described lower odds of ST-elevation in statin users.  In a crude 
analysis, the current study showed an attenuated severity of MI presentation in statin users, 
which was lost on adjustment.  Since information on MI type was only available from a sub-
sample of patients in the main study and the majority of these from MINAP patients, it is 
possible that selection bias affected the results in this study, or that there was not enough 
power to identify a real effect of statins.  However, it is also possible that our study was 
better adjusted that those described above because information on confounders was 
measured prospectively. 
 
7.8.3.3 Infarct size 
Two small studies of previous statin use prior to first MI described smaller infarct in 
statin users.  One studied only patients without previous atherosclerotic disease, and 
although statin users had smaller infarcts, no adjusted analysis was performed.[265]  The 
other study was well-adjusted for demographics, cardiovascular disease risk factors and 
multivessel disease, still showing an association with infarct size.[266]  As described above, 
a true association between statins and infarct size may have been obscured by selection bias 
of patients in whom peak troponin was recorded.   
 
7.8.3.4 Mortality 
In the UK, statins, like aspirin, are recommended for patients at high cardiovascular 
disease risk.  While statins were not associated with any of the outcomes at multivariate 
analysis, they were crudely associated with lower mortality, which is opposite to the crude 
association seen in aspirin users due to the prescribing of statins across all risk groups.  
A null association of previous statin use on mortality was also reported in another 
study of patients without prior atherosclerotic disease.[265]  While other studies have shown 
evidence for lower mortality in the statin treated group, these were all retrospective in design 
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so confounders may have been measured poorly.  The current study is the first to describe 
the association between statins and mortality in general populations and despite a strong 
beneficial effect in preventing MI, [39, 41] statins appear to have no effect on outcomes in 
patients who still have MI. 
 
7.8.4 Strengths 
Data quality is a major strength of this study.  The MI outcomes were validated in 
Chapter 4, and were shown to have a high positive predictive value and accurate data on 
timing.  MI records were taken from all four data sources (GPRD, HES, MINAP and ONS) 
to gather the most representative sample.  A unique strength of this study was inclusion of 
patients who died before hospital admission.  All other previous studies have been unable to 
investigate fatal MI events.  If patients who made it to hospital were systematically different 
to those who did not in terms of their previous aspirin use, the associations produced by 
previous studies may have been biased.  This is therefore the first study to present findings 
in a general population.   
Patient records from the GPRD are prospectively collected, with repeated measures 
of smoking, blood pressure, and detailed records of cardiovascular disease risk factors and 
atherosclerotic disease diagnoses.  Prescribing data from the GPRD are of excellent quality 
because all drugs prescribed in primary care are automatically recorded in the dataset, 
including the product prescribed, the date and the dosage.  For statins and other drugs 
unavailable over the counter, the data on patients receiving these agents are complete.  This 
detailed prospective data allowed analysis of duration and dose, which had not previously 
been examined in patients with MI.   
In the main analysis, atherosclerotic disease diagnoses and cardiovascular disease 
risk factors were present if a patient had a ‘definite’ Read or ICD code for that diagnosis 
based on clinician rating.  A sensitivity analysis indicated that addition of ‘possible’ terms 
did not materially change the results.  
 
7.8.5 Weaknesses 
While the data on prescribing in the GPRD are of high quality, over the counter use 
of drugs is not recorded.  Therefore, aspirin data are likely to be incomplete if the GP has 
recommended use of aspirin without a record of prescriptions.  Over the counter use of 
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aspirin is cheaper than a prescription; general practitioners may not prescribe aspirin through 
their computer system, and instead recommend that the patient purchase and use aspirin.  In 
some cases, patients may not visit their GP at all and purchase the drugs.  There are currently 
no information available regarding over the counter use of aspirin for the patients in this 
study.  Misclassification of aspirin exposure would have attenuated the associations 
described here, so it is possible that an association between aspirin use, infarct size or 
mortality was missed.   
Additionally, there is currently no information available regarding collection of 
prescriptions or compliance, which is a drawback of using routinely collected data for 
research.  However, in this analysis receiving repeat prescriptions was used an indicator of 
drug use, and the majority of current users had received more than one prescription.   
 As discussed in the limitations of Chapter 6, the risk factor measures adjusted for in 
this analysis may not accurately reflect true cardiovascular disease risk at the time of MI 
because they were based on averages of repeated measures collected during follow-up.  
Other strategies to deal with repeated measurements of blood pressure and cholesterol over 
time may have been more useful (last measurement prior to MI, mean of measurements in 
the year prior to MI), although these were not explored in this analysis.  The potential 
misclassification of risk factors means that there may be some residual confounding in the 
estimate of the association between current aspirin use and ST-elevation at MI.   
Missingness in measurement of total and HDL cholesterol, smoking and blood 
pressure is a further disadvantage of routinely collected data and had two consequences in 
this analysis.  First it limited the power to determine the independent association of aspirin 
and statin with each outcome at multivariate analysis.  Second it may have introduced 
selection bias at multivariate analysis.  The majority of missingness was in the measurement 
of cholesterol and patients who have had cholesterol measurements may not have been 
representative of those who did not.  Some may have been healthy patients who had 
cholesterol measured in a well-patient check, while others may have had measurements due 
to being overweight or because the GP considered them to be at high risk.   
Because the mechanisms of missingness cannot be determined and the assumption 
of missing at random may not be valid, the option of multiple imputation was not pursued.  
However, a further exploration of the missingness mechanism with more data may aid our 
interpretation of these results. 
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This level of missingness is unsurprising given that the patients in this study did not 
have diagnosed atherosclerotic disease and many of them were likely to be at low global 
cardiovascular disease risk.  Importantly, levels of cholesterol measurement were high in 
users of statins, reflecting its use as a lipid lowering medication.  
As discussed above, MI type and infarct size were only available for subsample of 
the whole dataset, which may have been biased in terms of the patients included. It is 
unclear what effect this had on the results. 
The Framingham risk score is not necessarily a good predictor in a UK population.  
In this analysis, all patients had MI and their predicted risk should therefore have been high, 
but risk scores did not reflect this.  The Framingham risk score was derived from patients in 
the United States, and a systematic review has shown that in some populations it over-
predicts and in other populations it under-predicts CHD.[278]  The Framingham risk score 
has been criticised because it does not take into account potentially important factors 
including BMI, family history and social deprivation, which studies have repeatedly shown 
are important predictors of coronary disease.  However, in a sensitivity analysis, adjusting 
for socioeconomic status, BMI and family history of CHD, there was no effect on the 
estimates produced in the main analyses. 
Finally, a comparison of statin and aspirin use at admission in MINAP to the GPRD 
data used in this analysis revealed substantial discrepancies, particularly for aspirin use.  
This is likely to reflect MINAP recording aspirin administration in the ambulance or 
emergency room, in addition to use for primary prevention that was captured in GPRD.  
Comparison of statin use revealed nearly 80% agreement in current use, and 90% agreement 
in never use, which indicates that the exposure measurement in this study, although likely 
imperfect, was adequate.   
 
7.8.6 Implications for research 
There is uncertainty regarding the benefits of aspirin for primary prevention.  Trials 
are ongoing to assess its relative benefits and harms.  In these trials it would be useful to 
examine whether MI outcomes, including infarct severity, infarct size and mortality, are 
improved in aspirin users.  In the context of a trial setting, it would be possible to collect 
further data on the extent of atherosclerosis in patients who do have MI, along with detailed 
information of their medical history at baseline and during follow-up. This would allow 
extensive adjustment for confounders and may give an indication of the true effect of aspirin 
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use, and duration of use, on outcomes at MI.  It would also be pertinent to collect data on 
non-fatal outcomes following MI, which some studies have suggested are improved in 
aspirin and statin users, and may affect patient quality of life and longer term mortality after 
MI. 
 
7.8.7 Implications for policy 
In this analysis, statins had no beneficial or detrimental associations with infarct 
presentation, size or subsequent short term mortality.  Given the beneficial effects of statins 
shown by randomised trials for the primary prevention of MI, current recommendations for 
statin use in primary prevention are unaffected by these results. 
Aspirin is not currently recommended for the primary prevention of cardiovascular 
disease.  The evidence from this study alone is insufficient to make any firm conclusions 
regarding the beneficial effects of prior aspirin in users who still have MI.   
 
7.8.8 Conclusion 
In this UK primary care population of MI patients, prior aspirin use and longer 
duration of use were markers for attenuated MI severity.  No associations were observed 
between prior statin use and infarct severity, size, or subsequent mortality.  Decreased 
infarct severity in aspirin users has been described by other authors but due to the 
observational nature of these studies, there is a strong possibility of residual confounding by 
the underlying differences between users and non-users of primary prevention medications.  
Therefore, the evidence is insufficient to make any conclusion regarding the beneficial 
effects of prior aspirin use at MI.   
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7.9 Chapter summary 
• Aspirin and statin use is recommended to patients at high cardiovascular disease risk, 
yet studies have shown that their use prior to MI is associated with improved 
outcomes. 
• A review of the literature showed some evidence for attenuated infarct severity, 
smaller infarct size, and some differences in short term mortality in aspirin and statin 
users.  However, no studies focused on use of these drugs for primary prevention of 
MI. 
• In this study, 8,104 patients without previously diagnosed atherosclerotic disease were 
categorised as current, previous or never users of aspirin and statins.  Dose and 
duration of use were also examined.  MI severity (measured by ST-elevation at MI), 
infarct size and 30 day mortality outcomes were compared between groups. 
• There was strong evidence that current aspirin use was a marker of decreased 
likelihood of ST-elevation at MI, and that longer term aspirin use was associated with 
decreased likelihood of ST-elevation at MI.  However, aspirin use was not associated 
with infarct size or mortality.  There were no associations between statin use and MI 
severity, infarct size or mortality. 
• Given the known benefits of statins in primary prevention, the lack of associations 
shown here between statin use and outcomes at MI do not provide evidence against 
the recommendations to prescribe statins in patients at high risk.  
• The evidence described here suggests that aspirin use is associated with attenuated MI 
severity, and may represent a causal effect given the association was present at each 
level of Framingham risk.  However, data limitations regarding over the counter 
aspirin use and selection bias introduced by missingness of key cardiovascular disease 
risk factors must be considered when interpreting these results. 
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Chapter 8 Discussion 
 
 
8.1 Summary 
This chapter draws together the main findings and key discussion points of the four 
major analyses presented in this thesis.  A summary of the research undertaken is first 
presented, followed by a description of the key findings of each study and its place in the 
context of other research.  The main strengths and limitations of the work are then discussed, 
followed by the implications for policy and future research. 
 
8.2 Summary of research undertaken 
 
Four analyses were undertaken: 
I. A prospective study to compare capture, risk factors, mortality and diagnostic 
validity of MI in primary care, hospital discharge, disease registry and mortality 
statistics.  
 
II. A prospective study to examine the evolution of atherosclerotic disease and 
cardiovascular disease risk prior to first MI.   
 
III. A prospective study of the occurrence, timing and effect of ischaemic presentations, 
including new atherosclerotic disease in different arterial beds and chest pain before 
non-fatal and fatal MI. 
 
IV. A prospective study to examine the use of aspirin and statins prescribed prior to first 
MI for primary prevention and the effects on infarct presentation, size and short term 
mortality.   
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8.3 Capture, risk factors, mortality and diagnostic validity of MI 
in primary care, hospital discharge, hospital registry and 
mortality statistics 
8.3.1 Key findings 
• In a comparison of the recording of non-fatal MI across three data sources (GPRD, 
HES, MINAP), around a third were captured by three sources, and two thirds by at 
least two sources.   
 
• Capture of fatal MI was over 80% in ONS mortality records, but only half of 
patients who died within seven days of a MI record were recorded with MI in 
GPRD, suggesting that researchers should use both sources when capturing fatal MI 
events. 
 
• Cardiovascular disease risk factor prevalences and other co-existing conditions were 
similar across patients identified in GPRD, HES and MINAP.  While early mortality 
was higher in GPRD, which (unlike HES and MINAP) includes out of hospital MI, 
one year mortality rates in cohorts from each of the sources were similar.  This 
shows that the cohorts of MI patients captured by each source were similar and there 
are unlikely to be important selection biases between sources. 
 
• The timing of MI tended to be concordant where more than one source captured a 
patient’s MI. 
 
• These results indicate that although their sensitivity is suboptimal, the cohorts of 
MIs identified in each source are of sufficient quality to be used in this thesis and for 
wider research studies.  
 
8.3.2 Findings in the context of other research 
• The quality of MI records in GPRD and HES has been previously internally 
validated and both showed high positive predictive value compared to case note 
review. The incidence of MI in the GPRD has also been shown to be broadly 
comparable to other UK sources (see Chapter 2, Data Sources).  However, few data 
are available regarding the external validity of these sources at the patient level, 
including the completeness of capture for each source.  To our knowledge, the 
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external validity of MI records in MINAP and ONS has not previously been 
reported.   
 
• Our results were in accordance with the majority of single-source comparisons for 
GPRD and HES, but our study was the first to compare records of MI across sources 
in primary care, hospitalisation, MI registry and cause-specific mortality data and 
the first to look at the validity of the timing of MI.  It was also the first to report on 
the validity of ONS and MINAP MIs. 
 
• Capture of MI in hospitals may be expected to be lower given that patients may have 
MI secondary to the cause of their admission, or in non-cardiac wards.  Lack of 
recording in the GPRD (particularly non-fatal MI) may be the most difficult to 
explain because patients would require lifelong secondary prevention and CHD 
monitoring.  Work is currently underway to decode the non-coded section of the 
GPRD data, which could hold valuable information regarding patient morbidity, and 
could explain some of the non-capture in GPRD.   
 
 
8.4 The evolution of atherosclerotic disease and risk factors 
prior to MI 
8.4.1 Key findings 
• Of hospitalised patients identified with their first MI, the majority with previously 
diagnosed atherosclerotic disease had been diagnosed for several years before MI 
(median 6.7 years), allowing an extended period of time for the use of secondary 
prevention.  However, a premonitory period was identified in the 90 days prior to 
MI, where the rates of both incident coronary disease and the frequency of chest 
pain consultations were increased. 
 
• 56.5% of first MI patients did not have previously diagnosed atherosclerotic disease.  
In the majority of these patients there was at least one elevated traditional 
cardiovascular disease risk factor, and therefore targets for primary prevention.  
 
• 7.2% of patients with first MI had no previously diagnosed atherosclerotic disease, 
and no previously recorded elevated cardiovascular disease risk factors.  These 
patients had their MI without warning. 
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8.4.2 Findings in the context of other research 
• The prevalences of coronary, peripheral and cerebrovascular disease were in line 
with estimates from international registry data and UK data sources.  Additionally, 
our findings regarding the prevalence of MI patients without elevated cardiovascular 
disease risk factors were similar to published data. 
 
• Our study showed a similar duration of atherosclerotic disease compared to one 
other study that estimated the duration of coronary disease prior to MI. 
 
• However, this study was the first to have estimated the proportion of MIs that were 
unheralded by both atherosclerotic disease and elevated cardiovascular disease risk 
factors.  Therefore, ours is the first study to identify the proportion of patients who 
have MI ‘without warning’.  Similarly, no studies have described the evolution of 
different atherosclerotic disease manifestations prior to MI.   
 
 
8.5 Timing and effect of ischaemic presentations prior to MI 
8.5.1 Key findings 
• Patients with recorded chest pain, new onset atherosclerotic disease, or new 
manifestations of atherosclerotic disease in the 90 days prior to MI had lower 
mortality in the week after infarct compared to patients who were unheralded by 
these manifestations.  However, patients with MI unheralded by ischaemic 
manifestations had better longer term survival after MI. 
 
• Patients with ischaemic manifestations closest to the time of MI had the lowest 
mortality, but there was an effect of ischaemic presentations occurring up to 90 days 
prior to MI.   
 
• In patients where MI type was recorded, those with ischaemic presentations prior to 
MI were more likely to experience non ST-elevation MI. 
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8.5.2 Findings in the context of other research 
• There has been extensive research into the effects of preinfarction angina on 
mortality and non-fatal outcomes at MI.  Ischaemic preconditioning is the suggested 
mechanism by which patients with angina shortly before MI have improved 
outcomes and better survival.   
 
• Whilst similar results have been described in hospital settings and in highly selected 
groups of patients, this is the first study to describe the phenomenon (a) in a primary 
care setting, (b) with prospectively collected exposure data, including detail on 
timing of exposure, (c) for ischaemia in coronary and non-coronary arterial beds, (d) 
in a general population setting including patients who die before reaching hospital, 
and (e) in both patients with ST-elevation and non ST-elevation MI. 
 
• Ischaemic preconditioning has been proven experimentally to prevent myocardial 
cell death, but the effects of preinfarction angina shown in this and other studies 
have not been proven to be causally related to improved outcomes.   
 
• Possible mechanisms include: 
i. the formation of collateral channels.  This is unlikely to explain the strong 
effects on survival in patients manifesting with ischaemia very closely 
before MI; 
ii. an increased atherosclerotic burden in patients manifesting with ischaemia 
prior to their MI, which is associated with NSTEMI, which is known to 
have better short term survival than STEMI.  In our study there was 
insufficient power to adequately assess the effects by MI type and this 
would be a priority for future research;  
iii. a mechanism involving ischaemic preconditioning.  
 
8.6 Aspirin and statins for primary prevention and MI 
outcomes 
8.6.1 Key findings 
• In accordance with UK guidelines, patients without diagnosed atherosclerotic 
disease and higher cardiovascular disease risk tended to receive prescriptions of 
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aspirin and statins prior to MI.  However, many patients categorised at high risk 
prior to MI were not in receipt of these medications.   
 
• Patients prescribed aspirin prior to MI had less severe infarcts, as indicated by fewer 
ST-elevation MIs.  Longer duration of aspirin use was also associated with less 
severe infarcts.  There was no association between prior aspirin use and infarct size 
or mortality.   
 
• Statins were not associated with MI type, size or subsequent mortality. 
 
8.6.2 Findings in the context of other research 
• The studies identified in the literature showed similar results in the association 
between aspirin use and ST-elevation at MI.  However, all studies, including the 
analysis in this thesis, were observational and therefore subject to residual 
confounding by poorly measured or unmeasured variables.  Therefore, although 
aspirin appears to be a marker for attenuated infarct severity, the causal mechanism 
driving this association is unknown.   
 
• Several previous studies have reported an association between aspirin use and 
infarct size, which was not repeated in the current study.  Whether the associations 
described in the literature are artefacts of poorly conducted analyses or unmeasured 
confounders, or whether the sample of patients in our study with infarct size 
recorded was biased, is unclear.  The same is true for the lack of associations shown 
for the effects of statin use.  
 
• The reported effects of aspirin on short term mortality were variable, with studies 
showing no effect, beneficial effects and harmful effects at multivariate analysis.  
These effects may be so widely different between studies due to differing degrees of 
measurement and adjustment for confounding variables at multivariate analysis, or 
differing prescribing guidelines across study populations.  The data in the current 
study suggested that patients using aspirin in the UK were at higher cardiovascular 
disease risk and of a more advanced age, and therefore had higher crude mortality, 
but that aspirin had no independent association with mortality.   
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8.7 Strengths 
• Traditionally in studies of MI, patients are identified at hospitalization and therefore 
detailed, prospectively collected data prior to MI are not available.  In this study 
hospital MI data from MINAP and HES were combined with primary care records 
from the GPRD, and mortality data from ONS.  This created a rich longitudinal 
dataset, which allowed us to reconstruct the patient journey from a healthy state, 
through MI and to death.  Due to the detailed nature of data held by the GPRD, a 
wealth of atherosclerotic disease and cardiovascular disease risk factor data were 
gathered for each patient, without the errors in recall associated with ascertaining 
this information at the time of hospitalisation.   
• The second major strength of these analyses was the statistical power.  Each analysis 
included over 8,000 patients, each with prospective data regarding pre and post-
hospital exposures.   
• Linkage of the four sources provided the unique opportunity to validate MI by 
comparing patient records between sources, and to research MI as the first 
manifestation of disease, which would not have been possible using one source 
alone.   
• Importantly, the patients included in GPRD are representative of the UK population, 
and so the patients included in this study are likely to be representative of all MI 
patients in the UK.  The data have also been extensively validated and shown to be 
of high quality for research. 
• Pre-MI follow-up for all patients was sufficient.  In the GPRD, all patients were 
registered in their practice for at least one year prior to MI (and in fact, most patients 
had several years of follow-up before MI), so there was sufficient time for any 
disease or risk factors to be detected by the GP and recorded electronically.  Patients 
without any pre-MI consultations with the GP were excluded, but did not introduce 
a minimum consultation rate as this could have biased patient selection towards 
sicker patients. 
• For three of the analyses, patients were included who did not reach hospital.  
Inclusion of both fatal and non-fatal MI in our analyses allowed the effect in the 
general population to be established, which has not been feasible in many other large 
studies of MI. 
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8.8 Limitations 
• The main limitations of each data source were described in Chapter 2 and major 
limitations of each analysis were discussed in their respective chapters.  The overall 
limitations of the thesis are discussed here.   
• The GPRD holds a wealth of data on each patient but is limited by the fact that it 
only holds symptoms and diagnoses reported by patients during consultations and is 
routinely collected data rather a than researcher-led study.  Therefore, if patients do 
not report symptomatic disease or poor health to their GP, it will not be captured by 
the dataset, resulting in misclassification.  For most GPRD data, if a patient does not 
have any codes relating to a condition, then they are regarded as being negative for 
that condition and there is no ‘missing’ data.  For measurement of risk factors such 
as blood pressure or lipid levels, there is sometimes missingness, which is a problem 
for analyses focussing on these variables as main exposures and outcomes, but less 
so for analyses such as those presented here.  
• While the linked data provided unique opportunities and great strengths in terms of 
data quality, there were some drawbacks to the wealth of data.  Since GPRD, HES 
and MINAP often held the same kind of information on a patient, their concordance 
with respect to cardiovascular disease risk factors and atherosclerotic disease, for 
example, could be compared.  Throughout this thesis, the most sensitive approach in 
categorising patients with morbidity was followed, i.e. patients were categorised as 
positive if identified as such in any data source.  This could have led to some 
misclassification of risk factors and disease.  However, the misclassification would 
unlikely to have been differential with respect to the outcomes in this analysis, and 
so would have attenuated the associations described. 
• These analyses were observational.  For the analysis of ischaemic presentations prior 
to MI, observational clinical data are likely to be the gold standard as patients cannot 
be randomised to have ischaemia prior to MI.  However, in the analysis of primary 
prevention medications, despite extensive adjustment at multivariate analysis, there 
is a possibility of residual confounding by indication.  While a trial for statins in 
primary prevention in patients at high risk would be not ethically acceptable due to 
the known benefits of statins, trials of aspirin in primary prevention are ongoing.  By 
randomising patients to receive aspirin or not, confounding by indication is 
eliminated. 
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8.9 Implications for public health and policy 
• Suboptimal capture of MI across data sources indicates that use of one or even two 
sources is likely to be insufficient in estimating the true incidence of MI in the UK.  
Instead, healthcare commissioners and policy-makers should use multiple linked 
sources in estimating incidence and costs for healthcare provision.   
• Roughly half of first MIs were heralded by diagnosed atherosclerotic disease.  While 
current policy recommends use of aspirin, statins and blood pressure lowering drugs 
in these patients, our data suggested that there is room for improvement in the 
provision of these medications.  A drive to promote the importance of the use of 
secondary prevention medications in patients with coronary, cerebrovascular and 
peripheral arterial disease could substantially reduce the incidence of MI. 
• Given the most recent statistics published by the British Heart Foundation indicating 
an estimated 124,000 MIs in the UK per year, and assuming that 70% of these are 
first MIs (as described in the MONICA and GRACE MI registers), our results 
suggest that approximately 49,000 MIs occur as the first manifestation of 
atherosclerotic disease every year and 6,000 of these occur without warning.  These 
are large numbers and indicate that current policy for primary prevention 
recommending the measurement of cardiovascular disease risk, and management of 
that risk should continue to be followed with care.  An understanding of whether 
MIs occur in these patients due to missed opportunities for care is a priority for 
further research. 
• The current UK guidelines for primary prevention recommend the use of statins but 
not the use of aspirin.  The results described here uphold these guidelines, as they do 
not indicate a positive or negative impact of these drugs on patient mortality. 
 
8.10 Future research 
• For researchers working with one of these four sources, it would be useful to 
improve the search strategies used to identify MI patients, so that incidence is 
estimated more accurately. 
• Importantly, this was a case-only analysis.  A comparison to atherosclerotic disease-
free controls would be pertinent to aid our understanding of MIs that occur as the 
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first manifestation of disease, and in particular those that occur without warning.  
This may reveal missed opportunities for care in the assessment or management of 
cardiovascular disease risk, or could elucidate novel risk factors for MI.   
• To enhance our understanding of the effects of ischaemic presentations shortly 
before MI on MI outcomes, our analysis should be repeated in a larger population of 
hospitalised MIs in whom MI type has been recorded.  If the short term mortality 
benefits described in patients who experience ischaemia are shown exclusively in 
STEMI patients, then this would support the idea of preconditioning in these 
patients, rather than simply confounding by underlying atherosclerotic disease. 
• Since the four data sources were linked for the first time in 2010, more GPRD 
practices have consented to the linkage and therefore more data are being made 
available from all data sources.  The new Clinical Practice Research Datalink has 
plans to incorporate every NHS patient into the dataset.  Utilising data for the whole 
of the UK would bring power to detect effects that current analyses were 
underpowered to detect. 
• The possibility of confounding by indication in patients receiving aspirin and statin 
for primary prevention cannot be unravelled using observational data.  Patients 
randomised in trials to receive aspirin and statins for primary prevention should 
measure both fatal and non-fatal outcomes at the time of MI to gauge their effects on 
these outcomes, in addition to their primary preventative benefits or harms and 
without confounding by indication.   
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8.11 Conclusions 
The work presented in this thesis utilised linked data from four UK data sources, 
providing the unique opportunity to study patients with MI as the first manifestation of their 
atherosclerotic disease.  Although our study showed that the capture of MI in each source 
was suboptimal, there was evidence that all four sources contributed cohorts of MI of 
sufficient quality to be used in this thesis. 
In describing the evolution of atherosclerotic disease prior to MI, this analysis 
showed that over half of first MI patients were experiencing their first manifestation of 
disease.  This has two implications: firstly it highlights the importance of measuring and 
managing cardiovascular disease risk for primary prevention, and secondly it underlines the 
need for further research into these events which, if not fatal, instantly transform a person 
without known atherosclerotic disease into a coronary heart disease patient requiring 
intensive, lifelong secondary prevention treatment. 
In examining the survival of patients experiencing MI as the first manifestation of 
disease, those who presented to their general practitioner with ischaemia shortly before MI 
had a lower rate of mortality in the seven days after MI than patients who first manifested 
with MI, but that their subsequent mortality was poorer.  This finding may represent an 
ischaemic preconditioning effect in patients with pre-infarct ischaemia.  While the concept 
of ischaemic preconditioning has been proven in experimental studies, its relevance to the 
clinical setting is unproven and further research, including the possibility of harnessing its 
effects, is required. 
In the final analysis aspirin and statins for primary prevention were not 
independently associated with a survival benefit following MI, although there was some 
indication that aspirin use was a marker of reduced severity of MI.  Statin use has proven 
effectiveness in the primary prevention of MI in patients at high cardiovascular disease risk, 
and the results here indicate no harm or benefit of statin use on outcomes at MI.  Conversely, 
the effects of aspirin as a primary preventative medication and its effects on outcomes at the 
time of MI require further study, as no clear benefits or harms were discernible in this study 
and the beneficial effects of aspirin for primary prevention have recently been called into 
question. 
Together, these results provide a unique insight into the pre-MI experience of 
patients with a first MI, which is difficult area of research due to their sudden nature. These 
findings represent a step forward in our understanding of these unexpected events.  
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8.12 Chapter summary 
 What previous studies have shown What this study found Key unanswered questions 
I.  Capture and validity of MI in 
GPRD, HES, MINAP and ONS 
Previous studies have reported high 
positive predictive value of GPRD and HES 
MI, but poor completeness of HES MI.   
Capture of MI in each of the four sources 
was suboptimal, but MIs that were 
recorded tended to be accurate and timely.  
Can we alter our search strategies in finding 
patients with MI in each source? 
II.  Heralding of first MI by 
atherosclerotic disease and 
cardiovascular disease risk 
factors 
No previous studies assessed heralding of 
first MI by both atherosclerotic disease and 
cardiovascular disease risk factors. 
56.5% had no previously diagnosed 
atherosclerotic disease, and 7.2% of 
patients experienced MI without warning.   
In patients who appear to have MI without 
warning, were coronary risk factors 
measured and treated appropriately in line 
with current guidelines? 
III.  Manifestations of ischaemia 
prior to MI and effects on MI 
outcomes 
There is an apparent protective effect of 
preinfarction angina on outcomes at MI. 
 
Patients with manifestations of ischaemia 
prior to MI had a lower rate of mortality in 
the seven days after MI, but this beneficial 
effect was lost after seven days. 
What role does MI type have in the effect of 
previous manifestations of ischaemia and 
outcomes at MI? 
IV.  Use of aspirin and statin for 
primary prevention and effects 
on MI outcomes 
Aspirin and statins have a protective effect 
on MI severity and infarct size.  The effects 
on mortality are unclear. 
 
Aspirin use and longer duration of use 
were associated with some attenuation of 
MI severity in hospitalised patients.  There 
were no other associations between use of 
aspirin or statins and infarct size, 
presentation and mortality. 
Is aspirin or statin use associated with a 
beneficial effect on non-fatal outcomes? 
Are there differences in MI outcomes in 
patients randomised to receive aspirin 
compared to those randomised to not 
receive aspirin? 
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Chapter 10 Appendix A 
 
10.1 Appendices for Chapter 2 
 
10.1.1 GPRD patient acceptability criteria 
GPRD patient acceptability criteria (determining whether a patient’s file can be used 
for research purposes): 
• An empty or invalid first registration date; 
• Absence of a record for a year of birth; 
• A first registration date prior to their birth year; 
• A transferred out reason with no transferred out date; 
• A transferred out date with no transferred out reason; 
• A transferred out date prior to their first registration date; 
• A transferred out date prior to their current registration date; 
• A current registration date prior to their first registration date; 
• A current registration date prior to their birth year; 
• A gender other than Female/Male/Indeterminate; 
• An age of greater than 115 at end of follow up; 
• Recorded health care episodes in years prior to birth year; and 
• Registration status of temporary patients. 
 
If any of these conditions are true then the patient is labelled unacceptable, and is not 
recommended for use in research. 
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10.1.2 Linkage of GPRD, HES, MINAP and ONS 
Purpose of the linkage 
Linkage of these GPRD, HES, MINAP and ONS mortality statistics goes some way 
in addressing the weaknesses and using the strengths of each individual data source.  The 
linkage was instigated by the Cardiovascular disease research using Linked Bespoke studies 
and Electronic Records (CALIBER) programme, established in 2009.  CALIBER aims to 
improve the aetiology and prognosis of specific coronary phenotypes through linkage of data 
sources.  Linkage of the four data sources described here creates a unique opportunity to 
examine the detailed medical history of patients who present with MI and to follow the 
patient journey in the pre- and post-MI periods, through to death.   
 
How was the linkage done? 
The linkage was performed by a Trusted Third Party (TTP) to maintain the 
confidentiality of the patients involved in the linkage.  Of the 600 practices who contribute 
data to the GPRD, 244 consented for their data to be linked to further data sources.  This 
includes linkage to HES, ONS and MINAP data.  In November 2010, the patient identifiers 
from these 244 practices were sent to the TTP.  At the same time, patient identifiers from 
HES, ONS and MINAP were also sent to the TTP.  The TTP used deterministic linkage 
based on NHS number, date of birth, postcode and gender.  Of the 5.8 million patients sent 
for linkage, 4.4 million had a valid NHS number in GPRD and HES, and 4.2 million (94%) 
of these were eligible for the MINAP linkage, based on the following criteria: 
• Active registration with a consenting practice at some point during the data coverage 
period of ONS, HES or MINAP (Table 10.1);  
• Marked as an acceptable patient in the November 2010 version of GPRD; and 
• EITHER the patient is matched 1:1 between GPRD and HES by their NHS number, 
date of birth and gender OR the patient had a valid NHS number, but was not matched 
to any patient in the HES data (i.e. they had not been hospitalised).  
The data used in this thesis consists of only those patients who were matched by the 
linkage, or who had a valid NHS number (i.e. who should have appeared in HES or MINAP 
if they were hospitalised with an acute coronary syndrome).  Therefore, visitors to the UK, 
and patients who registered with primary care temporarily would not have been linked.   
Appendix A 
351 
 
Linkage success statistics 
Since the linkage was carried out by a Trusted Third Party, no details regarding the 
success rates of the linkage were available in this study.   
 
 Coverage periods of the linked data 
Each of the data sources has been recording data from a different point in time.  The 
GPRD began collecting data in 1987, HES in 1997, MINAP in 2003, and ONS recording is 
available from 1995.  Table 10.1 describes the time periods covered by each source.  
Analysis of MI in this thesis is restricted to the time when all sources were providing data so 
that in the absence of error, each hospitalised MI patient would be recorded in GPRD, HES 
and MINAP, and each fatal MI would be recorded in GPRD and ONS. 
 
Table 10.1 Coverage periods of each data source 
 
Data source Coverage period Unique patient identifiers 
GPRD 1987 – 11/2010 NHS number, date of birth, 
gender, postcode 
HES 01/04/1997 – 31/10/2010 NHS number, date of birth, 
gender, postcode 
MINAP 01/01/2003 – 31/03/2009 NHS number, date of birth, 
gender, 
ONS 02/10/1995 – 19/10/2010 NHS number, date of birth, 
gender, 
 
Linkage of ONS 
The ONS linkage was performed in only those patients who had been admitted to 
HES at any point in their lives.  Analyses showed that this may have led to roughly 2% 
underestimation of mortality in patients who had never been admitted to HES.   
 
Validation of the linkage 
The trusted third party performed the linkage and therefore few details are available 
about the success rate of patient linkage.  Additional work concerning the validity of the 
linkage is currently underway by the CALIBER group.  
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Ethical approvals and funding 
CALIBER is funded by the Wellcome Trust and the National Institute of Health 
research.  CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC 
approval (ref ECC 2-06(b)/2009 CALIBER dataset).  
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10.2 Appendices for Chapter 3 
10.2.1 MI code lists 
GPRD MI code lists 
Table 10.2 GPRD Read codes used to define MI in this thesis 
GPRD 
medical 
code Read code Read term Code classification 
35674 14A3.00 H/O: myocardial infarct <60 History of MI 
40399 14A4.00 H/O: myocardial infarct >60 History of MI 
50372 14AH.00 H/O: Myocardial infarction in last year History of MI 
23579 G310.00 Postmyocardial infarction syndrome History of MI 
4017 G32..00 Old myocardial infarction History of MI 
16408 G32..11 Healed myocardial infarction History of MI 
17464 G32..12 Personal history of myocardial infarction History of MI 
9555 G33z500 Post infarct angina History of MI 
61670 889A.00 Diab mellit insulin-glucose infus acute myocardial infarct Definite MI 
241 G30..00 Acute myocardial infarction Definite MI 
13566 G30..11 Attack - heart Definite MI 
2491 G30..12 Coronary thrombosis Definite MI 
30421 G30..13 Cardiac rupture following myocardial infarction (MI) Definite MI 
1204 G30..14 Heart attack Definite MI 
1677 G30..15 MI - acute myocardial infarction Definite MI 
13571 G30..16 Thrombosis - coronary Definite MI 
17689 G30..17 Silent myocardial infarction Definite MI 
12139 G300.00 Acute anterolateral infarction Definite MI 
5387 G301.00 Other specified anterior myocardial infarction Definite MI 
40429 G301000 Acute anteroapical infarction Definite MI 
17872 G301100 Acute anteroseptal infarction Definite MI 
14897 G301z00 Anterior myocardial infarction NOS Definite MI 
8935 G302.00 Acute inferolateral infarction Definite MI 
29643 G303.00 Acute inferoposterior infarction Definite MI 
23892 G304.00 Posterior myocardial infarction NOS Definite MI 
14898 G305.00 Lateral myocardial infarction NOS Definite MI 
63467 G306.00 True posterior myocardial infarction Definite MI 
3704 G307.00 Acute subendocardial infarction Definite MI 
9507 G307000 Acute non-Q wave infarction Definite MI 
1678 G308.00 Inferior myocardial infarction NOS Definite MI 
30330 G309.00 Acute Q-wave infarct Definite MI 
17133 G30A.00 Mural thrombosis Definite MI 
32854 G30B.00 Acute posterolateral myocardial infarction Definite MI 
29758 G30X.00 Acute transmural myocardial infarction of unspecif site Definite MI 
34803 G30y.00 Other acute myocardial infarction Definite MI 
28736 G30y000 Acute atrial infarction Definite MI 
62626 G30y100 Acute papillary muscle infarction Definite MI 
41221 G30y200 Acute septal infarction Definite MI 
Continued... 
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GPRD MI code list continued... 
GPRD 
medical 
code Read code Read term Code classification 
46017 G30yz00 Other acute myocardial infarction NOS Definite MI 
14658 G30z.00 Acute myocardial infarction NOS Definite MI 
15661 G310.11 Dressler's syndrome Definite MI 
68357 G31y100 Microinfarction of heart Definite MI 
18842 G35..00 Subsequent myocardial infarction Definite MI 
45809 G350.00 Subsequent myocardial infarction of anterior wall Definite MI 
38609 G351.00 Subsequent myocardial infarction of inferior wall Definite MI 
72562 G353.00 Subsequent myocardial infarction of other sites Definite MI 
46166 G35X.00 Subsequent myocardial infarction of unspecified site Definite MI 
36423 G36..00 Certain current complication follow acute myocardial infarct Definite MI 
24126 G360.00 Haemopericardium/current comp folow acut myocard infarct Definite MI 
23708 G361.00 Atrial septal defect/curr comp folow acut myocardal infarct Definite MI 
37657 G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn Definite MI 
59189 G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI Definite MI 
59940 G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct Definite MI 
69474 G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct Definite MI 
29553 G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI Definite MI 
32272 G38..00 Postoperative myocardial infarction Definite MI 
46112 G380.00 Postoperative transmural myocardial infarction anterior wall Definite MI 
46276 G381.00 Postoperative transmural myocardial infarction inferior wall Definite MI 
41835 G384.00 Postoperative subendocardial myocardial infarction Definite MI 
68748 G38z.00 Postoperative myocardial infarction, unspecified Definite MI 
96838 Gyu3400 [X]Acute transmural myocardial infarction of unspecif site Definite MI 
10562 G307100 Acute non ST segment elevation myocardial infarction Definite MI 
12229 G30X000 Acute ST segment elevation myocardial infarction Definite MI 
 
Table 10.3 GPRD Read codes used to define Creatine kinase codes 
 
GPRD 
medical 
code Read code Read term Code classification 
14350 44H8.00 Serum creatinine phosphokinase MB isoenzyme level Result not recorded 
49201 44HJ.00 Plasma creatinine phosphokinase MB isoenzyme level Result not recorded 
43046 44l5.00 MB/total creatine kinase ratio Result not recorded 
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Table 10.4 GPRD Read codes used to define troponin codes 
 
GPRD 
medical 
code 
Read 
code Read term Code classification 
97137 44p3.00 Cardiac troponin negative Normal/negative 
97001 44p2.00 Cardiac troponin positive Abnormal/positive 
13803 44MC.00 Serum troponin T level Result not recorded 
13806 44ME.00 Plasma troponin I level Result not recorded 
13800 44MG.00 Serum troponin I level Result not recorded 
43984 44MH.00 Plasma troponin T level Result not recorded 
 
 
Table 10.5 GPRD Read codes used to define cardiac marker codes of unspecified type 
 
GPRD 
medical 
code Read code Read term Code classification 
19634 44H2.00 Cardiac enzymes normal Normal/negative 
5221 44H3.00 Cardiac enzymes abnormal Abnormal/positive 
60664 44H3000 Cardiac enzymes abnormal - first set Abnormal/positive 
2403 44H..00 Cardiac enzymes Result not recorded 
61960 44H1.00 Blood sent: cardiac enzymes Result not recorded 
27207 44HI.00 Cardiac markers Result not recorded 
19849 44HZ.00 Cardiac enzymes NOS Result not recorded 
   
Appendix A 
356 
 
HES and ONS MI code list 
 
Table 10.6 ICD-10 codes to define MI in this thesis 
 
ICD-10 
code ICD-10 term 
I21 Acute myocardial infarction 
I210 Acute transmural myocardial infarction of anterior wall 
I211 Acute transmural myocardial infarction of inferior wall 
I212 Acute transmural myocardial infarction of other sites 
I213 Acute transmural myocardial infarction of unspecified site 
I214 Acute subendocardial myocardial infarction 
I219 Acute myocardial infarction, unspecified 
I22 Subsequent myocardial infarction 
I220 Subsequent myocardial infarction of anterior wall 
I221 Subsequent myocardial infarction of inferior wall 
I228 Subsequent myocardial infarction of other sites 
I229 Subsequent myocardial infarction of unspecified site 
I23 Certain current complication follow acute myocardial infarct 
I230 
Haemopericardium as current comp following acute myocardial 
infarction 
I231 
Atrial sept defect as current comp following acute myocardial 
infarction 
I232 
Ventric sep defect as current comp following acute myocardial 
infarction 
I233 
Rup cardiac wall without haemopericardium as current complication 
following acute MI 
I234 
Rup chordae tendinae as current comp following acute myocardial 
infarction 
I235 
Rup papillary muscle as current complication following acute 
myocardial infarction 
I236 
Thromb atrium/auric append/vent as current complication following 
acute MI 
I238 Other current complication following acute myocardial infarction 
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10.2.2 Consultation types included in the calculation of consultation rate 
 
Figure 10.1. Consultation types included in the calculation of consultation rate 
  
• Clinic 
• Night visit, Deputising service 
• Follow-up/routine visit 
• Night visit, Local rota 
• Night visit, practice 
• Out of hours, Practice 
• Out of hours, Non Practice 
• Surgery consultation 
• Acute visit 
• Emergency Consultation 
• Telephone call to a patient 
• Home Visit 
• Hotel Visit 
• Nursing Home Visit 
• Residential Home Visit 
• Twilight Visit 
• Triage 
• Walk-in Centre 
• Co-op Telephone advice 
• Co-op Surgery Consultation 
• Co-op Home Visit 
• Night Visit 
• Telephone Consultation 
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10.2.3 Flow chart of data losses for Chapters 5, 6 and 7 
 
 
MI: myocardial infarction; AAA: abdominal aortic aneurysm; MINAP: Myocardial Ischaemia National 
Audit Project; GPRD: General Practice Research Database; HES: Hospital Episode Statistics; ONS: 
Office for National Statistics mortality data.  
 
Figure 10.2 Flow chart of data losses from 2.5 million GPRD patients to the 11,255 
pateints described in Chapter 5, 16,429 patients described in Chapter 6 and 8,104 
patients described in Chapter 7.  
44,294
patients with MI in 
HES (April 1997-
August 2010)
17,397
patients with MI in 
MINAP (January 2003-
August 2009)
22,499 MIs occurring before 1st
January 2003
1,305 events af ter 31st December 
2008
14,029 patients with a history of  MI
63,478
patients with MI at any time
25,645 patients
49,449 patients
8,530 patients (i) without 1 year of  
UTS registration before MI (ii) aged 
<18 at MI, (iii) with discrepant age 
or sex between MINAP and GPRD 
data, or (iv) without any 
consultations in their GPRD 
record.
17,115 patients
10,393
patients with MI in 
ONS (January 2001-
October 2010)
33,169
patients with MI in GPRD
(January 1960-February 
2010)
2.5 million patients in 
the GPRD dataset
Chapter 7:
8,104 patients with no 
previous atherosclerotic 
disease
Chapter 6:
16,429 patients who had 
previous heart failure, 
cardiac arrest or AAA but no 
ischaemic atherosclerotic 
disease
Chapter 5:
11,255 patients whose MIs 
were recorded in HES or 
MINAP
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10.3 Appendices for Chapter 4 
 
10.3.1 GPRD Read code list used for validation chapter 
Table 10.7 GPRD Read codes used to define myocardial infarction in the validation 
chapter 
 
GPRD 
medical 
code 
Read 
code Read term 
Code 
classification 
241 G30..00 Acute myocardial infarction MI unknown type 
1204 G30..14 Heart attack MI unknown type 
1677 G30..15 MI - acute myocardial infarction MI unknown type 
1678 G308.00 Inferior myocardial infarction NOS MI unknown type 
2491 G30..12 Coronary thrombosis MI unknown type 
3704 G307.00 Acute subendocardial infarction MI unknown type 
5387 G301.00 Other specified anterior myocardial infarction MI unknown type 
7783 323..00 ECG: myocardial infarction MI unknown type 
8935 G302.00 Acute inferolateral infarction MI unknown type 
9507 G307000 Acute non-Q wave infarction MI unknown type 
10562 G307100 Acute non ST segment elevation myocardial infarction NSTEMI 
12139 G300.00 Acute anterolateral infarction MI unknown type 
12229 G30X000 Acute ST segment elevation myocardial infarction STEMI 
13566 G30..11 Attack - heart MI unknown type 
13571 G30..16 Thrombosis - coronary MI unknown type 
14658 G30z.00 Acute myocardial infarction NOS MI unknown type 
14897 G301z00 Anterior myocardial infarction NOS MI unknown type 
14898 G305.00 Lateral myocardial infarction NOS MI unknown type 
15661 G310.11 Dressler's syndrome MI unknown type 
17133 G30A.00 Mural thrombosis MI unknown type 
17689 G30..17 Silent myocardial infarction MI unknown type 
17872 G301100 Acute anteroseptal infarction MI unknown type 
18842 G35..00 Subsequent myocardial infarction MI unknown type 
23708 G361.00 Atrial septal defect/curr comp folow acut myocardal infarct MI unknown type 
23892 G304.00 Posterior myocardial infarction NOS MI unknown type 
24126 G360.00 Haemopericardium/current comp folow acut myocard infarct MI unknown type 
26972 3234.00 ECG:posterior/inferior infarct MI unknown type 
26975 3233.00 ECG: antero-septal infarct. MI unknown type 
28736 G30y000 Acute atrial infarction MI unknown type 
29553 G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI MI unknown type 
29643 G303.00 Acute inferoposterior infarction MI unknown type 
29758 G30X.00 Acute transmural myocardial infarction of unspecif site MI unknown type 
30330 G309.00 Acute Q-wave infarct MI unknown type 
30421 G30..13 Cardiac rupture following myocardial infarction (MI) MI unknown type 
32272 G38..00 Postoperative myocardial infarction MI unknown type 
32854 G30B.00 Acute posterolateral myocardial infarction MI unknown type 
34803 G30y.00 Other acute myocardial infarction MI unknown type 
35119 G501.00 Post infarction pericarditis MI unknown type 
36423 G36..00 Certain current complication follow acute myocardial infarct MI unknown type 
37657 G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn MI unknown type 
38609 G351.00 Subsequent myocardial infarction of inferior wall MI unknown type 
40429 G301000 Acute anteroapical infarction MI unknown type 
41221 G30y200 Acute septal infarction MI unknown type 
41835 G384.00 Postoperative subendocardial myocardial infarction MI unknown type 
Continued... 
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Continued... 
GPRD 
medical 
code 
Read 
code Read term 
Code 
classification 
45809 G350.00 Subsequent myocardial infarction of anterior wall MI unknown type 
46017 G30yz00 Other acute myocardial infarction NOS MI unknown type 
46112 G380.00 
Postoperative transmural myocardial infarction anterior 
wall MI unknown type 
46166 G35X.00 Subsequent myocardial infarction of unspecified site MI unknown type 
46276 G381.00 
Postoperative transmural myocardial infarction inferior 
wall MI unknown type 
52705 3236.00 ECG: lateral infarction MI unknown type 
55401 3235.00 ECG: subendocardial infarct MI unknown type 
59032 323Z.00 ECG: myocardial infarct NOS MI unknown type 
59189 G363.00 
Ruptur cardiac wall w'out haemopericard/cur comp fol ac 
MI MI unknown type 
59940 G364.00 
Ruptur chordae tendinae/curr comp fol acute myocard 
infarct MI unknown type 
61670 889A.00 Diab mellit insulin-glucose infus acute myocardial infarct MI unknown type 
62626 G30y100 Acute papillary muscle infarction MI unknown type 
63467 G306.00 True posterior myocardial infarction MI unknown type 
68357 G31y100 Microinfarction of heart MI unknown type 
68748 G38z.00 Postoperative myocardial infarction, unspecified MI unknown type 
69474 G365.00 
Rupture papillary muscle/curr comp fol acute myocard 
infarct MI unknown type 
72562 G353.00 Subsequent myocardial infarction of other sites MI unknown type 
96838 Gyu3400 
[X]Acute transmural myocardial infarction of unspecif 
site MI unknown type 
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Table 10.8 Recording in primary care, hospital data, ACS registry and death registry of MI patients and records in other data sources within 30 
days 
 
  Non-fatal MI  MI and death of any cause within seven days 
  Primary care 
(GPRD, 
N=13,282) 
Hospital 
admission 
(HES, 
N=12,096) 
ACS registry 
(MINAP, 
N=9,464) 
  Primary care 
(GPRD, 
N=2,009) 
Hospital 
admission 
(HES, 
N=1,248) 
ACS 
registry 
(MINAP, 
N=623) 
Cause 
specific 
mortality 
(ONS 
N=2,882) 
  n (cum %) n (cum %) n (cum %)   n (cum %) n (cum %) n (cum %) n (cum %) 
What 
was 
recorded 
in 
GPRD? 
STEMI 705 (5.3) 664 (5.5) 557 (5.9)   11 (0.6) 7 (0.6) 6 (1) 7 (0.2) 
NSTEMI 2,624 (19.8) 1,948 (21.6) 1,347 (20.1)   9 (0.5) 6 (1) 3 (1.4) 7 (0.5) 
MI NOS 9,953 (74.9) 6,437 (74.8) 4,782 (70.6)   1,989 (99.0) 469 (38.6) 224 (37.4) 1,607 (56.2) 
Unstable angina or ACS     304 (77.3) 408 (75)       7 (39.2) 4 (38) 11 (56.6) 
Other cardiac     1,104 (86.5) 959 (85.1)       112 (48.2) 58 (47.4) 191 (63.3) 
Chest pain     331 (89.2) 282 (88.1)       59 (52.9) 38 (53.5) 71 (65.7) 
Evidence for contact with secondary care±     647 (94.5) 595 (94.4)       303 (77.2) 152 (77.8) 428 (80.6) 
Transfer out of GPRD practice     102 (95.4) 65 (95)       266 (98.5) 128 (98.4) 526 (98.8) 
None of the above*     559 (100) 469 (100)       19 (100) 10 (100) 34 (100) 
                  
What 
was 
recorded 
in HES? 
Primary diagnosis of MI (I21-I23), 1st hospital episode 9,049 (68.1) 12,096 (100) 6,865 (72.5)   482 (24) 1,248 (100) 423 (67.9) 1,065 (37) 
Primary diagnosis of MI (I21-I23) after 1st episode 619 (72.8)     516 (78)   81 (28)     30 (72.7) 97 (40.3) 
Unstable angina 643 (77.6)     655 (84.9)   25 (29.3)     10 (74.3) 36 (41.6) 
Other cardiac 976 (85)     786 (93.2)   150 (36.7)     51 (82.5) 199 (48.5) 
Chest pain 125 (85.9)     76 (94)   11 (37.3)     3 (83) 16 (49) 
None of the above† 1,870 (100)     566 (100)   1,260 (100)     106 (100) 1,469 (100) 
*For both HES and MINAP MI patients, the most common GPRD codes if none of the listed codes were recorded included  'telephone encounter', 'home visit' and codes indicating blood pressure 
readings and blood tests (which are some of the most commonly codes used in the GPRD data source). 
†For both GPRD and MINAP MI patients, the most common ICD codes if none of the listed codes were recorded included end-stage renal disease, hypertensive renal disease, and 
unknown/unspecified causes of morbidity.  
±Evidence for contact with secondary care included codes for hospital discharge, attendance at accident and emergency, consultation with a cardiologist, etc. 
Continued...  
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Table  10.8 continued...  Recording in primary care, hospital data, ACS registry and death registry of MI patients and records in other data sources 
within 30 days   
 
  Non-fatal MI MI and death of any cause within seven days 
  Primary care 
(GPRD, 
N=13,282) 
Hospital 
admission 
(HES, 
N=12,096) 
ACS registry 
(MINAP, 
N=9,464) 
  Primary care 
(GPRD, 
N=2,009) 
Hospital 
admission 
(HES, N=1,248) 
ACS registry 
(MINAP, 
N=623) 
Cause specific 
mortality (ONS 
N=2,882) 
  
n (cum %) n (cum %) n (cum %)   n (cum %) n (cum %) n (cum %) n (cum %) 
                  
What was 
recorded 
in 
MINAP? 
STEMI 3,392 (25.5) 3,440 (28.4) 3,917 (41.4)   152 (7.6) 276 (22.1) 348 (55.9) 303 (10.5) 
NSTEMI 3,294 (50.3) 3,425 (56.8)  5,547 (58.6)    81 (11.6) 147 (33.9)  275 (44.1)  193 (17.2) 
Discharge diagnosis of unstable angina 375 (53.2) 421 (60.2)       14 (12.3) 28 (36.1)     38 (18.5) 
Admission diagnosis of ACS (including MI) 121 (54.1) 138 (61.4)       17 (13.1) 26 (38.2)     37 (19.8) 
No record in MINAP 6,100 (100) 4,672 (100)       1,745 (100) 771 (100)     2,311 (100) 
                  
What was 
recorded 
in ONS? 
MI (I21-I23) underlying               1,621 (80.7) 1,066 (85.4) 496 (79.6) 2,882 (100) 
MI (I21- I23) any other cause               176 (89.4) 71 (91.1) 50 (87.6)     
Other coronary disease (I20-I25) underlying               109 (94.9) 51 (95.2) 32 (92.8)     
Other coronary disease (I20-I25) any other 
cause               24 (96.1) 18 (96.6) 13 (94.9)     
None of the above               79 (100) 42 (100) 32 (100)     
*For both HES and MINAP MI patients, the most common GPRD codes if none of the listed codes were recorded included  'telephone encounter', 'home visit' and codes indicating blood pressure 
readings and blood tests (which are some of the most commonly codes used in the GPRD data source). 
†For both GPRD and MINAP MI patients, the most common ICD codes if none of the listed codes were recorded included end-stage renal disease, hypertensive renal disease, and 
unknown/unspecified causes of morbidity.  
±Evidence for contact with secondary care included codes for hospital discharge, attendance at accident and emergency, consultation with a cardiologist, etc. 
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Table 10.9 Recording of non-fatal GPRD MI in HES and MINAP within 30 days by type of GPRD record (number and %) 
 
Code or category N patients with code 
HES primary 
MI, first 
episode 
HES primary 
MI, not first 
episode 
HES other CHD MINAP STEMI MINAP NSTEMI 
MINAP 
unstable 
angina 
Table                           
 Clinical 15,252 9,040 (68.2) 618 (4.7) 1,615 (12.2) 3,390 (25.6) 3,290 (24.8) 373 (2.8) 
 Referral 114 45 (40.9) 3 (2.7) 19 (17.3) 28 (25.5) 8 (7.3) 4 (3.6) 
 Test 22 13 (61.9) 2 (9.5) 0 (0) 6 (28.6) 3 (14.3) 0 (0) 
               
Entity code              
 Medical history 13,789 8,853 (68.7) 606 (4.7) 1,573 (12.2) 3,333 (25.9) 3,214 (24.9) 366 (2.8) 
 CHD register 6,637 4,679 (71.1) 283 (4.3) 699 (10.6) 2,002 (30.4) 1,501 (22.8) 180 (2.7) 
 CV/BP consultation 4 1 (25) 0 (0) 2 (50) 1 (25) 1 (25) 0 (0) 
 Well person concerns 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 Cause of death 1,265 75 (70.8) 2 (1.9) 8 (7.5) 10 (9.4) 29 (27.4) 2 (1.9) 
 Serum cholesterol 2 2 (100) 0 (0) 0 (0) 1 (50) 1 (50) 0 (0) 
 ECG 20 11 (57.9) 2 (10.5) 0 (0) 5 (26.3) 2 (10.5) 0 (0) 
               
Read term              
 Acute myocardial infarction 5,189 3,450 (66.5) 239 (4.6) 665 (12.8) 1,420 (27.4) 1,115 (21.5) 167 (3.2) 
 MI - acute myocardial infarction 3,294 2,159 (65.5) 124 (3.8) 419 (12.7) 916 (27.8) 725 (22) 98 (3) 
 Acute non ST segment elevation myocardial infarction 2,624 1,886 (71.9) 168 (6.4) 320 (12.2) 102 (3.9) 1,200 (45.7) 64 (2.4) 
 Acute myocardial infarction NOS 749 496 (66.2) 49 (6.5) 86 (11.5) 161 (21.5) 181 (24.2) 26 (3.5) 
 Acute ST segment elevation myocardial infarction 708 614 (86.7) 16 (2.3) 55 (7.8) 460 (65) 62 (8.8) 6 (0.8) 
 Inferior myocardial infarction NOS 446 373 (83.6) 7 (1.6) 20 (4.5) 255 (57.2) 29 (6.5) 14 (3.1) 
 Anterior myocardial infarction NOS 114 92 (80.7) 2 (1.8) 8 (7) 66 (57.9) 11 (9.6) 3 (2.6) 
 Other specified anterior myocardial infarction 78 50 (64.1) 4 (5.1) 9 (11.5) 28 (35.9) 6 (7.7) 1 (1.3) 
 Heart attack 73 31 (42.5) 8 (11) 13 (17.8) 12 (16.4) 14 (19.2) 0 (0) 
Continued... 
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Code or category 
N 
patients 
with 
code 
HES primary 
MI, first 
episode 
HES primary 
MI, not first 
episode 
HES other 
CHD MINAP STEMI 
MINAP 
NSTEMI 
MINAP 
unstable 
angina 
 Acute anterolateral infarction 58 48 (82.8) 2 (3.4) 3 (5.2) 29 (50) 4 (6.9) 1 (1.7) 
 Acute inferolateral infarction 57 45 (78.9) 2 (3.5) 2 (3.5) 31 (54.4) 2 (3.5) 2 (3.5) 
 Acute non-Q wave infarction 38 24 (63.2) 2 (5.3) 5 (13.2) 3 (7.9) 11 (28.9) 1 (2.6) 
 Acute anteroseptal infarction 34 28 (82.4) 1 (2.9) 1 (2.9) 16 (47.1) 6 (17.6) 1 (2.9) 
 Acute subendocardial infarction 30 22 (73.3) 1 (3.3) 1 (3.3) 1 (3.3) 11 (36.7) 1 (3.3) 
 ECG: myocardial infarction 28 12 (42.9) 2 (7.1) 2 (7.1) 6 (21.4) 2 (7.1) 0 (0) 
  Posterior myocardial infarction NOS 23 14 (60.9) 2 (8.7) 2 (8.7) 8 (34.8) 4 (17.4) 0 (0) 
 Silent myocardial infarction 22 2 (9.1) 0 (0) 3 (13.6) 0 (0) 1 (4.5) 0 (0) 
 Postoperative myocardial infarction 18 1 (5.6) 1 (5.6) 4 (22.2) 1 (5.6) 3 (16.7) 0 (0) 
 Mural thrombosis 16 3 (18.8) 0 (0) 3 (18.8) 0 (0) 0 (0) 0 (0) 
 Acute inferoposterior infarction 16 13 (81.3) 0 (0) 1 (6.3) 8 (50) 3 (18.8) 1 (6.3) 
 Lateral myocardial infarction NOS 14 8 (57.1) 0 (0) 3 (21.4) 6 (42.9) 1 (7.1) 0 (0) 
 Dressler's syndrome 12 0 (0) 0 (0) 6 (50) 0 (0) 0 (0) 0 (0) 
 Other acute myocardial infarction 8 6 (75) 0 (0) 2 (25) 1 (12.5) 2 (25) 0 (0) 
 Acute septal infarction 8 2 (25) 1 (12.5) 1 (12.5) 3 (37.5) 0 (0) 0 (0) 
 Attack - heart 7 2 (28.6) 0 (0) 1 (14.3) 2 (28.6) 0 (0) 0 (0) 
 Subsequent myocardial infarction 7 2 (28.6) 0 (0) 2 (28.6) 1 (14.3) 2 (28.6) 0 (0) 
 Other acute myocardial infarction NOS 7 2 (28.6) 0 (0) 1 (14.3) 0 (0) 1 (14.3) 0 (0) 
 ECG: antero-septal infarct. 6 1 (16.7) 0 (0) 0 (0) 0 (0) 1 (16.7) 0 (0) 
 Coronary thrombosis 5 2 (40) 0 (0) 2 (40) 1 (20) 2 (40) 0 (0) 
 Thrombosis - coronary 5 3 (60) 0 (0) 1 (20) 0 (0) 3 (60) 0 (0) 
 Subsequent myocardial infarction of inferior wall 4 3 (75) 0 (0) 0 (0) 3 (75) 0 (0) 0 (0) 
 ECG:posterior/inferior infarct 3 2 (66.7) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 0 (0) 
 Acute posterolateral myocardial infarction 3 2 (66.7) 0 (0) 0 (0) 2 (66.7) 0 (0) 0 (0) 
 True posterior myocardial infarction 3 3 (100) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 
Continued... 
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Code or category 
N 
patients 
with 
code 
HES primary 
MI, first 
episode 
HES primary 
MI, not first 
episode 
HES other 
CHD MINAP STEMI 
MINAP 
NSTEMI 
MINAP 
unstable 
angina 
 Acute atrial infarction 2 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 
 Acute transmural myocardial infarction of unspecif site 2 2 (100) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 
 Acute Q-wave infarct 2 0 (0) 0 (0) 1 (50) 0 (0) 0 (0) 0 (0) 
 Post infarction pericarditis 2 1 (50) 0 (0) 1 (50) 1 (50) 0 (0) 0 (0) 
 Postoperative myocardial infarction, unspecified 2 0 (0) 0 (0) 1 (50) 0 (0) 0 (0) 0 (0) 
 Atrial septal defect/curr comp folow acut myocardal infarct 1 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 
 
Thrombosis atrium,auric 
append&vent/curr comp foll acute 
MI 
1 0 (0) 0 (0) 1 (100) 1 (100) 0 (0) 0 (0) 
 Certain current complication follow acute myocardial infarct 1 1 (100) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 
 Acute anteroapical infarction 1 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 
 Postoperative subendocardial myocardial infarction 1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 
 ECG: myocardial infarct NOS 1 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
  Subsequent myocardial infarction of other sites 1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 
Note:  Agreement varied between specific Read terms used to identify MI in GPRD.  Read terms stating MI with an anatomical location (e.g. ‘Acute 
anterolateral infarction’) were associated with a HES primary record of MI within 30 days in about 80% of cases, whereas for less specific terms stating 
‘acute myocardial infarction’ the proportion was slightly lower, at 67%.  Even fewer patients with Read terms stating ‘heart attack’ or ‘coronary thrombosis’ 
had a HES primary record of MI (43% and 40%, respectively) (supplementary table 3).  There was a similar pattern in the Read codes associated with MI in 
the ACS registry. 
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Table 10.10 Recording of fatal and non-fatal HES MI in GPRD and MINAP within 30 days by type of HES record (number and %) 
Non-fatal MI 
 
MI record 
in HES 
N patients Any GPRD MI GPRD STEMI GPRD NSTEMI GPRD MI NOS GPRD other CHD MINAP STEMI MINAP NSTEMI MINAP unstable 
angina 
ICD I21 10,870 8,221 (75.6) 610 (5.6) 1,731 (15.9) 5,880 (54.1) 1,227 (11.3) 3,213 (29.6) 3,009 (27.7) 368 (3.4) 
ICD I22 1,213 823 (67.8) 53 (4.4) 216 (17.8) 554 (45.7) 178 (14.7) 225 (18.5) 415 (34.2) 53 (4.4) 
ICD I23 13 5 (38.5) 1 (7.7) 1 (7.7) 3 (23.1) 3 (23.1) 2 (15.4) 1 (7.7) 0 (0) 
 
 
Fatal MI 
 
MI record 
in HES 
N patients Any GPRD MI GPRD STEMI GPRD NSTEMI GPRD MI NOS GPRD ACS or 
other cardiac 
MINAP STEMI MINAP NSTEMI MINAP unstable 
angina 
ICD I21 1,098 415 (37.8) 7 (0.6) 5 (0.5) 403 (36.7) 100 (9.1) 254 (23.1) 128 (11.7) 21 (1.9) 
ICD I22 146 67 (45.9) 0 (0) 1 (0.7) 66 (45.2) 19 (13) 22 (15.1) 18 (12.3) 7 (4.8) 
ICD I23 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 
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Table 10.11 Recording of fatal and non-fatal MINAP MI in GPRD and HES within 30 days by type of MINAP record (number and %) 
 
Non-fatal MI 
MI record 
in MINAP 
N patients GPRD any MI GPRD STEMI GPRD NSTEMI GPRD MI NOS GPRD ACS or 
other cardiac 
HES primary first 
episode MI HES primary MI, 
not first episode 
HES other 
CHD 
STEMI 3,917 3,381 (86.3) 489 (12.5) 105 (2.7) 2,787 (71.2) 241 (6.2) 3,430 (87.6) 91 (2.3) 276 (7) 
NSTEMI 5,547 3,305 (59.6) 68 (1.2) 1,242 (22.4) 1,995 (36) 1,126 (20.3) 3,435 (61.9) 425 (7.7) 1,165 (21) 
 
Fatal MI 
MI record 
in MINAP 
N patients GPRD any MI GPRD STEMI GPRD NSTEMI GPRD MI NOS GPRD ACS or 
other cardiac 
HES primary first 
episode MI HES primary MI, 
not first episode 
HES other 
CHD 
STEMI 348 152 (43.7) 5 (1.4) 0 (0) 147 (42.2) 23 (75.9) 276 (79.3) 5 (1.4) 23 (6.6) 
NSTEMI 275 81 (29.5) 1 (0.4) 3 (1.1) 77 (28) 39 (14.2) 147 (53.5) 25 (9.1) 38 (13.8) 
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10.3.2 Prevalence and concordance of atherosclerotic disease and risk 
factors in each data source 
 
Prevalence and concordance in MINAP and GPRD 
The prevalences of angina, PAD, CVD and heart failure were higher in GPRD for 
all disease types, but was similar for PCI and CABG.  Despite small differences in 
prevalences, concordance was above 90% for all diagnoses.  Concordance for risk factors 
and medication use was also relatively high, although there were some differences in 
prevalence.  The prevalences were lower in MINAP, particularly for medication use.  This is 
due to high amounts of missingness in these MINAP variables (missing was defined as 
concordant in this analysis). 
 
Table 10.12 Prevalence and concordance of key atherosclerotic disease diagnoses, 
cardiovascular disease risk factors and medications used in the six months before MI in 
8,059 patients   
 
For 8059 MINAP cases 
Prevalence in 
MINAP 
N=8,059 
Prevalence in 
GPRD 
N=8,059 
% 
concordance 
MINAP vs 
GPRD* 
Atherosclerotic disease       
Angina 15.6 20.3 90.2 
PAD 3.2 8.7 93.5 
CVD 5.8 7.6 94.9 
Heart failure 3.0 5.9 95.0 
PCI 1.9 1.6 98.1 
CABG 1.6 1.8 99.3 
Risk factors 
Hypertension 39.3 39.3 82.5 
Diabetes 13.4 13.4 97.1 
Overweight or obese 12.5 12.4 99.6 
Dyslipidaemia 21.1 13.6 80.3 
Family history 16.7 21.6 84.6 
Medications before AMI 
Statins 16.2 26.0 92.0 
Antiplatelets 16.6 28.2 82.1 
Beta blockers 11.9 19.0 93.5 
  ACEI 14.4 27.4 92.3 
*Assuming missingness in MINAP is concordant with GPRD 
 
Appendix A 
369 
 
Sensitivity and specificity of GPRD and MINAP 
If GPRD is taken as the gold standard diagnosis, the sensitivity of a MINAP record 
of previous diagnoses or medication use is low (ranging from 24% for heart failure to 78% 
for diabetes).  Specificity of MINAP is better, ranging from 46% for statin use to 85% for 
diabetes). 
If MINAP is taken as the gold standard diagnosis, the sensitivity of a GPRD record 
of previous diagnosis or medication use is variable (ranging from 30% in dyslipidaemia to 
89% in diabetes).  The specificity of GPRD is even higher, ranging from 78% in 
hypertension to nearly 100% for the recording of CABG. 
 
Table 10.13 Sensitivity and specificity of MINAP with respect to GPRD, and GPRD 
with respect to MINAP for key atherosclerotic disease, risk factors and medication use 
before MI in 8,059 patients 
 
For 8,059 MINAP cases 
Sensitivity 
of MINAP 
Specificity 
of MINAP 
Sensitivity 
of GPRD 
Specificity 
of GPRD 
Atherosclerotic disease         
Angina 57.4 78.0 74.8 91.4 
PAD 22.6 78.2 62.4 93.1 
CVD 44.4 77.7 58.6 96.3 
Heart failure 24.4 78.9 48.0 95.7 
PCI 47.3 80.6 40.3 99.1 
CABG 71.2 81.5 80.0 99.6 
Risk factors 
Hypertension 65.7 68.9 80.8 78.2 
Diabetes 77.9 84.8 89.3 98.0 
Dyslipidaemia 46.8 62.9 30.0 91.7 
Family history 29.1 34.1 37.6 84.4 
Medications before MI 
Statins 45.9 46.4 73.5 90.2 
Antiplatelets 43.9 84.7 74.4 81.7 
Beta blockers 42.4 48.5 67.3 93.9 
  ACEI 40.9 47.5 78.1 88.4 
PAD: peripheral arterial disease; CVD: cerebrovascular disease; PCI: percutaneous coronary 
intervention; CABG: coronary artery bypass graft; ACEI: angiotensin converting enzyme inhibitors. 
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Concordance in HES and GPRD 
Concordance of atherosclerotic disease, PCI and CABG was high between HES and 
GPRD.  Recording of hypertension, dyslipidaemia and family history were lower in HES.   
 
Table 10.14 Prevalence and concordance of key atherosclerotic disease diagnoses, 
cardiovascular disease risk factors and medications in the six months before MI in 
12,005 patients 
 
  
 For 12,005 HES cases 
HES 
prevalence 
N=12,005 
GPRD 
prevalence 
N=12,005 
% concordance 
HES vs GPRD* 
Atherosclerotic disease       
Angina 10.0 22.0 84.8 
PCI 1.3 1.7 98.6 
CABG 1.3 1.9 98.2 
PAD 3.8 9.3 92.4 
CVD 4.8 9.1 93.0 
TIA 1.2 5.9 94.6 
Heart failure 5.0 7.2 93.6 
Cardiac arrest 0.9 0.2 99.0 
Risk factors 
Hypertension 21.6 49.2 65.6 
Diabetes 8.9 15.9 92.5 
Dyslipidaemia 5.4 13.8 85.4 
  Family history 17.9 21.2 74.4 
*Assuming absence of codes in both HES and GPRD indicate a negative result. 
Note: cardiovascular medications are not recorded in HES. 
PAD: peripheral arterial disease; CVD: cerebrovascular disease; PCI: percutaneous coronary 
intervention; CABG: coronary artery bypass graft; TIA: transient ischaemic attack. 
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Sensitivity and specificity of GPRD and HES 
The specificity of records in GPRD and HES were both high and all measures were 
above 80%.  The sensitivity of diagnoses was less high.   
 
Table 10.15 Sensitivity and specificity of HES with respect to GPRD, and GPRD with 
respect to HES for key atherosclerotic disease, risk factors and medication use before 
MI in 12,005 patients 
 
For 12,005 HES cases 
Sensitivity 
of HES 
Specificity 
of HES 
Sensitivity 
of GPRD 
Specificity 
of GPRD 
Atherosclerotic disease         
Angina 38.1 97.9 83.7 84.9 
PCI 46.7 99.5 64.5 99.1 
CABG 36.8 99.4 56.6 98.8 
PAD 29.5 98.9 73.4 93.2 
CVD 38.1 98.5 71.8 94.1 
TIA 15.1 99.6 72.3 94.9 
Heart failure 39.9 97.7 57.9 95.4 
Cardiac arrest 20.0 99.2 4.8 99.8 
Risk factors 
Hypertension 37.0 93.4 84.4 60.4 
Diabetes 54.5 99.6 96.6 92.1 
Dyslipidaemia 16.9 96.4 43.0 87.8 
  Family history 31.9 85.9 37.8 82.4 
Note: cardiovascular medications are not recorded in HES. 
PAD: peripheral arterial disease; CVD: cerebrovascular disease; PCI: percutaneous coronary 
intervention; CABG: coronary artery bypass graft; TIA: transient ischaemic attack. 
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10.4 Appendices for Chapter 5 
 
10.4.1 Literature review search strategy  
Table 10.16 Medline search strategies. 
 
Search number Terms included 
1. Myocardial 
infarction 
The following MI synonyms in the title: 
 
myocardial infarct* OR stemi OR heart attack OR cardiac 
infarct* OR acute infarct* OR STEAMI OR coronary attack OR 
myocardial thrombosis OR coronary thrombosis OR coronary 
infarct* OR heart infarct* OR Q wave infarct* OR acute 
coronary OR pre-infarct* OR preinfarct* 
  
2. Heralding 
synonyms 
The following terms in the title: 
 
before OR preced* OR herald* OR previous* OR prior OR 
earlier OR advance OR former OR ahead OR sooner OR pre-
exist* OR exist* OR precur* OR prodrom* OR anteced* OR 
presence OR history OR prevalen* OR recogni* OR document 
OR record* OR preinfarct* OR pre-infarct* 
 
3. Inclusion 
criteria 
1 & 2, restricted to studies in humans and in the English 
language 
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10.4.2 Heralding by atherosclerotic disease, by calendar year 
 
Figure 10.3 Proportion of patients with previously diagnosed atherosclerotic disease, 
by calendar year of myocardial infarction, with 95% confidence intervals (N=11,255) 
 
 
10.4.3 Initial manifestation of atherosclerotic disease in patients heralded by 
atherosclerotic disease 
Table 10.17 Initial previous disease manifestation in cases, and duration of disease 
before MI in 11,255 patients 
 
    Median duration 
before MI, years 
(IQR) n (%) 
Any atherosclerotic disease 4,897 (43.5) 6.7 (2.5-11.9) 
Coronary disease 3,170 (29.7) 3.7 (0.8-8.4) 
Stable angina 1,686 (15) 8.1 (3.1-13.3) 
Unstable angina 163 (1.4) 0.9 (0-4.9) 
PCI or CABG 104 (0.9) 11.4 (0.8-18.3) 
Heart failure 516 (4.6) 4.4 (1.5-8.3) 
Cardiac arrest 13 (0.1) 4.9 (0.1-7.7) 
CHD not otherwise specified 688 (6.1) 7.9 (3-12.2) 
Other atherosclerotic disease 1,678 (16.1) 5.6 (2.3-9.9) 
Cerebrovascular disease 943 (8.4) 6.9 (2.9-12.5) 
Peripheral arterial disease 735 (6.5) 5.9 (2.6-9.8) 
Unknown atherosclerotic disease 49 (0.4) 7.7 (2.5-11.9) 
MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary 
artery bypass graft; CHD: coronary heart disease; IQR: inter-quartile range. 
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10.4.4 Heralding by atherosclerotic disease, by myocardial infarction type 
Table 10.18 The prevalence of atherosclerotic disease at any time, by MI type 
(N=6,871) 
 
  
STEMI (N=3,304) 
NSTEMI 
(N=3,567) 
n (%) n (%) 
Any atherosclerotic disease 973 (29.4) 1,799 (50.4) 
Coronary disease 695 (21) 1,472 (41.3) 
Stable angina 509 (15.4) 1,177 (33) 
Unstable angina 58 (1.8) 215 (6.0) 
PCI or CABG 87 (2.6) 215 (6.0) 
Heart failure 133 (4) 422 (11.8) 
Cardiac arrest 15 (0.5) 37 (1.0) 
CHD not otherwise specified 371 (11.2) 864 (24.2) 
Other atherosclerotic disease 460 (13.9) 839 (23.5) 
Cerebrovascular disease 237 (7.2) 444 (12.4) 
Peripheral arterial disease 231 (7.0) 466 (13.1) 
Unknown atherosclerotic disease 18 (0.5) 52 (1.5) 
STEMI: ST-elevation myocardial infarction; NSTEMI: non ST-elevation myocardial infarction; 
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CHD: 
coronary heart disease; IQR: inter-quartile range. 
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10.4.5 Demographics in patients with and without elevated vascular disease 
risk factors 
Table 10.19 Demographic distribution of patients without previously diagnosed 
atherosclerotic disease and with or without elevated cardiovascular disease risk 
(N=6,358) 
 
    
No disease with risk 
factors* 
N=5,548 
Without warning 
N=810 Total 
Median age, years (IQR) 65 (56-76) 73 (62-82) 66 (56-77) 
Female, n (%) 1,896 (34.2) 270 (33.3) 2,166 (34.1) 
Ethnicity, n (%)  
White 4,443 (80.1) 644 (79.5) 5,087 (80) 
South Asian 45 (0.8) 4 (0.5) 49 (0.8) 
Other 109 (2) 15 (1.9) 124 (2) 
Unknown 951 (17.1) 147 (18.1) 1,098 (17.3) 
IMD quintile, n (%) 
1 (Least deprived) 1,117 (26) 205 (32.6) 1,322 (26.8) 
2 951 (22.1) 141 (22.5) 1,092 (22.2) 
3 906 (21.1) 123 (19.6) 1,029 (20.9) 
4 764 (17.8) 111 (17.7) 875 (17.8) 
5 (Most deprived) 559 (13) 48 (7.6) 607 (12.3) 
Consultations per year, n 
(IQR) 5.0 (2.6-8.5) 3.5 (1.7-6.6) 4.7 (2.4-8.3) 
Years of pre-MI GPRD 
registration, n (IQR) 8.5 (5.4-13.2) 8.3 (5.2-13.3) 8.4 (5.3-13.2) 
                
IMD: index of multiple deprivation; IQR: inter-quartile range; GPRD: General Practice 
Research Database 
*Patients without previously diagnosed atherosclerotic disease, but with elevated 
cardiovascular disease risk factors or using one or more cardiovascular medications. 
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10.4.6 Sensitivity analyses figures 
 
Figure 10.4 Proportion of patients heralded, by percentile of consultation rate (95% 
CIs) (N=11,255) 
 
 
 
 
 
Figure 10.5 Rate of onset of atherosclerotic disease before MI in patients whose first 
date of atherosclerotic disease was inside UTS, with 95% confidence intervals.  Note 
that patients whose first date of atherosclerotic disease diagnosis was before the start of 
their UTS follow-up were dropped from analysis (N=11,255) 
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Abstract 
Aims: It is widely thought that ST-elevation myocardial infarction (STEMI) is more likely 
to occur without warning (i.e. an unanticipated event in a previously healthy person) than 
non ST-elevation myocardial infarction (NSTEMI), but no large study has evaluated this 
using prospectively collected data.   
Methods and results: We identified patients experiencing STEMI and NSTEMI in the 
national registry of myocardial infarction for England and Wales (Myocardial Ischaemia 
National Audit Project), for whom linked primary care records were available in the General 
Practice Research Database (as part of the CALIBER collaboration). We compared the 
prevalence and timing of atherosclerotic disease and major cardiovascular risk factors 
including smoking, hypertension, diabetes, and dyslipidaemia, between patients later 
experiencing STEMI to those experiencing NSTEMI.   
8174 myocardial infarction patients were included (3780 STEMI, 4394 NSTEMI). The 
proportion occurring unheralded by previously diagnosed atherosclerotic disease, risk 
factors or chest pain was 14% (95% CI: 13-16%) in STEMI and 9% (95% CI: 9-10%) in 
NSTEMI, but there was a greater prior atherosclerotic burden in NSTEMI than STEMI 
patients. The rate of heralding coronary diagnoses was particularly high in the 12 months 
before infarct; 4.1 times higher (95% CI: 3.3-5.0) in STEMI and 3.6 times higher (95% CI: 
3.1-4.2) in NSTEMI compared to the rate in earlier years.   
Conclusion: Acute myocardial infarction occurring without prior coronary, cerebrovascular 
or peripheral arterial disease, risk factors or symptoms is uncommon for both STEMI and 
NSTEMI.  Better understanding of the antecedents in the year before myocardial infarction 
is required. 
Key words: epidemiology, myocardial infarction, cardiovascular diseases, risk factors
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Background 
The extent to which first acute myocardial infarction (AMI) with or without ST-
elevation is heralded by previous symptomatic atherosclerotic disease, major risk factors or 
symptoms has important implications for understanding the etiology of each phenotype, as 
well as the provision of optimal services.  Studies which retrospectively evaluate medical 
history suggest that prior atherosclerotic disease is common in people with AMI,(1-5) and 
patterns differ according to ST-elevation myocardial infarction (STEMI) and non ST-
elevation myocardial infarction (NSTEMI).  Patients with NSTEMI tend to have higher 
levels of angina,(6, 7) heart failure symptoms,(8) CABG and PCI,(6, 9, 10) and peripheral 
vascular disease(7) compared to patients with STEMI.  
However many of these studies take a single, retrospective snapshot of medical 
history and have important limitations.  They may underestimate the burden of prior disease 
(i.e. falsely inflating the estimate of unheralded AMI) and may poorly reflect the timing of 
initial and subsequent manifestations of disease.   To our knowledge, no large scale study to 
date has evaluated the extent and nature of STEMI and NSTEMI heralding using 
prospectively collected information on the onset of atherosclerotic disease (in coronary, 
cerebral and peripheral circulations) and other risk factors. 
Therefore this paper aims to compare the evolution of atherosclerotic disease and 
cardiovascular risk between people going on to experience STEMI and NSTEMI.  Using 
prospectively collected longitudinal primary care data linked to detailed hospital data on 
acute coronary syndromes, we describe the initial manifestation, distribution and timing of 
different atherosclerotic presentations before first STEMI and NSTEMI, and the proportion 
of MIs that occur without any previously diagnosed atherosclerotic disease, cardiovascular 
risk factors or chest pain.   
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Methods 
Study design 
As part of the CALIBER research programme (Cardiovascular disease research 
using Linked Bespoke studies and Electronic Records, www.caliberresearch.org),(11) the 
records of patients presenting with STEMI and NSTEMI in the Myocardial Ischaemia 
National Audit Project (MINAP) were linked to longitudinal electronic health records from 
primary care from the General Practice Research Database (GPRD). 
MINAP 
MINAP is the national registry of patients admitted to hospitals in England and 
Wales with ACS.(12)  The MINAP dataset records timing of symptom onset and admission, 
clinical features and investigations (including ECG results and cardiac biomarkers), past 
medical history, hospital treatment and discharge diagnosis.(12)   
GPRD 
The GPRD is a primary care database containing anonymised patient records from 
general practices for approximately eight percent of the UK population (5.2 million 
patients).(13)  General practitioners (GPs) play a key role in the UK healthcare system as 
they are responsible for primary health care and specialist referrals. Patients are affiliated to 
a practice, which centralizes the medical information from the GP (diagnoses, symptoms, 
prescriptions, treatments and health behaviors), specialist referrals, and hospitalizations, so 
that GP data provide a comprehensive longitudinal health record.  Around 40% of the 
general practices in GPRD permit linkage of individual patient records with other data 
sources.(14)  Data from these practices, all in England, are used in the current study.  
Linkage  
Linkage of MINAP with GPRD permits researchers to establish a longitudinal 
patient journey before and after ACS, while providing greater clinical detail on ACS events 
than is reliably available within GPRD.  The pseudoanonymised dataset was created using a 
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Trusted Third Party to perform the linkage, based on patient NHS number, date of birth, 
gender and postcode.(11)   
Definition of acute myocardial infarction 
STEMI or NSTEMI was defined by details recorded in MINAP, following the joint 
American Heart Association / European Society of Cardiology definition.(15) In order to 
confine the analysis to first acute myocardial infarction (AMI), we excluded patients with a 
history of AMI noted in their MINAP record, or with evidence of AMI in their GPRD record 
prior to the first AMI recorded in MINAP. We included patients fulfilling the following 
criteria: at least eighteen years of age at AMI, first AMI occurring between 1st January 2003 
and 31st December 2008; registered with the GPRD practice at the time of AMI; with at least 
one year of observation before AMI and at least one consultation during pre-AMI follow-up 
to allow prevalent diagnoses to be recorded once a patient joins a practice (Supplementary 
Figure 1).   
 
Identifying atherosclerotic cardiovascular disease and risk factors in the 
linked data 
MINAP and GPRD data were used to identify atherosclerotic disease and 
cardiovascular risk factors among study patients. Atherosclerotic disease included cardiac 
disease, (AMI, stable angina, unstable angina, cardiac arrest, heart failure, coronary heart 
disease (CHD) not otherwise specified, receipt of percutaneous coronary intervention (PCI) 
and coronary artery bypass graft (CABG));  ischemic cerebrovascular disease, including 
stroke, non stroke cerebrovascular disease and transient ischemic attack; peripheral arterial 
disease (PAD), including abdominal aortic aneurysm.   
Risk factors investigated were smoking (categorized as non, ex, current or unknown 
at the time of AMI), hypertension (either diagnosed hypertension or three consecutive raised 
(>140/90mm Hg) measurements), dyslipidaemia (abnormal lipid measurements or 
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management of high lipids) and diabetes (diagnosed diabetes or insulin prescription) and 
were defined by codes in the primary care or MINAP hospital record.  We also determined 
whether patients had been prescribed blood pressure lowering, lipid-lowering or antiplatelet 
medications in the six months before AMI.   Missing data from MINAP variables and 
absence of any diagnostic codes in the GPRD were taken to indicate absence of the risk 
factor or morbidity.  
 
Determining onset and duration of diagnosed atherosclerotic disease before 
AMI 
For patients whose AMI was heralded by a diagnosis of atherosclerotic disease, we 
took the earliest record of any atherosclerotic disease before AMI in the GPRD to be the 
date of onset (data on timing of prior disease is not recorded in MINAP).  Where this code 
was for a prevalent diagnosis (e.g. ‘history of stroke’) or the morbidity was recorded only in 
MINAP, the date of onset was recorded as missing.  The earliest date of each subtype of 
atherosclerotic disease (coronary, cerebrovascular, peripheral arterial) was ascertained using 
the same method.  This allowed calculation of the duration of diagnosed disease before AMI 
and the rate of diagnosis before STEMI and NSTEMI.   
Consultation or admission for chest pain in the linked data 
In patients without diagnosed atherosclerotic disease, we assessed the frequency of 
primary care consultations for chest pain.   
Statistical analysis 
The proportions with diagnosed atherosclerotic disease and risk factors were 
calculated for STEMI and NSTEMI patients. Since the age and sex profiles of STEMI and 
NSTEMI patients differed, we included each atherosclerotic disease/risk factor in turn in an 
age- and sex-adjusted logistic regression model to determine whether the odds of prior 
disease/risk factor differed between STEMI and NSTEMI patients, after accounting for age 
and sex differences.  We used the models to assess interaction between age and sex.  We 
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also calculated the age and sex standardized prevalences of each atherosclerotic disease 
subtype and risk factor for STEMI and NSTEMI patients, using the age and sex distribution 
of the study population as the standard.   
To investigate the timing of disease prior to AMI, we calculated rates of new 
coronary, cerebrovascular, and peripheral arterial disease in one-year timebands in the 
period before AMI, and rates of new coronary diagnoses and chest pain consultations in one-
month timebands in the period before AMI. We used Poisson regression to calculate rate 
ratios and 95% confidence intervals, comparing the rate of coronary diagnosis in the year 
before AMI to the rate in the previous nine years, and also to test for linear trend in the rate 
of diagnosis in the years leading to AMI.  All analyses were performed in STATA.  The 
study details are registered online at clinicaltrials.gov (NCT01379131) and a time-stamped 
detailed analytic protocol is available on request.  CALIBER has received ethics approval 
(ref 09/H0810/16) for creation of linked pseudoanonymised data encompassing GPRD and 
MINAP. 
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Results 
We identified 8174 first AMI patients who met the eligibility criteria.  Their median 
age was 71 (IQR 59-80), 2946 (36%) were women and 3780 (46%) had STEMI.  The 
median duration of follow-up before AMI was 8.7 years (overall 77,228 person years of 
follow-up).  Table 1 shows the demographic and hospital admission characteristics of 
patients by AMI type.   
[Table 1] [Figure 1] 
Acute myocardial infarction occurring with and without heralding 
Among patients with STEMI, 29% had prior atherosclerotic disease, 56% had no 
prior atherosclerotic disease diagnosis but at least one cardiovascular risk factor and 0.6% 
experienced only chest pain, leaving 14% (95% CI: 13-16%) unheralded.  In NSTEMI 
patients 50% had previous disease, 40% had no previous disease but at least one 
cardiovascular risk factor, 0.7% reported only chest pain and 9% (9-10%) experienced 
unheralded AMI (Figure 1). Thus NSTEMIs were more often heralded by prior 
atherosclerotic disease rather than other risk factors only. STEMIs were more likely to be 
unheralded than NSTEMIs, but the absolute proportions of unheralded MIs were low for 
both types.  
Diagnosed atherosclerotic disease before first AMI 
Overall 3326 (41%) of patients had previously diagnosed atherosclerotic disease.  
Patients with NSTEMI experienced more disease (STEMI 29%, NSTEMI 50%, age and sex 
standardized values 32% and 47%, respectively, P<0.001) and this pattern was consistent 
across age groups, for men and women and for different atherosclerotic disease 
manifestations, even after standardizing for age and sex (Table 2).  There was no age-sex 
interaction. Coronary disease was the most common presentation before AMI, diagnosed in 
21% of STEMI patients and 41% of NSTEMI; most of these patients had stable angina (16% 
in STEMI and 33% in NSTEMI).  Although most patients with previous disease had a 
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coronary diagnosis, 9% of STEMIs and 10% of NSTEMIs were heralded only by PAD 
and/or atherosclerotic cerebrovascular disease. 
Thirty percent of patients were diagnosed with disease in only one arterial bed, 9% 
in two and 2% in three.  The extent of disease differed by AMI type (age and sex adjusted 
logistic regression P<0.001); overall 15% of patients with NSTEMI had disease at more than 
one site, compared to 6% in STEMI, Figure 2).    
[Figure 2] [Table 2] 
Of the 3326 patients with atherosclerotic disease diagnoses, we were able to 
estimate a date of disease onset for 2891 (87%; 84% STEMI, 89% NSTEMI).  Throughout 
the ten years preceding infarction, the rates of diagnosis of coronary, cerebrovascular and 
peripheral disease were higher in NSTEMI than STEMI (Figure 3).  The rates of 
cerebrovascular disease and PAD remained stable throughout follow-up, with an upward 
trend towards AMI over time (average increase in rate per one year timeband: 1.06 (95% CI 
1.03-1.10), P<0.001).  Rates of coronary disease were higher than rates of peripheral or 
cerebrovascular disease throughout follow-up, consistent with the higher prevalence of 
coronary disease at the time of AMI. 
In contrast to the patterns observed in cerebrovascular and peripheral diseases, the 
rate of coronary disease diagnosis rose rapidly in the year before AMI (Figures 3 & 4A).  
Compared to the rate in the previous nine years, the rate of coronary diagnosis was 4.1 times 
higher (95% CI: 3.3-5.0) in the year before STEMI and 3.6 (3.1-4.2) times higher in the year 
before NSTEMI.  Figure 4A shows that these increases were largely restricted to the three 
months before infarct, during which 159 (2%) patients were first diagnosed with coronary 
disease or received a coronary intervention (stable angina (n=102), unstable angina (n=17), 
CHD of unspecified type (n=26), PCI/CABG (n=14)).  A similar pattern was observed in the 
rate of chest pain consultations in patients without diagnosed atherosclerotic disease (Figure 
4B).       
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Among patients with prior atherosclerotic disease, the median duration between first 
diagnosis and STEMI was 6.2 years (IQR 2.2-11.7) and in NSTEMI 7.6 years (3.2-13.4) 
(Table 2).  The median duration of all atherosclerotic diseases combined was longer in 
NSTEMI at all age groups and for men and women (Supplementary Table 1).  Importantly, 
the duration of diagnosed disease tended to be long: 26% of atherosclerotic disease heralding 
in STEMI and 35% in NSTEMI was ten or more years’ duration (48% and 57% five or more 
years, respectively).   
 
Use of cardiovascular medications in patients with atherosclerotic disease 
Of those with previously diagnosed atherosclerotic disease, 87% were being 
prescribed one or more of aspirin, statins and blood-pressure lowering treatment in the six 
months before AMI, but only 34% were receiving all three. 
 
Cardiovascular risk factors and medications in patients without previous 
atherosclerotic disease 
Fifty nine percent of AMIs were unheralded by previously diagnosed atherosclerotic 
disease (71% STEMI, 50% NSTEMI).  Overall 79% of these patients had at least one 
elevated or treated risk factor (ever had a record of diabetes, hypertension, dyslipidaemia, 
current smoking, or a prescription for statins, blood pressure lowering or antiplatelets in the 
six months before MI). This was the same in STEMI (79%) and NSTEMI (80%) (Table 3). 
The most common risk factors were diagnosed hypertension or recent use of blood pressure 
lowering drugs (42% of STEMI patients and 53% of NSTEMI), and current smoking (39.8% 
STEMI, 28.3% NSTEMI); one or both of these risk factors was present in 70% of STEMI 
and 80% of NSTEMI patients.  STEMI patients tended to have a slightly lower burden of 
cardiovascular risk factors than NSTEMI (median two risk factors in STEMI patients, three 
in NSTEMI).   
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Discussion 
We found that heart attack without clinically ascertained and recorded warning is 
uncommon.   In the first large-scale evaluation of coronary, cerebral and peripheral 
atherosclerotic disease manifestations, risk factors and symptoms prior to STEMI and 
NSTEMI using prospectively collected data, we found large differences in the pattern of 
diagnosed atherosclerotic disease by AMI type in the period leading up to AMI.  While the 
proportion of AMI that occurs without disease, cardiovascular risk factors, medications or 
chest pain (i.e. ‘out of the blue’) was slightly higher in STEMI, an important proportion of 
unheralded AMIs are NSTEMI (14% versus 9%, respectively).  We also found that there 
was a premonitory period for both MI types during which the rates of both coronary disease 
diagnosis and chest pain consultation were raised, but there was no equivalent increase in the 
rate of peripheral artery or cerebrovascular disease diagnoses.      
Previous atherosclerotic disease and risk factors 
Uniquely, our study provided prospective data on the rate of onset of different 
subtypes of atherosclerotic disease in the years leading to AMI.  Patients with NSTEMI had 
a consistently higher rate of coronary, cerebrovascular and peripheral disease diagnosis 
throughout follow-up compared to STEMI.  This is in line with other studies showing that 
patients with NSTEMI are more likely to have prior atherosclerotic disease than STEMI 
patients.(6-10, 16, 17)   
Our results describing the extent of disease across vascular territories are also 
similar to published findings for NSTEMI, (5) and we have shown that in STEMI patients, 
disease in two or more sites is less common.  This is consistent with the idea that NSTEMI 
patients tend to be a sicker group overall.  The widely different pattern in the prevalence and 
rate of onset of atherosclerotic disease between AMI types lends support to the hypothesis 
that STEMI and NSTEMI are two different patho-physiological entities (NSTEMI is more 
often caused by a non-occlusive thrombus and STEMI is more often caused by a complete 
occlusion(18)). 
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If AMI occurs without prior symptomatic atherosclerotic disease, to what extent can 
it be considered to occur “out of the blue”?   Although a substantial proportion of infarcts 
were unheralded by diagnosed atherosclerotic disease, the majority of these had at least one 
cardiovascular risk factor (smoking, hypertension, dyslipidaemia, diabetes) or were being 
treated with a cardiovascular medication.  The relatively high prescription of antiplatelets 
before both STEMI and NSTEMI indicates that general practitioners (GP) suspected a high 
risk of atherosclerotic disease in many of these patients.  Our findings are consistent with 
other prospective studies showing high risk factor burdens in AMI patients overall.(19, 20)   
To our knowledge, there are no other estimates for the proportion of STEMI and 
NSTEMI occurring without heralding.  We have shown that unheralded AMI is uncommon, 
occurring in roughly one in ten patients in our study.  The true prevalence of unheralded 
AMI is likely to be lower than our data suggest because our data were from general practice 
where risk factors are recorded opportunistically during patient consultations.   
Premonitory period 
Clinical experience and retrospective studies have long suggested that AMI might be 
preceded by premonitory symptoms of chest pain presenting to a family physician or 
ambulatory care.(21, 22)  Our study extends knowledge in several respects.   First we 
confirmed this association with prospective data.  Second we found that there were increases 
in coronary disease diagnoses and chest pain consultations in both STEMI and NSTEMI.  
This is in contrast to the widely-held view that STEMI is usually of sudden onset.  Third we 
showed that the increases were specific to coronary diagnoses and chest pain, rather than 
disease in cerebral or peripheral circulations, suggesting a local rather than systemic pro-
thrombotic state. 
Clinical implications and missed opportunities for care? 
In patients with previously diagnosed atherosclerotic disease or risk factors, AMI 
represents the unmet potential of secondary prevention, and primary prevention respectively.   
Despite a clear premonitory period where many patients were diagnosed with coronary 
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disease shortly before AMI, the majority of disease was diagnosed long in advance of both 
AMI types.  Therefore there is an extended period during which secondary prevention could 
be implemented.  Our data describing the use of secondary prevention measures in the six 
months before AMI showed that most patients with diagnosed atherosclerotic disease were 
receiving one of either statins, aspirin or blood pressure-lowering drugs, but only a third 
were in receipt of all three, indicating that there are likely to be missed opportunities for 
secondary prevention in this group. 
Interestingly, while coronary disease was the most common pre-AMI presentation, 
ten percent of both STEMIs and NSTEMIs were heralded by peripheral artery disease and/or 
cerebrovascular disease alone.   This emphasises the importance of further efforts to improve 
the secondary prevention following diagnoses in the cerebral and peripheral arteries in order 
to prevent an important proportion of AMI. The high prevalence of risk factors in both 
STEMI and NSTEMI suggests the importance of tackling the widely reported missed 
opportunities for implementation of existing interventions known to be effective.(23-26)  
Additionally, lowering blood pressure and lipids in those not diagnosed as hypertensive or 
dyslipidemic may also prevent AMI as the risk associated with blood pressure and lipids is 
not binary.     
 
Strengths 
The main strength of this study is the quality of data from the linked MINAP and 
GPRD records.  MINAP collects data from all hospitals in England and undergoes annual 
assessments to ensure the data are of research quality.(27)  ECG and cardiac marker results 
are recorded and our STEMI and NSTEMI case definitions were based on the international 
definition of AMI.(15)  The recording of admission date in MINAP allowed us to interpret 
the timing of previous atherosclerotic disease diagnoses in relation to AMI.  The GPRD is 
representative of the UK population(13) and roughly half of GPRD practices consented to 
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linkage with MINAP; patients in practices that participated in the linkage were 
representative of the GPRD as a whole.(14)   
The primary care GPRD data are collected prospectively as part of usual clinical 
care and therefore are not subject to recall bias or differential error related to outcome.  Data 
regarding new diagnoses and treatment of disease were available for a median of 8.7 years 
before AMI, allowing sufficient time for incident diagnoses to arise and be recorded.   The 
GPRD closely monitors data quality and the recording of a wide range of atherosclerotic 
disease outcomes have undergone validation in GPRD studies, which, for example, have 
compared the electronic data to paper-based medical records or compared the rate of a 
condition in the GPRD to an external source.  These have shown most diagnoses to be of 
high quality.(28-31)   
Our analysis was based on patients with ‘definite’ atherosclerotic disease diagnoses, 
using diagnostic codes which had been rated by two clinicians as being indicative of disease.  
If ‘possible’ diagnoses were included, the proportion with previous disease rose from 41% to 
44%; this small change indicates that our ‘definite’ atherosclerotic disease definition had 
high sensitivity.   
 
Weaknesses 
Inclusion of only hospitalised cases from MINAP will have introduced a selection 
bias towards patients who survived for long enough to reach hospital.  Therefore, our results 
cannot necessarily be generalised to patients who die outside hospital, and we cannot rule 
out that the prevalence of heralding factors may differ among those dying of AMI before 
hospital admission.   
Because our analyses of heralding are based largely on general practice data, 
symptomatic atherosclerotic disease may be undiagnosed if patients do not consult their GP.  
We excluded only fourteen patients without any consultations as these patients never had an 
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opportunity for measurement of risk factors or morbidity.  However, introducing a minimum 
consultation rate could introduce a bias towards sicker patients. The data available for this 
analysis did not allow us to differentiate between patients with a low consultation rate 
because of good health and those that did not consult despite symptomatic disease. 
 
Implications for research 
A small but important proportion of STEMI and NSTEMI do appear to occur with 
no recognised heralding signs and further research is warranted to better characterise these 
phenotypes, their causes and their prognosis. For patients with different forms of heralding 
the challenge remains to better characterise short term risk of coronary events in order to 
identify for which patients this represents a (potentially remediable) premonitory period. 
 
Conclusion 
The majority of STEMIs and NSTEMI were heralded by prior disease or at least one 
other risk factor, suggesting that opportunities for prevention may be being missed. 
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Figure legends 
 
Figure 1. Previous atherosclerotic disease and risk factors in patients with first ST-
elevation myocardial infarction (STEMI, N=3780) and non ST-elevation myocardial 
infarction (NSTEMI, N=4394).   
 
Figure 2. Proportion of patients with ST-elevation myocardial infarction (STEMI, 
N=3780), (above) and non ST-elevation myocardial infarction (NSTEMI, N=4394) 
(below), with different combinations of disease in one, two or three arterial beds 
(CHD: coronary heart disease; PAD: peripheral arterial disease; CVD: 
cerebrovascular disease).  71% of STEMI patients and 50% of NSTEMI patients 
were unheralded by atherosclerotic disease at any site. 
 
Figure 3.  Rate of coronary heart disease (CHD), peripheral arterial disease (PAD) 
and cerebrovascular disease (CVD) in the ten years before diagnosis of ST-
elevation myocardial infarction (STEMI) and non ST-elevation myocardial infarction 
(NSTEMI) (with 95% confidence intervals).  Note: each time point covers a one year 
timeband (1=0-1 years before AMI, 2=1-2 years before AMI, etc). 
 
Figure 4. Rate of coronary diagnosis (A) and chest pain consultations (B) in the 
months leading to ST-elevation myocardial infarction (STEMI) and non ST-elevation 
myocardial infarction (NSTEMI), with 95% confidence intervals.  Consultations for 
chest pain are only in those without diagnosed atherosclerotic disease.  Note: each 
time point covers a one month timeband (0-1 months, 1-2 months, etc). 
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Table 1.  Demographics and hospital admission characteristics of STEMI and 
NSTEMI patients. 
    STEMI (N=3780) NSTEMI (N=4394)
Age, y* 67.0 (57.0-77.0) 74.0 (63.0-82.0) 
Female, n (%) 1172 (31.0) 1774 (40.4) 
Ethnicity, n (%) 
White 3146 (83.2) 3739 (85.1) 
South Asian 13 (0.3) 18 (0.4) 
Other 59 (1.6) 63 (1.4) 
Unknown 562 (14.9) 574 (13.1) 
ECG at admission, n (%) 
ST segment elevation 3552 (94.0) 0 (0) 
Left bundle branch block 87 (2.3) 246 (5.6) 
ST segment depression 0 (0.0) 1144 (26.0) 
T wave changes only 0 (0.0) 1024 (23.3) 
other abnormality 0 (0.0) 836 (19.0) 
Normal ECG 0 (0.0) 473 (10.8) 
Unknown 141 (3.7) 671 (15.3) 
Peak troponin at admission, µg/L*† 5.2 (1.2-25.0) 1.0 (0.3-3.9) 
Heart rate at admission, bpm*† 76.0 (63.0-90.0) 80.0 (68.0-98.0) 
Systolic BP at admission, mmHg*† 138.0 (120.0-157.0) 140.0 (121.0-160.0) 
STEMI indicates ST-elevation MI; NSTEMI, non ST-elevation MI; BP, blood pressure.  
*Continuous variables are expressed as medians, with 25th and 75th percentiles. 
†Completeness in peak troponin, heart rate and systolic BP 85, 77 and 77%, respectively. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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10.5 Appendices for Chapter 6 
10.5.1 Literature review search strategy 
Table 10.20 Search terms and search strategy used in identifying studies 
 
Search number Terms included 
1. Myocardial 
infarction 
MYOCARDIAL INFARCTION (as a Medical Subject 
Heading, with all subheadings included and all sub-terms 
in the MeSH tree) in the keywords.   
 
OR 
 
The following MI synonyms in the keywords, title or 
abstract: 
 
myocardial infarct* OR stemi OR heart attack OR cardiac 
infarct* OR acute infarct* OR coronary attack OR 
myocardial thrombosis OR coronary thrombosis OR 
coronary infarct* OR heart infarct* OR Q wave infarct* OR 
acute coronary 
  
2. Preinfarction 
angina or 
ischaemic 
preconditioning 
 
The following terms in the keywords, title or abstract: 
ischaemic precond* OR ischemic precond* OR preinfarct* 
OR pre-infarct* 
OR 
ISCHEMIC PRECONDITONING (as a Medical Subject 
Heading) 
3.  1 & 2, restricted to studies in humans and in the English 
language 
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10.5.2 Directed acyclic graph for Chapter 6 
 
Figure 10.6 Directed acyclic graph to describe the analysis in Chapter 6 
 
In this analysis, the exposure of interest was a new ischaemic presentation in the 90 
days prior to MI.  The outcome of interest was coronary heart disease mortality.  The 
cardiovascular disease risk factors were included in the analysis to account for the 
underlying level of atherosclerotic disease (unmeasured), which was associated with 
experiencing a new ischaemic presentation and with subsequent post-MI mortality.  
Analyses were also undertaken to account for the possibility of faster time to admission in 
patients with new ischaemic presentations, the prescription of  cardiovascular drugs, and for 
the potential association with MI type,   
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10.5.3 Cox regression model diagnostics 
 
 
Figure 10.7 Log log plot of the hazards, in patients with no prior ischaemic 
presentations, new ischaemic presentations in the 90 days before myocardial infarction 
(MI), and existing ischaemic diseases with no new presentations in the 90 days before 
MI (N=16,439) 
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10.6 Appendices for Chapter 7 
10.6.1 Literature review search strategy 
Table 10.21 Search terms for literature review 
 
Search number Terms included 
1. Myocardial 
infarction 
MYOCARDIAL INFARCTION (as a Medical Subject Heading, with 
all subheadings included and all sub-terms in the MeSH tree) in 
the keywords.   
 
OR 
 
The following MI synonyms in the title or keywords: 
 
myocardial infarct* OR stemi OR heart attack OR cardiac infarct* 
OR acute infarct* OR STEAMI OR coronary attack OR myocardial 
thrombosis OR coronary thrombosis OR coronary infarct* OR 
heart infarct* OR Q wave infarct* OR acute coronary  
2. Therapies The following terms as Medical Subject headings, where possible, 
in the keywords: 
 
Therapeutics (MeSH)  
Hydroxymethylglutaryl-CoA Reductase Inhibitors 
Pravastatin (MeSH)  
Lovastatin (MeSH)  
Aspirin (MeSH)  
Ticlopidine (MeSH) 
statin (keyword) 
antiplatelet (keyword) 
lipid-lowering (keyword) 
3. Synonyms to 
indicate use 
before 
infarction 
The following in the title:  
 
[before OR preced* OR herald* OR previous* OR prior OR earlier 
OR advance former OR ahead OR sooner OR pre-exist* OR exist* 
OR precurs* OR prodrom* OR anteced* OR presence OR history 
OR prevalen* OR recogni* OR document* OR record*]  
* Indicates any ending to the term is searched for. 
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10.6.2 Directed acyclic graph for Chapter 7 
 
MI: myocardial infarction; CHD: coronary heart disease 
Figure 10.8 Directed acyclic graph for the analysis in Chapter 7 
 
In this analysis, the exposure of interest was prescription of aspirin or statins prior to 
MI.  The outcomes of interest were ST-elevation at MI, infarct size and coronary heart 
disease mortality.  The cardiovascular disease risk factors were included in the analysis to 
account for the underlying level of atherosclerotic disease (unmeasured), which was 
associated with receipt of aspirin or statins and with the outcome.  Therefore blood pressure 
lowering medication, age, sex, hypertension, total serum cholesterol, diabetes and smoking 
(as the most important cardiovascular disease risk factors) were included in the analysis as 
confounders.     
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10.6.3 Raw peak troponin and log-transformed peak troponin 
 
Figure 10.9 Peak troponin values in µg/L(left) and log-transformed peak troponin 
values (right) for all patients without previously diagnosed atherosclerotic disease 
(N=2,964) 
 
 
10.6.4 Additional aspirin results 
Duration of aspirin use 
 
 
Figure 10.10 Histograms describing the duration of aspirin use prior to MI in patients 
who were current users (left, N=761) and previous users (right, N=563) 
 
 
  
Appendix A 
410 
 
Frequency of aspirin prescription 
Histograms describing the number of prescriptions issued per user per year are 
shown in Figure 10.11 for current users and Figure 10.12 for previous users.  Most patients 
defined as current users received prescriptions between 3 and 14 times per year, reflecting 
the most common aspirin pack sizes of 100, 56 and 28.  Previous users most commonly had 
less than one prescription per year, indicating one off prescribing which is unlikely to reflect 
aspirin use for primary prevention.     
 
Figure 10.11 Histogram describing the number of aspirin prescriptions per year in 
patients defined as current aspirin users (N=761) 
 
 
 
Figure 10.12 Histogram describing the number of aspirin prescriptions per year in 
patients defined as previous aspirin users (N=563) 
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Stratification of MI presentation by aspirin use and Framingham risk 
 
Figure 10.13 Proportion of patients with ST-elevation at myocardial infarction in 
never, current and previous aspirin users at different levels of Framingham risk, with 
95% confidence intervals (N=4,010) 
 
 
 
 
Figure 10.14 Thirty day all-cause mortality in patients, stratified by duration of aspirin 
use (none versus years of current use (with 95% confidence intervals) (N=7,451) 
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Figure 10.15 Box plots to describe the median and inter-quartile range of peak troponin values at each level of Framingham risk, by 
aspirin use (N=2,964) 
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10.6.5 Additional statin results 
Duration of statin use 
 
Figure 10.16 Histograms describing the duration (in years) of statin use prior to MI in 
patients who were current users (left, N=804) and previous users (right, N=356) 
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Frequency of statin prescription 
Histograms describing the number of statin prescriptions per patient year in current 
and previous statin users are shown in Figure 10.17 and Figure 10.18.  For current users 
there are two large peaks in the number of prescriptions issued per year.  One of these is at 
13, corresponding to patients receiving a prescription every 28 days.  The other peak is at 7, 
corresponding to patients receiving prescriptions every 56 days.  Pack quantities of 28 and 
56 were the most frequently prescribed in this population.  The frequency in previous users 
indicates that many patients had frequently received statin prescriptions prior to MI. 
 
Figure 10.17 Histogram describing the number of statin prescriptions per patient year 
in current statin users (N=804) 
 
 
Figure 10.18 Histogram describing the number of statin prescriptions per patient year 
in previous statin users (N=356) 
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ST-elevation at MI by statin use, at different levels of vascular disease risk  
 
Figure 10.19 Proportion of patients with ST-elevation at myocardial infarction, in 
never, current and previous users of statins, at each level of Framingham risk (with 
95% confidence intervals) (N=4,010) 
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Infarct size by statin use, at different levels of vascular disease risk 
 
 
Figure 10.20 Box plots of peak troponin (in µg/L) for never, current and previous statin users, by Framingham risk category (N=2,964) 
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Demographic distribution by statin dosage 
Table 10.22 Demographic and risk factor characteristics in patients with first MI and no previous atherosclerotic disease, stratified by dose of statins 
prior to MI (N=804) 
 
    ≤10mg 20mg 40mg 80mg 
N patients 96 (11.9) 353 (43.9) 293 (36.4) 62 (7.7) 
Duration of use, median years (IQR) 1.5 (0.5-3.8) 1.7 (0.7-3.8) 1.8 (0.6-3.6) 4.1 (2.3-6.1) 
Age, median (IQR) 69 (58-76) 69 (60-75) 66 (59-74) 66 (57-74) 
Sex, n female (%) 35 (36.5) 145 (41.1) 112 (38.2) 26 (41.9) 
Smoking, n (%) 
Non-smoker 12 (12.5) 54 (15.3) 43 (14.7) 8 (12.9) 
Ex-smoker 57 (59.4) 209 (59.2) 166 (56.7) 39 (62.9) 
Current smoker 26 (27.1) 89 (25.2) 84 (28.7) 15 (24.2) 
Unknown 1 (1) 1 (0.3) 0 (0) 0 (0) 
Hypertension, n (%) 73.0 (76) 268.0 (75.9) 221.0 (75.4) 50.0 (80.6) 
Blood pressure lowering 71 (74) 272 (77.1) 234 (79.9) 50 (80.6) 
Total serum cholesterol in mmol/L, mean (SD) 5.6 (1) 5.6 (1) 5.8 (1) 6.0 (1.4) 
Diabetes, n (%) 43 (44.8) 154 (43.6) 128 (43.7) 39 (62.9) 
Framingham risk, n (%) 
<10% 17 (17.7) 69 (19.5) 51 (17.4) 14 (22.6) 
10-20% 44 (45.8) 178 (50.4) 156 (53.2) 36 (58.1) 
>20% 35 (36.5) 106 (30) 86 (29.4) 12 (19.4) 
Consultation rate per year, median (IQR) 6.7 (4.5-10.4) 7.2 (4.2-11.3) 7.3 (4.7-10.7) 9.5 (5.5-13.4) 
Years of pre-MI GPRD registration, median 
(IQR) 6.5 (4-10.1) 8.5 (5.7-12) 9.3 (6.3-14) 8.3 (5-13.3) 
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10.6.6 Chapter 7 regression model diagnostics 
Age and cholesterol were initially fitted in all regression models as linear variables.  
The assumption of linearity in the effects of these variables was checked by adding them as 
quadratic and cubic terms, and comparing models with likelihood ratio tests.  If the models 
with quadratic or cubic terms indicated a better fit, then these were retained in the model.  
Multiple linear regression model diagnostics 
Residuals from each multiple linear regression model were plotted on a histogram to 
check for normality.   
 
Figure 10.21 Multivariable adjusted model examining effects of aspirin and statin on 
infarct size 
 
 
 
 
Figure 10.22 Multivariable adjusted model examining effects of statin dose on infarct 
size 
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Cox regression model diagnostics 
Crude log-log plots of survival by aspirin use and by statin use were produced to 
check the proportional hazards assumption of the Cox model.  For aspirin (below), the 
survival curves were roughly parallel in each stratum of aspirin use.  Additionally, the 
proportional hazards assumption was checked in the multivariable-adjusted model using 
Schoenfeld residuals.  If there was evidence against the assumption of proportional hazards, 
an interaction with time was fitted.  After fitting an interaction with time at 7 days where 
required, there was no evidence against the assumption of proportional hazards in any model 
(P>0.1).   
The crude log-log survival plot by statin use showed some potential for non-
proportionality.  However, there was no evidence of non-proportionality in the final model 
(global test of proportional hazards, P=0.8010).  Test of proportional hazards for the statin 
duration Cox model also showed no evidence against the assumption of proportional hazards 
(P=0.7381). 
 
 
 
Figure 10.23 Log-log survival plot for aspirin use on 30 day all-cause mortality 
(N=8,104) 
 
  
Appendix A 
420 
 
 
 
Figure 10.24 Log-log plot for statin use on 30 day all-cause mortality (N=8,104) 
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10.6.7 Sensitivity analysis 
Adjusting for further risk factors 
Table 10.23 OR for ST-elevation in patients with MI, from the main analysis, and 
further adjusted for BMI, family history and socioeconomic status 
 
    
Main analysis 
multivariable adjusted 
OR (95% CI)± (N=4,001) 
Further adjusted OR (95% 
CI)† (N=2,144) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.65 (0.48-0.88) 
Previous 1.02 (0.74-1.42)     1.03 (0.74-1.42) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     0.94 (0.74-1.20) 
Previous 0.96 (0.70-1.33)     0.93 (0.68-1.29) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
† Additionally adjusted for BMI, family history and socioeconomic status 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.24 Estimated relative infarct size in the main analysis, and further adjusted 
for BMI, family history and socioeconomic status 
 
    
Main analysis 
multivariable adjusted 
estimated relative infarct 
size (95% CI)± (N=2,912) 
Further adjusted estimated 
relative infarct size (95% CI)† 
(N=1,575) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.01 (0.72-1.40) 
Previous 1.01 (0.69-1.46)     1.04 (0.72-1.51) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     0.96 (0.73-1.27) 
Previous 0.82 (0.56-1.19)     0.80 (0.55-1.17) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.   ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
† Additionally adjusted for BMI, family history and socioeconomic status 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.25 Hazard ratios for 30 day mortality from the main analysis, and further 
adjusted for BMI, family history and socioeconomic status 
 
    
Main analysis 
multivariable adjusted HR 
(95% CI)± (N=4,088) 
Further adjusted HR (95% 
CI)† (N=2,231) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.01 (0.84-1.21) 
Previous 1.00 (0.81-1.24)     0.99 (0.80-1.23) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     1.03 (0.86-1.23) 
Previous 0.98 (0.77-1.24)     1.01 (0.80-1.29) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
† Additionally adjusted for BMI, family history and socioeconomic status 
*** P<0.001, ** P<0.01, * P<0.05 
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Using possible and definite diagnoses 
Table 10.26 OR for ST-elevation in patients with MI, from the main analysis, and in an 
analysis excluding possible atherosclerotic disease 
 
    
Main analysis multivariable 
adjusted OR (95% CI)± 
(N=4,001) 
Multivariable adjusted OR, 
including possible diagnoses 
(95% CI) (N=4,001) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.69 (0.51-0.95) * 
Previous 1.02 (0.74-1.42)     1.03 (0.73-1.44) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     1.00 (0.78-1.29) 
Previous 0.96 (0.70-1.33)     0.96 (0.69-1.34) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.27 Estimated relative infarct size in the main analysis and in an analysis 
excluding possible atherosclerotic disease 
 
    
Main analysis multivariable 
adjusted estimated relative 
infarct size (95% CI)± 
(N=2,912) 
Multivariable adjusted 
estimated relative infarct size, 
including possible diagnoses 
(95% CI) (N=2,912) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.05 (0.74-1.50) 
Previous 1.01 (0.69-1.46)     1.04 (0.70-1.53) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     1.02 (0.76-1.36) 
Previous 0.82 (0.56-1.19)     0.86 (0.58-1.26) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.    ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.28 Hazard ratios for 30 day mortality from the main analysis, and in an 
analysis excluding possible atherosclerotic disease 
 
    
Main analysis multivariable 
adjusted HR (95% CI)± 
(N=4,088) 
Multivariable adjusted HR, 
including possible diagnoses 
(95% CI) (N=4,088) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.07 (0.88-1.29) 
Previous 1.00 (0.81-1.24)     1.00 (0.80-1.25) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     0.93 (0.77-1.13) 
Previous 0.98 (0.77-1.24)     0.97 (0.75-1.25) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
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Other definitions of ‘current’ use 
Table 10.29 OR for ST-elevation in patients with MI, from the main analysis, and in an 
analysis where current use was defined as two or more prescriptions in the six months 
prior to MI 
 
    
Main analysis multivariable 
adjusted OR (95% CI)± 
(N=4,001) 
Multivariable adjusted OR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,001) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.71 (0.52-0.96) * 
Previous 1.02 (0.74-1.42)     0.92 (0.67-1.26) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     0.97 (0.76-1.24) 
Previous 0.96 (0.70-1.33)     0.96 (0.70-1.32) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.30 Estimated relative infarct size in the main analysis, and in an analysis 
where current use was defined as two or more prescriptions in the six months prior to 
MI 
 
    
Main analysis 
multivariable adjusted 
estimated relative infarct 
size (95% CI)± (N=2,912) 
Multivariable adjusted 
estimated relative infarct 
size, using alternative 
definition of 'current' use 
(95% CI) (N=2,912) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.12 (0.80-1.57) 
Previous 1.01 (0.69-1.46)     0.87 (0.60-1.25) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     0.97 (0.73-1.28) 
Previous 0.82 (0.56-1.19)     0.83 (0.57-1.21) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.    ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.31 Hazard ratios for 30 day mortality from the main analysis, and in an 
analysis where current use was defined as two or more prescriptions in the six months 
prior to MI 
    
Main analysis 
multivariable adjusted HR 
(95% CI)± (N=4,088) 
Multivariable adjusted HR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,088) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.06 (0.88-1.28) 
Previous 1.00 (0.81-1.24)     0.98 (0.79-1.21) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     0.97 (0.81-1.16) 
Previous 0.98 (0.77-1.24)     0.96 (0.75-1.22) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
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Table 10.32 OR for ST-elevation in patients with MI, from the main analysis, and in an 
analysis where current use had a zero day buffer 
 
    
Main analysis multivariable 
adjusted OR (95% CI)± 
(N=4,001) 
Multivariable adjusted OR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,001) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.69 (0.51-0.93) * 
Previous 1.02 (0.74-1.42)     0.95 (0.69-1.29) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     0.93 (0.72-1.19) 
Previous 0.96 (0.70-1.33)     1.00 (0.75-1.35) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.33 Estimated relative infarct size in the main analysis, and in an analysis 
where current use had a zero day buffer 
 
    
Main analysis multivariable 
adjusted estimated relative 
infarct size (95% CI)± 
(N=2,912) 
Multivariable adjusted 
estimated relative infarct 
size, using alternative 
definition of 'current' use 
(95% CI) (N=2,912) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.03 (0.73-1.45) 
Previous 1.01 (0.69-1.46)     0.95 (0.67-1.37) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     0.92 (0.68-1.23) 
Previous 0.82 (0.56-1.19)     0.94 (0.67-1.32) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.    ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.34 Hazard ratios for 30 day mortality from the main analysis, and in an 
analysis where current use had a zero day buffer 
 
    
Main analysis multivariable 
adjusted HR (95% CI)± 
(N=4,088) 
Multivariable adjusted HR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,088) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.02 (0.84-1.23) 
Previous 1.00 (0.81-1.24)     1.04 (0.85-1.27) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     1.00 (0.83-1.21) 
Previous 0.98 (0.77-1.24)     0.92 (0.74-1.16) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
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Table 10.35 OR for ST-elevation in patients with MI, from the main analysis, and in an 
analysis where current use had a 28 day buffer 
 
    
Main analysis multivariable 
adjusted OR (95% CI)± 
(N=4,001) 
Multivariable adjusted OR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,001) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.66 (0.49-0.88) ** 
Previous 1.02 (0.74-1.42)     1.06 (0.76-1.48) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     0.96 (0.76-1.22) 
Previous 0.96 (0.70-1.33)     0.95 (0.68-1.33) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.36 Estimated relative infarct size in the main analysis, and in an analysis 
where current use had a 28 day buffer 
 
    
Main analysis multivariable 
adjusted estimated relative 
infarct size (95% CI)± 
(N=2,912) 
Multivariable adjusted 
estimated relative infarct 
size, using alternative 
definition of 'current' use 
(95% CI) (N=2,912) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.04 (0.75-1.43) 
Previous 1.01 (0.69-1.46)     0.95 (0.65-1.39) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     1.00 (0.76-1.32) 
Previous 0.82 (0.56-1.19)     0.78 (0.52-1.14) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.    ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
 
Table 10.37 Hazard ratios for 30 day mortality from the main analysis, and in an 
analysis where current use had a 28 day buffer 
 
    
Main analysis 
multivariable adjusted HR 
(95% CI)± (N=4,088) 
Multivariable adjusted HR, 
using alternative definition 
of 'current' use (95% CI) 
(N=4,088) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.05 (0.88-1.25) 
Previous 1.00 (0.81-1.24)     0.99 (0.79-1.24) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     0.97 (0.81-1.16) 
Previous 0.98 (0.77-1.24)     0.97 (0.75-1.25) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
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Adjusting for consultation rate 
 
Table 10.38 OR for ST-elevation in patients with MI, from the main analysis, and in an 
analysis adjusting for consultation rate 
 
    
Main analysis 
multivariable adjusted 
OR (95% CI)± (N=4,001) 
Multivariable adjusted OR, 
with adjustment for 
consultation rate (95% CI) 
(N=4,001) 
Aspirin 
Never 1 - 1 - 
Current 0.66 (0.49-0.89) **  0.67 (0.50-0.90) ** 
Previous 1.02 (0.74-1.42)     1.05 (0.76-1.46) 
Statins 
Never 1 - 1 - 
Current 0.95 (0.75-1.21)     0.97 (0.76-1.23) 
Previous 0.96 (0.70-1.33)     0.98 (0.71-1.36) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.39 Estimated relative infarct size in the main analysis, and in an analysis 
adjusting for consultation rate 
 
    
Main analysis 
multivariable adjusted 
estimated relative 
infarct size (95% CI)± 
(N=2,912) 
Multivariable adjusted 
estimated relative infarct 
size, with adjustment for 
consultation rate (95% CI) 
(N=2,912) 
Aspirin 
Never 1 - 1 - 
Current 0.99 (0.72-1.38)     1.12 (0.80-1.57) 
Previous 1.01 (0.69-1.46)     0.88 (0.61-1.28) 
Statins 
Never 1 - 1 - 
Current 0.98 (0.74-1.30)     0.98 (0.74-1.30) 
Previous 0.82 (0.56-1.19)     0.84 (0.58-1.22) 
Note: estimated relative infarct size was calculated by exponentiating the coefficients from the 
multiple linear regression model.    ± Adjusted for all other drug use, age, sex, hypertension, 
diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
 
Table 10.40 Hazard ratios for 30 day mortality from the main analysis, and in an 
analysis adjusting for consultation rate 
 
    
Main analysis 
multivariable adjusted 
HR (95% CI)± (N=4,088) 
Multivariable adjusted HR, 
with adjustment for 
consultation rate (95% CI) 
(N=4,088) 
Aspirin 
Never 1 - 1 - 
Current 1.05 (0.87-1.25)     1.04 (0.87-1.25) 
Previous 1.00 (0.81-1.24)     1.00 (0.81-1.24) 
Statins 
Never 1 - 1 - 
Current 0.97 (0.81-1.16)     0.97 (0.81-1.16) 
Previous 0.98 (0.77-1.24)     0.98 (0.77-1.24) 
± Adjusted for all other drug use, age, sex, hypertension, diabetes, smoking, total cholesterol 
*** P<0.001, ** P<0.01, * P<0.05 
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Chapter 11 Appendix B (CD) 
 
11.1 Code lists 
 
11.1.1 Read code lists for GPRD 
11.1.2 ICD-10 code lists for HES and ONS 
11.1.3 OPCS-4 codes for HES 
 
11.2 CALIBER data manual 
 
11.3 Analytic protocols for the analyses in this thesis 
 
11.4 Approvals for the analyses in this thesis 
 
